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Sumário 
 
Várias doenças causadas pelo sistema imunitário, como doenças 
autoimunes, alergias ou rejeição de transplantes, são causadas por uma 
resposta inadequada a alguns antigénios. Uma possível forma de tratar 
estas doenças consiste na indução de tolerância específica e robusta. A 
tolerância imunitária é definida como a ausência de resposta por parte do 
sistema imunitário a um dado antigénio, mantendo-se competente para 
responder a antigénios distintos. Existem vários mecanismos que 
asseguram tolerância imunitária a antigénios do próprio e vários antigénios 
ambientais, tais como a selecção negativa no timo de linfócitos 
autorreactivos juntamente com o desenvolvimento de células T 
reguladoras (Treg) que suprimem autorreactividade; locais 
imunoprivilegiados como a placenta; citoquinas imunorreguladoras como a 
IL-10; e o controlo na periferia de linfócitos maturos através de apoptose, 
anergia, competição e diferenciação de diferentes populações celulares 
reguladoras. Nos últimos vinte anos tem sido dada muita ênfase a uma 
população de células T reguladoras caracterizada pela elevada expressão 
de CD25 (a cadeia alfa do receptor de IL-2) e de Foxp3 (um factor de 
transcrição). Com a aquisição de informação sobre as Tregs, os 
imunologistas têm tido a capacidade de desenvolver novas estratégias 
para diferenciar e expandir esta população celular, sendo inclusivamente 
utilizadas Tregs como terapia celular em ensaios clínicos. 
Uma forma eficaz de induzir tolerância imunitária em modelos animais 
consiste na utilização de anticorpos monoclonais (MAbs), dirigidos a 
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moléculas envolvidas na activação de linfócitos. Vários estudos em 
modelos animais de patologias do sistema imunitário demonstram a 
eficácia destes MAbs na indução de uma tolerância robusta a longo prazo. 
O anti-CD4 não depletante, em particular, é bastante eficaz na indução de 
tolerância imunitária em transplantação e autoimunidade induzindo uma 
população de Tregs. 
No trabalho descrito nesta tese demonstrámos que o anti-CD4 não 
depletante é capaz de induzir tolerância num modelo animal de asma 
alérgica, que é uma patologia dependente de uma resposta imunitária do 
tipo Th2. O bloqueio do CD4 concomitante com a exposição ao alergénio 
leva à indução de um estado de tolerância específica para esse antigénio, 
mantendo-se a competência do sistema imunitário para responder a 
outros antigénios diferentes. Com base nestes resultados, onde para a 
indução de tolerância utilizámos antigénios administrados juntamente com 
um adjuvante (alum), decidimos estudar a indução de tolerância a outras 
proteínas. Com efeito, estudos prévios mostraram ser particularmente 
difícil induzir tolerância a factor VIII (FVIII) em modelos animais de 
hemofilia, utilizando anti-CD4 ou outros anticorpos indutores de 
tolerância. Decidimos reavaliar a indução de tolerância a FVIII em hemofilia 
com base na hipótese que um adjuvante poderia facilitar esse processo. 
Com efeito verificámos que a administração de FVIII com alum permite a 
obtenção de tolerância robusta ao factor de coagulação com anti-CD4. 
Estes resultados poderão parecer contra-intuitivos pois os adjuvantes são 
conhecidos pela sua capacidade de potenciar respostas imunitárias e não 
de as inibir. No entanto é provável que para indução terapêutica de 
tolerância seja necessário que o antigénio a tolerar seja apresentado de 
forma eficaz à maioria de células T efectoras específicas durante o período 
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em que o anti-CD4 se mantém em níveis terapêuticos. Um adjuvante 
poderá assim facilitar a apresentação de antigénios pelas células 
dendríticas durante este período. Esta hipótese será avaliada em 
experiências futuras. 
Finalmente, procurámos identificar os mecanismos celulares e 
moleculares associados à indução de tolerância imunitária a proteínas em 
adjuvante. Como está descrito na literatura que o anti-CD4 promove, em 
transplantação e autoimunidade, a diferenciação de Tregs Foxp3+, 
assumimos que o mesmo mecanismo estaria envolvido na indução de 
tolerância a proteínas em alum. Contudo, verificámos ser possível indução 
de tolerância em animais deficientes em Foxp3. No entanto o estado de 
tolerância depende de IL-10, pois não é possível induzir tolerância em 
animais na ausência desta citoquina. Para além deste mecanismo de 
tolerância dominante dependente de IL-10 também está envolvido um 
componente recessivo, que depende da anergia e apoptose de células 
efectoras específicas 
 É possível que a combinação de estratégias que promovem 
mecanismos indutores de tolerância independentes de Foxp3 e outras 
estratégias que promovam tolerância mediada por Treg possam ser 
explorados de um modo sinergético para alcançar um estado de tolerância 
mais robusto e em situações mais estringentes. 
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Abstract 
 
Several immune mediated diseases, such as autoimmunity and 
allergy or transplant rejection are consequence of inappropriate immune 
responses towards specific antigens. The therapeutic induction of robust 
immune tolerance has, therefore been considered the Holy Grail of 
immunology since the pioneering work of Medawar and colleagues who 
have demonstrated the feasibility of tolerance induction. Immune 
tolerance is defined as the unresponsive state to a set of antigens by an 
immune system that remains immune competent to respond to unrelated 
antigens. A wealth of mechanisms has evolved to achieve immune 
tolerance to self as well as many environmental antigens.  These 
mechanisms include negative selection in the thymus together with the 
production of regulatory T cells dedicated to the prevention of auto 
reactivity; cytokines like IL-10; immune privileged sites; and peripheral 
control of effector T cells by apoptosis, anergy, competition, and 
differentiation of several types of regulatory immune cells.  In the last 
twenty years much emphasis has been given to a powerful regulatory T 
(Treg) cell population initially characterized by the high expression of CD25 
(the alpha chain of the IL-2R), that express the transcription factor  Foxp3. 
Over the years a significant amount of information on Tregs has been 
acquired which empowered the immunologists to devise new strategies to 
differentiate and expand these cells and ultimately to use them as cellular 
therapies. 
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One strategy known to induce immune tolerance takes advantage 
of biological agents such as monoclonal antibodies (MAbs) that can 
specifically target certain molecules modulating immune responses. 
Several studies in different animal models of immune disorders have 
shown the efficacy of MAbs at inducing long term specific immune 
tolerance. Non depleting anti-CD4 MAb has been shown able to induce 
immune tolerance in transplantation and autoimmunity by inducing a 
specific Treg population.  
In the work presented in this thesis we have shown that non 
depleting anti-CD4 can induce robust tolerance to soluble antigens in a 
mouse model of allergic asthma – a Th2-driven pathology. CD4-blockade at 
the time of allergen exposure can lead to antigen-specific tolerance 
therefore sparing the immune response to other antigens.  
Based on these findings, where the allergen is administered 
together with an adjuvant, we revisited immune tolerance to therapeutic 
proteins using a mouse model of hemophilia. It had been reported that 
tolerance induced with MAbs (such as anti-CD4) was difficult to induce to 
proteins like factor VIII. We hypothesized that an adjuvant, such as alum, 
that in the animal models of allergy allows tolerance induction to model 
antigens and allergens, may be useful to facilitate tolerance to FVIII. We 
confirmed that indeed tolerance induction to FVIII can be induced when 
alum is used as an adjuvant – a counter-intuitive finding given the 
tendency of adjuvants to boost, rather than inhibit, immune responses. We 
believe that for proper tolerization of antigen-specific cells it is essential to 
have adequate antigen presentation. Therefore an adjuvant can facilitate 
the process. This hypothesis will be addressed in future studies.  
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Finally, we investigated the cellular and molecular mechanisms 
underlying the induction of tolerance to proteins using non-depleting anti-
CD4. We anticipated that induction of Foxp3+ T cells would be a major 
mechanism given prior studies that have clearly established induced 
Foxp3+ Tregs in tolerance induction in transplantation and autoimmunity. 
However, we found that tolerance to proteins in alum could be induced in 
Foxp3-deficient mice, but not in the absence of IL-10.  In addition to the 
dominant tolerance mechanism IL-10-dependent we found evidence for a 
recessive mechanism based on the activation-cell death and anergy of 
antigen-specific cells following activation under the cover of anti-CD4. 
We believe it may be possible to take advantage of both Foxp3-
independent and Foxp3-dependent mechanisms to achieve a more robust 
state of immune tolerance. 
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For many decades self/non-self discrimination by the immune 
system was assumed to be a consequence of clonal selection of effector T 
cells. Although the concept of horror autotoxicus was postulated by Ehrlich 
over a century ago, the first model proposing the elimination of self-
reactive T cells during thymic development was only proposed in 1959 [1]. 
This clonal selection theory is still regarded as the major mechanism 
underlying central tolerance: the events in the thymus during early T cell 
differentiation that lead to the deletion of potentially self-reactive T cells.  
 
In the thymus cortex CD4+CD8+ (DP) cells originating from CD4-CD8- 
(DN) T cell precursors [2] establish their first ligations with MHC molecules. 
Failure to engage an MHC within 3 to 4 days results in death for these T cell 
precursors [3]. This event is called “death by neglect” and eliminates 
around 95% of these cells as they fail to receive essential survival signals 
[3]. The remaining 5% cells survive by engaging the MHC of cortical thymic 
epithelial cells (cTECs) loaded with intracellular protein fragments [4] thus 
receiving a survival signal that allows positive selection [5]. Defects in the 
ZAP-70 signaling can alter the T cell repertoire and favor autoimmunity by 
allowing the survival of autoreactive cells that would otherwise be deleted 
[6-8]. Upon positive selection T cells become single positive for CD4 or CD8 
[9] and in the medulla suffer further refinement of their specificity by 
engaging MHC molecules on medullary thymic epithelial cells (mTECs) and 
dendritic cells in a process called negative selection [10]. In the medulla 
mTECs expressing high levels of both CD80 and MHC class II are also 
positive for Aire [11]. Aire directs expression of self-antigens within the 
thymus preventing autoimmunity by negative selection of cognate T cells 
[12, 13] in a dose dependent fashion [14].  
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However clonal selection does not explain the entire scope of 
immune tolerance. It became apparent that dominant cellular immune 
regulatory mechanisms, exerted by T cells, have a critical role in 
suppressing autoimmune targeting by peripheral T cells [15]. This issue has 
been controversial until a definite characterization of the phenotypic and 
functional characteristics of this population of T cells dedicated to 
tolerance maintenance was established [16]. Environmental cytokines and 
co-stimulatory factors may favor a functionally unique differentiation 
program for T cells that experience strong TCR signaling leading to a 
selection by agonist interaction of Treg cells with a repertoire skewed 
towards self-reactivity [17]. In the thymic development of natural Tregs 
(nTreg) CD28 plays a key role, as deficiency in CD28 or its ligands B7-1/B7-2 
lead to decreased thymic nTreg cells [18-20]. CD28 signaling is provided by 
thymic APCs [21] which might suggest that specialized APCs can be 
responsible for the different T cell populations selected by agonist. 
Downstream of CD27/B7 pathway, c-Rel a member of the NFκB family is a 
crucial factor for nTreg development in the thymus [22]. Mice deficient in 
c-Rel have shown a reduction in Foxp3+CD4SP cells in the thymus and in 
the periphery [23], while NF-κB1 had no effect [23]. In addition to co-
stimulation, cytokine signaling is also of major importance, especially IL-2. 
Nevertheless IL-2 might have a redundant effect with other common γ-
chain cytokines like IL-15 as the lack of IL-2 is less significant in reducing 
nTregs than the lack of its receptor IL-2Rβ [24-26]. Thymic Treg 
development appears to follow a two-step instructive model: TCR 
engagement leads to upregulation of CD25 (IL-2Rα) and other components 
of the proximal IL-2 signaling pathway and, subsequently, to IL-2-
dependent expression of Foxp3 [27]. Curiously STAT5 constitutive 
expression deflects thymocytes normally destined to become naive T cells 
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into the Treg cell lineage [28] which further supports the crucial role of IL-2 
in nTreg development. 
Treg cells are characterized by expression of the forkhead-family 
transcription factor Foxp3, whose function is indispensable for their 
development, maintenance and function [29]. Nr4a triple KO mice to show 
that Nr4a receptors have redundant yet crucial roles in thymic Treg cell 
development [30] acting as effectors of thymic CD4+ T cell fate by 
‘translating’ the strength of TCR signaling [30]. Epigenetic studies show 
that nTregs have a stable Foxp3 expression due to the demethylation of 
CpG motif in the Foxp3 locus [31].  
While central tolerance ensures that most T cell that exit to the 
periphery do not recognize self-antigens, peripheral tolerance ensures a 
cellular mechanism, mediated by regulatory cells, that self-antigens 
effector T cells that eventually escape to the periphery recognizing are 
suppressed and do not lead to autoimmune pathology. 
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Figure 1. The reactivity of the TCR for self-MHC ligands defines the 
outcome of the DP T cells. Cells with no ability to react with thymic ligands will die 
by neglect. Those with low affinity are positively selected and become CD4+ or 
CD8+ T cells. Those with too high affinity undergo clonal deletion to preserve self-
tolerance. Those cells that receive intermediate TCR signaling in the thymus suffer 
an agonist selection and acquire a special phenotype with distinct function. 
 
Recently it is becoming apparent that the importance of dominant 
regulation goes beyond the discrimination of self and non-self: it also 
discriminates between harmful and innocuous. In fact, cellular 
mechanisms, as detailed below, persistently patrol the organism 
preventing the onset of inflammation, namely allergic inflammation. The 
biological significance of this active tolerance-imposing mechanism is well 
demonstrated by the severity of the allergic and autoimmune syndrome 
that arises in individuals that lack this ability to tolerate self and harmless 
antigens.   
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Indeed, the organism is constantly exposed to non-pathogenic 
antigens that, in healthy individuals, are tolerated. It is, however, common 
(and becoming increasingly frequent) that an overzealous immune system 
will activate and develop effector responses to such harmless antigens 
developing allergy and other inflammatory diseases. Over the last decades 
allergic diseases, including allergic asthma, atopic dermatitis and food 
allergy, have become a major health problem in developed countries [32]. 
Despite the advances in the understanding of the pathophysiology of 
allergy and in its clinical management, allergic pathology remains a 
significant burden on the quality of life and economy of western society. 
Several strategies have been devised to overcome the pathological 
immune response by inducing immune tolerance.  
A major cellular mechanism in maintaining immune tolerance is 
the population of natural (or thymic derived) Foxp3+ Treg cells [33, 34]. 
Indeed these have been clearly implicated as potent inducers of a non-
responsive state in several immune mediated pathologies like 
autoimmunity, transplantation, graft-versus-host disease, and allergy [35-
39]. It has been shown, in allergy, that regulatory T cells can be transferred 
conferring specific tolerance to subsequent challenges with the allergen 
[40, 41]. In addition, depletion of the regulatory T cells can have a 
detrimental effect in allergic airway hyperreactivity [42]. Importantly 
Foxp3-deficiency, in mice and human beings, leads to a severe immune 
deregulation syndrome characterized by allergic and autoimmune 
manifestations that are rapidly fatal [43]. In addition to the important role 
of natural Foxp3+ Treg cells (nTreg) in preventing autoimmunity, it has 
become established that Foxp3 expression can be peripherally induced 
following T cell activation in presence of TGF-β [44]. These peripherally 
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induced Treg cells (iTreg) are believed to be important for tolerance 
induction to non-self-antigens, including allergens [44].  
Induction of regulatory T cells 
 
The study of peripheral induction of Treg cells was greatly facilitated 
with the use of Rag-insufficient TCR-transgenic mice, with the TCR specific 
for a non-self antigen. In these mice nTregs cannot be formed in the 
thymus due to the absence of a selecting thymic antigen. In 2003 it was 
shown that conventional T cells can be converted into iTreg in vitro when 
activated in presence of TGF-β[45]. In addition those iTreg cells were fully 
capable of controlling airway hyper reactivity (AHR) in previously sensitized 
mice [45-49]. It was subsequently found that reducing or blocking the 
available amount of TGF-β exacerbates AHR [50, 51], while the local 
delivery of this cytokine or adoptive transfer of T cells engineered to 
express latent TGF-β rescue mice from antigen sensitization and therefore 
prevent AHR[52, 53]. Interestingly, sub-optimal TCR signaling together with 
TGF-β greatly enhances iTreg conversion [54], which is in agreement with 
in vivo data showing that repeated low doses of allergen exposure 
promotes the emergence of Foxp3+ iTregs expressing TGF-β on the 
membrane[55]. Under sub-optimal TCR stimulation, obtained with a low-
dose of plate bound anti-CD3 or with DCs pulsed with a low dose of agonist 
peptide, as well as, with down-modulation of the TCR with non-depleting 
anti-CD4, promotes iTreg conversion in the absence of exogenous TGF-β 
[56]. Under those conditions Foxp3 expression still requires TGF-β, but the 
T cells can produce TGF-β, and benefit from the presence of this cytokine 
for conversion to Treg [56].   
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In addition to the importance of TGF-β for iTreg conversion, some 
studies showed that TGF-β can directly inhibit GATA3 expression thus 
impairing Th2 differentiation [57-59]. Because the Th2 response is 
impaired, the production of IL-4 is diminished, and this has a direct impact 
on B cell class switch preventing IgE and favoring IgA production [60]. 
It is also becoming apparent that the environment influences the 
outcome of T cell activation, and the decision to induce Foxp3 and 
regulatory properties. Several reports have shown that the mucosal 
surfaces have a role in establishing an iTreg population: alveolar epithelial 
cells have been reported to participate in iTreg induction in a mechanism 
dependent of MHC class II expression and TGF-β [61]. Both alveolar and 
gut epithelia have been shown to depend on retinoic acid together with 
TGF-β to induce tolerance [62, 63]. It was also found that retinoic acid in 
the presence of TGF-β impaired STAT6 binding to the Foxp3 promoter 
therefore enhancing histone acetylation and reverting the repressive the 
effect of IL-4 on the Foxp3 promoter[64].  
Despite the critical role of TGF-β in iTreg induction and henceforth 
tolerance, this cytokine can also have some adverse effects since it is 
instrumental in the differentiation of Th17 and Th9 together with IL-6 and 
IL-4, respectively [65, 66]. Note that although Treg cells can prevent allergic 
autoimmune encephalomyelitis (EAE), a disease promoted by Th17 cells, 
mice with T cells with a dominant negative receptor for TGF-β1 do not 
develop EAE as Th17 cells are not induced [67]. Moreover, TGF-β has also 
been implicated in tissue remodeling, by induction of collagen expression 
in fibroblasts, as well as goblet cell proliferation and mucus production 
[68]. 
 
Introduction 
Page 28  Ana Água-Doce  
 
Regulatory T cells and IL-10 
 
Although TGF-β is the major known driver of iTreg differentiation, 
IL-10 has been shown to be another key player that has been vastly 
described in protection from allergic diseases [69]. 
Studies with bee venom specific immunotherapy have shown that 
tolerance to the allergen can be induced in a process that is IL-10-mediated 
[70]. In addition, respiratory exposure tolerance induction to OVA relied on 
antigen specific CD4+regulatory cells that produced IL-10 [71]. Tolerance 
was transferrable and abrogated when IL-10 or ICOS ligand was blocked. 
Interestingly, those regulatory cells shared some features with effector Th2 
cells: both populations expressed IL-4 and IL-10 although in different 
amounts. While the regulatory cells primarily release IL-10, the effectors 
rely on IL-4 as the main cytokine. It has been suggested that different types 
of effector cells, including Th2, produce IL-10 at the end of the immune 
response in a mechanism that is important in limiting their inflammatory 
behavior [72]. IL-10 producing T cells have been described able to control 
the late response in allergic asthma by reducing neutrophilia [73]. It has 
been suggested that Foxp3-negative IL-10 producing T cells, can be 
induced following activation in presence of IL_10, and constitute a 
population of regulatory cells different from Foxp3+ Tregs that are named 
TR1 [74, 75]. TR1 cells have been identified in mice and humans, and there 
are currently clinical trials [39, 76]. There are several other lines of 
evidence demonstrating the crucial role of IL-10 in the prevention of 
airway inflammation: IL-10-deficient mice have an exacerbated allergic 
airways response with high levels of pro-inflammatory cytokines like IL-5 
and IFN-γ in the BAL [77]. Furthermore, intranasal administration of rmIL-
10, concurrently with OVA, inhibited both airway neutrophilia and 
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eosinophilia [78]. It was also shown that allergen-specific CD4+CD25+ Tregs 
can suppress allergic airway disease in vivo through an IL-10-dependent 
mechanism [48]. In this study, adoptive transfer of Treg cells reduced AHR, 
Th2 and eosinophil recruitment into the airways, and secretion of Th2-type 
cytokines. The effect was IL-10 mediated, since neutralizing anti–IL-10R 
abrogated suppression. In addition, these effects were independent of IL-
10 production by the CD4+CD25+ regulatory cells themselves [48]. 
Unlike TGF-β, IL-10 does not directly influence B cell class switch 
[79]. However it is possible that indirectly, by inhibiting the inflammatory 
response, IL-10 shapes the humoral outcome. Indeed, it was proposed that 
IL-10 may favor the ratio of IgG4/IgE ratio [80]. In fact immunotherapy 
studies show that Th2 responses can be suppressed by IL-10 secreting 
regulatory cells accompanied by an increase of circulating IgG4 [81, 82]. 
Different subsets of regulatory T cells 
 
Foxp3+ Treg cells, despite an apparent phenotypic uniformity and 
immunosuppressive function, can have different subtypes with distinct 
genetic signatures. The first major division was identified between nTreg 
and iTreg, where the first are enriched in Helios, a transcription factor that 
is primarily expressed in T-lineage cells and early precursors [83, 84]. While 
nTreg cells have epigenetic mechanisms that stabilize Foxp3 expression 
allowing them to be a stable differentiated cell lineage, TGF-β induced 
Tregs lack those mechanisms having incomplete demethylation of the 
Foxp3 gene [31]. Therefore, although iTreg cells have high levels of Foxp3, 
the expression of Foxp3 is less stable [31, 85, 86]. In addition, conserved 
non-coding DNA sequence (CNS) elements at the Foxp3 locus encode 
information defining the size, composition and stability of the Treg cell 
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population [87]. CNS3, which binds c-Rel, has a drastic effect on the 
frequency of Treg cells generated in the thymus. Contrary to CNS3, CNS1 
has no effect on thymic generation of Treg cells but is essential for 
induction of iTregs [87]. CNS1 contains a TGF-β–NFAT response element, 
so these results could represent the requirement of TGF-β and NFAT for 
Treg induction in the periphery [87-89]. Although CNS2-deficient T cells can 
acquire Foxp3 expression, they fail to maintain Foxp3 expression on their 
progeny due to the failure on recruitment of Foxp3–Runx1–Cbf-β 
complexes to CNS2 after demethylation of the CNS2 CpG island [87, 90]. 
Interestingly CNS1 deficient mice had no lymphoproliferative disorder. 
However, it can be argued that these animals kept in clean facilities have a 
minimal exposure to foreign antigens and thus nTreg may be sufficient to 
maintain homeostasis in such conditions. In effector T cells, GATA-3 is a 
hallmark of the Th2 cells, but Treg cells can also express GATA-3, that binds 
both to the Th2 cell locus and to the CNS2 of Foxp3 locus [91]. In fact, 
there is a dramatic increase of GATA-3 binding to CNS2 compared to 
conventional T cells, suggesting that GATA-3 regulates CNS2 activity in Treg 
cells [91]. 
There is strong evidence that the CCR7-dependent continuous 
migration of DC from the lung to its draining LNs is required for the 
transport of inhaled Ag and thereby for the proper composition of APCs in 
the LN. These processes are essential to induce peripheral tolerance of T 
cells [92]. The co-stimulation with ICOS, crucial for regulatory phenotype 
polarization in allergy[93], promotes the down-regulation of CCR7 and 
CD62L after activation, leading to a reduced return of activated CD4 T cells 
to the lymph nodes and a more efficient entry into the lungs[94]. 
Regulatory T cells express CCR4 and CD103 induced by antigen-driven 
activation in the lymph nodes. In addition, the accumulation of Tregs in the 
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skin and lung airways is impaired in the absence of CCR4 expression [95]. 
Mice without CCR4 in the Treg compartment develop lymphocytic 
infiltration and severe inflammatory disease in the skin and lungs [95]. 
Some studies suggest that CCR4 has a prominent role in effector Th2 
homing [96]. Despite their differences it seems both regulatory and 
effector T cells share the response to homing factors [97, 98]. 
But GATA-3 is not the only transcription factor characteristic of 
effector T cell responses that can be expressed by Foxp3+ Treg cells. Under 
the influence of IFN-γ, Foxp3+ Treg cells can express the Th1-defining 
transcription factor T-bet [99]. T-bet expression by Foxp3+ Treg cells 
induces the expression of the chemokine receptor CXCR3, necessary for 
these Treg cells to accumulate at the site of type-1 inflammation. T-bet 
expression was thus required for the homeostasis and function of Treg 
cells during type-1 inflammation [99]. 
It is likely that the regulation of different types of immune 
response require the participation of specialized subsets of regulatory 
cells. This way, iTreg cells induced in an environment favorable to Th1 or 
Th2 type of immune responses, require the appropriate chemokine 
receptors to give them access to the same locations as effector T cells 
(Figure 2).  
Th17 cells that have been implicated in autoimmunity and allergy 
share with iTreg cells the need for TGF-β to differentiate [100]. The 
decision of antigen-stimulated cells to differentiate into either Th17 or 
iTreg depends on the cytokine balance of IL-6, IL-21 and IL-23 that relieve 
Foxp3-mediated inhibition of RORγt [101]. These results indicate that 
Foxp3 and RORγt are transcription factors that antagonize each other in 
the lineage differentiation. 
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Figure 2. Differentiation of effector and regulatory T cells under the 
influence of different cytokines.  
Different types of immune responses carry different cytokine 
microenvironments that can influence both effector and regulatory T cell 
differentiation. Like the effector T cells, regulatory T cells can also display different 
molecules on their surface that will allow them to migrate to the inflammation 
site. Although this seems to be a feature mostly associated with iTregs, the Tfregs, 
whose precursors are nTregs, also change their chemokine receptor profile in 
order to enter the follicles and exert their regulatory functions. 
 
Another subset of T cells, the follicular T helper cells (Tfh), is mostly 
spatially confined to secondary lymphoid organs, more precisely to the B 
cell follicles [102]. Tfh cells express high levels of the transcription factor 
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Bcl-6, that impairs the expression and function of other transcription 
factors specific for other CD4 subsets: Tbet, GATA3, and RORγt, thereby 
regulating cytokine production by Tfh cells [103, 104]. Tfh cells 
differentiate under the influence of ICOS: ICOSL and IL-21 but 
independently of any other cytokine [105]. In addition, the characteristic 
anatomical distribution of Tfh cells is dependent of CXCR5 that endows 
access to the B cell follicle [102, 106, 107]. It has been recently found that 
also this subset of effector T cells has a specialized regulatory counterpart 
[98, 108, 109]. It was found that Foxp3+ Treg cells can be found within the 
B cell follicle [110], sharing many characteristics of Tfh and Treg cells [98, 
108, 109]. Importantly,  
Bcl-6 can be co-expressed with Foxp3 as it seems Foxp3 expression 
is not inhibited by Bcl-6.  These follicular regulatory T cells (Tfr) are 
immune-suppressive and can control de magnitude of the germinal center 
response [98, 108, 109]. In addition, they exhibit a CTLA4hiGITRhiIL-10hi 
phenotype that is characteristic of activated Tregs [98, 108, 109]. However, 
the Tfr origin is quite distinct from the other induced Treg cells previously 
described. Tfr cells do not derive from the commitment of conventional 
CD4 T cells, but result from acquisition of “follicular” characteristics 
(namely Bcl-6 expression) by natural Foxp3+ Treg cells[98, 108, 109]. In fact 
sorted Tfh cells exposed to optimal conditions to induce Foxp3 expression 
in conventional T cells (including TGF-β) resist conversion to Tfr  [108] . 
Given the importance of the germinal center response for allergy, it is likely 
that Tfr cells can play an important role in regulating IgE production. 
Besides conventional T cells, also natural killer T (NKT) cells are 
important players in defining the outcome of immune responses. Notably, 
invariant NKT (iNKT) cells were found able to help B cell differentiation, 
germinal-center formation, affinity maturation and immunoglobulin 
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response that was uniquely dependent on iNKT cell–derived IL-21, 
although the GCs maintain a small size throughout the reaction [111, 112]. 
This contribution of iNKT cells for humoral responses can be added to their 
ability to contribute to allergic airways diseases by producing IL-4 and IL-13 
[113, 114], or IL-17[115, 116]. But iNKT cells can also have a regulatory 
role, namely in preventing 
EAE following administration of its TCR agonist [117, 118]. We and 
other recently described that activation of murine or human iNKT cells in 
presence of TGF-β induces Foxp3 expression and acquisition of suppressive 
function [117, 119].  
 
Influencing regulatory T cells in allergy 
 
The understanding of the mechanisms involved in regulatory T cells 
generation and function may lead to novel strategies to restore immune 
tolerance where it has been lost. As TGF-β and IL-10 play a crucial role in 
tolerance induction, several studies on immune tolerance induction took 
advantage of environments rich in those anti-inflammatory cytokines. To 
our advantage the mucosa itself is an anatomical location rich in these 
immune mediators [120].  
Airborne antigens can be transferred from the mother to the 
newborn through milk [121]. Breastfeeding-induced tolerance was found 
to be mediated by induced Foxp3+ Treg cells and dependent on TGF-β 
[121]. On the other hand it has been proposed that metallo-matrix 
proteases, derived from commensal bacteria in the gut, can facilitate the 
conversion of latent TGF-β to its active form, thus favoring iTreg 
differentiation [122]. In addition, CD103+ dendritic cells in the mucosa-
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draining lymph nodes have been shown effective in promoting conversion 
of iTregs in the gut, mediated by TGF-β and the synthesis of retinoic acid, a 
powerful inducer of Foxp3 expression [62, 123, 124]. Furthermore, vitamin 
D receptor deficient mice were associated with a reduction in tolerogenic 
CD103+ dendritic cells favoring the development of effector type T cells 
[125]. Vitamin D3 can be used to induce human and mouse naive CD4+ T 
cells to differentiate in vitro into regulatory cells that produced only IL-10, 
but no IL-5 and IFN-γ, and furthermore retain strong proliferative capacity 
[126]. Several other studies put vitamin D3 in relevance as acting directly 
on T cells to induce IL-10+ regulatory cells and also influencing levels of 
TGF-β [127-129]. These data suggest that the mucosa, in particular the gut, 
has several mechanisms that can favor immune tolerance. Sublingual 
immunotherapy (SLIT) and oral immunotherapy (OIT) are becoming more 
relevant as effective tolerance-inducing strategies to treat inhalant as well 
as food allergies [130].  
Allergen specific immunotherapy (SIT) which comprehends of SLIT, 
OIT and subcutaneous immunotherapy (SCIT) has been in clinical use for 
around 100 years [131] and consists on the administration of increasing 
doses of an allergen [132]. It has been shown that both Foxp3+ and IL-10 
positive regulatory T cells can be induced during the course of SIT 
protocols [133, 134]. Furthermore, allergen-specific TR1 cells, in healthy 
individuals, have been suggested to play a key role in preventing 
pathologic responses [82, 131, 135]. While the presence of IL-10 leads B 
cells to produce IgG4 in detriment of IgE [136, 137], TGF-β drives B cells to 
switch to IgA production [135]. Another approach to direct the organism 
towards a tolerant state arises from the results that suggest that reduced 
TCR stimulation favors the induction of a regulatory phenotype on the T 
cells [56, 138, 139]. Blockade of molecules involved in the immune synapse 
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has been suggested as an approach to achieve suboptimal TCR activation 
[56, 139]. Blockade of CD4 was shown a robust approach to achieve Treg-
mediated dominant tolerance in transplantation [140-142]. The realization 
that active regulatory mechanisms, such as the ones mediated by Treg 
cells, can prevent pathological immune responses to harmless antigens is 
changing the way immunotherapy is perceived. In very diverse fields of 
immunology, ranging from cancer immunotherapy to autoimmunity and 
allergy, regulatory mechanisms need to be considered when therapeutic 
interventions are designed to boost or dampen the immune response. The 
realization that different subsets of regulatory T cells exist may offer the 
possibility to fine tune such interventions in order to achieve optimal 
therapeutic benefit with limited immunosuppressive consequences in 
unrelated immune responses. 
At a time when therapeutic interventions rely increasingly in 
potentially immunogenic drugs – such as recombinant proteins to correct 
genetic diseases or monoclonal antibodies, where even the human 
antibodies can be immunogenic due to their unique idiotypes [143, 144], 
the issue of tolerance induction to non-self antigens will not be restricted 
to allergy and transplantation, but a growing concern for drug efficacy. 
 
Induction of Dominant Tolerance Using Monoclonal 
Antibodies 
 
Ever since the description of classical transplantation tolerance by 
Medawar and colleagues [145], the attainment of clinical transplantation 
tolerance has been considered the “Holy Grail” of immunology. Two 
decades have passed since the initial demonstration that long-term 
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transplantation tolerance can be induced following a brief treatment with 
monoclonal antibodies (MAb)[146-148] and that tolerogenic anti-CD4 MAb 
can be used to treat EAE [149]. However, the mechanisms by which 
tolerance is induced and maintained are not yet fully understood. In recent 
years it has become clear that antibody induced transplantation tolerance 
leads to both deletion of some alloreactive clones and regulatory T cells 
cell expansion [38, 150]. 
In the first examples of peripheral tolerance induced with MAb, 
depleting anti-CD4 MAb was used to induce tolerance in mice to foreign 
immunoglobulins [146, 147]. It was soon demonstrated that depletion of 
CD4+ T cells was not required for tolerance induction, as similar results 
were obtained using Fab’2 fragments [151, 152], non-depleting isotypes 
[153]or non-depleting doses of synergistic pairs of anti-CD4 MAb [154]. In 
other studies a brief treatment with anti-CD4 MAb was also shown to lead 
to long-term acceptance of skin grafts differing in multiple minor antigens 
[153], even in pressensitized recipients [155]. The same results were also 
demonstrated for heart grafts across major histocompatibility complex 
(MHC) barriers [156, 157] or concordant xenografts [156]. The treated 
animals accepted the transplanted tissues indefinitely without the need for 
immunosuppression, and remained fully competent to reject unrelated 
(third-party) grafts. Clearly the antibody treatment had rendered them 
tolerant to antigens belonging to the transplanted tissue (see Fig. 3). 
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Figure 3. Induction of transplantation tolerance with monoclonal antibody 
(MAb). Mice transplanted under the cover of tolerogenic MAb accept skin grafts 
indefinitely. To demonstrate that mice are indeed tolerant, one can simultaneously 
transplant a new graft of the tolerized type and graft an unrelated third-party 
donor, showing that tolerant mice remain fully competent to reject latter. 
Following these studies, it became clear that MAb, other than anti-
CD4, could be used to impose peripheral transplantation tolerance (see 
Table 2). Tolerance induced with MAb, such as CD4 or CD154 (CD40-
Ligand), is dependent on Treg cells both CD4+CD25+ and CD4+CD25- [158]. 
These Treg cells can be demonstrated both within lymphoid tissue and 
infiltrating the tolerated transplant [159]. The dominant tolerance state, 
maintained by the Treg cells, allows the immune system to resist the 
adoptive transfer of non-tolerant lymphocytes without tolerance break 
down [153, 160]. In addition, adoptively transferred non-tolerant 
lymphocytes are rendered tolerant and regulatory when allowed to coexist 
with the initial cohort of Treg cells—a process usually referred to as 
infectious tolerance [142, 161, 162]. The dominant tolerance state can be 
extended through linked suppression to additional antigens, if those new 
antigens are provided genetically linked with the tolerated ones within a 
new transplant [141, 161, 163, 164]. 
In addition to tolerogenic antibodies, several experimental 
procedures may be used to facilitate tolerance induction.  
Such is the case with the administration of donor bone marrow 
(BM), or donor blood (donor- specific transfusion [DST]). The elimination of 
cell populations that may create an obstacle to graft survival with weak 
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tolerogenic antibodies is also commonly used. Such is the case for CD154 
tolerogenic antibodies, able to induce dominant tolerance within the CD4+ 
T cells, but when used alone cannot prevent skin graft rejection mediated 
by CD8+ T cells [164, 165]. As a consequence, CD8 depletion is often used 
when the tolerogenic properties of CD154 MAb are studied. 
Tolerogenic MAbs have been also used to reprogram the immune 
system in animal models of autoimmune diseases [166]. However, it has 
been more difficult to confirm that the tolerant state, so induced, is 
dominant and mediated by Treg cells than in the context of 
transplantation, as experiments with third-party antigens are harder to 
conduct. Nevertheless, the characterization of the phenotype of the 
dominant Treg population in maintaining self-tolerance as being 
CD4+CD25+Foxp3+ has permitted the confirmation that tolerogenic MAbs, 
such as the ones directed toward CD3, can prevent autoimmunity by 
eliciting Treg cells that maintain the tolerant state in a dominant manner 
[167]. As a consequence, it appears that MAbs, known to be able to induce 
dominant transplantation tolerance, may also restore dominant self-
tolerance in autoimmunity.  
 
Induction of tolerance in allergic respiratory disorders 
with MAb. 
 
The advances in the knowledge about the allergic disease have 
empowered researchers to pursue new therapies within the 
immunomodulatory agents. The complicated network of cells and 
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molecules involved in the Th2 response has given several opportunities 
that are being explored towards the treatment of diseases such as allergic 
asthma [168, 169]. 
 
 
Figure 3. The complex network of the allergic airway sensitization. The 
antigen recognized by the Toll-like receptor 4 (TLR4) induces the tissue to release 
cytokines that promote not only dendritic cell (DC) maturation but also T cell 
differentiation from nuocites (ILC) [170] and recruitment of innate immune cells 
like mast cells and basophils. The Th2 cell will later recruit more innate cells like 
the eosinophils by the release of IL-5, and promote B cell differentiation into a 
plasma cell that releases immunoglobulins that potentiate and perpetuate the 
disease. IgE and IgG1 can bind and activate mast cells and basophils by means of 
the FcξRI [171-173] triggering the release of histamine that can affect several cell 
types in immune and non-immune systems [174]. 
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Most strategies rely on either blockade of cytokines or blockade of 
co-activators and co-stimulators molecules (see table 1). The majority of 
the research developed has had positive results and is now in clinical trials 
[169]. There is little evidence however in the literature on how these 
therapies affect the regulatory T cell population. The IL2:Anti-IL-2 MAb is 
described to promote an IL-10 secreting Foxp3+ T cell population that 
effectively induces tolerance in allergic airway disease [175]. We recently 
shown that a non-depleting anti-CD4 monoclonal antibody can induce in 
mice robust, antigen-specific tolerance to house dust mite, even in pre-
sensitized animals [46]. In addition, a similar strategy was effective to 
prevent peanut-induced anaphylaxis in mice [176]. Co-stimulation 
blockade was also shown to be effective in preventing allergic sensitization 
in mice. Regarding the different modalities for co-stimulation blockade, on 
one hand CTLA4Ig was shown able to greatly reduce the secretion of IL-4 
but not enough to impair Th2 response [177]. On the other hand, 
treatment with OX40L-blocking MAbs inhibited to some extent allergic 
immune responses induced by TSLP in the lung and skin, preventing Th2 
inflammatory cell infiltration, cytokine secretion and IgE production in mice 
and nonhuman primate models of asthma [178]. [179]. Based on previous 
studies of tolerance induction to alloantigens following co-stimulation 
blockade, it is likely the mechanism also relies on Treg cells [162, 180]. 
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Table 1. Immunomodulatory MAbs used in allergic pathologies 
Antibody Target Effect Reference 
IL-2:anti-IL2 Prophylactic and tolerogenic [175]  
IL-4 Is prophylactic in AHR but no effect in eosinophilia [181, 182] 
IL-5 Anti-inflammatory [182, 183] 
IL-13 Prevents progression in established disease [184, 185] 
IL-25 Prophylactic and anti-inflammatory [186] 
IL-33 Anti-inflammatory [187] 
TSLP Anti-inflammatory [188] 
LFA-1 Prophylactic [189, 190] 
CD4 Prophylactic and prevents progression of established 
disease 
[46] 
CD23 Anti-inflammatory [191, 192] 
OX40L Prophylactic [178] 
CD40 Has a prophylactic role when administered together 
with CTLA4Ig 
  
[179] 
CTLA4Ig Together with anti-CD40L is prophylactic [177] 
CD147 Anti-inflammatory [193] 
CCR3 Ablate eosinophilia in established AHR [194] 
TIM-1 Anti-inflammatory [195] 
TIM-3 Prophylactic [196] 
TNF Prophylactic [197] 
4-1BB/4-1BBL Prophylactic and anti-inflammatory [198-200] 
IgE Prophylactic  [201, 202] 
TACI-Ig Prophylactic [203] 
 
Nevertheless blockade of cytokines is more effective in the 
prevention of Th2 inflammation rather than the induction of Treg cells. 
Apart from the IL2: Anti-IL-2 none of the other studies targeting cytokines 
shows an effect on regulatory populations. In these cases it is important to 
take into account that the blocking antibody is present at the time of 
inflammation thus removing an important intervenient of the 
inflammatory process. IL-33 is not directly involved in the inflammatory 
process but rather on the very early process of sensitization[204, 205] 
orchestrating innate and adaptive immunity in a unique fashion via 
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basophils, mast cells, eosinophils, innate lymphoid cells, NK and NKT cells, 
nuocytes, Th2 lymphocytes and a CD34+ precursor cell population[204]. It 
would be interesting to see if the anti-IL33 is able to induce a regulatory 
population, perhaps through a modulatory effect on the DCs. Some 
immune modulators like the anti-TIM-3 and anti-4-1BBL show a remarking 
increase in the levels of IFNγ [196, 199] suggesting a Th1 deviation [196] as 
the mechanism of regulation of a Th2 response. 
 
Induction of transplantation tolerance with MAb. 
 
Most animal studies have been performed in mice, although rats 
and nonhuman primates have been tolerized to foreign antigens and 
transplants with MAb. Transplant rejection or tolerance does not depend 
exclusively on the degree of mismatch between host and donor. Different 
strains of mice exhibit distinct behavior concerning the capacity to reject or 
become tolerant to transplants [206, 207], which may be further 
modulated upon exposure to infectious microorganisms. Active viral 
infection, with lymphocytic choriomeningitis virus (LCVM), at the time of 
tolerance induction with costimulation blockade and DST can prevent the 
effectiveness of the tolerization treatment leading to graft rejection [208-
210]. However, this effect seems to be virus-specific, with some viral 
infections (e.g. murine cytomegalovirus and vaccinia virus) not leading to 
graft rejection [209]. A persistent viral infection with lymphocytic 
choriomeningitis virus clone 13 can also prevent the establishment of 
transplantation tolerance with a costimulation blockade-based regimen, 
and the antibody treatment can prevent an effective antiviral immune 
response [210]. Furthermore, the persistence of memory T cells elicited by 
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prior exposure to infectious agents has been reported as a barrier to the 
induction of transplantation tolerance, even in the absence of concomitant 
infection [211]. This phenomenon is generally known as heterologous 
immunity. An explanation for these findings may be the cross-reactivity 
between viral and transplantation antigens [209, 212]. However, these 
obstacles do not seem to be complete. With coreceptor blockade, instead 
of costimulation blockade, it has been possible to induce tolerance to 
allografts in mice or rats previously primed to donor antigens [155, 157]. In 
addition, infection of tolerized mice (with anti-CD4+ DST) with murine 
influenza PR8, at d 7 following heart transplantation, did not lead to 
impaired antiviral responses or to graft rejection [213].  
 
Table 2. Therapeutic MAb Used to Induce Transplantation 
Tolerance 
Antibody Target Transplantation Reference 
CD2 Delayed rejection of islet allografts and xenografts [214] 
CD3 Tolerance to hearts allografts [215] 
CD3+CD2 Long term acceptance to heart grafts [216] 
CD4 Tolerance to antigens [153, 217] 
CD4+CD8 Tolerance to minor mismatched skin, MHC-mismatched and 
xenogeneic heart grafts 
[153, 161] 
CD4+CD8+CD154 Tolerance to MHC-mismatched skin [141] 
CTLA4-Ig Xenogeneic pancreatic islets [218] 
CD45RB Long term survival of MHC mismatched islets and kidney 
transplants 
[219, 220] 
CD45RB+CD154 Long term survival of MHC-mismatched skin [221] 
CD134(OX40L) Long term survival of minor mismatched heart allografts [222] 
CD134L+CTLA4-Ig Long term acceptance of MHC-mismatched hearts grafts [223] 
CD154 MHC-mismatched pancreatic islets [224] 
CD145+CD8dep Tolerance to minor mismatched skin [162, 164] 
CD154+CTLA4-Ig Long term acceptance of MHC mismatched skin  [225, 226] 
LFA-1 Tolerance to soluble antigens [152] 
LFA1+ICAM-1 Long term acceptance of MHC-mismatched hearts grafts [227] 
IL-2+IL-15 Ig Long term acceptance of MHC-mismatched islets in diabetic 
NOD mice 
[228] 
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 In general, the hierarchy of strains, from the easiest to tolerize to 
the most difficult, is as follows: C3H, CBA/Ca, DBA/2, BALB/c, and C57Bl/6. 
Apparently, these properties are not primarily due to the MHC molecules 
present in each strain. For instance, B10.BR mice, expressing identical MHC 
molecules to CBA/CA mice, are as difficult to tolerize as C57Bl/6 with 
whom they share only minor antigens[206] . The genetic basis of strain 
variability is still unknown. 
Several studies have used T-cell receptor (TCR) transgenic animals, 
where all T cells share the same TCR. Even in these mice, it has been 
possible to use MAb, such as non-depleting CD4 or CD154, to induce a 
state of dominant tolerance where the de novo peripheral generation of 
Treg cells can be demonstrated [217]. It should be noted that prior to 
tolerization, these TCR-transgenic animals have no demonstrable 
CD4+CD25+Foxp3+ Treg cells. 
The capacity to accept a transplant also depends on the graft itself. 
In general, the greater the genetic disparity between donor and recipient, 
the more difficult it becomes to prevent rejection. The donor strain itself 
may also contribute to different outcomes in terms of tolerance. For 
example, BALB/c grafts are harder to tolerize than C57Bl/6 grafts in CBA/Ca 
recipients [141, 229]. In addition, different organs have been shown to 
have distinct requirements for succumbing to tolerance induction [230, 
231]. Vascularized grafts are, in general, more easily accepted than non-
vascularized grafts, such as skin. Acceptance of the liver is relatively easy to 
achieve, with many different liver allografts being spontaneously accepted 
by permissive strains without any treatment [232]. Kidney allografts are 
also occasionally spontaneously accepted in rodents, although not as 
consistently as liver [231]. In contrast, pancreatic islets and heart allografts 
are usually rejected in the absence of therapeutic intervention. It should be 
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noted that in diabetic animals, such as non-obese diabetic (NOD) mice, it is 
more difficult to induce tolerance to islet allografts presumably because a 
primed autoimmune response must be overcome in addition to the 
allogeneic barrier [228, 233]. The rejection of small intestine seems to be 
more vigorous than the above mentioned organs [231, 234]. However, skin 
grafts are even more difficult to tolerize as some treatments, capable of 
preventing rejection of heart allografts, are ineffective in inducing long-
term survival of skin allografts[235-238]. It is known that both CD4+ and 
CD8+ T cells can contribute to skin graft rejection, with each population 
capable of rejecting grafts independently [217]. 
Several antibodies and fusion proteins have been shown to be 
effective at inducing dominant transplantation tolerance, either on their 
own or in combination (see Table 2). It is interesting to note that virtually 
all MAb able to induce peripheral tolerance, target molecules involved in 
the formation of the immune synapse: the coreceptor molecules CD3, CD4, 
and CD8 [153, 216]; CD45RB [219]; the costimulatory molecules CD154 and 
CD28 [218, 224, 226]; and the adhesion molecules leukocyte function-
associated antigen 1 and intercellular adhesion molecule-1 [152, 227]. It is 
thus possible that tolerance induction requires T-cell activation under 
suboptimal conditions, i.e., in the presence of reagents that interfere with 
efficient T-cell activation, although this does not extend to conventional 
immunosuppressive agents [139]. It has been reported that successful 
induction of dominant tolerance following coreceptor blockade leads to 
expansion of Treg cells [162], and elimination of alloreactive cells through 
activation-induced cell death [225, 239]. Some conventional 
immunosuppressive drugs, such as corticosteroids and calcineurin 
inhibitors like cyclosporine-A and tacrolimus, by preventing T-cell 
activation and activation-induced cell death can abrogate the induction of 
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dominant tolerance [225, 239-241]. The use of donor BM to induce 
tolerance by deletion of alloreactive clones does not seem to be affected 
by those drugs [211]. Other immunosuppressive drugs, such as rapamycin 
or mycophenolate mofetil, do not seem to prevent tolerance induction and 
may be useful in addition to the tolerogenic MAb [225, 241]. The impact 
of the novel immunosuppressant FTY720, which induces a reversible 
sequestration of T cells in secondary lymphoid organs, in tolerance 
induction has not been established [242]. Given that Treg cells can be 
found in tolerated allografts[159] , it will be important to assess whether 
the impact on T-cell migration may prevent the onset of dominant 
tolerance. 
Induction of Tolerance With MAb in Autoimmunity 
 
The use of MAb to restore the state of dominant regulation has 
been tested in several animal models of autoimmune and immune-
inflammatory dis-ease. Some of the most common examples are listed in 
Table 3. Such animal models can be divided into three broad categories: (1) 
animals developing the dis-ease spontaneously, (2) animals where the 
disease is induced experimentally, and (3) TCR-transgenic animals where 
most or all the T cells are specific for a self-antigen. It should be noted that 
some animals, initially described as developing an autoimmune disease 
spontaneously, were later found to develop the disease following an 
environmental challenge. This is the case for SKG mice, carrying a mutation 
of the ZAP-70 gene, that develop chronic autoimmune arthritis with 
features closely resembling rheumatoid arthritis (RA) [7]. In spite of initial 
reports suggesting that autoimmune arthritis was spontaneous, it was 
recently shown that the disease is triggered by Dectin-1 agonists such as 
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zymosan [243]. It is also important to note that the immune systems of 
most animals used in animal models of autoimmune disease behave as 
lymphopenic [244]. Lymphopenia is a common feature in animal models of 
autoimmunity, appearing to be associated with the breakdown of 
tolerance [244]. In transplantation experiments it was shown that T-cell 
depletion in advance of treatment with costimulation blockade + DST 
constituted a barrier for tolerance induction [223]. Apparently, this effect 
is because of the acquisition of functional memory T cells [245]. It remains 
to be established whether tolerizing regimens, successful in inducing 
tolerance in pressensitized recipients [155, 157], will remain effective 
when used with lymphopenic animals.  
Some of the most common animal models of autoimmune 
pathology are as follows: 
Autoimmune diabetes: NOD mice spontaneously develop insulin-
dependent diabetes and are a model of type I diabetes mellitus. Disease in 
these animals, as in humans, appears to be of autoimmune etiology that is 
heavily influenced by both genetics and environment [221, 246]. The 
similarity between diabetes in the NOD mice and humans is extensive, 
including the influence of sex on the incidence of disease: whereas about 
80% of female mice at 6 months of age are diabetic, only 20% of males 
develop the disease [247]. BB rats also develop autoimmune diabetes 
spontaneously but, as in humans, the disease incidence is similar in both 
sexes and not affected by gonadectomy or androgen administration [248]. 
The immune system of these rats is severely lymphopenic. Another rat 
model of diabetes is the LEW.1WR1 rat (RT1u/u/a) where the disease occurs 
spontaneously with a cumulative frequency of approximately 2% at a 
median age of 59 d. Both sexes are affected, and islets of acutely diabetic 
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rats are devoid of β cells whereas α and δ cell populations are spared 
[249]. 
 
Table 3. Animal Models of Autoimmune Diseases 
 Associated human disease Reference 
Mouse models   
Spontaneous   
NOD Type 1 diabetes [221] 
NZBXNZW SLE [250] 
MRL/lpr SLE [251] 
K/BXN RA [225, 252] 
T/R- (TCR transgenic to MBP) MS [253] 
Induced   
DBA/1+Type II collagen in IFA RA [254-256] 
SKG+Dectin-1 agonists RA [7, 243] 
BALB/c + Spinal cord homogenate in CFA MS [257] 
SJL + PLP in CFA MS [258] 
SLJ + Thyroglobulin in CFA Autoimmune Thyroiditis [259] 
Rat models   
Spontaneous   
BB/wor Type 1 diabetes [260] 
Komeda diabetes-prone (KDP) Type 1 diabetes [261] 
Lewis (LEW.1AR1/Ztm) Type 1 diabetes [262] 
Induced   
Lewis + retinal pigment epithelium-
specific 65-kDa protein peptides 
Autoimmune uveitis [263] 
Lewis + MBP in CFA MS [264] 
Wistar + MBP in CFA MS [231] 
Wistar + testis homogenate Autoimmune orchitis [265] 
CFA, Complete Freund’s Adjuvant; IBD, Inflammatory Bowel Disease; IFA, Incomplete 
Freund’s Adjuvant; MBP, Myelin Basic Protein; MS, Multiple Sclerosis; RA, Rheumatoid 
Arthritis; SLE, Systemic Lupus Erythematosus 
 
RA: the most commonly used animal models of autoimmune 
arthritis are mice and rats in which the disease is induced with type II 
collagen and incomplete Freund’s adjuvant [254-256]. In these cases, the 
disease usually affects larger joints of the limbs and is self-limited. K/BxN 
mice spontaneously develop a progressive joint-specific autoimmune 
disease between 3 and 5 wk of age. Pathology of disease in K/BxN mice is 
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similar to human RA, with pannus formation, synovial hyperplasia, 
increased synovial fluid volume, and chaotic remodeling of cartilage and 
bone in the distal joints in the later stages [225, 252]. SKG mice, harboring 
T cells more resistant to TCR stimulation, also develop chronic autoimmune 
arthritis. Although disease in K/BxN mice is mediated by antibodies and can 
be adoptively transferred to healthy recipients by transferring the serum, 
in SKG mice arthritogenic T cells are sufficient to cause the disease as their 
adoptive transfer into lymphocyte-deficient hosts triggers autoimmune 
arthritis [7]. 
Multiple sclerosis: EAE is characterized by T cell-mediated 
destruction of the myelin sheath in the central nervous system. Myelin 
basic protein, myelin/oligo-dendrocyte glycoprotein, and proteolipid 
apoproteins when administered with adjuvant to mice or rats can induce 
autoreactive T cells that cause the disease [258, 266, 267]. The same 
outcome has been reported following the administration of syngeneic 
mouse spinal cord homogenate in complete Freund’s adjuvant [257]. TCR 
transgenic mice in the RAG/- background, in which all T cells express a TCR 
directed to a myelin protein, spontaneously develop EAE with 100% 
incidence at 8 months [253, 268]. Interestingly, the disease is abrogated by 
the presence of additional CD4+ T cells from wild-type syngeneic mice 
[269, 270]. 
Systemic lupus erythematosus (SLE): MRL/lpr mice spontaneously 
develop a disease similar to SLE, because of defective apoptosis of 
activated B cells as the mice are deficient in Fas/FasL [250]. Other mouse 
strains, such as the NZB x NZW and the BXSB, also develop a SLE-like 
syndrome that appears to be influenced by multiple genes [250]. 
Several MAb have been tested for the treatment of autoimmune 
dis-eases. In many cases such MAb do not aim to restore tolerance but 
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rather to control the inflammatory process (such as the anti-tumor 
necrosis factor a or the anti-interleukin-1 MAb)[271], or induce 
immunosuppression by elimination of pathogenic lymphocyte populations 
(such as T-cell depletion with CAMPATH or B-cell depletion with anti-CD20) 
[272, 273]. However, tolerogenic MAb have also been reported to have a 
beneficial effect on the prevention or treatment of autoimmune 
pathology, although in many cases the true re-establishment of dominant 
self-tolerance based on T-cell regulation remains to be confirmed (see 
Table 4). 
CD3: therapy with nonmitogenic CD3 MAb has been shown to 
prevent and revert type 1 diabetes in NOD mice and in virus-induced 
autoimmune diabetes [274-276]. Different from most other tolerogenic 
MAb, anti-CD3 seems to be more effective if used after the onset of 
disease, apparently because activated T cells are the main targets of this 
treatment [275]. In autoimmune arthritis the use of this anti-body was not 
shown to be as effective as in type 1 diabetes, but in both systems, 
treatment causes a reduction in serum interferon-y and an increase in 
interleukin-4, interpreted as deviation to a Th2 response [277]. Anti-CD3 
MAb were also shown to lead to an increase in Treg cells able to suppress 
diabetogenic T cells and maintain a state of dominant tolerance [167, 278]. 
CD4: following initial reports showing a beneficial effect of anti-
CD4 on the treatment of EAE in rats [149], it has been shown prevent the 
onset of diabetes in NOD mice, as well as preventing pancreatic islet 
damage in recently established disease, with the animals tolerating islet 
trans-plants from prediabetic syngeneic donors or even islet allografts 
[208, 279-282]. The same MAb have also been shown to prevent the onset 
of experimental autoimmune arthritis as well as to ameliorate overt 
arthritis [283-285]. 
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Several other MAb, such as the ones targeting CD154, CTLA4-Ig, 
and CD134L, have been shown effective in preventing or treating several 
experimental autoimmune diseases (see Table 4). 
 
Table 4. Targets of Therapeutic MAb in Experimental 
Autoimmune Diseases 
MAb Animal/disease  Outcome Reference 
CD2 Lewis rats (EAM) Prevents onset [286] 
 Lewis rats (EAE) Prevents onset [287] 
 BB/wor rats  
(type 1 diabetes) 
Prevents onset [260] 
CD3 NOD mouse  
(type 1 diabetes) 
Ameliorates established disease [167, 274-276] 
 DBA/1 mouse (CIA) Delayed onset with reduced 
severity 
[277] 
CD4 NOD mouse  
(type 1 diabetes) 
Prevents onset [208, 279-281] 
 NZB/NZW mouse  
(murine SLE) 
Ameliorates established disease [288] 
 DBA/1 mouse (CIA) Prevents onset and ameliorates 
established disease 
[289, 290] 
CD30L NOD mouse  
(type 1 diabetes) 
Prevents onset [291] 
OX40L SJL mouse (EAE) Ameliorates established disease [258] 
 C.B-17 SCID (IBD) Ameliorates established disease [292] 
CTLA4-Ig BALB/c mouse (EAE) Ameliorates established disease [257] 
 NZB/NZW mouse  
(murine SLE) 
Prevents onset [293-296] 
 BXSB mouse (SLE) Delayed onset with reduced 
severity 
[297] 
CD154 Marmoset monkey  
(EAE) 
Prevents onset [298] 
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 B6/A (C57BL/6XA/J)  
(AOD) 
Prevents onset [299] 
 B10.BR mouse  
(EAU) 
Ameliorates established disease [300] 
 SJL mouse (EAT) Less severity [259] 
 NZB/NZW mouse  
(murine SLE) 
Prevents onset [292, 
301-303] 
CD40 Marmoset monkey  
(EAE) 
Prevents onset [304] 
CD137 DBA/1 mouse (CIA) Prevents onset [305] 
 NZB/NZW mouse  
(murine SLE) 
Ameliorates established disease [306] 
 C.B-17 SCID (IBD) Ameliorates established disease [307, 308] 
 C57BL/6 (EAE) Ameliorates established disease [267] 
LFA-1 NOD mouse  
(type 1 diabetes) 
Prevents onset [309] 
EAE, Experimental Allergic Encephalomyelitis; EAM, Experimental Autoimmune 
Myelitis; AOD, Autoimmune Ovary Disease; CIA, Collagen Induced Arthritis; EAU, 
Experimental Autoimmune Uveoretinitis; IBD, Inflammatory Bowel Disease; MS, 
Multiple Sclerosis; SLE, Systemic Lupus Erythematosus. 
 
MAb have been used either to prevent the onset of experimental 
autoimmune diseases, or to treat overt autoimmunity. It is usually 
assumed that newly formed T cells exported from the thymus create an 
obstacle for dominant tolerance maintenance. In some stringent 
experimental systems, the use of thymectomized animals can facilitate 
maintenance of the tolerant state [221]. Dominant tolerance, however, has 
been induced in either euthymic or thymectomized animals in many 
experimental systems, including stringent MHC-mismatched skin 
transplantation [141]. The presence of the thymus is required for the 
induction of tolerance based on mixed-chimerism, where thymic deletion 
of alloreactive clones occurs [310]. For the prevention of autoimmunity, 
animals are often treated from the neonatal period [299]. In some 
experiments, anti-CD3 MAb have been shown to be successful in treating 
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overt diabetes in NOD mice, restoring a state of dominant tolerance 
mediated by Treg cells [274, 275]: 
 
Tolerance vs. Immunosuppression 
 
Long-term allograft survival following MAb treatment does not 
prove dominant tolerance has been successfully induced. To demonstrate 
tolerance, it is necessary to confirm that the immune system is fully 
competent to mount a response against antigens other than the tolerated 
ones. Usually, a simultaneous transplant of tolerated-type and unrelated 
third-party grafts is used, to confirm that tolerant animals remain able to 
reject specifically the third-party transplant (see Fig. 4). 
 
The Antigen Specificity of the Tolerant State 
 
The putative antigen-specificity of the tolerant state is frequently 
demonstrated simply by grafting a third-party and a tolerated type 
transplant, and observing that only third-party grafts are rejected. 
However, given the possible differences in the “rejectability” of the 
different types of grafts (see Subheading 2.1.), such results should be 
approached with caution [38]. Ideally, these studies should be performed 
in crisscross experiments: mice should be tolerized, in independent 
experiments, to transplants of different types. Then both groups should be 
tested for capacity to reject the appropriate third-party grafts (see Fig. 4). 
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Figure 4. Crisscross experiment to demonstrate antigen specific tolerance. 
To account for possible strain variations in tissue “rejectability”, tolerance can be 
assessed in mice tolerized to two different strains. The antigen specificity of the 
tolerant state will determine that animals from both groups reject grafts from the 
third-party strain. The same sort of experiment can be used to test the antigen 
specificity of putative regulatory T cell populations following their adoptive 
transfer into lymphocyte-defined animals. 
 
Alternatively linked suppression can be used as an exquisite and 
straightforward assay for both specificity and the dominant nature of 
tolerance (see below). 
Dominant Tolerance 
 
A direct way to assess the dominant tolerance status of an animal 
is through the infusion of T cells with the capacity to reject the graft. In 
such a challenge, T cells obtained from the spleens of naïve animals can be 
used [153, 160]. If the transfused cells are allowed to coexist with the 
tolerant ones for 6 wk, it becomes possible to demonstrate that they 
themselves have been rendered tolerant by ablating the initial population 
of T cells with depleting MAb directed to a specific marker [142, 162]. This 
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recruitment of T cells toward a regulatory function is generally known as 
infectious tolerance. 
Instead of using T cells from naïve wild-type animals, it is possible 
to transfuse TCR-transgenic T-cells specific for the tolerized alloantigens 
[267]. This experimental setting allows the study of dominant tolerance 
effects on the cells being subjected to active regulation [267]. 
An alternative strategy to demonstrate dominant tolerance is to 
deplete putative populations of Treg cells, such as CD4+ or CD25+ T cells, 
unleashing aggressive cells to mediate rejection. It should be noted, 
however, that tolerizing treatments are often associated with a partial 
deletion of the alloreactive clones [225, 239]. In addition, besides the 
major populations of Treg cells (identified as CD4+CD25+ and CD4+CD25) 
other minor populations of Treg cells may persist. This seems to be the 
case for CD8+ or double negative (CD4 CD8 ) Treg cells [231, 311] in the 
light of which, it is not surprising that, in some cases, ablation of the major 
Treg cell populations—such as the CD4+ or the CD25+ cells—does not lead 
to the rejection of tolerized allografts. 
Linked suppression has been used as an efficient assay for 
confirmation of both antigen-specificity of tolerized animals and for the 
dominant state of tolerance [141, 312]. These experiments are based on 
the observation that, once dominant tolerance has been established to a 
set of antigens present in an allograft, new transplants with cells 
simultaneously expressing tolerated antigens and third-party antigens are 
not rejected (see Fig. 5) [163]. These data have been interpreted as 
evidence that Treg cells specific for the tolerated antigens actively 
suppress the aggressive cells directed to the “linked” third-party antigens. 
With time, those aggressive clones will themselves become tolerized, 
because animals start to accept transplants with the third-party antigens in 
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the absence of the tolerated ones. It should be noted that third-party 
grafts, where the tolerated set of antigens is absent, are readily rejected in 
control animals. Linked suppression has been demonstrated in situations 
where tolerance is induced with coreceptor blockade, costimulation 
blockade or a combination of the two [141, 163, 164]. 
 
 
Figure 5. Linked suppression. Animals tolerized to skin grafts of type A 
accept skin grafts from (AXB) F1 donors, where third part B antigens are 
endogenous to cells that also express A antigens (top row). However, B type grafts 
are readily rejected, even if a concomitant tolerated A type graft is given (bottom 
row). Furthermore, the animals that accept the (AXB) F1 grafts with the “linked” 
antigens become tolerant to grafts of the third party B type. 
 
Although MAb have been successful in inducing dominant 
tolerance in animal models of allergy, transplantation and autoimmune 
diseases, it will be important to investigate whether similar strategies can 
in different contexts give rise to different outcomes in specific regulatory 
populations. These experimental systems have been useful in 
understanding the biology of Treg cells and the suppressive mechanisms 
maintaining dominant tolerance. But besides such important contributions 
toward the basic understanding of the immune system and its regulation, 
there is a potential for clinical application of tolerogenic MAb. Besides the 
above immune disorders the use of MAb as immune modulators is now 
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being adopted, in the context of inhibitor generation in protein 
substitution therapies. Recent observations have shown that MAb 
equivalent to the ones used in murine studies can be successfully used to 
induce tolerance in primates [217, 240, 313]. Furthermore, a recent clinical 
trial has shown a beneficial effect of tolerogenic CD3 MAb in autoimmune 
diabetes [314]. There are, therefore, reasons for optimism concerning the 
clinical use of tolerogenic antibodies in human immune pathology. 
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Aims of the Thesis 
 
Over the years several strategies have been developed to induce 
immune tolerance in a range of immune pathologies. One reagent that has 
proven effective in inducing long-term tolerance in transplantation and 
autoimmunity is a non-depleting isotype of anti-CD4 MAb. However, the 
induction of immune tolerance with anti-CD4 has been shown easier to 
achieve to alloantigens in transplants than to single proteins, such as FVIII 
in mouse models of hemophilia. These observations can be considered 
surprising given the greater “mismatch” in models of transplantation 
compared to hemophilia. 
The current thesis addresses the issue of tolerance induction to 
proteins, such as allergens or FVIII. We assessed how adjuvants can play a 
role in facilitating tolerance induction and, finally, what are the different 
mechanisms leading to tolerance to the same foreign antigens when they 
are delivered as part of a transplanted tissue or as a protein in alum. 
As a consequence, the first chapter of the results describes a 
variety of experiments that were designed to demonstrate whether it is 
possible to induce tolerance to allergens (house dust mite) or a model 
antigen (OVA) in a mouse model of allergic asthma. We found that CD4 
blockade is remarkably effective in inducing long term tolerance to those 
antigens, while the immune system remains fully competent to respond to 
unrelated antigens and inclusively to develop allergic airways disease to 
those unrelated antigens. 
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The second chapter of the results assessed whether an adjuvant 
(alum) can be used to facilitate the induction of immune tolerance to FVIII 
in a mouse model of hemophilia. We found that indeed alum can facilitate 
tolerance, even in mice that have been primed in advance of tolerance 
induction. 
Finally, the third chapter of the results describes experiments 
where we investigated the mechanisms underlying the induction of 
tolerance to foreign proteins in alum, and how those mechanisms differ 
from tolerance induced to the same antigens when they are presented 
within transplanted tissue. We found that tolerance to proteins in alum is 
mediated by recessive mechanisms based on the apoptosis and anergy of 
effector cells, together with dominant mechanisms that are Foxp3-
independent and IL-10-dependent.  
The use of monoclonal antibodies to neutralize key molecules 
involved in the differentiation of inflammatory cells and to neutralize 
cytokines and other molecules involved in the inflammatory process is 
becoming exceptionally popular. There is a wealth of such components in 
clinical trials and some already in clinical use. Although promising anti-CD4 
hasn’t yet been fully availed by the scientific and clinical community. 
Targeting a key molecule in the activation of the helper T cell this 
tolerogenic agent can influence the effector and regulator populations 
tipping the balance of the immune system towards a specific, robust 
tolerance.  
It is the purpose of this work to demonstrate the effectiveness of 
anti-CD4 in inducting tolerance in Th2 biased immune disorders while 
sparing the system to respond to unrelated antigens. We also aim to show 
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that primed cells are still susceptible to the tolerizing effect of CD4 
blockade. In transplantation and autoimmunity CD4 is described to induce 
putative Tregs nevertheless other mechanisms have come forward and we 
hope to demonstrate that in soluble protein tolerance induction the 
mechanism has a recessive and dominant component independent of 
Foxp3+ Tregs. We also hope to understand if adjuvants can have a 
beneficial role in potentiating the tolerogenic effect of the anti-CD4 MAb. 
Lastly and taking together the objectives stated above it seems 
pressing to evaluate if inducing tolerance in a Foxp3+ Treg independent 
fashion can be combined with the Foxp3+ Treg dependent mechanism to 
boost tolerance induction.  
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Prevention of house dust mite induced allergic 
airways disease in mice through immune tolerance 
 
Introduction 
 
The control of deleterious immune responses causing diseases, such as 
allergy, autoimmunity and transplant rejection, has been one of the main 
objectives of immunologists. Moreover, the global prevalence of this type 
of diseases has been steadily increasing. 
Several strategies have been recently described to induce tolerance to 
allergens thus preventing allergic airways disease [81, 315-317]. In brief, 
they can rely on the induction of dendritic cell (DC) populations or 
regulatory T cells (Treg) able to control pathologic T cell clones, in a 
process where IL-10 and TGF-β can participate [47, 121, 315, 318-321]. In 
addition, disease prevention may be achieved by skewing the immune 
response from a Th2 to a Th1 phenotype [196].  
In fact, the realization of the critical importance of T cells in the 
pathogenesis of allergic airways disease was well demonstrated by studies 
where anti-CD4 monoclonal antibodies (MAbs) causing the depletion of 
this T cell subset could prevent the disease in mice [322]. Such pre-clinical 
studies with CD4 T cell depletion provided the rationale for clinical trials 
with depleting anti-CD4 MAbs where the short-term benefit observed was 
probably associated with transient immune suppression [323]. As a 
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consequence, the interest has shifted towards MAbs capable of blocking 
molecular interactions but without leading to direct cell lysis.  
Some reports have shown prevention of allergic airways disease 
following the blockade of T cell co-stimulatory or co-receptor molecules 
with non-depleting MAbs, but it remains unclear whether long-term 
antigen-specific tolerance is achieved or what are the mechanisms 
involved [178, 179, 324, 325]. We now describe CD4 blockade at the time 
of exposure with a model antigen, ovalbumin (OVA), or a clinically relevant 
allergen, house dust mite (HDM), can induce antigen-specific tolerance and 
protection from allergic airways disease. The mechanism leading to 
antigen-specific tolerance without affecting protective immune responses 
(including Th2-type responses) to additional antigens is independent of a 
switch between a Th2-type and Th1-type immune response. Since CD4 
blockade is achieved with a non-depleting MAb, T cells not activated by the 
antigen remain unaffected to mount protective immune responses 
towards unrelated antigens at a later time.  
Tolerance induction by CD4 blockade is robust enough to be effective 
in pre-sensitized animals and even in animals where AHR was previously 
established. The tolerant mice show protection from allergic 
manifestations elicited by intranasal exposure to the antigen: they do not 
develop airways eosinophilia, goblet cell hyperplasia, production of Th2 
cytokines in the lung, production of antigen-specific IgE or IgG1, and, 
importantly, do not develop airway hyperreactivity (AHR) in response to 
inhaled methacholine (MCh).  
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Materials and Methods  
 
Experimental animals 
BALB/c mice were bred and maintained under specific pathogen-free 
facilities. Animals were sensitized, at the times described in the text, by i.p. 
injection of 20 µg in 2.0 mg of endotoxin-free aluminum hydroxide (Alugel-S, 
Serva, Heidelberg, Germany) of OVA or β-LG (Sigma, St Louis, USA) previously 
run through a DetoxyGel column (Pierce, Rockford, USA), or HDM extract 
(Greer, Lenoir, USA). In all experiments animals were age and sex matched. 
Ethics Statement  
All experiments involving animals were approved by Direcção Geral 
Veterinaria (approval 018831). Mice were bred and maintained under 
specific pathogen free (SPF) conditions.  
Antibodies and reagents 
Non-depleting anti-CD4 (YTS177) [153] and the isotype control 
(YKIX302) MAbs were produced in our laboratory using Integra CL1000 
flasks (IBS, Chur, Switzerland), and purified from culture supernatants by 
50% ammonium sulfate precipitation, dialyzed against PBS, and the purity 
checked by native and SDS gel electrophoresis. The hybridomas were 
generously provided by Professor Herman Waldmann (Oxford, UK).  
Bronchoalveolar Lavage (BAL) 
Airways were washed through the trachea with 3 ml of cold PBS 1% 
BSA (Sigma). The BAL was centrifuged, ressuspended in PBS, and the cells 
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counted with a hemocytometer. Differential cell counts were performed 
on cytospin samples stained with Giemsa-Wright (Sigma). At least 200 cells 
from each sample were counted, using blinded slides, to determine the 
relative frequency of each cell type. In addition, in some experiments 
eosinophilia was independently confirmed by flow cytometry using GR-1 
(eBiosciences, San Diego, CA, USA), CCR3 (BD Pharmingen, San Diego, USA), 
and MHC-class II MAbs (produced in-house), with eosinophils identified 
based on the SSC/FSC profile and as the GR1intMHCclass II-CCR3+ cells [326]. 
Quantification of immunoglobulins and cytokines  
Serum titers of OVA-specific IgG1, IgG2a, and IgE were measured by 
ELISA using the following: IgG1 and IgG2a (SouthernBiotech, Birmingham, 
USA) with anti-OVA IgG1 standard from Serotec, Oxford, UK; IgE (BD-
Pharmingen) with anti-OVA IgE standard from Abcam (Cambridge, UK). 
Cytokine titers were determined in fresh BAL and lung homogenates. 
Cytokine ELISAs were performed using the following kits: IL-4, IL-5 (BD-
Pharmingen).  
Histology 
Lungs were perfused with 4% formalin solution (Sigma), collected and 
sectioned. Staining was performed using hematoxilin/eosin, and periodic 
acid-Schiff (PAS) stain. Photographs were taken using a Leica DM2500 
microscope and a Leica DFC420 camera.  
Respiratory mechanics and methacholine responsiveness 
Airway responsiveness was determined 24 hours after last intranasal 
OVA challenge. Changes in the respiratory input impedance (Zrs) were 
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measured using a modification of the low frequency forced-oscillation 
technique (LFOT) in mice anesthetized with 10 μl/g of xylazine (2 mg/ml, 
Ronpum, Bayer, Germany) and ketamine (40 mg/ml, Merial, Lyon, France), 
tracheotomized and ventilated (FlexiVent, SciReq, Montreal, Canada). Mice 
were hyperventilated at 450 breaths/min and Zrs was measured during 
periods of apnea using a 16 s signal containing 19 prime sinusoidal 
frequencies as described elsewhere [327]. Calculation of airway resistance 
(Raw), tissue damping (G) and tissue elastance (H) is obtained from the Zrs 
spectrum using FlexiVent software (SciReq). AHR was measured by 
exposure to an aerosol containing increasing doses of MCh (Sigma), 
following a baseline measurement after the delivery of a saline aerosol.  
Statistical analysis 
Statistical significance was determined using the two-tailed non-
parametric Mann-Whitney test and P values <0.05 were deemed 
significant (*, P<0.05; **, P<0.01; ***, P<0.001). 
 
Results 
 
Co-receptor blockade with non-depleting anti-CD4 MAb prevents 
allergic sensitization in mice 
 
Using a well established murine model of allergic airways disease we 
sought to determine if non-depleting MAbs targeting the T cell co-receptor 
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molecule CD4 were effective in preventing allergic sensitization with HDM 
or a model antigen (OVA). 
BALB/c mice were sensitized with two i.p. injections of OVA-alum or 
HDM-alum on days 1 and 14, and challenged with 50 μg OVA or HDM i.n. 
on days 20, 21 and 22 (Figure 1A). Experimental groups were treated with 
1 mg i.p. of anti-CD4 or an isotype control on the days before and after 
each immunization, and sacrificed 24 hours following the last intranasal 
challenge.  
Mice treated with anti-CD4 had a marked reduction in BAL eosinophils 
when compared with sensitized animals, to levels similar to naïve animals 
or animals sensitized in the absence of the antigen (Figure 1B, and Figure 
S1). The absence of goblet cell hyperplasia and inflammatory infiltrate in 
the airways of anti-CD4 treated mice was confirmed by histology (Figure 
1C). Furthermore, anti-CD4 treatment prevented effective generation of 
Th2-driven OVA- and HDM-specific IgG1 and IgE (Figure 1D). We could not 
detect Th1-driven antigen-specific IgG2a in any animal (not shown). 
Animals treated with anti-CD4 showed a marked reduction of IL-4 and IL-5 
in lung homogenates to levels similar to naive animals (Figure 1E). 
Importantly, we found no evidence for Th1 or Th17 deviation (as inferred 
by levels of IFNγ or IL-17), nor increased levels of the immune-regulatory 
cytokine IL-10 (not shown). Cytokines in BAL were similar to lung 
homogenates (not shown). 
To study the functional impact of the treatment we assessed AHR in 
response to increasing doses of inhaled MCh. Our data show that anti-CD4 
treatment prevented AHR (Figure 1F and Figure S2).   
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Figure 1. Prevention of allergic sensitization with anti-CD4 MAb. (A) 
Female BALB/c mice were sensitized with 20 μg OVA-alum or 50 μg HDM-Alum i.p. 
and challenged with 50 μg OVA or HDM in saline i.n. on the indicated days. Some 
animals were treated with 1 mg anti-CD4 or an isotype control i.p. as shown. Naive 
mice, not subjected to any intervention, were also studied as a control group. (B) 
Cellular composition of the BAL. Animals treated with anti-CD4 have less 
eosinophils in the BAL (n=6, *** P<0.001). (C) Histological sections of lung tissue 
were stained with haematoxylin/eosin and PAS (inset). Anti-CD4-treated mice 
have reduced inflammatory infiltrate and goblet cell hyperplasia, to levels similar 
to naive controls. Bars represent 10 µm (2.5 µm in the inset). (D) Quantification of 
serum OVA- and HDM-specific IgG1 and IgE. Anti-CD4 MAb treated mice show a 
significant reduction of the Th2-driven immunoglobulins (n=6, *** P<0.001 and ** 
P<0.01 as indicated). (E) The Th2 cytokines IL-4 and IL-5 were down to basal levels 
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in lung homogenates of anti-CD4 treated mice (n=6, * P<0.05 and *** P<0.001). (F) 
Invasive measurement of respiratory mechanics shows that animals treated with 
anti-CD4 MAbs had reduced airway resistance to increasing doses of inhaled MCh, 
when compared with sensitized control animals (n=8). Data (B-F) are 
representative of at least three independent experiments. 
 
The tolerance state is maintained following clearance of the MAb 
 
We then studied whether tolerance induction with non-depleting anti-
CD4 would protect the animals from subsequent exposure to the same 
antigens, at a time the therapeutic MAb had been cleared. For this purpose 
treated mice with anti-CD4 at the time of initial sensitization with OVA or 
HDM, and the same mice were again immunized with the same antigens 50 
days following the initial treatment (Figure 2A). 
Sensitization with OVA-alum or HDM-alum did not lead to airways 
eosinophilia in mice previously exposed to the same antigens under the 
cover of non-depleting anti-CD4 (Figure 2B and Figure S1). Furthermore, 
the treated mice also failed to produce antigen-specific IgG1 and IgE to 
OVA-alum and HDM-alum (Figure 2C). And importantly, AHR to increased 
concentrations of inhaled MCh was also absent in anti-CD4 treated mice 
(Figure 2D and Figure S2).  
We could therefore conclude that a short course of anti-CD4 was 
leading to long-term effects. Although the MAb we used (clone YTS177) is 
known to have a non-depleting isotype [153], and we confirmed anti-CD4 
treatment was not directly leading to T cell lysis (not shown), we had to 
confirm the treated mice remained immune competent. 
Results - Prevention of HDM induced allergic airways disease in mice through immune tolerance 
Ana Água-Doce Page 73 
 
 
Figure 2. Tolerized mice resist subsequent sensitization and challenge. (A) 
BALB/c mice were initially sensitized with OVA or HDM under the cover of anti-
CD4 as described in Figure 1.  Those mice were sensitized with the same antigens 
on days 50 and 64, and subsequently challenged i.n. (B) Animals treated with anti-
CD4 were protected from BAL eosinophilia (n=6, ** P<0.01 for OVA; * P<0.05 for 
HDM). (C) CD4-blockade prevented production of IgG1 and IgE in subsequent 
sensitizations (n=6, *** P<0.001 and ** P<0.01 as indicated). (D) Tolerance to OVA 
or HDM prevented AHR to inhaled MCh (n=6). Data are representative of three 
independent experiments 
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Tolerant mice remain immunocompetent 
 
In order to study the antigen-specificity of tolerance induction, we 
used a second unrelated antigen: β-lactoglobulin (β-LG). We compared 
immune responses to OVA and β-LG, since these are two defined antigens 
with similar characteristics, while HDM is a complex protein extract 
containing many distinct antigens.  
BALB/c mice were treated with non-depleting anti-CD4 MAb together 
with OVA-alum (tOVA) or β-LG-alum (tβ-LG) in order to establish immune 
tolerance to those antigens (Figure 3A). At day 50 the animals were 
immunized with the same antigen used at the time of tolerization (day 0) 
or with the second unrelated antigen. All mice were subsequently 
challenged i.n. with the same antigen used at day 50. All animals remained 
protected from mounting airways inflammation in response to the antigen 
used for tolerization, but fully competent to undergo a Th2 response to the 
second antigen leading to airways eosinophilia, production of IgE and IgG1, 
and AHR (Figure 3B-D and Figure S2). These results suggest that CD4-
blockade affects specifically the T cells that are being activated at the time 
of treatment, and sparing non-activated cells, thus leading to antigen 
specific tolerance where immune responses against different antigens are 
not suppressed. 
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Figure 3. Mice treated with anti-CD4 are competent to respond to 
unrelated antigens. (A) Mice initially tolerized to OVA or β-LG (as described in 
previous figures) were sensitized i.p. with a different antigen at days 50 and 64, 
and challenged i.n. with the same antigen used at day 50. (B) Only animals 
tolerized to the same antigen used for sensitization at day 50 were protected from 
BAL eosinophilia (n=6, *** P<0.001). (C) Tolerance induction to OVA did not 
prevent subsequent production of β-LG-driven IgE or IgG1, conversely, tolerance 
to β-LG did not hamper the generation of OVA-specific IgG1 or IgE (n=6, *** 
P<0.001). (D) AHR in response to MCh was observed in animals tolerized to an 
antigen different from the one used for subsequent sensitization (tOVA >β-LG and 
tβ-LG >OVA) (n=8, * P<0.05 at 10 mg/ml MCh). Data are representative of two 
independent experiments. 
 
Tolerance can be achieved in sensitized mice. 
 
To assess whether tolerance can be induced in pre-sensitized mice, 
BALB/c mice sensitized with OVA or HDM were treated with the same 
antigen under the cover of anti-CD4 50 days following initial sensitization 
(Figure 4A). For consistency with previous experiments we maintained the 
tolerance-inducing regime as two administrations of antigen-alum + anti-
CD4 two weeks apart.  
We found, both OVA- and HDM-sensitized mice treated with anti-CD4 
were prevented from AHR, maintaining normal airway response to 
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increased concentrations of inhaled MCh (Figure 4B and Figure S2). We 
confirmed the efficient sensitization of all groups of immunized animals by 
the presence of antigen-specific IgG1 and IgE antibodies in sera (not 
shown), although the mice had not been exposed to prior airway 
inflammation. As a consequence, the protection from AHR is effective in 
spite of high titers of antigen-specific immunoglobulins – possibly 
representing an impact on the late-phase response, and dissociation 
between high IgE and AHR. 
 
Figure 4. Tolerogenic effect of anti-CD4 treatment is antigen-specific and 
effective in sensitized animals. (A) BALB/c mice sensitized with OVA-alum or HDM-
alum were tolerized to the same antigens on days 50 and 64, and challenged i.n. 
with the same antigens. (B) Sensitized mice subsequently treated with OVA or 
HDM under the cover of anti-CD4 showed protection from AHR (n=8 for OVA, n=6 
to HDM). Data are representative of two independent experiments. (C) Mice were 
initially sensitized with OVA-alum or β-LG-alum, and tolerized to the same or a 
different antigen on days 50 and 64. All mice were challenged i.n. with the same 
antigen used for initial sensitization. (D) Mice treated with a different antigen 
together with anti-CD4 did not show reduced BAL eosinophilia (OVA >tβ-LG and β-
LG >tOVA) while treatment with anti-CD4 and the same antigen used for 
sensitization showed a significant reduction of BAL eosinophilia (OVA>tOVA and β-
LG >tβ-LG; n=6, *** P<0.001). Data are representative of two independent 
experiments. 
 
We then assessed whether tolerance induction in pre-sensitized mice 
remained antigen-specific. BALB/c mice sensitized with OVA-alum or β-LG-
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alum were treated with anti-CD4 MAb, 50 days following the initial 
intervention, in the presence of either the initial (OVA or β-LG) or a 
different antigen (β-LG or OVA, respectively; Figure 4C). Sensitized mice 
were protected from airway eosinophilia when treated with anti-CD4 in 
the presence of the same antigen used for sensitization (OVA >tOVA and β-
LG >tβ-LG, Figure 4D). The protective effect was, therefore, not due to the 
persistence of the therapeutic antibody in circulation at the time of 
intranasal exposure to the antigen since mice immunized with a different 
antigens not present during anti-CD4 treatment (and therefore with 
equivalent doses of circulating anti-CD4 at the time of challenge) were not 
protected (OVA >tβ-LG and β-LG >tOVA). The observation that animals 
receiving the antibody treatment together with a different antigen than 
used for immunization develop inflammatory changes similar to untreated 
control animals, or animals exposed to alum in the absence of the antigen 
(Figure S1), are consistent with the antigen-specificity of the tolerance 
state described above.  
 
Mice exposed to allergic airways disease can be protected from AHR 
following anti-CD4 treatment. 
 
However, it is understood that the onset of inflammation in the 
airways becomes a significant hurdle for immune modulation leading to 
tolerance. Therefore, we investigated whether mice sensitized to OVA or 
HDM and exposed to the antigen i.n. could benefit from subsequent anti-
CD4 treatment (Figure 5A). A single i.n. challenge with antigen in sensitized 
mice was sufficient to induce AHR (Figure S3). 
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We found that administration of HDM under the cover of non-
depleting anti-CD4 30 days following induction of allergic airways disease 
was effective in preventing AHR following subsequent challenge with the 
same antigen (Figure 5B). We repeated the same studies with OVA with 
similar results (Figure 5B and Figure S2).   
 
Figure 5. Protection from AHR in animals previously exposed to airways 
inflammation. (A) Balb/c mice sensitized and challenged i.n. with HDM-alum or 
OVA-alum were tolerized to the same antigens on days 50 and 64, and challenged 
i.n. with the same antigens. (B) The animals treated with HDM or OVA under the 
cover of anti-CD4 were protected from AHR in response to inhaled MCh (n=6, ** 
P<0.01 or *** P<0.001 as indicated). Data are representative of two independent 
experiments 
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Discussion 
 
Our data shows that CD4 blockade is effective in inducing antigen-
specific tolerance to a clinically relevant allergen (HDM), thus preventing 
the manifestations of allergic airways disease following intranasal allergen 
challenge: Th2 and eosinophilic infiltrate of the airways, goblet cell 
hyperplasia, and AHR. The tolerogenic treatment is not only effective in 
preventing the disease in naive animals, but also confers considerable 
protection to mice previously sensitized with the allergen. Although in 
different experiments we tested mice with different ages, we could not 
find an age-related difference in their response to induction of allergic 
airways disease (Figure S4). 
It should be noted that the use of tolerogenic MAbs in transplantation, 
with the same objective of preventing an inflammatory response to non-
self antigens, have resulted in a different outcome from what we have 
observed. In transplantation, tolerance induction in sensitized animals has 
been difficult to achieve, except when both anti-CD4 and anti-CD8 MAbs 
are combined [155], with anti-CD8 MAbs probably required to control pre-
committed effector T cells. Co-stimulation blockade with anti-CD40L has 
also been reported as less effective than anti-CD4, requiring depletion of 
CD8+ T cells even in non-sensitized animals [164, 165]. The obstacle 
created by sensitization in relation to tolerance induction is also evidenced 
by reports showing that heterologous immunity reduces the effectiveness 
of tolerogenic protocols in transplantation [211]. Our data shows that the 
anti-CD4 antibody treatment can also be beneficial to already sensitized 
animals. This may be due to the fact that the T effector cell frequency is 
significantly lower for allergens than for alloantigens and that the response 
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to allergens is predominantly restricted to the CD4+ compartment. It is 
likely that such different outcome observed in transplantation versus 
allergy may be due to the induction of different tolerogenic mechanisms. 
In fact our preliminary data suggests that Foxp3+ Treg cells may play a 
more important role in transplantation tolerance than in tolerance induced 
to allergens – something that still requires further elucidation. 
Our data also suggests it is likely that in sensitized mice the antibody 
treatment has an impact exclusively on the late response (mediated by Th2 
and NKT cells), without preventing the early response mediated by mast 
cell degranulation in response to their surface IgE cross-linking, as the 
allergen-specific IgG1 and IgE titers remain high in treated mice. But even 
without targeting early mast cell degranulation, the MAb treatment is 
likely to lead to a putative long-term benefit given the importance of the 
Th2-mediated response for the persistence of the inflammatory changes 
associated with airways remodeling and chronic manifestations of the 
disease [317]. This issue will require confirmation in chronic models of 
disease. 
The antigen-specificity of Treg cell-mediated tolerance has been a 
controversial issue [38, 141]. We show that effective tolerance induction 
requires the presence of the appropriate antigen at the time of CD4 
blockade leading to antigen-specific tolerance. In these experiments we 
waited 50 days following initial sensitization to minimize the amount of 
antigen still present in the animal at the time of the tolerogenic treatment. 
These data also established that MAbs administered at day 50 (Figure 3) 
were not contributing significantly to the prevention of the disease by 
being in circulation at the time of intranasal challenge, since no beneficial 
effect is observed in animals treated with the same antibody dose together 
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with an irrelevant antigen. Importantly, most previous studies addressing 
the putative tolerance-inducing potential of monoclonal antibodies, 
namely anti-CD4 [325], did not address the antigen-specificity of the 
phenomenon or the immune competence of treated mice. 
Several MAbs have been recently used as immune modulators in a 
wide range of diseases, including allergy [328]. Anti-CD4 MAbs have been 
evaluated both in pre-clinical non-human primate models of 
transplantation and autoimmunity, as well as in clinical studies [323, 329, 
330]. Their therapeutic effectiveness was modest, short-term, and likely to 
be a consequence of transient immunosuppression and not tolerance.  
With hindsight those unimpressive results are not surprising due to 
technical details related with dosing and the MAb characteristics. The 
clinical trials have used mouse or chimeric MAb that elicited immune 
responses leading to their rapid clearance [331]. In addition, most of those 
studies, including a clinical trial in human asthma (with the depleting anti-
CD4 MAb keliximab) [323], did not take advantage of non-depleting anti-
CD4 MAbs. Therefore, and as a consequence of the adverse side effects 
associated with depleting reagents, it was not possible to attain a 
neutralizing dose of anti-CD4 know to be the most effective for tolerance 
induction. At this time, particularly given the promising results with non-
depleting anti-CD3 in early onset diabetes patients [314], the past 
experience of anti-CD4 in human patients should be reassessed in face of 
current knowledge. On this note, a new non-depleting and less-
immunogenic humanized anti-CD4 MAb has been recently engineered, and 
its safety evaluated in human volunteers [332].  
Our results suggest the specific targeting of CD4 T cells in allergic 
airways disease can have a potent effect in achieving long-term protection 
Results - Prevention of HDM induced allergic airways disease in mice through immune tolerance 
Page 82  Ana Água-Doce  
 
from subsequent inflammatory changes induced by the same antigens. It 
remains to be established whether similar effects can be achieved in 
chronic allergic airways disease. 
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Supplementary Figures 
 
. 
Supplementary Figure 1. Prevention of allergic sensitization with anti-CD4 
MAbs. Female BALB/c mice were sensitized with 20 μg OVA-alum i.p. and 
challenged with 50 μg OVA in saline i.n. on the indicated days. Some animals were 
treated with 1 mg anti-CD4 or an isotype control i.p. as shown. Naive mice, not 
subjected to any intervention, were also studied as a control group and compared 
with mice injected with adjuvant in the absence of antigen at the time of 
sensitization. (A) Cellular composition of the BAL of mice treated with anti-CD4 at 
the time of sensitization. (B) Cellular composition of the BAL of mice treated with 
anti-CD4 at the time of initial sensitization, but subjected to additional 
sensitization at a subsequent time. (C) Cellular composition of the BAL of 
sensitized mice treated with anti-CD4. 
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Supplementary Figure 2. Invasive measurement of respiratory mechanics. 
Data showing the impact of anti-CD4 treatment in tissue elastance and tissue 
damping in response to increasing doses of inhaled MCh. These graphs 
complement the data on airway resistance represented in the main figures 1 to 5. 
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Supplementary Figure 3. Induction of AHR following i.n. exposure to the 
antigen. Female BALB/c mice were sensitized with two shots of 20 μg OVA-alum 
i.p. 14 days apart, and challenged with 50 μg OVA in saline i.n. for three 
consecutive days (day 20-22), or just on day 20. Invasive measurement of 
respiratory mechanics was performed on the following day in presence of 
increasing doses of inhaled Mch. Both groups of mice, subjected to a single or 
three challenges with i.n. antigen, displayed similar levels of AHR (n=6, ** P<0.01, 
*** P<0.001).  
 
 
 
 
Supplementary Figure 4.. Allergic airways disease in mice with different age. 
Female BALB/c mice were sensitized with 20 μg OVA-alum i.p. and challenged with 
50 μg OVA in saline i.n. as indicated in Figure 1. Some animals were treated with 1 
mg anti-CD4 or an isotype control i.p. at the time of sensitization. Mice with 11 or 
20 weeks of age were used. No significant differences between mice of different 
ages.  
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Adjuvant facilitates anti-CD4 mediated immune 
tolerance to recombinant factor VIII in haemophilia by 
a Foxp3-independent mechanism that relies on IL-10 
 
Introduction 
 
For many patients with severe hemophilia, replacement therapy with 
recombinant clotting factors represents an immune challenge with non-
self proteins thus resulting in an immune response. As a consequence, 
immunoglobulins targeting infused clotting factors can lead to their 
inhibition (those immunoglobulins are termed inhibitors)[333]. Several 
approaches for immune tolerance induction (ITI), leading to the control of 
the production of clotting factor inhibitors, are currently used in 
hemophilia patients[334]. However, the success of ITI is not absolute and 
currently, at a time when viral contaminants in therapeutic products are a 
problem of the past, inhibitors became a major complication for 
hemophilia treatment. This has led to an increasing interest in developing 
new protocols for the induction of tolerance to therapeutically 
administered clotting factors[335]. Recent clinical trials have explored the 
putative higher tolerogenicity of factor VIII (FVIII) coupled with von 
Willebrand Factor (vWF), or B cell depletion with an anti-CD20 monoclonal 
antibody (MAb) rituximab[336, 337]. The outcome of those trials has 
shown, at the most, a modest improvement in ITI efficacy. Consequently, 
those ITI approaches were not generally adopted and the development of 
better strategies for ITI remains an unmet medical need[338]. 
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In recent years several strategies have been developed to promote 
immune tolerance towards alloantigens. Several studies have 
demonstrated that non-depleting monoclonal antibodies (MAbs) targeting 
T cell surface molecules are effective in achieving immune tolerance in 
transplantation and autoimmunity[148, 339]. There is, however, a contrast 
between the efficacy in achieving long-term tolerance with MAbs such as 
CD4 or CD40L administered at the time of transplantation in pre-clinical 
studies[140, 141, 340], with a transient effect observed when the same 
reagents are used to induce tolerance to human recombinant factor VIII 
(hFVIII) or factor IX (hFIX) in mice[341, 342]. Remarkably, when the 
recombinant clotting factors are expressed in tissues, for instance 
following viral transduction, tolerance induction appears to be easier to 
achieve[343]. 
These observations prompted us to investigate whether the difference 
between both outcomes is a consequence of differences in the way the 
antigen is presented to T cells for tolerance induction. It is plausible that 
efficient imposition of tolerance in vivo, would require an impact on a large 
proportion of the antigen-specific T cells, or stronger co-stimulation, 
something that can only be achieved in the presence of inflammation 
(namely in transplantation or viral transduction) or when an adjuvant is 
used.  
We found that the most clinically relevant adjuvant – aluminium 
hydroxide (alum) – facilitates the induction of tolerance to hFVIII in mice. 
Surprisingly, the mechanism underlying tolerance induction appears to be 
different from antibody-induced transplantation tolerance: while non-
depleting anti-CD4 induces Foxp3+ regulatory T cells that are indispensable 
for transplantation tolerance, we were able to induce tolerance to foreign 
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proteins in Foxp3-deficient mice. On the contrary, tolerance induction is 
critically dependent of IL-10, as it cannot be established in IL-10-/- mice.  
Adjuvants can therefore have two opposing roles: they can contribute 
to boost immune responses and to overcome natural tolerance, but they 
can be instrumental in facilitating therapeutically induced tolerance when 
in presence of appropriate tolerance-inducing reagents. 
 
Materials and methods 
 
Animals. BALB/c, C57Bl/6, B6.IL-10-/-, B6.Rag2-/-, and DO11.10.Rag2-/-, 
mice were bred and maintained under specific pathogen-free (SPF) 
facilities at the Instituto Gulbenkian de Ciência. Hemophilia-A mice (HemA) 
with a targeted disruption of exon 16 in the FVIII gene were initially 
generated by Kazazian and colleagues[344]. HemA mice backcrossed into 
C57Bl/6 and BALB/c background were generously provided by Professor 
David Lillycrap (Queen’s University, Kingston, Canada) and were 
maintained under SPF facilities at the Instituto de Medicina Molecular. The 
T/B monoclonal mice (T-Bmc, 17/9 DO11.10.RAG1-/-) bear monoclonal 
populations of T and B lymphocytes specific for chicken ovalbumin (OVA) 
323–339 and HA of influenza virus, respectively[345]. These mice were 
kept under SPF conditions at the Skirball Institute Central Animal Facility, 
New York University Medical Center. All procedures involving animals were 
approved by the Direção Geral de Veterinária (Lisbon) or New York 
University School of Medicine Institutional Animal Care and Use 
Committee (New York). 
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Animals were exposed to 1U hFVIII (Kogenate, Bayer, Germany), or to 
20 µg OVA (Sigma, St Louis, USA) previously run through a DetoxyGel 
column (Pierce, Rockford, USA). In some experiments the antigens were 
adsorbed in 2.0 mg of endotoxin-free aluminum hydroxide (Alu-gel-S, 
Serva, Heidelberg, Germany). In experiments involving alum the antigens 
were administered i.p. We confirmed that induction of inhibitors was 
similar through the i.p. or i.v. route. 
Monoclonal antibodies. Non-depleting anti-CD4 (YTS177.9)[153], the 
isotype control (anti-canine CD4; YKIX302), anti-CD25 (PC61), anti-IL-10R 
(1B1.1), and anti-TGFβ (1D11) MAbs were produced in house using Integra 
CL1000 flasks (IBS, Chur, Switzerland), and purified from culture 
supernatants by 50% ammonium sulfate precipitation, dialyzed against 
PBS, and the purity checked by native and SDS gel electrophoresis. 
YTS177.9 and YKIX302 hybridomas were generously provided by Professor 
Herman Waldmann (Oxford, UK).  
Quantification of immunoglobulins and cytokines. Serum titers of 
hFVIII-specific, OVA-specific, and HA-specific IgG1 were measured by ELISA 
using the following: IgG1-HRP (SouthernBiotech, Birmingham, USA) with 
anti-hFVIII IgG1 standard (Abcam, Cambridge, UK), anti-OVA IgG1 standard 
(Serotec, Oxford, UK) and anti-HA IgG1 standard (Sigma, St Louis, USA). The 
ELISA assay for IL-10 measurement was performed using a kit (Peprotech, 
London, UK) and according to the manufacturer’s instructions. 
Flow cytometry. Cells were stained with CD25-AlexaFluor488 (PC61; 
produced and conjugated in house), CD25-PE-Cy7 (PC61.5; eBioscience), 
Foxp3-APC (FJK-16s; eBioscience), CD3-PE-Cy7 (145-2C11; eBioscience), 
CD4-PerCp (RM4-5; BD Pharmigen),  and the DO11.10 TCR-specific KJ1-26 
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MAb conjugated with PE (BD Pharmigen) in PBS containing 0,01% NaN3, 
2% fetal bovine serum (FBS, Gibco) and 10 μg/ml Fc receptor blocking 
(2.4G2; produced and purified in house). Six color analyses were 
performed using a LSR Fortessa or a FACSCanto (BD Bioscience) with dual 
laser (488nm and 633nm) excitation. The analysis gate was set on the 
forward and side scatters to eliminate cell debris and dead cells. 
Bethesda assay. Inhibitory FVIII Abs were measured using the Bethesda 
assay and reported as Bethesda units/mL as previously described[346]. 
Briefly, mouse plasma was serially diluted in dilution buffer 
(Technochrom® FVIII:C, Technoclone, Austria) such that the residual FVIII:C 
for each sample was between 25% and 75%, mixed 1:1 with pooled normal 
human plasma (Factor VIII Inhibitor reagent Kit- Bethesda Units), and 
incubated for 2 hours at 37°C. The remaining FVIII activity was quantified 
using a chromogenic assay (Technochrom). For all samples, to reduce error 
in the assay and inconsistency between samples, the reported inhibitor 
titer in BU/mL was calculated from the dilution of plasma that yielded a 
residual FVIII:C of approximately 50%. By definition 1 BU/mL is defined as 
the dilution of plasma containing FVIII inhibitory activity that results in 50% 
inhibition of FVIII activity (FVIII:C). 
Statistical analysis. Statistical significance was determined using the 
two-tailed non-parametric Mann-Whitney U test and the Spearman test 
for correlation analysis. Statistical analysis was performed using Prism 4.0 
(GraphPad, San Diego, USA) and values of P<0.05 were deemed significant 
(*, P<0.05; **, P<0.01; ***, P<0.001). 
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Results 
 
hFVIII alum increases the tolerogenicity of anti-CD4 MAb. 
 
Alum has been used as an adjuvant in the formulation of human 
vaccines since 1926, having been administered to millions of humans to 
boost immunization[347, 348]. In order to exclude a putative strain 
influence in the outcome we treated BALB/c and C57Bl/6 mice with hFVIII 
or hFVIII-alum together with a non-depleting anti-CD4 MAb at the 
indicated time points (Figure 1a). Serum levels of anti-hFVIII IgG1 were 
measured following additional administrations of hFVIII. Our results 
confirmed that anti-CD4 treatment only has a moderate impact in 
preventing the generation of inhibitor antibodies to hFVIII (Figure 1b, c). 
However, when hFVIII-alum was used at the time of anti-CD4 treatment 
the concentration of hFVIII-specific antibodies remained significantly 
reduced even following multiple administrations of hFVIII up to 110 days 
following the initial treatment. Note that hFVIII-alum is, as anticipated, 
highly immunogenic due to the adjuvant properties of alum, leading to 
very high levels of anti-hFVIII immunoglobulins when used in the absence 
of anti-CD4.  
Next we investigated whether the route of administration of hFVIII-
alum could influence the tolerance induction. C57Bl/6 mice were therefore 
exposed to hFVIII-alum i.p. (as described above), or through the 
intramuscular or subcutaneous route. In addition, administration of anti-
CD4 and hFVIII was performed i.v. (Figure 1d). We found that tolerance 
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could be induced regardless of the route of administration of hFVIII-alum 
and anti-CD4. 
The “depot effect” has been regarded as a possible mechanism by 
which alum exerts its adjuvanticity[349]. According to this effect, 
adsorption of hFVIII in Alum would confer a slow release and consequently 
an increased half-life of hFVIII in vivo thus providing stable and long-term 
antigen presentation. This hypothesis is especially relevant as it has been 
described that sustained release of peptides, by an implanted osmotic 
pump, can lead to immune tolerance[350]. We addressed this issue by 
repeatedly injecting hFVIII every other day for two weeks in presence of 
anti-CD4 MAb. We found that animals exposed to multiple administrations 
of hFVIII+anti-CD4 still produced higher titers of anti-hFVIII IgG1 than 
animals treated with hFVIII-alum+anti-CD4 (Figure 1e). Our data show 
alum is potentiating the tolerogenicity of anti-CD4 MAb by a mechanism 
independent of the depot effect. 
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Figure 1. hFVIII-alum increases the tolerogenicity of anti-CD4 Mab. (A) C57Bl/6 
and Balb/c mice were treated with 1 U hFVIII or HFVIII-alum and 2 x 1 mg non-
depleting anti-CD4 (or isotype control) on the indicated days, followed by 
subsequent administrations of 1 U hFVIII as represented. The presence of serum 
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hFVIII-specific Ig was investigated at days 30, 60, and 90 or 110 following last 
administration of anti-CD4. (B) Serum concentration of hFVIII-specific IgG1 in 
C57Bl/6 mice (n=6; **: p<0.01), and (C) in Balb/c mice (n=6; *: p<0.05; **: p<0.01). 
(D) hFVIII-alum and anti-CD4 were administered according to the schedule 
represented in (A) through different routes (as indicated in the label). One group 
of mice remained untreated. All mice were then exposed to hFVIII and serum titres 
of anti-hFVIII were quantified. Animals that received hFVIII-alum together with 
anti-CD4 remained tolerant regardless the administration route (n=6; p<0.001). (E) 
Persistent serum levels of hFVIII did not prevent the generation of hFVIII-specific 
IgG1 in presence of anti-CD4. C57Bl/6 mice were treated with anti-CD4 MAbs in 
the days indicated above. Some mice were treated with 1 U hFVIII every other day 
for two weeks. We found that animals exposed to multiple administrations of 
hFVIII still produced higher titers of anti-hFVIII IgG1 than animals treated with 
hFVIII-alum (n=6; p<0.001). (F) Administration of the non-depleting anti-CD4 MAb 
(YTS177.9) does not lead to CD4 T cell depletion. DO11.10.Rag-/- mice were treated 
with 2 x 1 mg YTS177.9 and splenocytes were examined by flow cytometry for 
evidence of T cell depletion at day 7 (n=5; p, non-significant). 
 
Although the anti-CD4 MAb has a non-depleting isotype, we confirmed 
it does not lead to direct T cell depletion in vivo by treating DO11.10.Rag2-/- 
mice with anti-CD4. This way we could circumvent the coating of the CD4 
molecule, being able to accurately quantify CD4+ T cells by staining their 
transgenic TCR (identified with KJ26.1 MAbs). We found that the frequency 
of CD4+ splenocytes at day 7 following anti-CD4 treatment remained 
unchanged (Figure 1f).  
 
Tolerance induction requires IL-10 and is independent of Foxp3+ 
Treg cells. 
 
We and others have shown that transplantation tolerance can be 
induced with non-depleting anti-CD4 MAb, in a process that is Foxp3+ Treg 
cell-mediated and TGFβ-dependent[39, 159, 340, 351, 352]. In some 
conditions, IL-10 appears to play a role in transplantation tolerance[351, 
Results - Adjuvant facilitates anti-CD4 mediated immune tolerance 
Ana Água-Doce Page 95 
 
353]. In order to study the mechanism by which anti-CD4 MAb induces 
tolerance in hFVIII-alum treated animals, we used MAbs to block TGF-β or 
IL-10R at the time of treatment. In addition, another group of animals was 
treated with a depleting anti-CD25 MAb prior to treatment. We found IL-
10R-blockade during the initial two weeks had a dramatic effect in 
preventing tolerance induction (Figure 2a). However, only a modest 
increase in the concentration of anti-hFVIII IgG1 was observed in mice 
subjected to depletion of CD25+ T cells or to neutralization of TGF-β.  
 
Figure 2. Tolerance induction requires IL-10 and is independent of Foxp3+ Treg 
cells. (A) Mice were treated with hFVIII-alum and anti-CD4 as described in Figure 
1A. Different groups were also treated with the indicated MAbs. All mice were 
exposed to 1 U hFVIII on days 30 and 60. Serum concentrations of hFVIII-specific 
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IgG1 were determined on days 30, 60, and 90 (n=5; **: p<0.01; ***: p<0.001). (B) 
Representative dot-plots and (C) quantification of splenic Foxp3+ T cells from 
animals treated with anti-CD4 MAb or an isotype control, at day 90 (n=5; p, non-
significant). (D) T/B monoclonal mice (T-Bmc) T-Bmc Foxp3-deficient mice (T-Bmc 
FoxP3sf), were immunized on days 1 and 14 with OVA-HA-alum in the presence of 
non-depleting anti-CD4 or an isotype control. Serum HA-specific IgG1 was 
determined on day 24 (n=5; p<0.001). (E)  IL-10-/- and IL-10+/+ mice were treated 
with hFVIII-alum and anti-CD4 MAbs as described above.  The serum concentration 
of hFVIII-specific IgG1 was quantified on day 90 (n=6; p<0.001). (A-E) Data are 
representative of two independent experiments.  
 
These data suggest Foxp3+ Treg cells may only have a minor role in 
mediating tolerance in our model. In fact, no differences were found in 
percentages or absolute numbers of CD4+CD25+Foxp3+ cells in the spleen 
of animals treated with hFVIII-alum + anti-CD4 when compared to the 
positive group (hFVIII-alum + isotype) 90 days after the induction of 
tolerance (Figure 2b and 2c).  
Given the fact that experimental mice have a polyclonal T cell 
repertoire, putative changes in the frequency of antigen-specific Treg cells 
may be beyond the limit of detection. In addition, anti-CD25 depletion with 
PC61 is known to spare a significant number of Foxp3+ Treg cells[354]. We 
therefore used Foxp3-deficient mice to directly assess if tolerance to a 
foreign protein could be induced in the absence of Foxp3+ Treg cells. Since 
Foxp3-deficiency leads to severe autoimmunity we had to perform this 
experiment in mice devoid of autorreactive T cells. We used T/B Foxp3sf 
monoclonal mice (T-Bmc FoxP3sf), characterized by monoclonal populations 
of T and B lymphocytes specific, respectively, for chicken ovalbumin 323–339 
(OVA) and heme-aglutinin (HA) of influenza virus[345]. As a consequence, 
we had to use a cross-linked protein of OVA-HA as a model antigen instead 
of hFVIII. Treatment of T-Bmc mice with OVA-HA-alum and anti-CD4 MAb 
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was equally effective in the presence or absence of functional Foxp3 
(Figure 2d).  
To further confirm the key role of IL-10 in inducing tolerance to hFVIII, 
we treated IL10-/- mice with hFVIII-alum + anti-CD4 MAb. We confirmed 
that it was not possible to prevent generation of anti-hFVIII IgG1 in IL10-/- 
mice by treatment with hFVIII-alum + anti-CD4 (Figure 2e).  
Taken together, our data show that induction of tolerance to hFVIII-
alum in the presence of anti-CD4 MAb is IL-10-dependent. 
 
Non-depleting anti-CD4 induces long-term prevention from 
inhibitor formation in hemophilia A mice. 
 
To determine if treatment with anti-CD4 could prevent the formation 
of FVIII inhibitors in hemophilia, we used mice deficient in FVIII (hemophilia 
A mice, HemA). We treated C57Bl/6 HemA mice with hFVIII-alum and anti-
CD4 MAb as described in Figure 1a. Our data show that HemA mice treated 
with anti-CD4 exhibited low serum concentration of anti-hFVIII IgG1 for 90 
days, even after multiple exposures to hFVIII (Figure 3a). In addition, we 
used the Bethesda Assay to measure the titer of FVIII inhibitors at day 90. 
We found that anti-CD4 treatment successfully prevented the formation of 
inhibitors in HemA mice (Figure 3b and 3c). Similar results were obtained 
with BALB/c HemA mice (Figure 3d and 3e). We also found that in addition 
to hFVIII-specific IgG1, the hFVIII-exposed HemA mice produced high titres 
of hFVIII-specific IgG2a and IgG2b, unless mice were treated with anti-CD4 
MAb (Supplemental Figure 1). While C57Bl/6 HemA mice predominantly 
produced IgG1 and IgG2a, BALB/c HemA mice produced lower titres of 
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hFVIII-specific IgG2a but higher titres of IgG2b. Our findings on the 
different isotype preferences by the two strains of HemA mice are 
consistent with previous reports[355].  
We confirmed that tolerance induction could also be achieved in HemA 
mice when hFVIII-alum was administered s.c. and the anti-CD4 MAb i.v. 
(Figure 3f and 3g). 
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  Figure 3. Non-depleting anti-CD4 induces long-term protection from 
inhibitor formation in hemophilia-A mice. (A) HemA mice were treated with 1 U 
hFVIII or HFVIII-alum and 2 x 1 mg non-depleting anti-CD4 (or isotype control) on 
the indicated days, followed by subsequent administrations of 1 U hFVIII as 
represented. The presence of serum hFVIII-specific Ig was investigated at days 30, 
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60, and 90 following last administration of anti-CD4 . (B) Quantification of serum 
hFVIII-specific IgG1 from C57Bl/6 Hem-A mice at day 30 and at day 90, following 
multiple exposures to hFVIII (n=8; p<0.001).  (C) Quantification of FVIII inhibitors 
from the serum of C57Bl/6 mice at day 90 (n=8; p<0.01). (D) Serum hFVIII-specific 
IgG1 from BALB/c Hem-A mice (n=4; p<0.01). (E) Quantification of hFVIII inhibitors 
from BALB/c Hem-A mice (n=4; p<0.05). (F) C57Bl/6 HemA mice were treated with 
hFVIII-alum (either i.p. or s.c.) and anti-CD4 (either i.p. or i.v., respectively), on 
days 1 and 14. One control group remained untreated, while another was treated 
with hFVIII + isotype control. Subsequent challenges were done by i.v. 
administration of hFVIII, in a total of 4 injections, given twice weekly starting on 
day 21. Quantification of the anti-hFVIII IgG1 levels and (G) Bethesda Units, 
measured one week after the final exposure to hFVIII (n=6; p<0.05). (H) 
Quantification of IL-10 concentration in supernatants of splenocytes from C57Bl/6 
Hem-A mice, collected at day 7 following initial treatment with HFVIII-alum + anti-
CD4. The splenocytes were stimulated with anti-CD3 for three days (n=3; p<0.05). 
(A-E)  Data are representative of two independent experiments. 
 
We also found that splenocytes collected from HemA mice treated 
with hFVIII-alum + anti-CD4 when stimulated in vitro in presence of anti-
CD3 were more prone to produce IL-10 than splenocytes from naïve non-
manipulated mice, or mice treated with an isotype control (Figure 3h). 
 
Tolerant mice remain immune competent. 
 
Although the anti-CD4 Mab clone has a non-depleting isotype (i.e. 
it does not directly lead to T cell lysis), we confirmed that mice treated 
with anti-CD4 remained immune competent. We used C57Bl/6 mice 
treated with anti-CD4 as described in Figure 1, but using hFVIII-alum or 
OVA-alum as the “tolerizing antigen” administered at the time of Mab 
treatment. We waited five weeks to minimize the potential persistence of 
antigen or anti-CD4. At day 50 and 64, the mice were exposed to the same 
or to the other antigen (Figure 4a). We found that treatment with anti-CD4 
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Mab prevented subsequent immunization to the same antigen without 
suppressing immune responses to the other antigen (Figure 4b and 4c). In 
other words, mice “tolerized” with OVA-alum could respond to subsequent 
immunization with FVIII-alum, but did not respond to OVA-alum. 
Conversely, mice “tolerized” with FVIII-alum did not respond to a later 
challenge with FVIII-alum, but were fully competent to produce antibodies 
following immunization with OVA-alum. 
 
Figure 4. Non-depleting anti-CD4-treated mice remain immune competent. (A) 
C57Bl/6 mice were treated as described previously with anti-CD4, but using FVIII-
alum or OVA-alum as the “tolerizing antigen” administered at the time of Mab 
treatment. Five weeks following the last MAb infusion the mice were exposed to 
the same or to the other antigen. Control groups were not treated with anti-CD4. 
(B) Some mice were immunized with hFVIII-alum on days 50 and 64, and serum 
hFVIII-specific IgG1 was quantified at day 73. We found that unlike mice initially 
treated with OVA-alum + anti-CD4, mice treated with hFVIII-alum + anti-CD4 
remained unresponsive to the subsequent immunization with hFVIII-alum (n=4; 
p<0.05). (C) Other mice were immunized at day 50 and 64 with OVA-alum, and 
serum OVA-specific IgG1 was quantified on day 73. Animals initially treated with 
hFVIII-alum + anti-CD4 remained competent to respond to immunization with 
OVA-alum, unlike mice initially treated with OVA-alum + anti-CD4 that remained 
tolerant to OVA (n=4; p<0.05). Data are representative of two independent 
experiments. 
 
These results show that treatment with anti-CD4 does not induce 
global immune suppression, but rather antigen-specific unresponsiveness. 
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Anti-CD4 MAb is effective in inducing tolerance following 
sensitization 
 
Unlike autoimmunity or allergy, in hemophilia there is an opportunity 
to induce tolerance in advance of immune sensitization, as the first 
exposure to the antigens is controlled by the clinician. However, since 
many hemophilia patients do not develop inhibitors, ITI strategies are 
often required when the patient is already sensitized. Previous studies 
suggested that CD4-blockade may be effective in sensitized hosts[46]. But 
hFVIII-specific IgG produced at the time of sensitization, given their long 
half-life, may obscure the eventual effectiveness of tolerance induction at 
a later time. 
To overcome this limitation, and since it is not feasible, in mice, to 
remove pre-existing FVIII-specific  IgG by plasmapheresis, we developed an 
experimental setting to address the role of CD4-blockade in pre-sensitized 
cells in the absence of preformed FVIII-specific IgG (Figure 5a). 
In brief, C57Bl/6 mice were immunized with hFVIII-alum at day 1 and 
14, and sacrificed at day 30. This immunization protocol leads to high 
concentration of hFVIII-specific IgG1 (198.0 ± 14.7 μg/ml). We collected 
and pooled T and B cells from spleen, pooled lymph nodes, and bone 
marrow. The lymphocytes were then adoptively transferred i.v. into 
congenic Rag2-/- or C57Bl/6 recipients. The recipient mice were then 
treated with hFVIII-alum + anti-CD4 Mab, and exposed to additional 
challenges with hFVIII (Figure 5a). 
Using Rag2-/- recipients we confirmed that the adoptively transferred 
primed T and B cells were sufficient to produce anti-hFVIII IgG1 (Figure 5b). 
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However, treatment with anti-CD4 was effective in preventing the 
production of hFVIII-specific IgG1 by those primed cells (Figure 5b). 
 
Figure 5. Anti-CD4 Mab is effective in inducing tolerance following 
sensitization. (A) C57Bl/6 mice were sensitized with hFVIII-alum at day 1 and 14, 
and sacrificed at day 30. Leukocytes from spleen, pooled lymph nodes, and bone 
marrow were collected and adoptively transferred i.v. into congenic Rag2-/- or 
C57Bl/6 recipients. The recipient mice were then treated with hFVIII-alum + anti-
CD4 Mab (or an isotype control) on the day of cell transfer and 14 days later 
(consistent with protocol represented in Figure 1A), and all groups of mice were 
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subsequently challenged with 3x 1U hFVIII on days 10, 12, and 14 following the 
last administration of anti-CD4. (B) Quantification of serum hFVIII-specific IgG1 in 
Rag2-/- recipient mice. Animals that received primed T and B cells were competent 
to produce anti-hFVIII IgG1 (n=5; p<0.001), but antibody production was 
abrogated in mice treated with anti-CD4 (n=5; p<0.001; N.D., not detected). (C) 
Concentration of serum hFVIII-specific IgG1 in C57Bl/6 mice transferred with 
primed T and B cells. Animals adoptively transferred with primed cells produced 
higher levels of hFVIII-specific IgG1 than animals that did not received primed cells 
(n=5; p<0.001). Treatment with anti-CD4 prevented production of hFVIII-specific 
IgG1 by the primed lymphocytes (n=5; p<0.001; N.D., not detected). Data are 
representative of two independent experiments. (D) C57Bl/6 mice were sensitized 
with hFVIII on days 1, 5, 10, and 15, and treated with hFVIII-alum and anti-CD4 
(either i.p. or s.c.) on days 35 and 50. Control mice received anti-CD4 without 
hFVIII. One control group had not been previously exposed to hFVIII. All mice 
received hFVIII i.v. on days 64, 66, 74, 76, 84, and 86. Quantification of anti-hFVIII 
IgG1 was performed on the indicated days. Mice treated with hFVIII-alum + anti-
CD4 (regardless of the route of administration) were protected from production of 
anti-hFVIII IgG1 following subsequent exposure to hFVIII (n=6; p<0.001). 
 
The adoptive cell transfer into C57Bl/6 mice showed that the 
adoptively transferred cells were indeed primed. Our data show that 
recipients of primed cells displayed a rapid and high magnitude secondary 
type immune response following exposure to hFVIII, when compared with 
control mice that did not receive primed cells, and that displayed a primary 
response (Figure 5c). We also observed that when the primed cells were 
transferred into C57Bl/6 mice, treatment with anti-CD4 Mab prevented 
production of anti-hFVIII IgG1 (Figure 5c). 
We then investigated whether hFVIII-alum + anti-CD4 could protect 
mice sensitized to hFVIII from further production of FVIII-specific 
antibodies.  We found that animals exposed to hFVIII when subsequently 
treated with hFVIII-alum (i.p. or s.c.) + anti-CD4 maintained the serum 
levels of FVIII-specific IgG1 in spite of repeated administrations of hFVIII 
(Figure 5d). The effect was not due to non-specific effects of anti-CD4, as 
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mice treated with anti-CD4 in the absence of hFVIII responded to 
subsequent exposure to hFVIII with the production of hFVIII-specific IgG1. 
These results demonstrate that anti-CD4 Mab treatment is effective in 
controlling the response to hFVIII in pre-sensitized animals. 
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Discussion 
 
Our results show that an adjuvant – alum – can enhance the ability of 
non-depleting anti-CD4 MAb to achieve tolerance to hFVIII. These results 
can appear counterintuitive as usually adjuvants, such as alum, are used to 
boost immunity namely leading to production of protective antibodies. It is 
likely that when tolerance is based on CD4-blockade it will be necessary 
that the majority of antigen-specific T cells will be exposed to the antigen 
during the time when the CD4-blocking MAb is present, and with optimal 
co-stimulation. In this regard, our results on the antigen-specificity of 
tolerance (Figure 4) also confirm that tolerance is imposed on the 
lymphocytes that are engaged in antigen recognition at the time of CD4-
blockade: our data show that exposure to hFVIII-alum + anti-CD4 can 
prevent subsequent immune responses targeting hFVIII, while allowing 
successful immunization to an unrelated antigen (OVA). Similar results 
were obtained in the converse experiment: when tolerance is induced with 
OVA-alum + anti-CD4, the animals can produce antibodies targeting hFVIII, 
following exposure to the clotting factor. We can conclude that the initial 
exposure to hFVIII-alum is therefore critical to control the FVIII-specific T 
cell clones, but does not affect T cell clones with other specificities.  
Given the previous reports showing a clear role of Foxp3+ Treg cells in 
transplantation tolerance induced with anti-CD4[39, 340, 356], it was 
surprising to find that tolerance induction to proteins in alum could be 
achieved in the absence of Foxp3 (Figure 2). We have confirmed that 
indeed tolerance induction to skin grafts, induced following anti-CD4 MAb 
treatment, is dependent of Foxp3+ Treg cells (data not shown). In the same 
fashion, several animal models of autoimmunity can be successfully 
Results - Adjuvant facilitates anti-CD4 mediated immune tolerance 
Ana Água-Doce Page 107 
 
treated with anti-CD4, by a mechanism that appears to be Foxp3-
dependent[357]. However, the systemic distribution a protein in alum 
appears to take advantage of an IL-10-dependent and Treg independent 
mechanism. This observation may explain the apparently contradictory 
results from transplantation studies using anti-CD4 for tolerance induction: 
while studies where a skin graft alone is used tolerance appears to be IL-
10-independent and Treg dependent[158, 340]; but studies where donor 
specific transfusion and a skin graft are used appear to rely on both Treg 
cells and IL-10[351, 353], suggesting that systemic distribution of the 
antigen may recruit a IL-10-mediated tolerogenic mechanism. It remains to 
be established the reason for the absolute requirement of Foxp3+ Treg cells 
in transplantation tolerance[356], while the same clone of non-depleting 
anti-CD4 MAb leads to Foxp3-independent immune tolerance in 
hemophilia. 
By neutralizing IL-10R in vivo during the first two weeks of anti-CD4 
treatment we could infer the participation of IL-10 in the mechanism 
leading to tolerance, but we could also establish the importance of that 
initial period for tolerance induction (Figure 2). This observation is 
consistent with the need to impose tolerance in antigen-specific cells 
during a window of time, after which the immune system regains the 
ability to respond to foreign antigens, as discussed above. In addition, by 
showing that repeated administrations of hFVIII (without alum) during 
those initial two weeks did not lead to long-term tolerance, as we 
observed when hFVIII-alum was used (Figure 1C), allowed us to exclude 
that tolerance facilitation by alum could be simply due to the “depot 
effect” leading to greater half-life of the antigen. 
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A usual concern in transplantation tolerance experiments is the 
influence of the genetic background in the results[229]. Some strains, 
namely C3H and CBA/Ca are known to be more permissive to the induction 
of transplantation tolerance than other strains like C57Bl/6 and BALB/c. In 
order to evaluate whether tolerance to hFVIII was strain-specific, we 
confirmed that long-term tolerance to hFVIII could be achieved in C57Bl/6 
and BALB/c mice, and in mice from those two strains deficient in FVIII 
(HemA mice). When we used hemophilic mice we could directly document 
the physiological impact of FVIII inhibitors, not only by their quantification 
using the Bethesda assay but also by our subjective assessment of bleeding 
from those mice. Treatment with hFVIII-alum + anti-CD4 led to long-term 
protection from the generation of inhibitors in the two strains of 
hemophilic mice. 
Several other MAbs targeting T cell co-receptors (namely anti-CD3) and 
co-stimulatory molecules have been shown effective in inducing immune 
tolerance in transplantation, autoimmunity, and allergic diseases[339, 
358]. Recently it was reported that antibodies targeting CD3 can induce 
long-term tolerance to FVIII in hemophilic mice[359]. In addition, MAb 
targeting ICOS are effective in inducing long term tolerance to hFVIII in 
mice, following gene therapy[343]. Concerning non-depleting anti-CD4 
there is, however, one special case of successful induction of long-term 
tolerance to foreign proteins in the absence of adjuvant – it is when the 
foreign protein is an immunoglobulin. In fact in some of the earliest 
demonstrations that non-depleting anti-CD4 can induce tolerance to 
foreign antigens, immunoglobulins (Ig) from different animal species were 
used as the tolerizing antigen[146, 147]. It is likely that the special 
tolerogenicity of foreign Ig compared with FVIII represents the fact that 
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antigen presenting cells can capture foreign Ig with specific Fc receptors 
for efficient presentation. 
Given the promising pre-clinical results, anti-CD4 MAb was among the 
very first MAb to enter clinical trials[329, 330]. The outcome of those early 
clinical trials was disappointing, which led to the search for alternative 
tolerance-inducing strategies. In retrospect, however, it is possible that the 
low efficacy was due to immaturity of the field. In fact, clinical trials in 
patients with rheumatoid arthritis and multiple sclerosis were not 
performed with  humanized MAb, and the low efficacy correlated well with 
the generation of Ig targeting the therapeutic MAb[331]. In addition, a well 
known clinical trial in asthma a different anti-CD4 MAb was used 
(keliximab) that caused significant T cell depletion[323]. More recently, 
pre-clinical studies with a humanized non-depleting anti-CD4 have shown it 
could induce tolerance in non-human primates to foreign Ig[217]. It is 
possible that the use of alum as an adjuvant, as we now describe, will allow 
tolerance induction to hFVIII but also to other therapeutic recombinant 
proteins, namely in enzyme replacement therapy.  
It is well established that the primed immune system is more resistant 
to tolerance inducing strategies. Nevertheless, most clinical situations 
would require tolerance induction in an immunized individual. In 
hemophilia, FVIII inhibitors are only produced in a proportion of patients. 
Therefore, tolerance induction should only be initiated in the patients that 
would require this intervention, and those patients can only be identified 
after the onset of inhibitors. However, the study of tolerance inducing 
strategies in mice previously immunized to hFVIII has been difficult due to 
the long half-life of hFVIII-specific IgG – the experimental readout. As a 
consequence, most studies in mice are restricted to the ability to induce 
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tolerance at the time of the initial exposure to hFVIII – an event that is 
controlled by the clinician. We developed an experimental system to study 
the effect of hFVIII-alum + anti-CD4 on the primed immune system (Figure 
5). Instead of removing pre-existent hFVIII-specific IgG by plasmapheresis – 
something that we could not do in mice – we transferred primed immune 
cells to a new host. This way it became possible to confirm that our 
protocol could prevent de novo production of hFVIII-specific antibodies by 
the primed cells. Such adoptive cell transfer system is unlikely to reproduce 
in its entirety the characteristics of a primed immune system. However, 
given the fact that anti-CD4 is able to prevent allergic airways disease in 
mice pre-sensitized to an allergen (house dust mite), it is likely that 
following clearance of circulating hFVIII inhibitors treatment with hFVIII-
alum + anti-CD4 will prevent subsequent antibody production. Consistent 
with our data, a report has shown that MAbs targeting ICOS and CD154 can 
prevent memory plasma cells to respond to FVIII[360].  
Taken together our results show that alum, in spite of its common use 
to boost immune responses, can be effective in enhancing the ability of 
non-depleting anti-CD4 MAb to induce long-term and antigen-specific 
tolerance to hFVIII in mice. The tolerogenic mechanism relies on IL-10 and 
is independent of Foxp3+ Treg cells. We believe that the use of alum, or 
other adjuvants, may constitute a strategy that could be applied to 
different immunogenic therapeutic proteins and other tolerance-inducing 
MAbs. In this case, our findings may be of interest beyond the field of 
hemophilia, namely in regard to enzyme replacement therapy. 
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Supplementary Figures 
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Supplementary Figure 1. Non-depleting anti-CD4 prevents production of 
hFVIII-specific IgG2a and IgG2b in HemA mice.  C57Bl/6 HemA (A, C) or BALB/c 
HemA mice (B, D) were treated with hFVIII-alum and anti-CD4 MAb (or an isotype 
control) as described in Figure 1A. The serum titres of hFVIII-specific IgG2a (A, B) 
or IgG2b (C, D) were quantified by ELISA at days 30 and 110 post-initial treatment. 
(A) The titre of hFVIII-specific IgG2a from C57Bl/6 HemA mice, at day 30 and at day 
90, following multiple exposures to hFVIII, was significantly reduced in mice 
treated with anti-CD4 (n=8; p<0.001).  (B) In BALB/c HemA mice there was no 
detectable hFVIII-specific IgG2a at day 30, but at day 90 there was a significant 
titre in mice treated with the isotype control (n=8; p<0.001). (C) Serum hFVIII-
specific IgG2b remained low in C57Bl/6 HemA mice throughout the experiment 
(n=8; non-significant). (D) BALB/c HemA mice displayed a significant increase in 
the serum titres of hFVIII-specific IgG2b at day 90, that was prevented following 
treatment with anti-CD4 (n=8; p<0.001). 
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Induction of Foxp3-independent dominant transplantation 
tolerance - Boosting immune tolerance by activation of 
complementary regulatory mechanisms 
 
Introduction 
 
Since the pioneering work of Medawar and colleagues several 
protocols have been proposed to achieve transplantation tolerance in the 
adult [352, 361-363]. One way to achieve robust tolerance is based on the 
induction of hematopoietic chimerism following transplantation of donor 
hematopoietic stem cells (HSC), leading to a recessive state of tolerance 
independent of Foxp3+ regulatory T (Treg) cells [364]. Other approaches, 
namely the use of monoclonal antibodies (MAbs) targeting T cell co-
receptors (CD3 or CD4) or co-stimulation (CD154), could lead to dominant 
transplantation tolerance in several animal models [142, 162, 365-368]. 
Such dominant tolerance was found to be associated with the peripheral 
induction of Foxp3+ Treg cells [340, 369]. In fact, it has been shown that 
Foxp3-deficient mice cannot be tolerized with protocols leading to 
dominant tolerance, such as non-depleting anti-CD4 [370]. 
Many MAbs that can induce dominant transplantation tolerance were 
also shown able to induce tolerance in autoimmunity, often associated 
with the induction of Foxp3+ Treg cells [371, 372], as well as tolerance to 
allergens or model antigens [373, 374]. 
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We became interested in the mechanisms leading to tolerance 
induction to antigens, and how adjuvants may influence the process 
following our observations that it is possible to induce tolerance to a 
protein with anti-CD4 in a mouse model of allergic airways disease [374], 
but difficult to induce tolerance to factor VIII (FVIII) with the same MAb (or 
with anti-CD154) in a mouse model of hemophilia [341, 342]. In fact, when 
the same antigen (FVIII) is expressed in tissues following gene therapy it 
can be readily tolerized [343] 
We therefore investigated the mechanisms leading to tolerance to a 
defined antigen (ovalbumin, OVA) when delivered as part of a skin graft 
(from OVA-actin transgenic mice) or delivered as OVA-alum i.p. We used 
OVA-specific TCR transgenic mice in two different genetic backgrounds 
(OT-II and DO11.10) and the same tolerance-inducing method (non-
depleting anti-CD4 MAb). 
Given the known association of Foxp3+ Treg cells and dominant 
tolerance, it was surprising to find that unlike tolerance to OVA-expressing 
skin grafts, the induction of tolerance to OVA-alum under CD4-blockade 
was Foxp3-independent as it could be induced in Foxp3-deficient mice. In 
this setting the tolerance induction triggered the reduction of the number 
of effector T cells, and simultaneously led to a IL-10-dependent tolerance 
state. It may therefore be possible to take advantage of Foxp3-
independent tolerance protocols to boost the efficacy of tolerance-
dependent tolerance induction. 
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Materials and methods 
 
Animals. C57Bl/6, BALB/c, C57BL/6-Tg(ACTB-OVA)916Jen/J (Jackson 
Laboratories), OT-II.Rag1-/- (Taconic), DO11.10.Rag1-/- (Jackson 
Laboratories), C57Bl/6.IL-10-/-, C57Bl/6.Rag2-/-, OT-II, DO11.10 and 
Wsh/Wsh mice were bred and maintained under specific pathogen-free 
(SPF) facilities at the Instituto Gulbenkian de Ciência. Experimental animals 
were sex-matched and between 6 and 8 weeks of age. The T/B monoclonal 
mice (T-Bmc, 17/9 DO11.10.RAG1-/-) bear monoclonal populations of T and 
B lymphocytes specific for chicken ovalbumin (OVA) 323–339 and HA of 
influenza virus, respectively [345]. These mice were kept under SPF 
conditions at the Skirball Institute Central Animal Facility, New York 
University Medical Center.  
Transplantation. Transplantation experiments were conducted by 
grafting full thickness skin on the lateral flank of recipient mice. Grafts 
were observed daily and considered rejected when no viable donor skin 
was present.  Procedures were conducted in accordance with guidelines 
from the Animal Use and Institutional Ethical Committees and approved by 
Direcção Geral de Veterinaria or New York University School of Medicine 
Institutional Animal Care and Use Committee (New York).  
Sensitization. Animals were sensitized, at the times described in the 
text, by i.p. injection of 10 µg of ovalbumin (OVA, grade V; Sigma, St Louis, 
USA) or β-lactoglobulin (Sigma), previously run through a DetoxyGel 
column (Pierce, Rockford, USA) following manufacturer instructions, and 
suspended in 2.0 mg of endotoxin-free aluminum hydroxide (Alu-gel-S, 
Serva, Heidelberg, Germany). Mice were intranasally challenged with 50 µg 
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of OVA in pyrogen-free saline and sacrificed 24 hours after the last 
challenge.  
Antibodies. Non-depleting anti-CD4 (YTS177) [153] and the isotype 
control rat anti-dog CD4 (YKIX302) MAbs were produced in our laboratory 
using Integra CL1000 flasks (IBS, Chur, Switzerland), and purified from 
culture supernatants by 50% ammonium sulfate precipitation, dialyzed 
against PBS, and the purity checked by native and SDS gel electrophoresis. 
The hybridomas were generously provided by Professor Herman 
Waldmann (Oxford, UK).  
Bronchoalveolar Lavage (BAL). The airways were washed through the 
trachea by slowly infusing and withdrawing 1 ml of cold PBS 10% BSA 
(Sigma) three times. Eosinophilia was quantified by flow cytometry using 
GR-1-FITC (eBiosciences, San Diego, CA, USA), CCR3-APC (BD Pharmingen, 
San Diego, USA), and MHC-class II-Percp.Cy5.5 (eBiosciences, San Diego, 
CA, USA), with the eosinophils identified based on the SSC/FSC profile and 
as the GR1intMHCclass II-CCR3- cells [326]. 
Histology. Lungs were perfused with 4% formalin solution (Sigma), 
collected and sectioned. Staining was performed using hematoxilin/eosin, 
and mucus containing cells were revealed using a periodic acid-Schiff (PAS) 
stain. Photographs were taken using a Leica DM2500 microscope and a 
Leica DFC420 camera.  
Quantification of immunoglobulins and cytokines. Serum titers of OVA-
specific IgG1, IgG2a, and IgE were measured by ELISA using the following 
kits: IgG1 and IgG2a (SouthernBiotech, Birmingham, USA) with anti-OVA 
IgG1 standard from Serotec, Oxford, UK; IgE (BD-Pharmingen) with anti-
OVA IgE standard from Abcam (Cambridge, UK). Cytokine titers were 
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determined in fresh lung tissue homogenate supernatants. Lung tissue was 
collected, homogenized in 100 mg/ml in HBSS (Gibco, Carlsbad, USA), 
centrifuged at 800g for 10 min and the supernatant collected. The ELISA 
assays were performed according to manufacturer’s instructions using the 
following kits: IL-13(Peprotech, London, UK); IL-4 and IL-5 (BD-
Pharmingen). 
CFSE staining and adoptive cell transfers. Single cell suspensions from 
spleen and LN from DO11.10.Rag-/- mice were ressuspended at 5x107 
cells/ml and stained with 5 μM of Carboxyfluorescein succinimidyl ester 
(CFSE, Invitrogen, Carlsbad, USA). The cells were washed, ressuspended in 
saline and injected i.v., in the tail vein of BALB/c mice at a total of 3.5x107 
cells per animal.  
Flow cytometry. Cells were stained for flow cytometric analysis with 
CD25-AlexaFluor488 (PC61; produced and conjugated in house), CD25-PE-
Cy7 (PC61.5; eBioscience), CD3-PE-Cy7 (145-2C11; eBioscience), CD8-APC-
AlexaFluor750 (53-6.7;), CD4-PerCp (RM4-5; BD Pharmigen), the DO11.10 
TCR-specific KJ1-26 MAb conjugated with PE or APC (BD Pharmigen) and 
Vβ5.1/5.2 TCR-FITC (MR9-4; eBioscience) plus Vα2 TCR-eFluor 450 (B20.1; 
eBioscience)  were used to determine the TCR transgenic populations in 
the OT-II mice. Cells were then washed and fixed using Foxp3 Staining Set 
(eBioscience). The cells were stained for intracellular cytokines and Foxp3 
with Foxp3-APC (FJK-16s; eBioscience), IFN-γ-FITC (XMG1.2; eBioscience), 
IL-13-PE (eBio13A; eBioscience), IL-4-FITC (BVD6-24G2; eBioscience) and IL-
5-APC (TRF K5; BD Pharmigen). Apoptotic cells were identified with 
Annexin V-biotin (BD Pharmigen) and Streptavidin-APC-Cy7 (eBioscience) 
labeled in Annexin V Binding Buffer (BD Pharmigen) according to 
manufacturer protocol. Propidium iodide solution was added right before 
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the cells were analyzed. Four and six color analyses were performed using 
a LSR Fortessa (BD Bioscience). The analysis gate was set on the forward 
and side scatters to eliminate cell debris and dead cells.  
Statistical analysis. Statistical significance was determined using the 
two-tailed non-parametric Mann-Whitney test and the log rank method. 
Statistical analysis was performed using Prism 4.0 (GraphPad, San Diego, 
USA) and P values <0.05 were deemed significant (*, P<0.05; **, P<0.01; 
***, P<0.001). 
 
Results 
 
CD4-blockade can induce immune tolerance to OVA in TCR-
transgenic mice. 
 
We have previously shown that long-term antigen-specific tolerance to 
allergens (house dust mite) can be achieved in mice [374]. The cellular and 
molecular mechanism underlying the tolerance state remained, however, 
to be elucidated. In order to follow the fate of antigen-specific cells as 
tolerance is established we used TCR-transgenic mice. We first investigated 
in DO11.10 mice whether tolerance to a model antigen (OVA) could still be 
induced when most of the T cell repertoire is directed towards that 
antigen. We found that CD4-blockade could prevent allergic airways 
disease induced with OVA in OVA-specific TCR-transgenic mice (Figure 1). 
DO11.10 mice treated with non-depleting anti-CD4 were protected from 
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peri-bronchiolar inflammatory infiltrates and hyperplasia of goblet cells 
(Figure 1A) as well as airways eosinophilia (Figure 1B). Furthermore the 
titers of OVA-specific IgG1 and IgE were significantly reduced in anti-CD4-
treated mice (Figure 1D, E). We also found that CD4-blockade prevented 
an increase in the concentration of Th2-type cytokines (IL-4, IL-5, and IL-13) 
compared to animals treated with an isotype control (Figure 1F). We 
confirmed that these results are reproducible in a distinct genetic 
background using OT-II mice, a second strain of OVA-specific TCR-
transgenic animals (Supplemental Figure 1). Note that the isotype of the 
anti-CD4 MAb is non-depleting as we have shown, for instance, by showing 
that it does not lead to alteration of the number of CD4 T cells in vivo that 
are not engaged in an immune response at the time of antibody treatment 
[372].  
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Figure 1. Tolerance induction with non-depleting anti-CD4 MAb is robust 
enough to prevent allergic airways disease in TCR transgenic mice. (A) OVA-specific 
female DO11.10 mice were sensitized with 20 μg OVA-alum i.p. and challenged 
with 50 μg OVA in saline i.n. on the indicated days. Some animals were treated 
with 1 mg anti-CD4 or an isotype control. Naive animals, not subjected to any 
intervention, were also studied as a control group. (B) Histological sections of lung 
tissue were stained with haematoxylin/eosin (left) and PAS (right). Airways from 
anti-CD4 treated mice show a reduction in the inflammatory infiltrate and an 
absence of goblet cell hyperplasia. Scale bar: 100 μm (25 μm in the inset). (C) Mice 
treated with anti-CD4 have a reduced number of eosinophils in the BAL (n=6, 
P<0.01). (D) The serum levels of OVA-specific IgG1 and (E) IgE are significantly 
reduced in anti-CD4 treated mice (n=6, P<0.001). (F) The concentration of Th2-
type cytokines (IL-4, IL-13 and IL-13) in lung homogenates were markedly 
diminished in anti-CD4 treated mice (n=6, **P<0.01 or ***P<0.001).  (A-F) Data 
are representative of two independent experiments. 
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Overall, these results show that CD4-blockade is able to prevent 
allergic airways disease, even in TCR-transgenic mice where most T cells 
are specific to the antigen driving the pathology. 
Immune tolerance to OVA is Foxp3-independent 
 
Given the high frequency of OVA-specific T cells, and the ability to 
identify these cells, it was possible to monitor changes in the frequency of 
OVA-specific T cells with different functional characteristics. Mice treated 
with anti-CD4 MAb showed a reduced frequency of Th2-type OVA-specific 
T cells in the mediastinal lymph nodes (MLN) (Figure 2A). In addition, these 
animals did not show an increased number of Th1 IFN-γ+ cells (Figure 2A). 
We also found that the frequency of OVA-specific Foxp3+ Treg cells did not 
change with the tolerogenic treatment (Figure 2B). Furthermore, 
DO11.10.Rag-/- mice, devoid of thymic derived Foxp3+ Treg cells [4], 
subjected to the same tolerance induction protocol did not develop 
detectable Foxp3+ T cells in the spleen or LNs (Figure 2C). 
Previous studies in transplantation have implicated the de novo 
generation of Foxp3+ Treg cells, in a TGF-β-dependent process, in 
tolerance induced with anti-CD4 or co-stimulation blockade [340, 369]. 
Furthermore, mast cells were shown to be critical for the establishment of 
such transplantation tolerance [375].  
We used mast cell deficient Wsh/Wsh mice, with a mutant allele at the 
W (c-kit) locus, to investigate whether mast cells were required for 
tolerance induction [376, 377]. The sensitization protocol was slightly 
modified in order to maximize airways inflammation in the C57Bl/6 genetic 
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background, with three injections of 10 µg OVA-alum on days 1, 7, and 14. 
The animals received three i.p. injections of MAb on days 0, 2, and 14. We 
observed that mast cell deficient mice treated with anti-CD4 are protected 
from airways allergic inflammation to the same extent as littermates with 
normal numbers of mast cells (Figure 2D). 
 
Figure 2. CD4-blockade leads to reduction of Th2 cells without concomitant 
Treg expansion. (A) OVA-specific T cells in MLN containing IL-4, IL-5, and IL-13 from 
animals treated with anti-CD4 MAb were reduced to numbers similar to mice not 
Results - Induction of Foxp3-independent dominant tolerance  
Ana Água-Doce Page 123 
 
exposed to OVA  (n=6, **P<0.01), while the number of IFN-γ+ OVA-specific T cells 
did not increase. (B) The frequency of OVA-specific Foxp3+ Treg cells remained 
unchanged in anti-CD4 treated mice. (C) There is no induction of Foxp3+ cells in 
DO11.10 Rag-/- animals treated with anti-CD4 MAb (D) Tolerance to OVA can be 
induced in mast cell deficient mice. We quantified BAL eosinophils from mast cell-
deficient Wsh/Wsh mice and wild-type (WT) littermates sensitized in the presence 
of anti-CD4 or an isotype control (as described in Figure 1A). Protection from 
airways eosinophilia following CD4-blockade was similar in both groups of mice 
(n=4, *** P<0.001). (E) BALB/c mice, treated as described in Figure 1A, were also 
injected with 1 mg of a neutralizing anti-TGF-β MAb on days -1, 2, 7, 13, 15. 
Neutralizing MAbs did not abrogate the protective effect of CD4-blockade (n=6, 
*P<0.05). (F) Eosinophils in the BAL of T-Bmc Foxp3sf mice and T-Bmc Foxp3-
sufficient littermates sensitized with OVA-HA-alum and challenged with OVA-HA 
i.n. according to the protocol described in Figure 1A. CD4-blockade prevented BAL 
eosinophilia in Foxp3-deficient mice, as well as in Foxp3 sufficient controls (n=8, 
P<0.001). (G) We also confirmed that Foxp3 deficient mice treated with anti-CD4 
had low levels of serum IgE (n=8, P<0.001). (H) Furthermore, the antigen-specific T 
cells (TCR transgenic) from Foxp3-deficient mice exposed to CD4-blockade did not 
polarize towards an IL-4, IL-5 or IFN-γ producing phenotype (n=8, P<0.001).  (A-H) 
Data are representative of two independent experiments. 
 
We also neutralized TGF-β (using the MAb 1D11) in BALB/c mice during 
tolerance induction. This neutralization did not hamper protection from 
allergic airways disease (Figure 2E). 
In order to definitely exclude a contribution for Foxp3+ Treg cells from 
tolerance induction with anti-CD4 we used T-Bmc.Rag-/- mice deficient in 
Foxp3 (T-Bmc Foxp3sf) [326]. These mice bear OVA-specific TCR transgenic 
T cells and HA-specific BCR knock-in B cells. They do not develop an 
autoimmune condition in the absence of Foxp3 since all their lymphocytes 
are monoclonal and non-self reactive. These mice were sensitized with 
OVA-HA-alum i.p., and latter exposed to OVA-HA i.n. Foxp3-deficient 
animals treated with anti-CD4 displayed similar protection from allergic 
airways disease as Foxp3 sufficient littermates (Figure 2F). The Foxp3 
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deficient animals were also prevented from generating IgE and did not 
display an increase in Th2 cells in MedLN (Figure 2G, H).  
 
Tolerance induction to OVA-expressing skin grafts in TCR-transgenic mice 
with CD4-blockade is Foxp3-dependent  
 
Given that our data on tolerance induction is independent of Foxp3 in 
OVA-specific TCR transgenic mice, is in apparent contradiction with 
previous reports showing transplantation tolerance in TCR-transgenic mice 
is Foxp3 dependent [340, 369], we assessed whether in OVA-specific TCR-
transgenic mice tolerance could be induced to OVA-expressing skin grafts. 
We transplanted OT-II.Rag-/- mice with skin from OVA-actin transgenic 
mice. The animals were treated with 1 mg anti-CD4 (or isotype control) on 
day 0 and 2 after transplantation. We found CD4-blockade induced long-
term skin graft survival (Figure 3A), with these mice showing a population 
of induced Foxp3+ Treg cells in draining LN and spleen (Figure 3B). To prove 
the Foxp3-dependency of transplantation tolerance we repeated the 
experiment with Foxp3-deficient OT-II.Rag-/-.Foxp3sc mice. We found that 
animals lacking functional Foxp3 could not be tolerized and readily 
rejected the skin grafts (Figure 3C). 
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Figure 3. Acceptance of OVA-expressing skin grafts by TCR-transgenic mice 
following CD4-blockade is Foxp3-dependent. (A) OT-II.Rag-/- mice were 
transplanted with skin grafts from OVA-actin transgenic mice in the presence of 
anti-CD4 MAb or an isotype control. Treatment with anti-CD4 led to long term 
acceptance of skin grafts in most animals (■, n=6, median survival time (MST)>100 
versus ● MST=10d in the isotype control group; ***P<0.001). (B) We observed the 
emergence of Foxp3+ Treg cells in the animals tolerized to OVA-expressing skin 
grafts (n=6, P<0.05). (C) The same experimental protocol in Foxp3-deficient OT-
II.Rag-/-.Scurfy mice failed to prolong graft survival (■, n=4, MST=13d). Transplant 
rejection occurred at the same time as control OT-II.Rag-/- (◌, n=4, MST=12d) or 
OT-II.Rag-/-.Scurfy mice (●, n=4, MST=13d) treated with an isotype control. (A-C) 
Data are representative of two independent experiments. 
 
Tolerance induction with OVA-alum + anti-CD4 has a recessive and 
dominant component  
 
To investigate the impact of anti-CD4 treatment in T cell proliferation 
and survival, CFSE-labeled OVA-specific T cells from DO11.10.Rag-/- mice 
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were adoptively transferred into BALB/c mice. The host animals were 
sensitized with OVA-alum i.p. in the presence or absence of anti-CD4 
treatment. Lung, mediastinal LN (MLN), mesenteric LN, and spleen T cells 
were isolated at day 4 and 7 following treatment and analyzed by flow 
cytometry. 
Consistent with a recent report on T cell response to OVA-alum 
administered i.p. [378], MLN displayed the highest number of T cells 
responding to the antigen. An observation of the CFSE dilution profile in 
OVA-specific T cells isolated from MLN may suggest that anti-CD4 
treatment prevents T cell proliferation, as the undivided cells are a greater 
proportion of the TCR-transgenic population unlike in mice injected with 
OVA alone (Figure 4A). But if anti-CD4 would exclusively target T cell 
proliferation one would expect the absolute number of TCR transgenic 
cells recovered from the undivided CFSE gate to be similar in mice treated 
with anti-CD4 and animals not exposed to OVA where cells do not divide at 
all. The enumeration of undivided and divided TCR transgenic cells from 
the different experimental groups does not support the hypothesis of 
inhibition of proliferation (Figure 4B). In fact, the number of undivided cells 
from anti-CD4 treated animals was remarkably similar to animals treated 
with OVA alone, where extensive proliferation does occur, and significantly 
lower than animals not treated with OVA. The difference between OVA 
and OVA + anti-CD4 treated groups is not in the undivided T cells but 
rather on the accumulation of T cells that underwent cell divisions. Given 
these data, either the anti-CD4 treatment is targeting the deletion of 
undivided cells or inducing the cell death of T cells entering cell cycle. 
The analysis of the TCR transgenic cells positive for the apoptosis 
marker annexin V showed that the frequency of apoptotic cells was similar 
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between undivided cells from all experimental groups (Figure 4C). Only the 
cells undergoing cell divisions from anti-CD4 treated mice had a significant 
increase in the frequency of apoptotic cells. As a consequence, besides a 
possible effect on T cell proliferation, anti-CD4 treatment preferentially 
induces the apoptosis of activated cells.  
 
Figure 4. Tolerance induction with anti-CD4 leads to reduction of effector T 
cells and emergence of an anergic and regulatory T cell population. Splenic and LN 
T cells from DO11.10.Rag-/- mice were stained with CFSE and injected i.v. into sex-
matched BALB/c hosts. Recipient mice were then treated with OVA-alum i.p. in 
presence or absence of anti-CD4. Control animals were not exposed to OVA. (A) 
Analysis of MLN at day 4. Dot plots were gated on CD3+ T cells. The numbers 
represent the frequency of T cells within the TCR transgenic cells. (B) Absolute 
number of DO11.10.Rag-/- cells recovered from MLN contained in each of the CFSE 
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regions displayed in (A). The difference in cell frequency between undivided cells 
from mice not injected with OVA is significantly higher than T cells from mice 
treated with OVA or OVA+anti-CD4 (n=5, *P<0.05). (C) Frequency of apoptotic cells 
(labelled with annexin V) within cells that did not divide or cells that have divided. 
The frequency of apoptotic cells is significantly higher within the T cells 
undergoing cell divisions from anti-CD4 treated animals (n=5, P<0.05). (D, E) In 
vitro proliferation of CFSE labelled OVA-specific T cells from DO11.10.Rag-/- mice 
(naive, or sensitized with OVA with or without anti-CD4) following three day 
culture in presence of DCs from BALB/c mice and OVA323-339 peptide. OVA-specific 
T cells from mice tolerized with anti-CD4 show impaired proliferative ability (n=6, 
***P<0.001). (F, G) Proliferation of CFSE-labelled T cells from naive OT-II.Rag-/- 
mice co-cultured for three days with T cells sorted from naïve, isotype, or anti-CD4 
treated DO11.10.Rag-/- mice. Stimulation was provided by DCs from (BALB/c x 
C57Bl/6) F1 mice loaded with OVA323-339  peptide. The OVA-specific T cells sorted 
from mice tolerized to OVA, but not from other mice, were able to prevent 
proliferation of effector OT-II cells (n=6, **P<0.01).  
 
However, some antigen-specific cells can still be isolated from tolerant 
mice, particularly when tolerance is induced in TCR-transgenic mice. We 
therefore investigated the in vitro properties of OVA-specific T cells from 
DO11.10.Rag-/- mice tolerized with the protocol described. By labeling the 
cells with CFSE and incubating those with OVA loaded bone marrow DCs; 
we could compare the proliferative ability of the OVA-specific T cells 
isolated from naive mice, mice sensitized with OVA-alum, or animals 
treated with anti-CD4 at the time of OVA-alum sensitization. We found 
that cells from tolerized mice proliferated less than T cells from the other 
two groups with a significant arrest in a non proliferative state (Figure 4D, 
E). 
To investigate whether these cells are suppressive, we labeled OVA-
specific T cells from naive OT-II mice with CFSE, and incubated these 
responder cells with OVA-specific cells from DO11.10.Rag-/- mice (naive, 
sensitized with OVA-alum, or tolerized with OVA-alum + anti-CD4). The 
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antigen presenting cells were OVA-loaded DCs from (BALB/c x C57Bl/6)F1 
mice, able to present OVA-peptides both in the context of H-2b and H-2d 
(therefore excluding a possible competition effect of both T cell 
populations for the same MHC molecules). We found that T cells from 
tolerant mice moderately suppress the proliferation of responder OT-II 
cells (Figure 4F, G). 
Taken together, these data show that CD4-blockade induces a 
significant reduction of effector T cell numbers by apoptosis and, 
simultaneously, the surviving T cells display moderate anergic and 
suppressive properties. 
 
IL-10 is critical for tolerance induction  
 
We then investigated whether the dominant component of the 
tolerance state was IL-10 dependent. For that we compared tolerance 
induction to OVA-expressing skin grafts or to OVA-alum in WT and IL-10-
deficient hosts.  
In transplantation experiments we found that transplantation 
tolerance could be readily achieved in WT mice but not in IL-10-/- mice 
treated with anti-CD4 (Figure 5A). 
Similarly, when IL-10-/- mice were sensitized with OVA-alum i.p. in 
presence of anti-CD4 they did not become protected from allergic airways 
disease as it was manifest by airways eosinophilia (Figure 5B). 
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Figure 5. Induction of immune tolerance with anti-CD4 is IL-10-dependent. (A) 
IL-10-/- mice and WT controls were transplanted with skin grafts from OVA-actin 
transgenic mice in the presence of anti-CD4 MAb. The grafts were rejected in anti-
CD4-treated IL-10-/- mice (■, n=5, MST=13d) at the same time as in untreated WT 
(□, n=6, MST=12d) or untreated IL-10-/- mice (●, n=5, MST=13d). (B) Allergic 
airways disease was induced in IL-10-/- mice and WT controls, some animals were 
treated with non-depleting anti-CD4 as described in Figure 1A. We used BAL 
eosinophilia as a surrogate marker of allergic airways disease. We found that CD4-
blockade could prevent airways eosinophilia in WT but not in IL-10-/- mice (n=6, 
***P<0.001). 
 
Tolerance induction to OVA-alum can lead to OVA-expressing skin graft 
acceptance 
 
Given the different requirement of Foxp3 expression when tolerance 
was induced to an OVA-expressing skin graft or to OVA-alum administered 
i.p. we investigated whether transplant acceptance or protection from 
allergic airways disease required a specific type of tolerance induction. 
First, we induced tolerance to OVA-expressing skin graft in C57Bl/6 mice, 
as described above. Then, at day 30 transplanted mice treated with anti-
CD4 (all with surviving skin grafts) or treated with an isotype control (all 
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rejected) were sensitized with OVA-alum i.p. and subsequently challenged 
with OVA i.n. as represented in Figure 6A. The challenge with OVA-alum 
did not lead to graft rejection and the tolerant mice were protected from 
airways eosinophilia to the same extent as mice treated with anti-CD4 at 
the time of OVA-alum sensitization (Figure 6C). 
We then performed the converse experiment: C57Bl/6 mice were 
tolerized to OVA-alum or the unrelated antigen β-lactoglobulin (β-Lg)-alum 
by concomitant treatment with anti-CD4 MAb (Figure 6D). At day 30 
following the last administration of the antigen all mice were transplanted 
with OVA-expressing skin grafts. We found that mice tolerized to OVA-
alum i.p. accepted the OVA expressing skin grafts. On the contrary, mice 
treated with anti-CD4 in presence of an unrelated antigen (β-Lg) readily 
rejected the OVA-expressing skin grafts. 
These data show that the tolerance state is antigen specific (as mice 
tolerized β-Lg do not support survival of grafts bearing a different antigen), 
and also show that tolerant mice remain competent to mount immune 
responses to unrelated antigens. 
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Figure 6. Tolerance induction to OVA-alum can lead to subsequent skin graft 
acceptance. (A) C57Bl/6 mice received skin grafts from OVA-actin transgenic mice 
in the presence of anti-CD4 MAb. On day 30 after transplantation the mice were 
sensitized with OVA-alum i.p. and challenged with OVA i.n. according to the 
scheme. (B) Mice tolerant to OVA-expressing skin grafts did not reject the 
transplants following sensitization with OVA-alum at day 30 and 44 (n=6, MST=12d 
vs. MST>60d, ***P<0.001). (C) Mice tolerant to an OVA-expressing skin graft were 
resistant to the induction of allergic airways disease with the same antigen, to the 
same extent as mice treated with anti-CD4 at the time of OVA-alum exposure. On 
the contrary, those animals that had rejected the skin graft had more exacerbated 
BAL eosinophilia (n=6, MST=12d, ***P<0.001). (D) C57Bl/6 mice were tolerized to 
OVA-alum or β-LG-alum by concomitant administration of anti-CD4. On the day 30 
following last MAb infusion these animals were transplanted with skin grafts from 
OVA-actin transgenic mice. (E)  Tolerance induction with OVA-alum and anti-CD4 
30 days prior to transplantation was sufficient for long-term graft acceptance in 
the absence of additional treatment (■, n=6, MST>60, P<0.01). However, mice 
tolerized to an unrelated third-party antigen (β-LG) rejected their grafts at the 
same time as animals that did not receive anti-CD4 (● and ▲, n=6, MST=14d). 
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Discussion 
 
Our data show that the same tolerance-inducing agent (non-depleting 
anti-CD4 MAb) can trigger different mechanisms leading to dominant 
tolerance depending on the context by which the antigen is presented to 
the immune system. Using TCR transgenic mice it was possible to 
demonstrate that tolerance to an antigen in a skin graft requires the 
peripheral induction of Foxp3+ Treg cells, while the delivery of the same 
antigen through the i.p. route with an adjuvant (alum) triggers a Foxp3-
independent tolerance mechanism that relies on IL-10 and apoptosis of 
effector cells. 
Our data demonstrates the critical role of the context in which an 
antigen is perceived by the immune system for therapeutic induction of 
tolerance. In fact, it has been paradoxical that the same reagents (such as 
non-depleting anti-CD4 or anti-154) can readily induce transplantation 
tolerance to multiple alloantigens [162, 366], including major antigens 
[162, 366], fail to achieve long-term tolerance to single proteins in the 
same mouse strains [341, 342]. However, the same antigen (FVIII) that is 
not tolerized when administered i.v. in the absence of adjuvants [341, 
342], appears to be easier to tolerize when expressed in tissues following 
transduction with viral vectors [343]. Our previous findings showing that 
robust dominant tolerance can be induced to allergens (house dust mite) 
in alum [374]  raised the hypothesis that it is necessary some adjuvanticity 
to achieve tolerance with MAbs that target T cell co-receptors or co-
stimulation. Such adjuvanticity can be provided by tissue inflammation (in 
transplantation or viral transduction) or with the use of an adjuvant like 
alum. 
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When we investigated the mechanisms leading to immune tolerance 
induced with OVA-alum administration under CD4-blockade it came as a 
surprise that the tolerance state was Foxp3-independent. In fact, most 
studies using anti-CD4 (or MAbs targeting other T cell molecules) have 
shown that tolerance was a consequence of peripheral Foxp3+ Treg 
induction and could not be induced in the absence of functional Foxp3 
[340, 370]. Importantly, the tolerance state achieved is long term, as mice 
tolerized with OVA-alum + anti-CD4 accept indefinitely OVA-expressing 
skin grafts at a later time as shown in Figure 6. In addition the tolerance 
state is antigen specific and not due to persistence of the tolerance-
inducing MAbs, because mice tolerized with β-LG-alum + anti-CD4 reject 
OVA-expressing skin grafts. These data also demonstrate that tolerant 
animals remain immunecompetent to mount immune responses towards 
unrelated antigens. 
By performing adoptive cell transfers of OVA-specific T cells into WT 
mice, we could follow the fate of antigen-specific cells as tolerance is 
induced. We found that CD4-blockade at the time of exposure to the 
antigen as an effect not only restricted to inhibition of proliferation but 
also favors apoptosis of the cells as they enter cell cycle. We have recently 
investigated the impact CD4-blockade, in vitro, at the time of activation 
where we found that the impact on the rate of cell proliferation and 
apoptosis is small, but with the assistance of mathematical models it was 
possible to demonstrate that such small effects over time lead to a major 
difference in the final outcome (Caridade et al, submitted). Previous 
studies with co-stimulation blockade had also shown that activation under 
those tolerogenic conditions lead to apoptosis of effector cells [280, 364, 
372], but in that case together with the induction of Treg cells [159, 343]. 
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We now found that the impact of apoptosis on the antigen specific T cells 
is not complete, with several cells surviving deletion. When we assessed 
those surviving antigen-specific cells we found that they have an anergic 
and immunosuppressive behavior in spite of lack of Foxp3 expression.  
We found that IL-10, unlike Foxp3, is key for the induction of immune 
tolerance. The implication of IL-10 in transplantation tolerance has been 
controversial with several studies able to demonstrate long-term 
transplantation tolerance in the absence of IL-10 [158, 340, 379]. The 
majority of studies that have shown a strong IL-10 requirement for 
transplantation tolerance have used donor blood transfusion as part of the 
tolerance inducing regimen [351, 353, 380]. It is possible that the systemic 
delivery of antigens mimics the boosting of an IL-10 dependent mechanism 
(in addition to the recessive mechanisms associated to apoptosis and 
inhibition of proliferation) that we described for OVA-alum. However, we 
found that in transplantation tolerance of OVA-expressing skin grafts IL-10, 
in addition to Foxp3, is essential even in the absence of donor blood 
transfusion. 
Given the fact that dominant transplantation tolerance can be 
extended to additional antigens present in a new transplanted tissue by a 
mechanism that was termed linked suppression [343], it may be possible to 
use immune dominant alloantigens to boost tolerance to tissues through a 
Foxp3-independent mechanism. But more important is the realization that 
effective tolerance to proteins, such as in allergic diseases or protein 
replacement therapies (namely in hemophilia or lysossomal storage 
diseases), may involve robust tolerance mechanisms that are independent 
of Foxp3.  
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Supplementary Figures 
 
Supplementary Figure 1. Tolerance induction with OVA-alum can improve 
subsequent skin graft acceptance in Foxp3 deficient mice. (A) OT-II Rag-/- Foxp3 
sufficient and insufficient mice were trated with OVA-alum in the presence of anti-
CD4. On day 30 after treatment, mice received skin grafts from OVA-actin 
transgenic mice in the presence of anti-CD4 MAb according to the scheme. (B) 
Foxp3 sufficient mice treated with OVA-alum were tolerant to OVA-expressing skin 
grafts and did not reject the transplants (n=6, MST=12d vs. MST>60d, ***P<0.001) 
Foxp3 insufficient mice showed a delayed rejection with some grafts surviving long 
term (n=3, MST=32). (C) Foxp3 sufficient mice induced low frequency of Foxp3+ T 
cells (n=6, MST=12d, ***P<0.001). (D) Ilustrative dot plots of CD25+Foxp3+ T cells 
within the OT-II T cell gate. 
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Supplementary Figure 2. Tolerance induction with non-depleting anti-CD4 
MAb is robust enough to prevent allergic airways disease in TCR transgenic mice. 
(A) OVA-specific female OT-II were sensitized with 20 μg OVA-alum i.p. and 
challenged with 50 μg OVA in saline i.n. as in Figure 1. Some animals were treated 
with 1 mg anti-CD4 or an isotype control. Naive animals, not subjected to any 
intervention, were also studied as a control group. Mice treated with anti-CD4 
have a reduced number of eosinophils in the BAL (n=6, P<0.01). The serum levels 
of OVA-specific IgG1 and (E) IgE are significantly reduced in anti-CD4 treated mice 
(n=6, P<0.001, **P<0.01 or ***P<0.001). Data are representative of two 
independent experiments. 
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Supplementary Figure 3. Tolerance induction with anti-CD4 leads to reduction 
of effector T cells and emergence of an anergic and regulatory T cell population. 
Splenic and LN T cells from OT-II.Rag-/- mice were stained with CFSE and injected 
i.v. into sex-matched BALB/c hosts. Recipient mice were then treated with OVA-
alum i.p. in presence or absence of anti-CD4. Control animals were not exposed to 
OVA. (A) Analysis of MLN at day 4. Dot plots were gated on CD3+ T cells. The 
numbers represent the frequency of T cells within the TCR transgenic cells. (B) 
Absolute number of OT-II.Rag-/- cells recovered from MLN contained in each of the 
CFSE regions displayed in (A). The difference in cell frequency between undivided 
cells from mice not injected with OVA is significantly higher than T cells from mice 
treated with OVA or OVA+anti-CD4 (n=5, *P<0.05). (C) Frequency of apoptotic cells 
(labelled with annexin V) within cells that did not divide or cells that have divided. 
The frequency of apoptotic cells is significantly higher within the T cells 
undergoing cell divisions from anti-CD4 treated animals (n=5, P<0.05). 
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The use of monoclonal antibodies targeting specific molecules has 
become an emerging therapy for immune mediated pathologies. 
Monoclonal antibodies have been used to neutralize inflammatory 
mediators [381], to deplete cells [382], to skew the immune responses 
[196], namely by reprogramming the immune system towards tolerance 
[383]. Antibodies targeting the immune synapse have been described to 
induce putative Tregs that can suppress effector responses [34, 159] thus 
tipping the balance towards a tolerant state of the immune system. 
This thesis focuses on CD4 blockade,  which has been shown to be 
very effective in preventing transplant rejection and autoimmunity [357, 
384] through the induction of a regulatory specific population of Foxp3+ T 
cells [148, 159]. In addition the tolerogenic effect of CD4 blockade 
molecule was shown effective in preventing immune responses to soluble 
proteins, therefore having a beneficial effect on pathogenic Th2 responses, 
namely in allergic diseases. The mechanism associated with type of 
tolerance induction, however, seems to be distinct from the tolerant state 
induced in the context of autoimmunity or transplantation. 
Airways inflammation induced by HDM or OVA in mice allowed us 
to show that CD4 blockade is effective in inhibiting airways hyperreactivity 
and remodeling, as well as in abrogating Th2 inflammation. Moreover, and 
for the first time, we were able to show that anti-CD4 treatment, in this 
animal model of allergic pathology, was not only exerting an anti-
inflammatory role but also, and most importantly, creating a state of 
antigen-specific tolerance. As a consequence, subsequent sensitization and 
challenges with the same antigen do not result in inflammation, while the 
immune system remained competent to respond to third-party antigens. A 
plethora of studies where co-stimulatory and co-activator blocking agents 
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were used did not distinguish the impact of the therapeutic agent on the 
onset of inflammation from its potential tolerogenic role [178, 179, 193, 
196]. The antigen-specific nature of therapeutically induced tolerance is 
not easy to demonstrate without crisscross type assays, given potential 
differences in the “immunogenicity” of different antigens. Therefore, it is 
necessary to show that the immune system tolerized to a given X protein 
can respond to a different Y one, but conversely it is possible to induce 
tolerance to Y, with the tolerant immune system capable to respond to X. 
This demonstration is of paramount importance to distinguish a state of 
immune tolerance from non-specific immune suppression. In the present 
studies we have shown that CD4 T helper cell responses remained 
unaffected, while other studies have previously shown that CD4 blockade 
does not impact on the CD8 T cell compartment [385]. We took particular 
care to separate in time the tolerization and sensitization stages as to avoid 
any residual presence of the anti-CD4 MAb. Another crucial finding was 
that primed cells are still susceptible to the tolerizing effect of anti-CD4. 
Previous studies have shown that non-depleting anti-CD4 preferentially 
eliminated naive CD4+ T cells rather than memory and effector CD4+ T cells 
[386]. Furthermore, induction of transplantation tolerance in primed mice 
required the combined action of anti-CD4 and anti-CD8 MAbs [155]. It 
could be argued that while in transplantation CD8 T cells participate as 
effector cells [387], in a Th2-mediated pathology (such as allergic asthma) 
CD8 T cells do not represent a significant obstacle for tolerance induction 
[388], thus making the tolerogenic role of CD4-blockade sufficient even in 
pre-sensitized mice. Possibly, the recently described Tc9 cells, CD8 T cells 
expressing IL-9, that appear able to contribute to the severity of Th2-
dependent airway inflammation [389], do not represent a major obstacle 
for tolerance induction through CD4 blockade. In addition it is likely that 
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allergens induce lower frequencies of effector T cells than alloantigens, 
thus making an immune system primed following transplantation harder to 
tolerize than when priming is achieved with a model antigen (such as OVA 
or FVIII) or an allergen (such as HDM).  
It was possible to observe that eosinophilia and airway 
hyperreactivity in anti-CD4-treated previously sensitized mice was 
reduced. It is hard to quantify the effects of CD4-blockade in the de novo 
production of immunoglobulins given the pre-existent high titers of IgE and 
IgG1 induced at the time of initial sensitization. This could be seen as an 
opportunity to further study the possible beneficial effects of anti-CD4 in 
chronic asthma models. 
Further studying the advantage of CD4 blockade in tolerance to 
soluble proteins we demonstrated that in a mouse model of hemophilia it 
is possible to induce tolerance to the coagulation factor used in the 
therapy of this disease. Again, the induced tolerance was antigen specific 
and primed cells remained susceptible to regulation. Trying to take one 
step further, we devised a method of having primed cells without the 
presence of immunoglobulins masking the permissive state and it was then 
possible to confirm that anti-CD4 can have an impact even in pre-sensitized 
cells. 
Cardinally our data points to an enhancing effect of the adjuvant 
alum in the ability of anti-CD4 to induce tolerance. Adjuvants are mainly 
known for their immunogenic role [390], thus seeming unwise to have such 
a compound synergizing towards creating tolerance. Alum in particular has 
many features that could explain its co-action with anti-CD4: it is known to 
increase the half-life of antigens; it is known its inability to augment cell-
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mediated immune responses, especially cytotoxic T-cell responses [391]; 
and it can modify antigen presentation  through inflammasomes [392]; 
among other roles that have not yet been characterized. We addressed 
several of these characteristics of alum. 
We increased the persistence of hFVIII through the administration 
of several shots of the protein during the tolerance induction period. We 
found that the presence of the adjuvant proved to be crucial for long term 
tolerance and could not be emulated by the simple prolongation of the 
presence of the antigen. Albeit alum certainly increases the antigen half-
life in vivo, this supposed depot-effect has been recently questioned, as it 
has been shown that the removal of alum deposits following immunization 
has no effect in reducing the humoral response [393]. We are still 
addressing any possible role for inflammasomes, using caspase-1- and 
NALP-3-deficientmice. Preliminary data obtained in our laboratory suggest 
that neither NALP-3 nor caspase-1 integrity are required for the facilitation 
of tolerance induction following administration of alum (data not shown). 
Alum, however, causes an accelerated influx of neutrophils and GR1+ IL4+ 
eosinophils [393-395] at the site of injection which can readily skew CD4 T 
cells towards a Th2 response and prime B cells. Instead of direct effects on 
the lymphocytes themselves, adjuvants seem to enhance T and B cell 
responses by directly engaging components of the innate immune system 
[396-398]. As such, different adjuvants can influence the type of effector 
CD4 T cells response, with some adjuvants promoting Th1 responses while 
others favor a Th2 polarization [399] and therefore influencing the isotype 
of antibodies produced by the B cells [400]. Naturally this notion implies 
that in vaccines the choice of the right adjuvant can represent an 
advantage regarding the nature of the protective memory cells generated. 
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But it could also mean that the type of adjuvant could help directing the 
type of tolerance mechanisms recruited at the time tolerance is induced 
with anti-CD4. Therefore, for Th2-mediated diseases the use of alum is 
beneficial, as we found out, while it could be possible that adjuvants such 
as CFA or poly-IC might have a greater beneficial role at inducing tolerance 
in Th1-mediated immune diseases. This could be an area for further 
investigation, especially since the beneficial effect of adjuvants for 
tolerance induction may not be restricted solely to anti-CD4. 
Prior studies have shown a clear role of Foxp3+ Treg cells in 
transplantation tolerance induced with anti-CD4 [39, 340, 356]. 
Unexpectedly, we found that tolerance induction to soluble proteins was 
independent of Foxp3. Systemic delivery of a protein in alum appears to 
induce a state of immune tolerance dependent on IL-10 and not on Foxp3+ 
Tregs. These findings question the reason for the absolute requirement of 
Foxp3+ Treg cells in transplantation tolerance [356], as the same clone of 
non-depleting anti-CD4 MAb leads to Foxp3-independent immune 
tolerance in hemophilia, and possibly in allergy. These results could explain 
the apparently contradictory observations from transplantation studies 
using anti-CD4 for tolerance induction: while some studies where a skin 
graft alone was used in the tolerance-inducing protocol appeared to be IL-
10-independent and Treg dependent [158, 340]; other studies where 
donor specific transfusion was administered in advance of skin 
transplantation appeared to rely on both Treg cells and IL-10 [351, 353]. 
Our data show that a protocol for tolerance induction that relies on IL-10 is 
sufficient to induce a state of tolerance robust enough to allow acceptance 
of a skin graft expressing the very same protein the subject was tolerized 
to. 
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One could speculate that the cytokine/ inflammatory environment 
in which tolerance is induced with an agent like anti-CD4 can influence the 
type of regulatory mechanisms (namely the nature of induced regulatory 
cells) that are generated. This issue, however, remains to be clarified. In 
any case the anatomic distribution of the same antigen – provided as part 
of a skin transplant or delivered systemically – can induce different 
mechanisms that have in common the maintenance of long term dominant 
tolerance. 
It has been shown that Tregs can produce IL-10 in vivo [401, 402]. 
Indeed both Foxp3+ or Foxp3- thymic precursors can give rise to IL-10 
producing cells [403]. Only Foxp3- thymic precursors can give rise to all 
types of subsets (Foxp3+IL-10+, Foxp3+IL-10-, Foxp3-IL-10+) through a 
mechanism that is TGF-β dependent and IL-10 independent [403]. 
Foxp3+IL-10- Treg cells tend to accumulate in the secondary lymphoid 
organs, lung and liver, while Foxp3+IL-10+ and Foxp3-IL-10+, are mostly 
found in Peyer’s patches, small and large intestine [402, 403]. Nevertheless 
in pathological situations such as asthma Foxp3-IL-10+ CD4 T cells with a 
regulatory function can be found in the lung [73]. The best described 
regulatory T cell type associated with a Foxp3-IL-10+ phenotype are the T 
regulatory type 1 cells (Tr1). These cells are develop from CD4+CD25- T cells 
under the influence of tolerogenic dendritic cells [404, 405] and exert their 
regulatory function by the extensive release of IL-10 [406].  
Our observations that IL-10 deficient mice fail to maintain long 
term tolerance to systemically-administered proteins and that we cannot 
find evidence for an increase in the frequency of Foxp3+ Tregs, suggest it is 
possible to induce tolerance in the absence of Foxp3 when the antigen is 
administered together with alum and anti-CD4. Indeed we confirmed this 
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hypothesis using Foxp3-deficient mice. Importantly, CD4+ T cells exposed 
to CD4-blockade in presence of the antigen become endowed with 
regulatory properties (in spite of lacking Foxp3 expression). These Foxp3- 
regulatory cells are able to mediate dominant tolerance. We could not 
conclusively show that these Foxp3- regulatory cells are Tr1 cells, although 
this possibility appears as a likely hypothesis.  
 We confirmed that indeed tolerance induction to skin grafts, with 
anti-CD4 MAb treatment is dependent on Foxp3+ Treg cells. In the same 
fashion, several animal models of autoimmunity can be successfully 
treated with anti-CD4, by a mechanism that appears to be Foxp3-
dependent [357]. On the other hand, we confirmed in transgenic models 
that tolerization with delivery of proteins in alum together with anti-CD4 
had no input of putative Foxp3+ Tregs. In fact we were able to establish 
that there is a combination of a recessive mechanism where specific 
effector cells are eliminated (but only when antigen, alum and anti-CD4 are 
present) diminishing drastically the effector CD4+ population (also known 
as AICD), while apparently a dominant mechanism outputs a T cell 
population that effectively suppresses the proliferation of naïve, antigen 
specific, T cells. Recessive mechanisms like AICD have been known to keep 
the balance between effector and regulatory mechanisms in immune 
tolerance [407]. Treatment with anti-CD3 MAbs, which have been used to 
prevent graft rejection [408, 409] and in clinical trials for the prevention of 
autoimmune diabetes [410], was shown to transiently deplete CD4+Foxp3- 
effector T cells  [275, 411] while CD4+Foxp3+ Treg cells show more 
resistance to this depletion [411] leading to an increase in frequency of 
regulatory cells. Also, in a GVHD model blockade of CD40-CD154 and 
CD80/CD86-CD28 interactions was shown to lead to peripheral elimination 
of host-reactive T cells [312, 412, 413]. In autoimmune encephalomyelitis 
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(EAE) anti-CD4 was also described to induce specific T cell depletion [384]. 
The deletion mechanism however remains unknown. Typically T cell death 
is induced by cell surface death receptors like Fas, or mitochondrial 
molecules such as Bim, Bad and Bax [414-417]. FcR-non-binding anti-CD3 
MAb was reported to induce effector T cell death in a Fas, Bcl-2 and 
caspase-3 independent fashion [411]. We have also investigated the 
mechanism behind the specific deletion induced by anti-CD4 MAb through 
the evaluation of its impact in tolerance generation in Fas-deficient or Lck-
driven Bcl-xl transgenic mice. We saw no attenuating impact in the 
tolerance induction in these mice models using anti-CD4 MAb (data not 
shown). However these results still need further confirmation and are very 
preliminary to draw any strong conclusion. Lastly we also analyzed the 
possible role for caspase-3, which is downstream of both intrinsic and 
extrinsic apoptosis pathway [417]. We found it was possible to induce 
tolerance to OVA-alum in a caspase-3 deficient mouse model. As before 
these results are too preliminary and remain to be further investigated. It 
seems there is enough evidence that the use of tolerogenic MAbs involves 
a mechanism of specific deletion of effector T cells, where, in some cases, 
there is a demonstrated association with a shift in the frequency of 
regulatory cells [409, 411]. It will be important to clarify the mechanism 
behind this T cell deletion that seems to be independent of the most 
obvious candidates (Fas, Bcl family and caspase-3). Activation-induced cell 
death in the periphery is associated with high intensity of TCR signaling 
[418], lack of cytokines such as IL-2 [419] or IL-12 [420] or impaired 
signaling at the immune synapse [421]. In vitro studies show that anti-CD4 
induces a suboptimal activation [56] that renders CD4+ T cells more 
susceptible to the effects of TGF-β in inducing Foxp3+ Tregs [45, 56]. On the 
other hand CD4+ T cells are described to need full interaction with MHC 
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class II molecules for the survival of resting CD4+ T cells in peripheral 
lymphoid organs [422] and that lack of CD4 expression on T cells increases 
their susceptibility to apoptosis leading to diminished survival [423]. In 
light of these facts it could be argued that CD4 blockade might be favoring 
the deletion of effector CD4+ T cells, with cells in different stages of 
differentiation displaying distinct susceptibilities to apoptosis. It will be 
important to clarify what are the characteristics of T cell subsets that 
render them more susceptible or resistant to apoptosis, namely whether 
anti-CD4 indiscriminately deletes T cells or if (like anti-CD3) shows a 
particular preference in depleting recently activated T cells and spares 
Helios+ Tregs [411]. 
In recent decades there was a remarkable increase in the 
understanding of the mechanisms that underlie immune system function. 
This has become an opportunity for the development of rational therapies 
for immune mediated diseases. The use of biological drugs, namely 
monoclonal antibodies, that can have a direct targeting of key molecules 
involved in the differentiation and behavior of immune cells has become 
common treatments in many diseases [328], The full potential of MAbs in 
inducing immune tolerance and their effect on primed cells remains largely 
an unaddressed medical need.  
The work of this thesis focuses on the induction of immune tolerance 
created by the use of non-depleting anti-CD4 MAb. It also presents the 
need of adequate adjuvants as potential tolerance facilitators. The findings 
in this work also propose the notion that the inflammatory environment 
can indeed lead to the induction of different regulatory mechanisms.  
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Induced IL-17–Producing Invariant NKT Cells Require
Activation in Presence of TGF-b and IL-1b
Marta Monteiro,1 Catarina F. Almeida,1 Ana Agua-Doce, and Luis Graca
IL-17 production by innate-like lymphocytes, including gd and invariant NKT (iNKT) cells, have been ascribed to speciﬁc lineages
that are endowed with this functional specialization during thymic differentiation. IL-17–producing iNKT cells have been de-
scribed as a CD42NK1.12 lineage in mice and CD161+ in humans. We found that, in mice, noncommitted iNKT cells can be
induced to produce IL-17 when activated in presence of TGF-b and IL-1b. This peripheral induction of IL-17 expression could be
observed in any subset irrespectively of CD4 and NK1.1 expression, the process leading to loss of NK1.1 expression and partial
CD4 downmodulation. Furthermore, induced IL-17–producing iNKT cells were sufﬁcient to drive neutrophilic airways inﬂam-
mation upon intratracheal adoptive cell transfer into congenic mice. Taken together, our data show that similarly to regulatory
T cells, which have a natural and peripherally induced subset, IL-17 production by iNKT cells can also be imprinted in natural
iNKT17 cells or peripherally induced. The Journal of Immunology, 2013, 190: 805–811.
I
nvariant NKT (iNKT) cells are a subset of unconventional
T lymphocytes that rearrange a limited repertoire of ab TCR
chains allowing the speciﬁc recognition of glycolipid Ags
presented by CD1d molecules (1). These cells can be found in mice
and humans, and display immune regulatory functions that may
contribute to either protective or deleterious immune responses in
several disease settings, including bacterial, viral, fungal, and pro-
tozoan infections, as well as in allergy and autoimmunity (2, 3).
In addition to the TCR, iNKT cells can express other receptors
from the T cell lineage, like the CD4 coreceptor, as well as mol-
ecules typical of NK cells, such as NK1.1 (1). The differential
expression of these particular molecules among iNKT lymphocytes
has been widely used to discriminate distinct developmental stages
in the thymus and mature iNKT cell subsets in the periphery (4–6).
These peripheral iNKT cells exhibit an effector/memory phenotype
even in the absence of prior stimulation. Its activated phenotype is
acquired during thymic differentiation, leading to the postulation
that iNKT cells could be selected and/or expanded by self-agonists
in the thymus (7). Upon Ag encounter, iNKT cells rapidly secrete
copious amounts of cytokines, inﬂuencing the recruitment and acti-
vation of several immune cells, including T and B lymphocytes,
macrophages, DCs, NK cells, and neutrophils (8–10).
In the past few years, several groups have demonstrated that
iNKT cells can also secrete IL-17 (4, 6, 11–14). This cytokine
plays a key role in the recruitment, activation, and migration of
neutrophils, and can act on a plethora of cell types to induce cy-
tokine and chemokine secretion (15–19). Effector CD4 T cells that
specialize in IL-17 secretion, termed Th17 cells, differentiate in
the periphery after activation in presence of TGF-b, IL-6, and IL-
1b produced mainly by innate cells, and rely on IL-23 and IL-21
for maturation and expansion after Th17 commitment (20–22). In
contrast, IL-17–secreting iNKT cells are believed to belong to a
distinct lineage that develops in the thymus, are more immature
than iNKT cells that produce IFN-g and IL-4, and constitute a
subset of recent thymic iNKT cell emigrants (23, 24). However,
the possibility that mature, uncommitted iNKT cells can respond
to activation under the inﬂuence of particular cytokines by se-
creting IL-17 was never addressed.
We investigated whether mature splenic iNKT cells can secrete
IL-17 when activated in the same cytokine context that directs
Th17 differentiation in naive conventional CD4 T cells. We
performed in vitro assays where we assessed the production of IL-
17 by unfractionated iNKT cells or by the distinct iNKT cell
subsets deﬁned by CD4 and NK1.1 expression stimulated in
presence of TGF-b, IL-6, and IL-1b. Surprisingly, we were able
to detect IL-17 expression, both intracellular or in the culture
supernatants, of all cultured iNKT cells, including the more
mature subsets that express NK1.1, CD4, or both. We adoptively
transferred these “induced” IL-17–producing iNKT cells to the
trachea of naive recipient mice and, even without any further
nasal challenge, they were able to induce airway neutrophilia
in the lungs. Our results clearly show that IL-17 secretion by
iNKT cells is not restricted to the NK1.12CD42 lineage com-
mitted in the thymus, but can also be acquired in the periphery
under speciﬁc cytokine contexts in which TGF-b, IL-6, and IL-1b
are being simultaneously produced. Such peripheral conversion
resembles the mechanism that generates induced regulatory T cells
(Tregs) in the periphery and endows iNKT cells with functional
power.
Materials and Methods
Mice
C57BL/6J (6–8 wk old) mice were bred and maintained under speciﬁed
pathogen-free conditions at the Instituto Gulbenkian de Cieˆncia. For each
experiment, animals were sex and age matched. Experiments were per-
formed according to the guidelines from the National Veterinary Depart-
ment and Institutional Ethical Comities.
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In vivo experiments
Mice were anesthetized with ketamine/xylazine, the trachea was surgically
exposed, and 50,000 cells were injected. In some experiments, mice received
100 mg neutralizing anti-mouse IL-17 or IFN-g (clones eBioMM17F3 and
R4-6A2, respectively, purchased from eBioscience) 24 h before cell trans-
fer. After 2 d, the mice were sacriﬁced, the trachea was cannulated, the
airways were lavaged three times with 1 ml ice-cold PBS, and the
bronchoalveolar lavage (BAL) was collected. The lungs were collected for
histological processing and H&E staining.
Flow cytometry and cell sorting
Mouse CD1d tetramers coupled to PE and loaded with PBS57 (an iNKT cell
ligand analog to a-galactosylceramide) were supplied by the National
Institutes of Health (NIH) Tetramer Facility. Fluorochrome-labeled mono-
clonal Abs speciﬁc to mouse TCRb (H57-597), NK1.1 (PK136), CD25
(PC61.5), CD4 (RM4-5), CD3 (145-2C11), CCR3 (83103), Gr-1 (RB68C5),
MHCII (M5/114.15.2), IL-17 (eBio 17B7), IFN-g (XMG1.2), and strep-
tavidin were all purchased from eBioscience. Neuropilin-1 (Nrp-1) was
detected as described elsewhere (24). For intracellular cytokine detection,
cells were incubated for 2 h 30 min with 50 ng/ml 4-a-phorbol 12-mystrate
13-acetate, 500 ng/ml ionomycin, and 10 mg/ml brefeldin A (Sigma). After
Ab surface staining, cells were ﬁxed and permeabilized using the Foxp3
staining set (eBioscience), then incubated with unconjugated anti-CD16/32
(clone 2.4G2) rat Ab and with anti-cytokine Abs. Data were acquired in
FACSCanto I (Becton Dickinson) and analyzed using FlowJo (Tree Star).
For cell sorting, murine iNKT cells were ﬁrst enriched by magnetic sepa-
ration, as described elsewhere (25), and samples were sorted on FACSAria I
(Becton Dickinson).
In vitro cell cultures
FACS-sorted populations of iNKTor CD4 T cells were cultured in IMDM+
GlutaMAX 5% FBS, 1% penicillin/streptomycin, and 0.01% 2-ME (all
from Invitrogen), at 37˚C 5% CO2. For cell stimulation, ﬂat-bottomed 96-
well plates were coated for 3 h with anti-CD3 (clone 145-2C11, at 2 mg/
ml) and anti-CD28 (clone 37.51, at 5 mg/ml) at 37˚C. In some experiments,
iNKT cells were stimulated by different concentrations of puriﬁed gly-
cosphingolipid 1 (GSL-1; provided by the NIH Tetramer Facility) in the
presence of 2 3 104 cells derived from a peritoneal lavage of a naive
C57BL/6 mouse as APCs. When indicated, the culture media were sup-
plemented with 1 ng/ml TGF-b (R&D Systems), 20 ng/ml IL-6 (R&D
Systems), 10 ng/ml IL-1b (eBioscience), and 10 mg/ml anti–INF-g (in-
house production). At the end of the culture period, supernatants were
collected and cells stained for ﬂow cytometry.
IL-17 detection in the culture supernatants
Quantiﬁcation of IL-17 in culture supernatants was performed in MaxiSorp
plates (Nunc) using the mouse IL-17 immunoassay kit (PeproTech),
according to the manufacturer’s instructions.
Statistical analysis
Data were analyzed using GraphPad Prism 5. The p values were calculated
by nonparametric unpaired t test with Welch’s correction (Mann–Whitney
U test), and p values ,0.05 were deemed signiﬁcant.
Results
Induction of IL-17 production by iNKT cells in presence of
IL-1b, IL-6, and TGF-b
It has been reported that IL-17–producing iNKT cells can be
identiﬁed in several organs (4, 23). We conﬁrmed that within the
iNKT population isolated from liver, spleen, or thymus of unma-
nipulated C57BL/6J mice, a small proportion of cells were positive
for IL-17 (Fig. 1A, 1B). In agreement with what has been described,
these IL-17+ iNKT cells were mostly CD42 and NK1.12 (Fig. 1C).
To investigate whether iNKT cell activation in the presence of
cytokines known to favor Th17 polarization could inﬂuence
iNKT cell fate, we stimulated splenic iNKT cells and naive CD4
T cells isolated from naive mice and puriﬁed by FACS with plate-
bound anti-CD3 and anti-CD28 in the presence of IL-1b, IL-6,
anti–IFN-g, and TGF-b. T cell activation in the presence of this
cytokine mixture has been described as being able to polarize
uncommitted CD4 T cells toward Th17 (26–28). We observed that
iNKT cells responded to the polarizing conditions in a similar way
as CD4 T cells, with TGF-b being essential for IL-17 expression
(Fig. 1D, 1E). In the end of the cultures, IL-17 could be detected
by intracellular staining in ∼25% of iNKT cells and 10% of CD4
T cells. Furthermore, IL-17 was present in the culture supernatant
of both iNKT and CD4 T cell cultures (Fig. 1E).
Because the in vitro system used to induce IL-17 expression in
iNKT cells could involve supraphysiological stimulation, we
assessed the capacity of iNKT cells to induce IL-17 when stim-
ulated by a microbial glycolipid presented by APCs. iNKT cells for
this assay remained untouched and were enriched only from
splenocytes by magnetic depletion of CD19+ CD62L+ and CD8+
cells, to avoid any extra stimulation provided by the tetramer used
to identify and isolate these cells by FACS. We then stimulated
iNKT cells with different concentrations of GSL-1, a microbial
Ag found in Sphingomonas spp. (29–31), in the presence of the
FIGURE 1. Expression of IL-17 by murine iNKT cells is induced in
presence of IL-1b, IL-6, and TGF-b. (A) Murine iNKT cells from livers,
spleens, and thymi of naive C57BL/6J mice (spleen depicted) were
indentiﬁed as CD1d/PBS57+ CD3+ cells. Unloaded CD1d tetramer control
staining to assess background level was also performed. (B) Freshly isolated
iNKT cells from the liver, spleen, and thymus of unmanipulated C57BL/6J
mice were stimulated with PMA/ionomycin in presence of brefeldin A for 3
h, and IL-17–producing cells were identiﬁed by ﬂow cytometry. (C) CD4
and NK1.1 expression of IL-17+ iNKT cells in the periphery. Data are
representative of two independent experiments, each with three mice. (D)
CD1d/PBS57+CD3+ cells and control CD4+ T cells were puriﬁed by FACS
and stimulated in triplicate wells by plate-bound anti-CD3 and anti-CD28 in
presence of IL-1b, IL-6, anti–IFN-g, and TGF-b. Negative controls were
deprived of exogenous TGF-b addition. After 4 d of culture, cells were
further stimulated as described in (B), and the accumulation of IL-17–se-
creting cells was assessed by ﬂow cytometry. (E) IL-17 concentration was
assessed by ELISA in the culture supernatants after 4 d of culture. Data are
representative of at least three experiments in which culture conditions were
set in triplicate. n = 3, *p , 0.05. (F) Splenic iNKT cells negatively
enriched through magnetic depletion of CD19+, CD62L+, and CD8+ cells
were cultured with peritoneal APCs and stimulated with various concen-
trations of GSL-1 in the presence of IL-6, IL-1b, and, when indicated, TGF-
b. IL-17 concentration was measured in the supernatant after 4 d of culture.
Data are presented as means of quadruplicate values 6 SEM and are rep-
resentative of two independent experiments.
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cytokine mixture used to polarize Th17 cells. After 4 d of culture,
IL-17 concentration in the supernatants was measured (Fig. 1F). In
conditions where TGF-b was not added, IL-17 production was
relatively low and comparable with the counterpart cultures where
iNKT cells were stimulated by plate-bound anti-CD3, independent
of the concentration of GSL-1 used for stimulation. In contrast,
when TGF-b was added in concert with IL-6 and IL-1b, IL-17
concentration in the supernatant was signiﬁcantly higher and
correlated with the concentration of Ag. These results are con-
sistent with our observations using anti-CD3 stimulation and
suggest that iNKT cells might be able to induce IL-17 expression
in vivo when stimulated by milder TCR stimuli from microbial
origin in the appropriate cytokine environment.
We also evaluated the need for each one of the reagents from
the polarization mixture in the induction of IL-17 expression by
iNKT cells. For that purpose, we cultured splenic iNKT and naive
CD4 T cells as described previously, but in the absence of TGF-b,
IL-6, IL-1b, or anti–IFN-g (Fig. 2A, 2B). In contrast with CD4
T cells, in which IL-17 induction absolutely requires cells to be
stimulated in the presence of TGF-b, IL-6, IL-1b, and anti–IFN-g
simultaneously, our results show that maximum IL-17 upregulation
in iNKT cells requires both TGF-b and IL-1b (Fig. 2A, 2C), but is
independent from exogenous addition of IL-6 and anti–IFN-g.
These observations indicate that stimulation of iNKT cells in
conditions where the cytokines that promote Th17 deviation are
present promotes an increased expression of IL-17 by these un-
conventional T lymphocytes.
All iNKT cell subsets deﬁned by CD4 and NK1.1 expression are
able to express IL-17 upon polarization
The identiﬁcation that IL-17 production by ex vivo–isolated
iNKT cells was restricted to a NK1.12CD42 subset, together with
the identiﬁcation of the thymic development of such subset, led to
the conclusion that IL-17 production was a characteristic of a thy-
mic-derived iNKT cell lineage committed to this particular func-
tion (4, 23). However, modulation of the expression of cell-surface
molecules after activation of iNKT cells, namely, NK1.1, has been
previously reported (32). This prompted us to investigate whether
the potential to acquire IL-17 expression was indeed restricted to
the NK1.12CD42 iNKT cell subset, and whether the CD4 and
NK1.1 phenotype remains unchanged after Th17 polarization.
For this aim, we puriﬁed by FACS the four iNKT subpopula-
tions deﬁned by the expression of NK1.1 and CD4, or naive CD4
T cells from the spleen of unmanipulated C57BL/6J mice (Fig. 3A),
and compared their ability to acquire the expression of IL-17 after
activation in conditions that favor Th17 polarization of conven-
tional CD4 T lymphocytes. In the absence of TGF-b, activation of
iNKT cells induced high IFN-g production, but not IL-17, in both
NK1.12CD4+ (CD4 single-positive [SP]) and NK1.1+CD4+ (double-
positive [DP]) iNKT cell subsets (Fig. 3B). In contrast, NK1.1+CD42
(NK1.1SP) and NK1.12CD42 (double-negative [DN]) iNKT cell
subpopulations exhibited signiﬁcant expression of IL-17 (6.20 6
2.01 and 9.20 6 0.80 cells, respectively) even in the absence of
TGF-b (Fig. 3B). These observations might be explained by the
expansion of pre-existent IL-17+ iNKT cells known to be contained
within the CD42 iNKT cell population (4, 6, 23).
In conditions in which TGF-b was present, however, all
iNKT cell subsets displayed a signiﬁcant frequency of iNKT cells
expressing IL-17 after activation (Fig. 3C) and secreted much
higher amounts of this cytokine to the culture supernatant than the
CD4 Th17-induced cells (Fig. 3D). These results suggest that,
regardless of the cell phenotype in terms of NK1.1 or CD4 ex-
pression, iNKT cells retain the potential to acquire IL-17–secret-
ing function after activation under proinﬂammatory conditions
where TGF-b, IL-1b, and eventually IL-6 are present.
We also found that after activation in Th17-polarizing con-
ditions, most iNKT cells downmodulated NK1.1, as it has been
widely reported after NKT cell activation (32), and to a lower
degree CD4 (Fig. 3E). This phenotypic change brings activated
iNKT cells to a phenotype closer to what has been described for
the natural IL-17–producing iNKT cells committed in the thymus.
Nrp-12 iNKT cells are amenable to induce IL-17 expression
It has been shown that iNKT cells that are educated in the thymus
to produce IL-17 can be identiﬁed within an Nrp-1+ population
(24). We therefore investigated whether in vitro induction of IL-17
expression was possible starting from Nrp-12 iNKT cells puriﬁed
by FACS (Fig. 4). Nrp-12 iNKT cells comprise .90% of total
splenic iNKT cells and, therefore, could be easily isolated with
a high purity degree (Fig. 4A). After 4 d of culture under Th17-
promoting conditions, the intracellular expression of IL-17 and
IFN-g were assessed (Fig. 4B, 4C). In the absence of TGF-b, IL-
17 expression was undetectable in cultured Nrp-12 iNKT cells,
whereas in the presence of this cytokine, around 3% of the cells
expressed IL-17. For comparison, we cultured in parallel Nrp-1+
iNKT cells under the same conditions. As expected, IL-17 ex-
pression in Nrp-1+ iNKT cells was drastically higher, with 15%
of the cells expressing IL-17 when the culture medium was not
supplemented with TGF-b, conﬁrming the existence of a pre-
committed population of IL-17–secreting iNKT cells (Fig. 4B,
4C). As before, IFN-g expression was consistently reduced in
cultures not supplemented with TGF-b. In summary, these data
show that peripheral iNKT cells can induce de novo expression
of IL-17 when activated under conditions that promote Th17
deviation in conventional CD4 T cells.
Induced IL-17–producing iNKT cells can drive neutrophilic
airways inﬂammation
Having established that peripheral iNKT cells can be amenable to
secrete IL-17 by cytokine polarization, we investigated whether
FIGURE 2. TGF-b and IL-1b are essential for IL-17 expression by
iNKT cells. iNKT and naive CD4 T cells from the spleen of unmanipulated
mice were isolated by FACS as described earlier and stimulated for 4 d by
plate-bound anti-CD3 and anti-CD28 in the presence of IL-1b, IL-6, anti–
IFN-g, and TGF-b (“complete” conditions) or in the absence of each one
of these reagents. (A and B) IL-17 concentration was measured in the
culture supernatants of iNKT (A) and CD4 T cells (B) at the end of the
culture period. (C) Intracellular staining for IL-17A and IFN-g of iNKT cells
cultured in different conditions after restimulation with PMA/ionomycin in
presence of brefeldin A. This experiment was performed twice with quad-
ruplicates. n = 4, *p , 0.05, **p , 0.01, ***p , 0.0001.
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those induced IL-17+ iNKT cells could maintain their function
in vivo, leading to inﬂammation.
It has been described that IL-17 production can induce in-
ﬂammatory changes in the airways (6). Thus, we performed
intratracheal adoptive cell transfers of 50,000 iNKT cells gener-
ated in a 4-d culture period under Th17-polarizing conditions (as
described earlier). As control populations, we used an equal
number of in vitro–generated Th17 CD4 T cells or activated
iNKT cells cultured in medium without TGF-b.
We found that animals transferred with IL-17–producing
iNKT cells developed peribronchiolar inﬂammatory inﬁltrates,
something that was also observed in animals transferred with
Th17 cells, but not activated iNKT cells (Fig. 5A). The analysis of
the cellular content of the BAL indicated a signiﬁcant recruitment
FIGURE 3. Induction of IL-17 expression in the iNKT cell subsets subdivided on the basis of NK1.1 and CD4 expression. (A) Splenic iNKT cells from
naive C57BL/6J mice were identiﬁed as CD1d/PBS57+TCRb+ cells and further subdivided in subpopulations deﬁned as NK1.12CD4+ (CD4 SP), NK1.1+
CD4+ (DP), NK1.1+CD42 (NK1.1 SP), and NK1.12CD42 (DN). (B) The four iNKT cell subsets deﬁned in (A) were puriﬁed by FACS, and 50,000 cells of
each subpopulation were stimulated with plate-bound anti-CD3 and anti-CD28 in the presence of IL-1b, IL-6, and anti–IFN-g with or without TGF-b. After
4 d of culture, cells were stimulated for 3 h with PMA/ionomycin in the presence of brefeldin A, and ﬂow cytometric analysis of IFN-g and IL-17 ex-
pression by each iNKT cell subset was performed. (C) Average frequency of IL-17+ iNKT cells in culture triplicates of the indicated subpopulations. (D)
Quantiﬁcation of IL-17 in culture supernatants by ELISA. Bars represent the average of triplicate cultures6 SEM (p, 0.05). (E) Assessment of NK1.1 and
CD4 expression at the end of the culture period. Data are representative of three independent experiments, each with triplicates. *p , 0.05.
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of neutrophils into the airways in the experimental group that have
received IL-17+ iNKT cells that was less pronounced in recipients
of Th17 CD4 T cells and undetectable in mice that have received
iNKT cells activated without TGF-b (Fig. 5B, 5C). Importantly,
the recruitment of neutrophils to the airways was prevented when
the mice received an injection of neutralizing anti–IL-17 Ab 24 h
before the IL-17+ NKT cell transfer (Fig. 5D). In contrast, neu-
tralization of IFN-g had no impact in neutrophils’ recruitment.
These results conﬁrmed that induction of IL-17+ iNKT cells is
able to generate a functionally competent population capable of
exerting in vivo IL-17–dependent effects comparable with what is
observed for Th17 CD4 T cells.
Discussion
In the last 5 y, a growing body of evidence has been raised
establishing iNKT cells as one of the several innate sources of
IL-17 (6, 11–14, 23). It has been shown that there is an RORg(t)-
dependent NKT cell subset lacking CD4 and NK1.1 expression
that commits to IL-17 secretion in the thymus (23). This ﬁnding
led to the general assumption that the ability of iNKT lymphocytes
to secrete IL-17 is restricted to a ﬁxed lineage. In addition, a re-
cent report has demonstrated that IL-17–committed iNKT cells
are included in the recent thymic emigrant pool that migrates to
the secondary lymphoid organs and is diluted after thymectomy,
which suggested that the pool of IL-17–competent iNKT cells
present in the lymphoid organs requires continuous thymic out-
put to be maintained (24). Furthermore, because most IL-17–se-
creting iNKT cells lack NK1.1 expression, it has been postulated
that the IL-17 response promoted by NKT cells relies on the ac-
tivation and expansion of cells from that lineage in the periphery.
However, it is well established that NK1.1 expression is pro-
foundly downmodulated after activation, which renders this mol-
ecule an unreliable lineage marker in the periphery, in a context of
TCR activation.
We have therefore addressed the question of whether the ex-
pression of IL-17 by iNKT cells could be an inducible competence
when these cells are stimulated under the same conditions pro-
moting the acquisition of a Th17 phenotype by naive conventional
CD4 T cells. Indeed, our in vitro studies clearly showed that IL-17
could be readily detected 4 d after initial stimulation of splenic
iNKT cells cultured in presence of a cytokine mixture including
FIGURE 4. Nrp-12 iNKT cells upregulate IL-17 after culture in the
presence of TGF-b, IL-6, and IL-1b. (A) iNKT cells were isolated from
the spleen of naive C57BL/6 mice and sorted according to the expression
of Nrp-1. (B) Puriﬁed Nrp-12 and Nrp-1+ iNKT cells were cultured in
Th17-polarizing conditions as described earlier, and IL-17 expression was
assessed by ﬂow cytometry at day 4. (C) Frequency of IL-17+ cells after 4 d
of culture of Nrp-12 and Nrp-1+ iNKT cells assessed by ﬂow cytometry.
Data are representative of two experiments, each one with triplicates. *p ,
0.05, ***p , 0.0001.
FIGURE 5. The presence of IL-17+ iNKT cells generated by cytokine
conversion in the airways is sufﬁcient to induce neutrophilia. IL-17+
iNKT cells were generated in vitro after stimulation of splenic iNKT cells
isolated by FACS by plate-bound anti-CD3 and anti-CD28 in the presence
of IL-1b, IL-6, anti–IFN-g, and TGF-b (iNKT17). iNKT cells cultured in
the absence of TGF-b (activated iNKT) and in vitro–generated CD4 Th17
cells (Th17) were used as controls. After 4 d of culture, 50,000 cells or the
same volume of 13 PBS was injected in the trachea of naive mice. Ani-
mals were sacriﬁced 2 d postinjection. (A) Histology sections of the lungs
stained with H&E showing peribronchiolar inﬁltrates in mice transferred
with iNKT17 and Th17 cells. Scale bar, 10 mm. (B) Airway neutrophilia
was assessed by ﬂow cytometric detection of neutrophils, identiﬁed as
Gr-1hiCCR32/+MHCII2 cells, in the BAL. (C) Absolute quantiﬁcation of
neutrophils in the BAL. A higher percentage (not shown) and absolute
number of neutrophils was observed in mice transferred with iNKT17
cells. Data are representative of two independent experiments with three
mice per group. (D) Absolute numbers of neutrophils in the BAL of mice
that have received an adoptive transfer of IL-17+ iNKT cells in the pres-
ence or absence of neutralizing anti–IL-17 and anti–IFN-g mAbs. *p ,
0.05, **p , 0.01.
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TGF-b and IL-1b. The fact that exogenous IL-6 is dispensable for
IL-17 expression by iNKT cells is not surprising and has been
reported by others (11, 33). However, because splenic iNKT cells
have been shown to be able to produce IL-6 in vitro after anti-CD3
and anti-CD28 stimulation (4), the role of this cytokine in in-
duction of de novo IL-17 production remains to be clariﬁed.
Notably, both the frequency of IL-17+ cells and the amount of
protein secreted to the culture media were signiﬁcantly higher in
iNKT cells when compared with the CD4 Th17-induced controls,
which is in accordance with the fact that NKT cells are proﬁcient
cytokine producers early after activation. The emergence of IL-
17+ iNKT cells is unlikely to be due to expansion of IL-17–lin-
eage–committed iNKT cells because few IL-17+ cells could be
detected in cultures where TGF-b was not added. To exclude this
possibility deﬁnitely, we adopted two strategies. First, we isolated
DP, CD4SP, NK1.1SP, and DN splenic iNKT cell subsets by FACS
and assessed induction of IL-17 in each individual population.
We observed that IL-17 expression was induced in all iNKT cell
subsets cultured under Th17-polarizing conditions, irrespectively
of their CD4 and NK1.1 phenotype, with CD4SP and DN pop-
ulations exhibiting the highest IL-17 expression. Indeed, these two
particular subsets, which include the naturally occurring thymus-
derived IL-17+ iNKT population, showed 5–10% of IL-17+
iNKT cells in cultures deprived of TGF-b, suggesting that the IL-
17+ precursors present have expanded. Of note, despite that ex-
ogenous TGF-b has not been provided in this experimental con-
dition, the culture medium might contain traces of this cytokine,
and thereby enable some level of TGF-b signal. Nevertheless, the
detection of IL-17 in cultures of NK1.1SP and DP subsets, which
do not include IL-17–lineage committed cells, clearly demon-
strates that it is possible to induce de novo expression of this
cytokine in iNKT lymphocytes outside the thymus, under con-
ditions that promote iNKT cell activation and concomitant se-
cretion of TGF-b, IL-6, and IL-1b.
The second strategy to demonstrate that IL-17 might be induced
de novo in iNKT cells that had not been committed in the thymus
to the NKT-17 lineage consisted of sorting by FACS the iNKT
cells lacking the expression of Nrp-1, which are deprived of IL-
17–committed cells. Our results show that although Nrp-12
iNKT cells stimulated in vitro in the presence of TGF-b, IL-6 and
IL-1b can indeed upregulate IL-17. However, despite the lower
frequency of conversion of Nrp-12 iNKT cells, compared with
Nrp-1+ iNKT cells, one must consider the fact that in vivo Nrp-12
iNKT cells are at least 10 times more abundant than Nrp-1+ cells.
Therefore, when unfractionated splenic iNKT cells are stimulated
in conditions that promote Th17 deviation, taking into account
that IL-17 expression will be induced or triggered in ∼3 and 40%
of iNKT cells from Nrp-12 or Nrp-1+ origin, respectively, it is
reasonable to assume that .40% of the IL-17+ iNKT cells are
generated from the Nrp-12 precursors. Thus, the contribution of
the Nrp-12 iNKT cell pool for the total number of IL-17+ cells is
similar to the input from the Nrp-1+ iNKT cell subset, suggesting
that peripheral induction of IL-17 in iNKT cells may be relevant in
physiological proinﬂammatory conditions.
Our results also show that induced IL-17+ iNKT cells have
almost completely downregulated NK1.1 expression from the
surface and, to a lesser extent, have downmodulated CD4. How-
ever, it is difﬁcult to accurately correlate the expression of IL-17
to NK1.1 and CD4 because the cells were stimulated in presence
of a Golgi apparatus and endoplasmic reticulum protein transport
inhibitor. Nevertheless, these observations indicate that in vivo
NK1.1 expression is not useful to distinguish IL-17+ NKT cells
of the thymic lineage from their peripherally generated counter-
parts. The expression of Nrp-1 by thymus-derived IL-17+
NKT cells (24) might represent a better strategy to circumvent this
limitation.
In Fig. 3B, we show the expression of IFN-g and IL-17A after
culture under Th17-polarizing conditions in iNKT cell subsets
deﬁned by NK1.1 and CD4 expression. Irrespective of the pres-
ence of TGF-b, IFN-g+ cells are always detected in every subset.
Most of these IFN-g+ cells are IL-17A2, but we cannot exclude
the presence of a minor population of cells that coexpress both IL-
17A and IFN-g. The existence of a double-producer population of
IL-17A and IFN-g has been documented for human CD4 Th17
cells (34–36) and, at least in these cells, correlates with a Th17
subset that coexpresses both CCR6 and CXCR3 chemokine
receptors. This subset is distinct from Th17 cells that coexpress
CCR6 together with CCR4, which, in turn, secrete IL-17 and IL-
22. This dichotomy derives in CD4 Th17 cells from distinct ac-
tivation contexts, in particular, in response to different types of
pathogens: for instance, whereas memory Th17 cells speciﬁc for C.
albicans are primarily found within the CCR6+CCR4+ subset,
Th17 cells speciﬁc forM. tuberculosis are mainly CCR6+CXCR3+.
This reﬂects a ﬁne-tuned coordination between the differentiation
of the appropriate effector functions in response to a given stimulus
and the migratory capacity of the effector cells. In the case of
iNKT cells that have acquired IL-17 in vitro, it is possible that
a similar association between effector molecules and distinct mi-
gratory potentials might exist. Indeed, studies of human iNKT cells
had already established a correlation between the type of chemo-
kine receptors expressed by Va24Vb11 T cells and the expression
of Th1 and Th2 cytokines, with IL-4 and IFN-g being preferen-
tially expressed by iNKT subsets expressing CCR4 and CXCR3,
respectively (37–39). Therefore, when we transferred such het-
erogeneous population to the trachea of mice, in addition to the
clear effect seen in the neutrophil recruitment to the lungs in result
of the IL-17 production, other cell populations might as well be
affected by other cytokines being produced.
The fact that IL-17+ NKT cells might have a central and pe-
ripheral origin resembles the scenario observed for Tregs, a spe-
cialized population of CD4 T lymphocytes fundamental for the
maintenance of immunological self-tolerance (40, 41). Tregs can
be generated in the thymus from CD4+CD8+ DP thymocytes that
undergo positive selection and acquire the expression of the
transcription factor Foxp3, or in the periphery, from naive CD4
T cell precursors that upregulate Foxp3 in response to activation in
presence of locally produced TGF-b (42–45). The ﬁrst are gen-
erally called natural Tregs and the latter induced Tregs, and both
are capable of exerting suppression of other cells’ functions by
similar mechanisms. Our results indicate that a similar dual origin
for IL-17+ iNKT cells might coexist physiologically. We therefore
propose that NKT cells committed to IL-17 secretion in the thy-
mus should be called “natural NKT17” cells, in contrast with the
“induced NKT17 cells” generated in the periphery.
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The study of immune regulation and tolerance has been traditionally associated with self/nonself-discrimination. However, the
ﬁnding that dominant tolerance, a model that puts in evidence the active role of regulatory T cells, can develop to nonself-
antigens suggests that the imposition of tolerance can be context dependent. This paper reviews the emerging ﬁeld of acquired
immune tolerance to non-self antigens, with an emphasis on the diﬀerent subsets of induced regulatory T cells that appear to
specialize in speciﬁc functional niches. Such regulatory mechanisms are important in preventing the onset of allergic diseases in
healthy individuals. In addition, it may be possible to take advantage of these immune regulatory mechanisms for the induction
of tolerance in cases where pathological immune responses are generated to allergens occurring in nature, but also to other
immunogens such as biological drugs developed for medical therapies.
1. Introduction
For many decades the self/nonself-discrimination by the
immune system was assumed to be a consequence of clonal
selection of eﬀector T cells. Compelling evidence has, how-
ever, imposed a revised view of self/nonself-discrimination:
dominant regulatory mechanisms, where regulatory T (Treg)
cells play a central role, are essential for maintenance of self-
tolerance [1]. But recently it is becoming apparent that the
importance of dominant regulation goes beyond the dis-
crimination of self and nonself: it also discriminates between
harmful and innocuous. In fact, cellular mechanisms, as
detailed below, persistently patrol the organism preventing
the onset of inﬂammation, namely, allergic inﬂammation.
The biological signiﬁcance of this active tolerance-imposing
mechanism is well demonstrated by the severity of the
allergic and autoimmune syndrome that arises in individuals
that lack these ability to tolerate self- and harmless antigens.
Indeed, the organism is constantly exposed to non-
pathogenic antigens that, in healthy individuals, are toler-
ated. It is, however, common (and becoming increasingly
frequent) that an overzealous immune system will activate
and develop eﬀector responses to such harmless antigens
developing allergy and other inﬂammatory diseases. Over
the last decades allergic diseases, including allergic asthma,
atopic dermatitis, and food allergy, have become a major
health problem in developed countries [2]. Despite the
advances in the understanding of the pathophysiology of
allergy and in its clinical management, allergic pathology
remains a signiﬁcant burden on the quality of life and
economy of western society. Several strategies have been
devised to overcome the pathological immune response by
inducing immune tolerance. This paper reviews the impact
of dominant regulatory mechanisms in the maintenance of
tolerance to foreign antigens, including allergens.
A major cellular mechanism in maintaining immune
tolerance is the population of natural (or thymic-derived)
Foxp3+ Treg cells [3, 4]. Indeed these have been clearly
implicated as potent inducers of a nonresponsive state in
several immune-mediated pathologies like autoimmunity,
transplantation, graft-versus-host disease, and allergy [5–9].
It has been shown, in allergy, that regulatory T cells can
be transferred conferring speciﬁc tolerance to subsequent
challenges with the allergen [10, 11]. In addition, depletion of
the regulatory T cells can have a detrimental eﬀect in allergic
airway hyperreactivity [12]. Importantly Foxp3 deﬁciency, in
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mice and human beings, leads to a severe immune disregu-
lation syndrome characterized by allergic and autoimmune
manifestations that are rapidly fatal [13]. In addition to
the important role of natural Foxp3+ Treg cells (nTreg) in
preventing autoimmunity, it has become established that
Foxp3 expression can be peripherally induced following T-
cell activation in presence of TGF-β [14]. These peripherally
induced Treg cells (iTreg) are believed to be important for
tolerance induction to nonselfantigens, including allergens
[14].
2. Induction of Regulatory T Cells
The study of peripheral induction of Treg cells was greatly
facilitated with the use of Rag-insuﬃcient TCR-transgenic
mice, with the TCR speciﬁc for a nonselfantigen. In these
mice nTregs cannot be formed in the thymus due to the
absence of a selecting thymic antigen. In 2003 it was shown
that conventional T cells can be converted into iTreg in
vitro when activated in presence of TGF-β [15]. In addition
those iTreg cells were fully capable of controlling airway
hyperreactivity (AHR) in previously sensitized mice [15–
19]. It was subsequently found that reducing or blocking
the available amount of TGF-β exacerbates AHR [20, 21],
while the local delivery of this cytokine or adoptive transfer
of T cells engineered to express latent TGF-β rescue mice
from antigen sensitization and therefore prevent AHR [22,
23]. Interestingly, suboptimal TCR signaling together with
TGF-β greatly enhances iTreg conversion [24], which is in
agreement with in vivo data showing that repeated low doses
of allergen exposure promotes the emergence of Foxp3+
iTregs expressing TGF-β on the membrane [25]. Under sub-
optimal TCR stimulation, which can be obtained by using
a low dose of plate bound anti-CD3 or DCs pulsed with
a low dose of agonist peptide or with downmodulation of
the TCR with nondepleting anti-CD4, iTreg conversion is
promoted in the absence of exogenous TGF-β [26]. Under
those conditions Foxp3 expression still requires TGF-β, but
the T cells can produce TGF-β and beneﬁt from the presence
of this cytokine for conversion to Treg [26].
In addition to the importance of TGF-β for iTreg con-
version, some studies showed that TGF-β can directly inhibit
GATA3 expression thus impairing Th2 diﬀerentiation [27–
29]. Because the Th2 response is impaired, the production of
IL-4 is diminished, and this has a direct impact on B-cell class
switch preventing IgE and favoring IgA production [30].
It is also becoming apparent that the environment inﬂu-
ences the outcome of T-cell activation and the decision to
induce Foxp3 and regulatory properties. Several reports have
shown that the mucosal surfaces have a role in establishing an
iTreg population: alveolar epithelial cells have been reported
to participate in iTreg induction in a mechanism dependent
of MHC class II expression and TGF-β [31]. Both alveolar
and gut epithelia have been shown to depend on retinoic acid
together with TGF-β to induce tolerance [32, 33]. It was also
found that retinoic acid in the presence of TGF-β impaired
STAT6 binding to the Foxp3 promoter therefore enhancing
histone acetylation and reverting the repressive eﬀect of IL-4
on the Foxp3 promoter [34].
Despite the critical role of TGF-β in iTreg induction
and henceforth tolerance, this cytokine can also have some
adverse eﬀects since it is instrumental in the diﬀerentiation
of Th17 and Th9 together with IL-6 and IL-4, respectively
[35, 36]. Note that although Treg cells can prevent allergic
autoimmune encephalomyelitis (EAE), mice with T cells
with a dominant negative receptor for TGF-β1 do not
develop EAE as Th17 cells are not induced [37]. Moreover,
TGF-β has also been implicated in tissue remodeling, by
induction of collagen expression in ﬁbroblasts, as well as
goblet cell proliferation and mucus production [38].
3. Regulatory T Cells and IL-10
Although TGF-β is the major known driver of iTreg diﬀeren-
tiation, IL-10 has been shown to be another key player that
has been vastly described in protection from allergic diseases
[39].
Studies with bee venom-speciﬁc immunotherapy have
shown that tolerance to the allergen can be induced in a
process that is IL-10 mediated [40]. In addition, respiratory
exposure tolerance induction to OVA relied on antigen
speciﬁc CD4+ regulatory cells that produced IL-10 [41].
Tolerance was transferrable and abrogated when IL-10 or
ICOS ligand was blocked. Interestingly, those regulatory
cells shared some features with eﬀector Th2 cells: both
populations expressed IL-4 and IL-10 although in diﬀerent
amounts. While the regulatory cells primarily release IL-
10, the eﬀectors rely on IL-4 as the main cytokine. It
has been suggested that diﬀerent types of eﬀector cells,
including Th2, produce IL-10 at the end of the immune
response in a mechanism that is important in limiting
their inﬂammatory behavior [42]. IL-10 producing T cells
has been described able to control the late response in
allergic asthma by reducing neutrophilia [43]. It has been
suggested that Foxp3-negative IL-10 producing T cells can
be induced following activation in presence of IL-10 and
constitute a population of regulatory cells diﬀerent from
Foxp3+ Tregs that are named TR1 [44, 45]. TR1 cells
have been identiﬁed in mice and humans, and there are
currently clinical trials [9, 46]. There are several other lines
of evidence demonstrating the crucial role of IL-10 in the
prevention of airway inﬂammation: IL-10-deﬁcient mice
have an exacerbated allergic airways response with high levels
of proinﬂammatory cytokines like IL-5 and IFN-γ in the BAL
[47]. Furthermore, intranasal administration of rmIL-10,
concurrently with OVA, inhibited both airway neutrophilia
and eosinophilia [48]. It was also shown that allergen-speciﬁc
CD4+CD25+ Tregs can suppress allergic airway disease in
vivo through an IL-10-dependent mechanism [18]. In this
study, adoptive transfer of Treg cells reduced AHR, Th2 and
eosinophil recruitment into the airways, and secretion of
Th2-type cytokines. The eﬀect was IL-10 mediated, since
neutralizing anti-IL-10R abrogated suppression. In addition,
these eﬀects were independent of IL-10 production by the
CD4+CD25+ regulatory cells themselves [18].
Unlike TGF-β, IL-10 does not directly inﬂuence B-cell
class switch [49]. However, it is possible that indirectly,
by inhibiting the inﬂammatory response, IL-10 shapes the
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humoral outcome. Indeed, it was proposed that IL-10 may
favor the ratio of IgG4/IgE ratio [50]. In fact immunotherapy
studies show that Th2 responses can be suppressed by IL-
10 secreting regulatory cells accompanied by an increase of
circulating IgG4 [51, 52].
4. Different Subsets of Regulatory T Cells
Foxp3+ Treg cells, despite an apparent phenotypic unifor-
mity and immunosuppressive function, can have diﬀerent
subtypes with distinct genetic signatures. The ﬁrst major
division was identiﬁed between nTreg and iTreg, where the
ﬁrst are enriched in Helios, a transcription factor that is
primarily expressed in T-lineage cells and early precursors
[53, 54]. While nTreg cells have epigenetic mechanisms
that stabilize Foxp3 expression allowing them to be a
stable diﬀerentiated cell lineage, TGF-β induced Tregs lack
those mechanisms having incomplete demethylation [55].
Therefore, although iTreg cells have high levels of Foxp3,
the expression of Foxp3 is less stable [55–57]. In addition,
conserved noncoding DNA sequence (CNS) elements at the
Foxp3 locus encode information deﬁning the size, compo-
sition, and stability of the Treg cell population [58]. CNS3,
which binds c-Rel, has a drastic eﬀect on the frequency
of Treg cells generated in the thymus. Contrary to CNS3,
CNS1 has no eﬀect on thymic generation of Treg cells but is
essential for induction of iTregs [58]. CNS1 contains a TGF-
β-NFAT response element, so these results could represent
the requirement of TGF-β and NFAT for Treg induction
in the periphery [58–60]. Although CNS2-deﬁcient T cells
can acquire Foxp3 expression, they fail to maintain Foxp3
expression on their progeny due to the failure on recruitment
of Foxp3-Runx1-Cbf-β complexes to CNS2 after demethy-
lation of the CNS2 CpG island [58, 61]. Interestingly
CNS1 deﬁcient mice had no lymphoproliferative disorder.
However, it can be argued that these animals kept in clean
facilities have a minimal exposure to foreign antigens and
thus nTreg may be suﬃcient to maintain homeostasis in such
conditions. In eﬀector T cells, GATA-3 is a hallmark of the
Th2 cells, but Treg cells can also express GATA-3, that binds
both to the Th2 cell locus and to the CNS2 of Foxp3 locus
[62]. In fact, there is a dramatic increase of GATA-3 binding
to CNS2 compared to conventional T cells, suggesting that
GATA-3 regulates CNS2 activity in Treg cells [62].
There is strong evidence that the CCR7-dependent con-
tinuous migration of DC from the lung to its draining LNs is
required for the transport of inhaled Ag and thereby for the
proper composition of APCs in the LN. These processes are
essential to induce peripheral tolerance of T cells [63]. The
costimulation with ICOS, crucial for regulatory phenotype
polarization in allergy [64], promotes the downregulation
of CCR7 and CD62L after activation, leading to a reduced
return of activated CD4 T cells to the lymph nodes and
a more eﬃcient entry into the lungs [65]. Regulatory T
cells express CCR4 and CD103 induced by antigen-driven
activation in the lymph nodes. In addition, the accumulation
of Tregs in the skin and lung airways is impaired in the
absence of CCR4 expression [66]. Mice without CCR4 in
the Treg compartment develop lymphocytic inﬁltration and
severe inﬂammatory disease in the skin and lungs [66]. Some
studies suggest that CCR4 has a prominent role in eﬀector
Th2 homing [67]. Despite their diﬀerences it seems both
regulatory and eﬀector T cells share the response to homing
factors [68, 69].
But GATA-3 is not the only transcription factor char-
acteristic of eﬀector T-cell responses that can be expressed
by Foxp3+ Treg cells. Under the inﬂuence of IFN-γ, Foxp3+
Treg cells can express the Th1-deﬁning transcription factor
T-bet [70]. T-bet expression by Foxp3+ Treg cells induces
the expression of the chemokine receptor CXCR3, necessary
for these Treg cells to accumulate at the site of type
1 inﬂammation. T-bet expression was thus required for
the homeostasis and function of Treg cells during type-1
inﬂammation [70].
It is likely that the regulation of diﬀerent types of
immune response requires the participation of specialized
subsets of regulatory cells. This way, iTreg cells induced in
an environment favorable to Th1 or Th2 type of immune
responses require the appropriate chemokine receptors to
give them access to the same locations as eﬀector T cells
(Figure 1).
Th17 cells that have been implicated in autoimmunity
and allergy share with iTreg cells the need for TGF-β to
diﬀerentiate [71]. The decision of antigen-stimulated cells
to diﬀerentiate into either Th17 or iTreg depends on the
cytokine balance of IL-6, IL-21, and IL-23 that relieve
Foxp3-mediated inhibition of RORγt [72]. These results
indicate that Foxp3 and RORγt are transcription factors that
antagonize each other in the lineage diﬀerentiation.
Another subset of T cells, the follicular T helper cells
(Tfh), is mostly spatially conﬁned to secondary lymphoid
organs, more precisely to the B-cell follicles [73]. Tfh cells
express high levels of the transcription factor Bcl-6, that
impairs the expression and function of other transcription
factors speciﬁc for other CD4 subsets: Tbet, GATA3, and
RORγt, thereby regulating cytokine production by Tfh cells
[74, 75]. Tfh cells diﬀerentiate under the inﬂuence of
ICOS:ICOSL and IL-21 but independently of any other
cytokine [76]. In addition, the characteristic anatomical
distribution of Tfh cells is dependent of CXCR5 that endows
access to the B-cell follicle [73, 77, 78]. We and others
have recently found that also this subset of eﬀector T cells
has a specialized regulatory counterpart [69, 79, 80]. It was
found that Foxp3+ Treg cells can be found within the B-
cell follicle [81], sharing many characteristics of Tfh and
Treg cells [69, 79, 80]. Importantly, Bcl-6 can be coexpressed
with Foxp3 as it seems Foxp3 expression is not inhibited by
Bcl-6. These follicular regulatory T cells (Tfr) are immune-
suppressive and can control de magnitude of the germinal
center response [69, 79, 80]. In addition, they exhibit a
CTLA4hiGITRhiIL-10hi phenotype that is the characteristic
of activated Tregs [69, 79, 80]. However, the Tfr origin is
quite distinct from the other induced Treg cells previously
described. Tfr cells do not derive from the commitment
of conventional CD4 T cells, but result from acquisition of
“follicular” characteristics (viz. Bcl-6 expression) by natural
Foxp3+ Treg cells [69, 79, 80]. In fact sorted Tfh cells
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Figure 1: Functional specialization of eﬀector and regulatory T cells. Diﬀerent types of immune responses carry diﬀerent cytokine
microenvironments that can inﬂuence both eﬀector and regulatory T-cell diﬀerentiation. In the same way eﬀector T cells when activated
in speciﬁc cytokine environment acquire specialized functions, induced regulatory cells (iTreg) can also activate the expression of diﬀerent
transcription factors (italics) that endow them access to diﬀerent anatomic compartments on the basis of the chemokine receptors they
express. Follicular regulatory cells (Tfr) represent an exception among peripherally induced Foxp3+ cells, as they are derived from natural
regulatory cells (nTreg) that acquire Bcl-6 expression, rather than from conventional CD4 T cells.
exposed to optimal conditions to induce Foxp3 expression
in conventional T cells (including TGF-β) resist conversion
to Tfr [79]. Given the importance of the germinal center
response for allergy, it is likely that Tfr cells can play an
important role in regulating IgE production.
Besides conventional T cells, also natural killer T (NKT)
cells are important players in deﬁning the outcome of
immune responses. Notably, invariant NKT (iNKT) cells
were found able to help B-cell diﬀerentiation, germinal-
center formation, aﬃnity maturation, and immunoglobulin
response that was uniquely dependent on iNKT cell-derived
IL-21, although the GCs maintain a small size throughout
the reaction [82, 83]. This contribution of iNKT cells for
humoral responses can be added to their ability to contribute
to allergic airways diseases by producing IL-4 and IL-13
[84, 85], or IL-17 [86, 87]. But iNKT cells can also have
a regulatory role, namely, in preventing EAE following
administration of its TCR agonist [88, 89]. We and others
recently described that activation of murine or human iNKT
cells in presence of TGF-β induces Foxp3 expression and
acquisition of suppressive function [88, 90].
5. Inﬂuencing Regulatory T Cells in Allergy
The understanding of the mechanisms involved in regulatory
T-cells generation and function may lead to novel strategies
to restore immune tolerance where it has been lost. As TGF-β
and IL-10 play a crucial role in tolerance induction, several
studies on immune tolerance induction took advantage of
environments rich in those anti-inﬂammatory cytokines. To
our advantage the mucosa itself is an anatomical location
rich in these immune mediators [91].
Airborne antigens can be transferred from the mother
to the newborn through milk [92]. Breastfeeding-induced
tolerance was found to be mediated by induced Foxp3+ Treg
cells and dependent on TGF-β [92]. It has been proposed that
metallomatrix proteases, derived from commensal bacteria
in the gut, can facilitate the conversion of latent TGF-β to
its active form, thus favoring iTreg diﬀerentiation [93]. In
addition, CD103+ dendritic cells in the mucosa-draining
lymph nodes have been shown eﬀective in promoting
conversion of iTregs in the gut, mediated by TGF-β and
the synthesis of retinoic acid, a powerful inducer of Foxp3
expression [32, 94, 95]. Furthermore, vitamin D receptor
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deﬁcient mice were associated with a reduction in tolerogenic
CD103+ dendritic cells favoring the development of eﬀector
type T cells [96]. Vitamin D3 can be used to induce human
and mouse naive CD4+ T cells to diﬀerentiate in vitro into
regulatory cells that produced only IL-10, but no IL-5 and
IFN-γ, and furthermore retain strong proliferative capacity
[97]. Several other studies put vitamin D3 in relevance as
acting directly on T cells to induce IL-10+ regulatory cells
and also inﬂuencing levels of TGF-β [98–100]. These data
suggest that the mucosa, in particular the gut, has several
mechanisms that can favor immune tolerance. Sublingual
immunotherapy (SLIT) and oral immunotherapy (OIT)
are becoming more relevant as eﬀective tolerance-inducing
strategies to treat inhalant as well as food allergies [101].
Allergen speciﬁc immunotherapy (SIT) which compre-
hends SLIT, OIT, and subcutaneous immunotherapy (SCIT)
has been in clinical use for around 100 years [102] and
consists on the administration of increasing doses of an
allergen [103]. It has been shown that both Foxp3+ and IL-10
positive regulatory T cells can be induced during the course
of SIT protocols [104, 105]. Furthermore, allergen-speciﬁc
TR1 cells, in healthy individuals, have been suggested to play
a key role in preventing pathologic responses [52, 102, 106].
While the presence of IL-10 leads B cells to produce IgG4 in
detriment of IgE [107, 108], TGF-β drives B cells to switch
to IgA production [106]. Another approach to direct the
organism towards a tolerant state arises from the results that
suggest that reduced TCR stimulation favors the induction
of a regulatory phenotype on the T cells [26, 109, 110].
Blockade of molecules involved in the immune synapse
has been suggested as an approach to achieve suboptimal
TCR activation [26, 110]. Blockade of CD4 was shown
a robust approach to achieve Treg-mediated dominant
tolerance in transplantation [111–113]. We recently showed
that a nondepleting anti-CD4 monoclonal antibody can
induce in mice robust, antigen-speciﬁc tolerance to house
dust mite, even in presensitized animals [16]. In addition,
a similar strategy was eﬀective to prevent peanut-induced
anaphylaxis in mice [114]. Costimulation blockade was also
shown eﬀective in preventing allergic sensitization in mice
[115]. Based on previous studies of tolerance induction to
alloantigens following costimulation blockade, it is likely the
mechanism also relies on Treg cells [116, 117]. Regarding the
diﬀerent modalities for costimulation blockade, on one hand
CTLA4Ig was shown able to greatly reduce the secretion of
IL-4 but not enough to impair Th2 response [118]. On the
other hand, treatment with OX40L-blocking mAbs inhibited
to some extent allergic immune responses induced by TSLP
in the lung and skin, preventing Th2 inﬂammatory cell
inﬁltration, cytokine secretion, and IgE production in mice
and nonhuman primate models of asthma [119].
6. Final Remarks
The realization that active regulatory mechanisms, such as
the ones mediated by Treg cells, can prevent pathological
immune responses to harmless antigens is changing the
way immunotherapy is perceived. In very diverse ﬁelds
of immunology, ranging from cancer immunotherapy to
autoimmunity and allergy, regulatory mechanisms need to
be considered when therapeutic interventions are designed
to boost or dampen the immune response. The realization
that diﬀerent subsets of regulatory T cells exist may oﬀer the
possibility to ﬁne tune such interventions in order to achieve
optimal therapeutic beneﬁt with limited immunosuppressive
consequences in unrelated immune responses.
At a time when therapeutic interventions rely increas-
ingly on potentially immunogenic drugs, such as recom-
binant proteins to correct genetic diseases or monoclonal
antibodies, where even the human antibodies can be immu-
nogenic due to their unique idiotypes [120, 121], the issue of
tolerance induction to nonselfantigens will not be restricted
to allergy and transplantation, but a growing concern for
drug eﬃcacy.
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T Cell Apoptosis and Induction of Foxp3+ Regulatory T Cells
Underlie the Therapeutic Efﬁcacy of CD4 Blockade in
Experimental Autoimmune Encephalomyelitis
Joana Duarte,*,† Nade`ge Carrie´,‡,x Vanessa G. Oliveira,*,† Catarina Almeida,*,†
Ana Agua-Doce,*,† Le´nia Rodrigues,*,† J. Pedro Simas,*,† Lennart T. Mars,‡,x and
Luis Graca*,†
The pathogenesis of multiple sclerosis requires the participation of effector neuroantigen-speciﬁc T cells. Thus, T cell targeting
has been proposed as a promising therapeutic strategy. However, the mechanism underlying effective disease prevention following
T cell targeting remains incompletely known. We found, using several TCR-transgenic strains, that CD4 blockade is effective
in preventing experimental autoimmune encephalopathy and in treating mice after the disease onset. The mechanism does not
rely on direct T cell depletion, but the anti-CD4 mAb prevents the proliferation of naive neuroantigen-speciﬁc T cells, as well
as acquisition of effector Th1 and Th17 phenotypes. Simultaneously, the mAb favors peripheral conversion of Foxp3+ regulatory
T cells. Pre-existing effector cells, or neuroantigen-speciﬁc cells that undergo cell division despite the presence of anti-CD4, are
committed to apoptosis. Therefore, protection from experimental autoimmune encephalopathy relies on a combination of dom-
inant mechanisms grounded on regulatory T cell induction and recessive mechanisms based on apoptosis of neuropathogenic cells.
We anticipate that the same mechanisms may be implicated in other T cell-mediated autoimmune diseases that can be treated or
prevented with Abs targeting T cell molecules, such as CD4 or CD3. The Journal of Immunology, 2012, 189: 1680–1688.
M
ultiple sclerosis (MS) is an inﬂammatory disease of the
CNS leading to progressive demyelination that is the
leading cause of neurologic disability among young
adults (1, 2). Genetic risk factors indicate that the heritable risk
of developing MS is associated with allelic variants of predomi-
nantly immune-related genes (3–7). The strongest association is
conferred by the human leukocyte/Ag locus (8). The inﬂammatory
response present within the demyelinating lesions mainly com-
prises CD4 and CD8 T cells as well as macrophages (9). The
commonly held view is that this response is autoreactive, targeting
CNS-derived Ags (10). The pathogenicity of this response is
modeled in experimental autoimmune encephalomyelitis (EAE),
a paralytic demyelinating disease that is induced in susceptible
animals after immunization with myelin Ags, such as myelin basic
protein (MBP) or myelin oligodendrocyte glycoprotein (MOG)
(11). By using these models, myelin-reactive B cells and CD8+
and CD4+ T cells have been identiﬁed as effector cells able to
drive CNS demyelination. Furthermore, functionally distinct CD4
T cell subsets (Th1 and Th17) are now recognized to cause CNS
tissue damage with distinct pathological features (10). Their path-
ogenicity is essentially mediated by the production of GM-CSF
(12–14). Conversely, regulatory T cells (Treg) have been shown
to limit the pathology or to prevent its onset (15–17).
Given the important role of T cells in the pathogenesis of MS,
several therapeutic strategies have been proposed that rely on T cell
targeting, namely T cell depletion, achieved with alemtuzumab,
an anti-CD52 mAb (18), but also strategies that block a4 integrin
function (19–22), as well as T cell retention by FTY720 (23, 24).
CD4 blockade, however, with nondepleting mAbs (that do not
lead to direct cell lysis) offer the opportunity to speciﬁcally
target Ag-speciﬁc cells engaged in T cell activation at the time
of mAb treatment, rather than having a nonspeciﬁc effect. Other
mAbs targeting molecules involved in T cell activation (such as
CD3 or CD154) can also lead to long-term immune tolerance in
preclinical models (25–28). Of note, anti-CD3 therapy generated
promising results in phase I/II clinical trials, delaying onset of
type I diabetes and treating psoriatic arthritis (29–31).
We have taken interest in nondepleting anti-CD4 mAb because
of its established capacity to induce T cell tolerance without im-
posing systemic immune-suppression (32–41). The efﬁcacy of
nondepleting anti-CD4 in transplantation stems from its ability
to impose a state of persistent T cell unresponsiveness, even when
the mAbs have long disappeared from the circulation, that can
spread to naive T cells through what was termed “infectious
tolerance” (42, 43).
Promising results in EAE following anti-CD4 treatment (32,
44–46) justiﬁed some of the earliest clinical trials of mAbs in
MS in the early 1990s (47). However, the immaturity of the ﬁeld
at that time led to discouraging results, namely due to the im-
munogenicity of the mAb (it was not humanized) and to adverse
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effects due to T cell depletion (48).The mechanisms underlying
the putative tolerogenic effect of anti-CD4 treatment in neuro-
inﬂammation were never fully characterized.
In this study, we evaluate the mechanisms underlying the pro-
tective effect of CD4 blockade in EAE. Using models of sponta-
neous and active EAE, we show that a nondepleting isotype of
anti-CD4 mAb can prevent and treat EAE without leading to
CD4 T cell depletion. Treated mice remained immunocompetent
against viral infection.
We found that the underlying mechanism of CD4 blockade
is distinct in naive and preactivated cells. Whereas CD4 blockade
on activated cells favored their commitment to apoptosis, CD4
blockade during the priming of naive cells halted proliferation
and effector differentiation and promoted the emergence of Foxp3+
Tregs.
It is a combination of halting the effector function of preactivated
cells together with the recruitment of naive cells into the regulatory
pool that allows CD4 blockade to be effective in TCR-transgenic
mice, even after the onset of the disease. As such, our data
provide insight into the cellular mechanisms that are deployed to
achieve EAE protection with putative tolerogenic mAbs.
Materials and Methods
Animals
C57BL/6 (B6; H-2b), MBP-speciﬁc TCR-transgenic Rag12/2 (TR2) mice
(H-2u) (49), and 2D2 MOG-speciﬁc TCR-transgenic mice (H-2b) (50) were
bred and maintained under speciﬁc pathogen-free conditions and used sex
matched between 8 and 10 wk age. All experimental protocols were
approved by the Local Ethics Committee and are in compliance with
European Union guidelines.
EAE induction
For active EAE, B6 mice were s.c. immunized with 100 mg MOG35–55
peptide (MEVGWYRSPFSRVVHLYRNGK) (Biopolymers Laboratory,
Harvard Medical School) emulsiﬁed in CFA solution (4 mg/ml myco-
bacteria in IFA). On the day of immunization and 2 d after, mice received
200 ng pertussis toxin (List Biological Laboratories) in 100 ml PBS
i.v. For 2D2 Th1 transfer, puriﬁed CD4+ T cells from 2D2 mice at
0.5 3 106 cells/ml were stimulated in vitro with 20 mg/ml NF-M15–35
(RRVTETRSSFSRVSGSPSSGF) peptide in the presence of IL-12 (20 ng/ml),
IL-2 (1 ng/ml), and irradiated syngeneic splenocytes (5–10 3 106). On
day 6, viable cells were restimulated with APCs and 20 mg/ml NF-M15–35
in the presence of IL-12 (20 ng/ml) and IL-2 (1 ng/ml). On day 9, 143 106
Th1 cells were injected into lightly irradiated (300 rads) syngeneic recipi-
ents. Disease severity was scored daily on a ﬁve-point scale: 1, tail atony;
2, hind limb weakness; 3, hind limb paralysis; 4, quadriplegia; 5, moribund.
Abs
Nondepleting anti-CD4 (YTS177) and isotype control (YKIX302) mAbs
were produced in our laboratory using Integra CL1000 ﬂasks (IBS Integra
Biosciences, Chur, Switzerland), puriﬁed by 50% ammonium sulfate pre-
cipitation, dialyzed against PBS, and purity was checked by native and SDS
gel electrophoresis. Hybridomas were generously provided by Prof. Herman
Waldmann (Oxford, U.K.).
Preparation of CNS mononuclear cells
Mice were perfused through the left cardiac ventricle with cold PBS. The
brain and spinal cord were dissected. CNS tissue was cut into pieces and
digested with collagenase type VIII (0.2 mg/ml; Sigma-Aldrich) in HBSS
at 37˚C for 30 min. Mononuclear cells were isolated by passing the tissue
through a 70-mm cell strainer, followed by a 30% Percoll (Sigma-Aldrich)
gradient and 20 min centrifugation at 2500 rpm. Mononuclear cells were
recovered from the pellet, resuspended, and used for further analysis.
Flow cytometry
Single-cell suspensions were stained with CD25-Alexa Fluor 488 and
PE-Cy7 (PC61.5), CD4-PE and PerCp-Cy5.5 (RM4-5), CD8-allophycocyanin-
Cy7 (53-6.7), Thy1.2-allophycocyanin-Cy7 (53-2.1), anti-MBP TCR clono-
type biotin (3H12) (51), TCR Vb11 (RR3-15), TCR Va3.2 FITC (RR3-16),
CD45.1 A700 and biotin (A20; all from eBioscience), and CD3-PerCp-Cy5.5
(145-2C11; BioLegend). Apoptotic cells were identiﬁed with 7-amino-
actinomycin D and annexin V-allophycocyanin labeled in annexin V
binding buffer (eBioscience). To prevent unspeciﬁc Ab capture by the Fc
receptors, cells were incubated with anti-CD16/32 (clone 2.4G2) prior to
staining. Samples were acquired on a FACSCanto or LSRII and analyzed
with FlowJo.
CFSE labeling
Cells were resuspended at 13 106 cells/ml incubated at 37˚C for 10 min in
the presence of 5 mM CFSE. To stop the staining, cold complete medium
was added.
Intracellular stainings
For intracellular cytokine staining, cells were isolated as described and
stimulated for 4 h in complete culture medium containing 50 ng/ml PMA,
500 ng/ml ionomycin, and 10 mg/ml brefeldin A (Sigma-Aldrich). After
staining of surface markers, cells were treated with a ﬁxation and per-
meabilization kit (eBioscience) and stained with IFN-g (XMG1.2), IL-17A
(ebio 17B7), and Foxp3 (FJK165) Abs from BD Biosciences and eBio-
science according to the manufacturers’ recommendations.
In vitro Th17 polarization
MBP-speciﬁc CD4+ T cells were sorted by magnetic separation with CD4
(L3T4) microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) from
healthy 30-d-old TR2 mice. Cell purities were between 92 and 96%. The
T cells were cultured for 5 d with bone marrow-derived dendritic cells (52)
and 10 mg/ml MBP peptide (MedProbe, Oslo, Norway) in IMDM/5% FBS
with 1 ng/ml TGF-b (R&D Systems), 20 ng/ml IL-6 (R&D Systems),
10 ng/ml IL-1b (eBioscience), and 10 mg/ml anti–INF-g (R46A2) with
or without 10 mg/ml anti-CD4 (YTS177). At the end of the culture, cells
were harvested and processed for ﬂow cytometry.
Cytokine production assays
Splenocytes (13 106) were plated in 96-well ﬂat-bottom plates and cultured
in complete medium (RPMI 1640 with GlutaMAX, supplemented with
10% FBS, 1% HEPES, 1% penicillin/streptomycin, 1% sodium pyruvate,
0.1% 2-ME; Invitrogen) with 20 mg/ml peptide (MBP or MOG35–55).
Supernatants were recovered after 72 h and cytokines were quantiﬁed by
sandwich ELISA for IL-10, IFN-g (PrepoTech, London, U.K.), or IL-17
(R&D Systems).
Adoptive transfer of naive T cells
CD4+CD62L+CD252 T cells were puriﬁed from CD45.1 congenic 2D2
mice in two steps using microbeads (MACS; Miltenyi Biotec): ﬁrst by
negative selection using mAbs to CD8 (YTS169), B220 (RA3-6B2),
Mac1 (CI:A3-1), and CD25 (7D4); followed by positive selection with
anti-CD62L–coated beads, providing 80% CD4+ T cells, of which 95%
were CD62L+CD44lo expressing the transgenic 2D2 TCR. Cells (1 3
105) were adoptively transferred into syngeneic B6 mice the day before
immunization.
Viral plaque assay
Mice were infected with murid herpesvirus (MuHV)-4 by intranasal in-
oculation of 104 PFU in 20 ml PBS under halothane anesthesia. At days 7
(peak of lytic infection) and 14 (resolution of lytic infection), lungs were
recovered and frozen at 280˚C. On the day of the assay, lungs were
homogenized in glutamine-free MEM complete media and submitted to
103 serial dilutions. To each dilution 5 3 105 BHK-21 cells were added.
Viruses were left to adsorb for 1 h in six-well plates, at 37˚C, followed
by 4 d incubation after addition of 3 ml media. At day 4 of culture, the
cell monolayer was ﬁxed with 4% formaldehyde and stained with 0.1%
toluidine blue. Viral plaques were counted with a Stemi SV6 magnifying
glass (Zeiss). Virus titers were determined from the average of the number
of counted viral plaques in duplicates.
Histology
Animals were perfused postmortem with 2% paraformaldehyde in PBS.
Tissues were embedded in parafﬁn, and tissue sections were stained with
H&E.
Statistical analysis
Statistical signiﬁcance was determined using the two-tailed nonparametric
Mann–Whitney U test, and p values of ,0.05 were deemed signiﬁcant
(*p , 0.05, **p , 0.01, ***p , 0.001).
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Results
Nondepleting anti-CD4 mAb prevents EAE
Previous studies primarily focused on the clinical amelioration
afforded by CD4 mAb treatment on EAE in Biozzi AB/H (45),
PL/J mice (44), and Lewis rats (32). Little is known regarding the
underlying mechanisms. To study the impact of nondepleting CD4
mAb on the encephalitogenic T cell response, we chose the most
widely used mouse model of EAE that is induced in C57BL/6
mice after immunization with MOG35–55. Control mAb-treated
mice (Fig. 1A) developed EAE on average 12 d after immuniza-
tion causing hind limb paralysis to most animals (maximum dis-
ease score, 3 6 0.4; Supplemental Table I). This paralytic disease
was fully prevented when mice were treated with CD4 mAb on
days 3 and 2 prior to immunization (Fig. 1, Supplemental Table I).
Histological analysis indicated that disease prevention correlated
with a reduced accumulation of immune cells in the CNS (Fig. 1B),
including CD4+ T cells (Fig. 1C). In vitro Ag recall experiments
indicate that treatment with CD4 mAb reduces the intensity of the
MOG35–55-speciﬁc T cell response. Fourteen days after immuni-
zation, splenocytes from control mAb-treated mice produced sig-
niﬁcantly higher concentrations of IL-17 and IFN-g in response
to MOG restimulation in vitro as compared with immunized mice
pretreated with CD4 mAb (Fig. 1D).
To test whether the efﬁcacy of the treatment would persist after
disease onset we treated mice with a single injection of 1 mg anti-
CD4 mAb on the day of disease onset. As shown in Fig. 1E, the
isotype control mAb-treated mice progressed from an initial tail
atony to full paralysis of the hind limbs. Anti-CD4 mAb treatment
halted disease progression, providing full disease remission 1 wk
after treatment (Fig. 1E, Supplemental Table I).
Mice treated with nondepleting anti-CD4 mAb remain
immunocompetent
To evaluate whether CD4 mAb-treated mice remain immuno-
competent after treatment withdrawal, we evaluated the capacity
of successfully treated mice to mount an antiviral immune re-
sponse against a g-herpesvirus infection. MuHV-4 causes transient
pneumonia in B6 mice. This acute viral infection is efﬁciently
cleared from the lungs after ∼14 d by a cell-mediated immune
response comprising both CD8+ and CD4+ T cells (53). We validated
the implication of the adaptive immune response and the CD4+
T cell response by infecting RAG2/2 and MHC class II2/2 mice,
respectively (Fig. 2). The RAG2/2 mice succumbed to uninhibited
viral infection, causing increased viral titers 7 d postinoculation
that proved lethal to all mice before day 14 (Fig. 2A). The role
of CD4+ T cells was revealed in MHC class II2/2 mice where the
absence of CD4+ T cells increased the dissemination of MuHV as
FIGURE 1. CD4 blockade treats active EAE in C57BL/6 mice. (A) CD4 mAb treatment prevents active EAE. Average clinical score of MOG35–55-
immunized mice treated with 1 mg nondepleting anti-CD4 mAb (n = 5;:) or isotype control mAb (n = 5; n) at 3 and 2 d prior to immunization. The mean
clinical score 6 SEM is presented for one representative experiment out of three. (B) Parenchymal inﬁltration of inﬂammatory cells is prevented following
CD4 blockade. H&E staining of transversal sections of the spinal cord 20 d after MOG35–55 immunization (original magniﬁcation3400). Control mAb (n =
3; middle column) and nondepleting CD4 mAb (n = 3; right column) were injected 3 and 2 d prior to immunization. Aged-matched nonimmunized mice
(n = 3; left column) were used as control. (C) CD4 mAb treatment prevents immune invasion of the CNS. Fifteen days after MOG35–55 immunization, CNS
mononuclear cells were obtained by Percoll gradient from mice treated with an isotype control (black bar; n = 5) and anti-CD4 mAb (white bar; n = 5) 3 and
2 d before immunization. Age-matched nonimmunized mice (gray bar; n = 5) were used as control. CD4+TCRb+CD82 T cells were quantiﬁed by ﬂow
cytometry. The data represent the mean number of CD4+ T cells per CNS 6 SEM and two representative dot plots. (D) Anti-CD4 mAb treatment reduces
the magnitude of the MOG35–55-speciﬁc T cell response. Ag recall experiments were performed on splenocyte cultures 14 d after MOG35–55 immunization.
The concentration of IFN-g and IL-17 was measured 72 h after in vitro stimulation with 20 mg/ml MOG35–55 (ﬁlled bars) or medium alone (open bar). Mice
were treated with control mAb (n = 5; middle) and anti-CD4 mAb (n = 5; right) 3 and 2 d prior to immunization. Age-matched nonimmunized mice
were used as controls. Data represent mean cytokine concentration 6 SEM. ND, not detected. (E) CD4 mAb therapy ameliorates established EAE.
Average clinical score of MOG35–55-immunized mice treated with a single injection of 1 mg nondepleting anti-CD4 mAb (n = 5;:) or isotype control mAb
(n = 5; n) on the day of disease onset. The data present the mean clinical score 6 SEM after disease onset (day 0) and correspond to one representative
experiment out of two. *p , 0.05, ***p , 0.001.
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indicated by higher viral titers 7 and 14 d postinfection (Fig. 2A).
This model of viral clearance was used to test the immunocom-
petence of mice previously treated with anti-CD4 or control mAb
2 and 3 d prior to MOG35–55 immunization. Thirty days after
immunization mice were intranasally infected with MuHV-4 and
the lungs were analyzed for virus content 7 and 14 d postinfection.
Control B6 mice were infected with MuHV-4 in the absence of
prior MOG-CFA immunization or CD4 blockade. As shown in
Fig. 2B, mice that were initially treated with CD4 mAb were
able to resolve the MuHV-4 virus infection detected at day 7
(Fig. 2B, top) by day 14 (bottom) with an efﬁciency equivalent
to nonmanipulated control mice.
To further illustrate that nondepleting CD4 mAb treatment
tolerizes only to Ags present at the time of treatment, we differ-
entially applied CD4 mAb treatment to mice immunized with
OVA and alum (Supplemental Fig. 1). We found that treatment
with nondepleting anti-CD4 mAb prior to OVA immunization did
not hamper subsequent immune responses to OVA (Supplemental
Fig. 1A). In contrast, administration of OVA at the time of anti-
CD4 treatment led to the induction of tolerance to this foreign
Ag, which manifested as impaired production of OVA-speciﬁc
IgG1 following subsequent OVA recall (Supplemental Fig. 1B).
CD4 blockade inhibits proliferation and functional
polarization of MOG-speciﬁc T cells
To study the fate of encephalitogenic T cells at the single-cell level,
we transferred a traceable population of naive MOG35–55-speciﬁc
CD4+ T cells into CD45.2 B6 mice prior to EAE induction. These
CD62L+CD252CD4+ T cells were puriﬁed from CD45.1 congenic,
2D2 transgenic mice expressing an I-Ab–restricted TCR (Va3.2–
Vb11) speciﬁc for MOG35–55 (50). As previously published, the
transferred MOG-speciﬁc T cells differentiate into pathogenic Th1
and Th17 cells and expand 3700-fold by day 9 after immunization
with MOG35–55 (54). As shown in Fig. 3A, the recipient mice
develop severe EAE that renders mice quadriplegic (maximum
disease score, 4.36 0.33) when injected with isotype control mAb
at days 0, 2, and 4 after immunization with MOG35–55. A similar
treatment with nondepleting CD4 mAb fully protected the recip-
ient mice from active EAE, as none of the animals developed any
clinical signs of EAE (Fig. 3A). This is not because of depletion
of the CD4 T cells, as the size of the CD4 T cell compartment
was unaltered between isotype control- and nondepleting CD4
mAb-treated mice (Fig. 3B). However, when selectively enumer-
ating the MOG35–55-speciﬁc T cells a statistically signiﬁcant re-
duction in the accumulation of 2D2 T cells was observed 9 d after
immunization in mice treated with the CD4 mAb (Fig. 3C). This
reduction was not associated with increased apoptosis, as the per-
centage of 2D2 T cells binding annexin V was similar in the isotype
control- and CD4 mAb-treated groups 3 d after immunization with
MOG35–55 (Fig. 3D).
CD4 blockade inhibited T cell priming of the encephalitogenic
T cell response as measured by CFSE dilution of the congenic
MOG-speciﬁc 2D2 T cells. In the isotype control-treated mice
most 2D2 T cells had undergone at least ﬁve cell divisions (51%)
by day 3. In the CD4 mAb-treated mice this represented only
8% of the 2D2 T cells (Fig. 3E, 3F, Supplemental Fig. 2). The
origin of this difference is likely to be bimodal, with less naive
2D2 T cells being activated after CD4 blockade, and second, that
2D2 T cells activated in the presence of CD4 blockade abort
their expansion, as suggested by the limited number of cell divi-
sions (Fig. 3E). Abortive T cell activation is characterized by
T cell proliferation in the absence of effector differentiation. Con-
sequently, we assessed whether CD4 blockade would prevent the
commitment of naive 2D2 T cells to the Th1 and Th17 effector
subsets 9 d after immunization. In vitro MOG35–55 recall dem-
onstrated a sizeable release of IL-17 and IFN-g in lymph node
cultures from isotype control-treated mice (Fig. 3G, Supplemental
Fig. 2C, 2D). In CD4 mAb-treated mice the Ag recall response
was downregulated, as indicated by the signiﬁcant reduction in
the release of effector cytokines (Fig. 3G). This was associated
with a similar reduced frequency of 2D2 T cells expressing IFN-g
or IL-17 (Fig. 3H, Supplemental Fig. 2C, 2D), indicating that CD4
mAb treatment blocks the differentiation of naive 2D2 T cells into
Th1 or Th17 effector cells. All data presented (Fig. 3B–H) were
obtained from the draining inguinal lymph nodes.
Lastly, we addressed the contribution of regulatory CD4+ T cells
to the immunomodulatory impact of nondepleting CD4 mAb treat-
ment. We assessed whether CD4 blockade during active immuni-
zation could favor the differentiation of naive T cells into induced
Foxp3+ Tregs. On day 9 after immunization with MOG35–55 in
CFA, we found an increased frequency of Foxp3+ 2D2 T cells
(p , 0.05), whereas the frequency of Foxp3+ Tregs within poly-
clonal T cells remained unchanged (Fig. 3I).
Effector T cells are committed to apoptosis under anti-CD4
treatment
To study the mechanism by which nondepleting anti-CD4 mAbs
treat established disease, as shown in Fig. 1E, we investigated
the in vivo impact of anti-CD4 on terminally differentiated ef-
fector T cells. To this end, we passively induced EAE in C57BL/6
mice by adoptively transferring 14 3 106 MOG-speciﬁc 2D2 cells
that were primed in vitro under Th1 polarization conditions (Fig.
4A) (55). Treating the recipient mice on days 0, 2, and 4 after Th1
transfer with anti-CD4 mAbs prevented the onset of disease in all
treated mice (Fig. 4A). To study the fate of the transferred congenic
2D2 cells, we assessed their accumulation in the CNS and cervical
lymph nodes 9 d after transfer, just prior to death of control mice
(mortality on days 11–13). In the diseased isotype control-treated
FIGURE 2. Mice treated with nondepleting anti-CD4 mAb remain im-
munocompetent. (A) To conﬁrm the role of CD4+ T cells in viral clearance,
CD4-deﬁcient MHC class II2/2 and Rag12/2 mice were intranasally in-
fected with 104 PFU MuHV-4. The viral load was quantiﬁed from lungs
collected at days 7 and 14 that correspond to the peak of pneumonia and
immune-mediated viral clearance. Rag12/2 mice died before day 14. MHC
class II2/2 mice did not resolve infection with the same efﬁcacy as did mice
treated with anti-CD4 30 d prior to infection (n = 5; *p , 0.05; NA, not
applicable). (B) C57BL/6 mice were immunized with MOG35–55 to induce
EAE and treated with anti-CD4 mAb (n = 5; middle) or control mAb
(n = 5; left) 3 and 2 d prior to immunization. Age-matched nonimmunized
mice (n = 5; right) were used as control. Thirty days later the mice were
infected as described above. The data show that anti-CD4–treated mice re-
solve infection with similar efﬁcacy to control groups. Data are representative
of two independent experiments.
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mice an average of 4 3 105 pathogenic 2D2 T cells could be
recovered per CNS, whereas in the CD4 mAb-treated group the
number of CNS inﬁltrating 2D2 T cells was signiﬁcantly reduced
(10-fold) (Fig. 4B). The transferred 2D2 T cells were also de-
tectable in the cervical lymph nodes, but the cell numbers did
not signiﬁcantly differ from the control-treated group (Fig. 4C).
However, in the CD4 mAb-treated group the fate of the patho-
genic 2D2 T cells was signiﬁcantly altered. As shown in Fig. 4D
and 4E, up to 40% of transferred encephalitogenic T cells were
undergoing apoptosis as measured by annexin V binding within
congenic 2D2 T cells. Taken together, our data suggest that CD4
blockade triggers different mechanisms in naive and fully polar-
ized Ag-speciﬁc cells. On naive T cells anti-CD4 mAb treatment
prevents T cell priming, whereas on terminally differentiated T cells
CD4 blockade predestines pathogenic T cells for apoptosis.
Anti-CD4 mAb treatment prevents fatal EAE in TCR-
transgenic mice
MBP-speciﬁc TCR-transgenic mice that are Rag1-deﬁcient (TR2)
spontaneously develop EAE between days 40 and 60 of life (49).
All of the TR2 mice develop a disabling disease that progresses
rapidly, leading to death within 5 d upon the initial clinical man-
ifestations. This model permitted us to assess the efﬁciency of
nondepleting CD4 mAb treatment during spontaneous neuro-
inﬂammation that develops without the need of adjuvant immu-
nization. Treating the TR2 mice with two shots of 1 mg anti-CD4
mAb between days 30 and 35 of age protected all mice from EAE
(incidence 0%; Supplemental Table I) when compared with iso-
type control-treated TR2 mice, all of which developed fatal EAE
(incidence 100%; Fig. 5A). The efﬁcacy of the non-depleting
CD4 mAb treatment is such that even delaying treatment after
FIGURE 3. Anti-CD4 inhibits proliferation and differentiation of MOG-speciﬁc T cells. (A) Anti-CD4 mAb treatment prevents active EAE in model
with traceable encephalitogenic T cells. Congenic 2D2 cells (1 3 105) were adoptively transferred into B6 mice and active EAE was induced by MOG35–55
immunization the following day. Mice were treated with anti-CD4 (n = 4) and control mAb (n = 4) on days 0, 2, and 4. The mean clinical score 6 SEM
is presented for one representative experiment out of 3. (B–F) Anti-CD4 mAb treatment inhibits T cell priming. CFSE-labeled naive 2D2 T cells (1 3 106)
were adoptively transferred into B6 mice prior to MOG35–55 immunization. Flow cytometry analysis was performed on day 3 in the draining lymph nodes
of mice treated with anti-CD4 mAb (n = 4; open bars) and control mAb (n = 4; ﬁlled bars) on days 0 and 2. By ﬂow cytometry it is possible to distinguish
the fate of encephalitogenic 2D2 cells (CD45.1+) from polyclonal CD4+ T cells. (B) Number of the total CD4+ T cell compartment among draining lymph
node cells. (C) Number of CD45.1+TCRVa3.2+CD4+ congenic 2D2 T cells in the draining lymph nodes. (D) Proportion of cells binding annexin V among
CD45.1 TCR Va3.2+CD4+ 2D2 T cells. (E) Representative dot plots showing CFSE dilution of CD45.1+TCR Va3.2+CD4+ 2D2 T cells after control mAb
(left panel) or anti-CD4 mAb treatment (right panel). (F) CFSE data expressed as the frequency of 2D2 cells that did not divide or cells that had undergone
cell divisions as assessed by CFSE dilution (left plot), and mean number of divisions of 2D2 T cells from mice treated with anti-CD4 (open bar) or a control
mAb (ﬁlled bar). (G–I) Anti-CD4 mAb treatment inhibits effector T cell differentiation and favors Foxp3+ Treg expansion. Naive 2D2 T cells (1 3 105)
were transferred into B6 mice and active EAE was induced by MOG35–55 immunization the following day. Mice were treated with anti-CD4 (n = 4) and
control mAb (n = 4) on days 0, 2, and 4. Mice were analyzed 9 d after immunization. (G) Splenocyte cultures were restimulated with 100 mg/ml MOG35–55
(ﬁlled bars) or cultured in the absence of Ag (open bars), and IL-17 release (left) and IFN-g (right) were measured after 72 h by sandwich ELISA. (H)
Ex vivo analysis of CD4+CD45.1+ 2D2 T cells for intracellular IL-17 (left) and IFN-g (right) expressed as absolute number of cytokine-positive 2D2
T cells. (I) Histograms representing the frequency of Foxp3+ cells within the polyclonal CD4+CD45.12 T cells (left) and within MOG-speciﬁc 2D2 T cells
(CD4+CD45.1+, right). The histograms represent cells from mice treated with anti-CD4 (dotted line) or an isotype control (thick line, frequency values in
italics). The data represent the mean 6 SEM of two independent experiments. *p , 0.05.
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onset (clinical score 1) still permitted the progression of disease
to be halted (Fig. 5B). In contrast, the isotype control treatment
failed to delay the lethal disease progression, resulting in the
death of all mice (Fig. 5B).
Similar to the active EAE setting, the overall CD4+ T cell
number is maintained following anti-CD4 treatment, conﬁrming
the nondepleting nature of the mAb (Fig. 5C). Unlike active EAE,
we did not ﬁnd evidence for increased apoptosis on autoantigen-
speciﬁc T cells from anti-CD4–treated mice (Fig. 5D). Because
TR2 mice are devoid of natural Tregs, we could conveniently
evaluate the induction of Treg differentiation in anti-CD4–treated
mice (Fig. 5E) (49). Two injections of 1 mg CD4 mAb in 30- to
35-d-old mice permitted the de novo generation of CD4+Foxp3+
T cells in cervical lymph nodes (Fig. 5E). The observed low
percentage of induced Foxp3+ Tregs is consistent with previous
reports of Treg-mediated tolerance induced in TCR-transgenic
Rag-deﬁcient mice (52, 56).
To study the underlying mechanism, we evaluated whether
in vitro stimulation of CD4+ MBP-speciﬁc TR2 cells with MBP-
loaded dendritic cells in the presence of anti-CD4 would alter
the balance between the protective and proinﬂammatory Treg and
Th17 populations. Addition of anti-CD4 to T cell cultures in Th17
polarizing conditions (in the presence of TGF-b and IL-6) led to
a decrease in Th17 cells with a simultaneous increase of Treg fre-
quency in a dose-dependent manner (Fig. 5F, 5G). This suggests
that, in addition to recessive tolerance, nondepleting CD4 mAbs
are able to convey dominant tolerance in animal models of CNS
autoimmunity.
Discussion
The availability of different TCR-transgenic animal models of
inﬂammatory demyelinating disease allows the study of mecha-
nisms underlying putative tolerance-inducing regimens that in-
ﬂuence different components of the immune system (57). In the
last decade several studies have supported a role for T cell-directed
therapies in the treatment of MS, where alemtuzumab is perhaps
the most prominent example (58). Additionally, depleting (27, 28)
and nonmitogenic (26, 59) anti-CD3 mAbs have been shown
effective in inducing long-term protection from EAE. We used
a nondepleting anti-CD4 mAb and found that CD4 blockade
can lead to long-term protection from EAE while triggering dif-
ferent outcomes in naive or preactivated effector T cells.
We found that CD4 blockade was able to prevent the onset of
EAE in MOG-CFA–immunized mice, as well as to impair disease
progression when anti-CD4 was administered following the on-
set of clinical manifestations of the disease. Importantly, anti-
CD4–treated mice remained fully competent to respond to unrelated
Ags (Supplemental Fig. 1) and to mount protective immune
responses toward a g- herpesvirus (MuHV-4). However, at the
time of anti-CD4 infusion there is a period where exposure to
foreign Ags leads to tolerance rather than to protective immunity.
Therefore, and depending on the pathogen characteristics, active
infection when anti-CD4 is administered may interfere with ef-
fective pathogen clearance. In fact, in the early 1990s there were
some promising studies with anti-CD4–induced EAE protection
(32, 44–46) that led to some of the earliest clinical trials with
therapeutic mAbs. However, the clinical development of this anti-
CD4 therapy for MS was soon abandoned because of adverse
effects related to CD4 T cell depletion (48). Our data show that,
similar to what was previously shown in transplantation (60), au-
toimmune arthritis (61), and allergic diseases (62, 63), the thera-
peutic effect mediated by anti-CD4 mAb does not require direct
T cell depletion.
To follow the fate of pathogenic T cells in vivo we adoptively
transferred MOG-speciﬁc cells from 2D2 mice. It is well de-
scribed that in EAE, the CNS suffers a massive inﬁltration by
activated lymphocytes, namely CD4 effector T cells, which break
the blood–brain barrier and recruit other proinﬂammatory cells to
the site of inﬂammation, leading to an increased severity of the
disease (64). We found that anti-CD4–treated mice did not show
any signiﬁcant inﬁltrates in the CNS while presenting a reduction
of MOG-speciﬁc TCR-transgenic cells in the cervical lymph node
FIGURE 4. CD4 blockade prevents Th1-induced EAE through induction of apoptosis. (A–D) MOG-speciﬁc 2D2 T cells were polarized toward Th1
phenotype in vitro and transferred (14 3 106/mouse) into syngeneic B6 mice. (A) Average clinical score of mice treated with anti-CD4 mAb (n = 4; n) or
control mAb (n = 4; :) at the day of Th1 transfer and on days 2 and 4. The mean clinical score 6 SEM is presented for one representative experiment
out of two. (B–E) Nine days after 2D2 Th1 transfer anti-CD4 mAb (n = 4; open bars) or control mAb (n = 4; ﬁlled bars) treated mice were sacriﬁced and the
number of CD4+CD45.1+TCR Va3.2+ T cells was determined by ﬂow cytometry among CNS-inﬁltrating mononuclear cells (B) and in the cervical lymph
nodes (C). (D) Proportion of cells binding annexin V among CD45.1+TCR Va3.2+CD4+ 2D2 T cells in the cervical lymph nodes. The data represent the
mean 6 SEM of two experiments. (E) Representative ﬂow cytometry data from cervical lymph nodes of mice transferred with Th1-polarized cells in the
absence of anti-CD4 (top) or subjected to CD4-blockade (bottom), showing higher frequency of cells binding annexin V in mice treated with anti-CD4
(histograms). *p , 0.05.
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(the number of nontransgenic CD4 cells did not change, con-
ﬁrming the nondepleting nature of the mAb used). We also found
that CD4 blockade acts by preventing T cell proliferation, as well
as preventing the differentiation of effector cells producing pro-
inﬂammatory cytokines. Our data show that the few encephali-
togenic cells that proliferate in mice treated with anti-CD4 are
committed to apoptosis, whereas in the control group they ac-
quire IL-17– and IFN-g–producing phenotypes (Supplemental
Fig. 2). The molecular triggers that lead to apoptosis in the pro-
liferating cells exposed to anti-CD4 mAb remain to be established.
Additionally, we also found that among the transferred MOG-
speciﬁc cells there is an expansion of Foxp3+ T cells. These
presumably induced Tregs can be especially important for the
long-term maintenance of the tolerance state.
We then studied the effect of CD4 blockade on preactivated
MOG-speciﬁc T cells, generally considered difﬁcult to regulate. In
fact, it was previously reported that MOG-speciﬁc Foxp3+ Tregs
are able to control naive neurotropic T cells but not activated
effector T cells (65). We found that preactivated 2D2 cells do
not cause pathology in the presence of CD4 blockade. Our data
show that preactivated 2D2 cells under the cover of anti-CD4 fail
to accumulate in the CNS, while being committed to apoptosis.
To further investigate the regulation of the balance between
Tregs and effector T cells we used Rag1-deﬁcient mice bearing
a T cell repertoire exclusively composed of MBP-speciﬁc T cells
and devoid of Foxp3+ Tregs (TR2) (49, 51). Despite the number
of potentially aggressive cells these animals were protected from
the development of EAE following a short course of nondepleting
anti-CD4. We found protection from EAE correlated with the
emergence of Foxp3+ Tregs in the periphery. This is in agreement
with several studies that support a role for Tregs in the control of
CNS inﬂammation. In fact, some studies have shown that TR2
mice can be protected from EAE following adoptive transfer of
Tregs from anti-MBP TCR-transgenic Rag1+/+ mice (51, 66, 67).
Our in vitro studies have conﬁrmed that blocking CD4 during the
activation of TCR-transgenic T cells under Th17 polarizing con-
ditions results in a decrease in IL-17–producing cells concomi-
tantly with a greater frequency of Foxp3+ cells in an anti-CD4
mAb dose-dependent way. It was indeed previously reported that
strategies leading to a reduction of stimulatory signals received
by the T cell (namely by reducing the concentration of agonist
peptides or using CD4 blockade) can favor Foxp3 upregulation
(52, 68). In all RAG2/2 TCR-transgenic strains tested, we observed
that the T cells that had acquired Foxp3 expression maintained
normal levels of transgenic TCR expression.
Taken together, our data show that T cells under distinct stages
of functional maturation respond differently to tolerance-inducing
protocols. Therefore, it is likely that some reagents able to induce
tolerance in naive T cells may be inadequate to effectively control
preactivated T cells. Similarly, strategies that suppress terminally
differentiated effector cells may be insufﬁcient to induce long-
term protection from the disease by promoting the peripheral
induction of Tregs. In a similar way to what we have previously
reported in an animal model of autoimmune arthritis (61), it appears
that the key to long-term tolerance in EAE is the resetting of
the abnormal effector Th1-Th17/Treg ratio. Importantly, naive
and effector cells appear to be regulated differently: CD4 block-
ade prevents the proliferation and effector polarization of naive
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FIGURE 5. Anti-CD4 treatment prevents fatal EAE in TR2 mice. (A) TR2 mice develop fatal spontaneous EAE between days 40 and 60 of life. TR2
mice were treated with 2 3 1 mg anti-CD4 between days 30 and 35 of life. Treated mice were protected from of the onset of EAE, whereas isotype-treated
controls developed fatal disease (n = 8; ***p , 0.001). These data are representative of three independent experiments. (B) To investigate the impact of
anti-CD4 treatment in established disease, TR2 mice were treated with anti-CD4 or an isotype control upon the ﬁrst manifestations of the disease.
CD4-treated mice were protected from severe EAE whereas control animals died within days (n = 5; ***p, 0.001). (C) Number of CD4+ T cells in cervical
lymph nodes of anti-CD4-treated and control mice (NS). (D) Frequency of apoptotic cells, identiﬁed by binding of annexin V and 7-aminoactinomycin D
(7AAD), in anti-CD4–treated and control mice (NS). (E) Number of CD4+Foxp3+ T cells in control and anti-CD4–treated mice, as well as representative
dot plots. Mice treated with anti-CD4 showed signiﬁcantly increased levels of Tregs (n = 4; **p , 0.01). (F and G) In vitro cultures of TR2 T cells
stimulated with MBP, under Th17 polarization conditions. (F) Representative dot plots and (G) quantiﬁcation of Foxp3+ (left) and IL-17+ (right) T cells.
Addition of anti-CD4 mAb led to a decrease in Th17 commitment and an increase in the frequency of Foxp3+ T cells expression in a dose-dependent way
(n = 4; *p , 0.05).
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T cells, while favoring Treg conversion; however, activated T cells
are predominantly regulated by favoring their commitment to
apoptosis.
Overall, our data show that effective tolerance-inducing strat-
egies in autoimmunity will have to induce naive cells to acquire
regulatory function important for the long-term maintenance of
tolerance, while simultaneously disarming the preactivated effector
T cells that may resist Treg-mediated regulation.
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Regulation of the Germinal Center Reaction by Foxp3+
Follicular Regulatory T Cells
Ivonne Wollenberg,*,† Ana Agua-Doce,*,† Andrea Herna´ndez,‡ Catarina Almeida,*,†
Vanessa G. Oliveira,*,† Jose Faro,†,‡,1 and Luis Graca*,†,1
Follicular helper T (TFH) cells participate in humoral responses providing selection signals to germinal center B cells. Recently,
expression of CXCR5, PD-1, and the transcription factor Bcl-6 has allowed the identiﬁcation of TFH cells. We found that a pro-
portion of follicular T cells, with phenotypic characteristics of TFH cells and expressing Foxp3, are recruited during the course of
a germinal center (GC) reaction. These Foxp3+ cells derive from natural regulatory T cells. To establish the in vivo physiologic
importance of Foxp3+ follicular T cells, we used CXCR5-deﬁcient Foxp3+ cells, which do not have access to the follicular region.
Adoptive cell transfers of CXCR5-deﬁcient Foxp3+ cells have shown that Foxp3+ follicular T cells are important regulators of the
GC reaction following immunization with a thymus-dependent Ag. Our in vivo data show that Foxp3+ follicular T cells can limit
the magnitude of the GC reaction and also the amount of secreted Ag-speciﬁc IgM, IgG1, IgG2b, and IgA. Therefore, Foxp3+
follicular regulatory T cells appear to combine characteristics of TFH and regulatory T cells for the control of humoral immune
responses. The Journal of Immunology, 2011, 187: 4553–4560.
G
erminal centers (GCs) are temporary structures in sec-
ondary lymphoid organs in which Ag-speciﬁc B cells
undergo extensive proliferation, class-switch recombin-
ation and somatic hypermutation (SHM), a unique process whereby
they can acquire higher afﬁnity for the Ag (1). Across several cell
divisions, high-afﬁnity GC cells are selected and differentiate
eventually into either memory cells or long-lived plasma cells,
providing the basis of a process called “afﬁnity maturation of
serum Abs”. Long-term humoral immunity, as it is achieved in
many prophylactic vaccines, is provided by those plasma cells
and memory B cells and is a critical component to protect the
body during subsequent infection (2).
In the last 15 y, an important body of information concerning the
role of so-called follicular helper T (TFH) cells in the GC reaction
(GCR) has been obtained. This particular subpopulation of CD4+
T cells is characterized by expressing high membrane levels of
CXCR5 (the receptor of the follicular chemokine CXCL13, es-
sential for follicular homing) and programmed death 1 [PD-1;
a key molecule for B cell survival and selection, presumably
through interaction with PD-ligand 2 (3)] and high levels of the
transcription factor Bcl-6 (4, 5). Productive interactions between
GC B cells and TFH cells are mediated by cognate interactions
through TCR and MHC class II–peptide interactions, CD40–
CD40L, and ICOS–ICOS ligand (6). When CD40–CD40L in-
teractions are prevented, the ongoing GCR stops and GCs dissolve
within 24 h (6). Mice that are deﬁcient in ICOS or ICOS ligand
also have impaired GC formation and isotype switching (7).
Triggering of the SHM process in GC B cells is also dependent on
CD40–CD40L interactions (8). Immunized mice that lack TFH
cells show reduced numbers of germinal center B cells, as well as
a reduction of Ag speciﬁc Ab (4). Besides direct B-TFH contact,
TFH cells also contribute to the GCR through soluble mediators
like IL-4 and IL-21 (9, 10). A recent report claimed distinct
subpopulations of blood CXCR5+ T cells can be found in humans
producing cytokines characteristic of Th1, Th2, and Th17 re-
sponses (11).
Deregulation of proliferation, mutation, and differentiation in
GCs can lead to detrimental outcomes, including oncogenesis and
immunodeﬁciency (12, 13). Moreover, it has been shown that
mutant B cells with self-speciﬁcity can be supported in GCs and
contribute to autoimmunity (14). Therefore, regulation of the qual-
ity and quantity of plasma cells and memory B cell populations in
GCs is important to prevent immunopathology.
How this regulation is achieved remains poorly understood. A
potential mechanism for this could be the presence within the
polyclonal follicular T cell population in GCs of some regulatory
T cells with speciﬁcity for ubiquitous self-antigens. In agreement
with that, theoretical modeling points to processes related to T cell
proliferation as being the dominant steps in the GC dynamics (15).
We thus propose the hypothesis that there are regulatory mecha-
nisms affecting Ag-speciﬁc TFH cells to prevent overly intense
GCRs and/or production of autoantibodies. A possible basis for
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some of the required GC regulation would be the involvement of
Foxp3+ regulatory T cells (Tregs) during the GCR.
Currently, little is known about Tregs in connection with GCs.
Some Tregs are known to express high levels of CXCR5 and to
display positive chemotaxis toward a CXCL13 gradient in vitro
(16). Furthermore, CD25+ T cells (presumably Tregs) were al-
ready shown to be present in the GCs of human tonsils and to
suppress in vitro T cell activation and Ig production by B cells
(16). In contrast, it was shown that within Peyer patches, Tregs
can originate TFH cells (17).
In this report, we show that in murine lymph nodes Tregs
participate in the GCR, contributing to both the dynamics and the
amplitude of the GCR. In addition, we show that those follicular
Tregs have an effect on Ab production during a T-dependent
immune response.
Materials and Methods
Mice and immunization
BALB/c, C57BL/6, CXCR52/2, OT2.Rag22/2 mice (TCR transgenic,
OVA-speciﬁc), Foxp3gfp knock-in mice (generously provided by A.Y.
Rudensky, Howard Hughes Medical Institute and Memorial Sloan-Ket-
tering Cancer Center, New York, NY), and TCRa2/2 mice (B6;129S2-
Tcratm1Mom/J, backcrossed to C57BL/6 background, from S. Tonegawa,
RIKEN-MIT Center for Neural Circuit Genetics and RIKEN Brain Science
Institute, Cambridge, MA) were maintained in speciﬁc pathogen-free fa-
cilities. Procedures were conducted in accordance with guidelines from the
Animal User and Institutional Ethical Committees.
Unless otherwise stated in the text, animals were immunized i.p. with
20 mg OVA (Sigma, St. Louis, MO) previously run through a DetoxyGel
column (Pierce, Rockford, IL) in 2 mg endotoxin-free aluminum hy-
droxide (alum; Alu-gel-S; Serva, Heidelberg, Germany).
Adoptive transfer
For adoptive cell transfers, single-cell suspensions from a pool of spleen and
LNs were sorted based on expression of CD4, CXCR5, PD-1, CD25, and
GFP (cells from Foxp3gfp reporter mice) in a FACSAria (Becton Dickinson,
Franklin Lakes, NJ), with doublet exclusion in all experiments. Unless
stated otherwise in the text, 1 3 104 cells of the indicated cell population
were injected intravenously into TCR-a2/2 mice. In all transfer experi-
ments, mice were immunized with OVA-alum 1 d after adoptive transfer.
Flow cytometry
Single-cell suspensions of draining LNs were analyzed by ﬂow cytometry
using mAb targeting: PD-1 (J43), CD4 (L3T4), Thy1.2 (53-2.1), Foxp3
(FJK-16s), Bcl6 (GI191E), GITR (DTA-1), CD103 (2E7), CD69 (H1.2F3),
CD25 (all from eBioscience), and anti-CXCR5 (2G8) and anti-Rat IgG2a
(R35-95) (BD Bioscience, San Diego, CA). Foxp3 staining was performed
using the Foxp3 Staining Set (eBioscience) following the manufacturer’s
instructions.
In vitro conversion
Sorted populations of 5 3 104 CD4 T cells were incubated for 3 d with
3 mg/ml plate-bound anti-CD3 (145-2C11; eBiosciences), 2 mg/ml soluble
anti-CD28 (eBiosciences), and 5 ng/ml TGF-b (R&D Systems).
Suppression assay
Sorted populations of Foxp3gfp+ T cells were cocultured in Terasaki plates
(Greiner, Frickenhausen, Germany) with g-irradiated APCs, and Foxp3gfp-
effector cells (1:3:1 ratio). Cultures were supplemented with 2.5 mg/ml
soluble anti-CD3 for 3 d, with the addition of 1 mCi 3H-thymidine (Amer-
sham, Sunnyvale, CA) in the last 12 h.
Confocal microscopy
Cryosections ﬁxed in acetone (20 mm; Sigma) and vibratome sections from
PFA-ﬁxed tissue (50 mm; Sigma) were obtained from draining LNs. For
Foxp3 staining sections were permeabilized with the Fix/Perm buffer from
the Foxp3 staining Set (eBioscience). Samples were stained with the fol-
lowing primary Abs: rabbit anti-CD3, anti-Ki67, anti-GFP, anti-OVA; and
rat anti-CD3 (Abcam), anti-IgM-TxRd (Southern Biotech, Birmingham,
AL), anti-KJ-FITC (Caltag, Carlsbad, CA), anti–CD4-alexa647 (Serotech),
peanut agglutinin (PNA)-FITC and PNA-bio (Vector, Burlingame, CA). We
used the following as secondary Abs: anti–FITC-alexa488, anti-rabbit Ig-
alexa488, anti-rabbit Ig-alexa647, anti-rat Ig-alexa633 (Invitrogen, Carlsbad,
CA); and avidin-rhodamine (Vector) and streptavidin-DyLight488 from
ThermoScientiﬁc (Rockford, IL). Images were acquired using an LSM710
confocal microscope (Zeiss, Jena, Germany) equipped with a 35 (0.16
numerical aperture [NA]; Zeiss), 310 (0.30 NA; Zeiss), 320 (0.80 NA;
Zeiss) and a 340 (1.30 NA; Zeiss) objective. Image analysis was per-
formed using the LSM image browser.
FIGURE 1. Kinetics of GCR and GC T cells. BALB/c mice were immunized with 20 mg OVA-alum i.p. and sacriﬁced at the indicated time points, when
cryosections of mesenteric lymph nodes were analyzed to follow the GCR. A, Average GC volume. GCs were identiﬁed by PNA staining and quantiﬁed by
confocal microscopy. The volume (in cubic micrometers) was calculated from the Z-stack, multiplying the area by the depth of the GC. B, Representative
stainings from nonimmunized mice, and mice sacriﬁced on days 4, 12, and 16 after immunization. Scale bar, 500 mm. C, Total number of T cells, and (D)
density of GC T cells during a GCR as analyzed by confocal microscopy. GC T cells were identiﬁed as CD3+ cells within the PNA area. E, Representative
staining from an LN on day 12 after immunization. Data are representative of two independent experiments. Scale bar, 50 mm. ***p , 0.001 (Mann–
Whitney nonparametric, two-tailed test).
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Quantiﬁcation of GC volume
The area of the ellipse circumscribing the GC was measured by the LSM
image browser software. The volume was then calculated from the Z-stack,
multiplying the area by the depth of the GC, and represented in cubic
micrometers (i.e., a volume of 100,000 mm3 is obtained in a structure of
100 3 100 mm and with a depth of 10 mm).
ELISA assay
Isotype-speciﬁc Ab titers in the serum were determined by ELISA on 96-
well plates (BD Falcon) coated with 50 mg OVA (grade V; Sigma) in
carbonate buffer (pH = 9.6) plus N3Na 0.01%. Nonspeciﬁc binding was
blocked with 1% BSA (AMRESCO, Solon, OH) in PBS plus Tween-20
0.05%. Sera were diluted 1:50 or 1:100 in PBST, and 3-fold serial dilutions
of serum samples were incubated. Negative controls (normal mouse serum
diluted 1:100) were included in all assays. The plates were washed, and 50
ml isotype-speciﬁc goat anti–mouse-HRP conjugates (Southern Biotech)
was added. ELISAs were developed with ABTS (2,29-azinobis [3-ethyl-
benzothiazoline-6-sulfonic acid]-diammonium salt) substrate (Sigma-
Aldrich). The OD at 405 nm was determined after 4, 5, and 6 min with
an automatic ELISA plate reader (Envision Multilabel Reader 2104, Perkin
Elmer) and the highest values were recorded.
Statistical analysis
Statistical signiﬁcance was determined using the two-tailed nonparametric
Mann–Whitney U test, and p , 0.05 was deemed signiﬁcant (in the ﬁg-
ures, *p , 0.05, **p , 0.01, ***p , 0.001).
Results
Codevelopment of the GCR and GC T cells
To analyze GC T cells, BALB/c micewere immunized with OVA to
trigger a GCR and sacriﬁced at days 0, 4, 12, and 16 to evaluate the
initiation, peak, and decline of the GCR. Mesenteric LNs were
FIGURE 2. Foxp3+ T cells can be found within the GC and represent a subpopulation of follicular T cells. BALB/c mice were immunized with 20 mg
OVA-alum i.p. and sacriﬁced at the indicated time points. A, Cryosections of LN were stained with PNA and anti-Foxp3 to identify Foxp3+ cells within the
GC. Scale bar, 20 mm. B, The density of Foxp3+ T cells within the GC during the course of a GCR was quantiﬁed by confocal microscopy. The density
corresponds to the total number of Foxp3+ cells within the PNA+ area divided by the measured GC volume. C, CD4+ lymphocytes from LNs of mice
immunized with OVA-alum 12 d before were studied by ﬂow cytometry. TFH cells were deﬁned as being CXCR5
+PD1+ as deﬁned by the represented gate.
The conventional extrafollicular T cells (non-TFH) were deﬁned as the CXCR5
2PD-12 cells. TFH cells had higher expression of Bcl-6 (top right). When we
studied the T cells within the TFH gate (middle row) and non-TFH gate (bottom row), we found that both populations had a proportion of cells expressing
Foxp3. We compared the expression of the indicated molecules within the Foxp3+ and Foxp32 populations of TFH and non-TFH cells. D, Follicular Foxp3
+
T cells (CD4+CXCR5+PD1+Foxp3+) and nonfollicular conventional Tregs (CD4+CXCR52PD-12Foxp3+) were sorted from the spleen and LNs of Foxp3gfp
reporter mice. Tregs (2 3 103) were cocultured in triplicate with g-irradiated APCs and Foxp3gfp2 effector cells (1:3:1 ratio). Cultures were supplemented
with 2.5 mg/ml soluble anti-CD3 Ab for 3 d, and 3H-thymidine was added in the last 12 h. Data are representative of two independent experiments. *p ,
0.05, **p , 0.01 (Mann–Whitney nonparametric, two-tailed test).
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collected, and 20-mm sections were stained with PNA and anti-
CD3 to identify GCs and T cells. After immunization, the GCR
peaked at ∼day 12 or a few days before, as measured by the av-
erage GC volume using confocal microscopy (Fig. 1A, 1B).
The quantiﬁcation of total T cells within the GCs revealed that
the kinetics of T cell numbers parallels that of the global GCR (Fig.
1C). However, we calculated the density of T cells within the GC
(i.e., number of T cells per unit of GC volume) because GC
volume increases during GCR. We found that the T cell density
was highest at day 4 after immunization (Fig. 1D), although the
real peak is probably a few days later.
Follicular T cells contain a Foxp3+ subset of suppressor cells
Given the observed changes in the density of T cells within the GC
during a GCR, we investigated the putative presence of an ac-
tive regulatory mechanism. Although Tregs were previously ob-
served in germinal centers (16, 18), the precise nature of follicu-
lar Tregs, their relationship with extrafollicular counterparts, and
their in vivo functional signiﬁcance has remained unknown. We
therefore investigated whether follicular Tregs represent a signiﬁ-
cant subpopulation of the T cells found in the GC.
As illustrated in Fig. 2A, Foxp3+ cells were readily detectable
in the GCs of mesenteric LNs. Interestingly, we found that the
density of Foxp3+ T cells peaked at day 12 after immunization
(Fig. 2B), at the time when the density of T cells was reduced (Fig.
1D) and the contraction phase of the GCs was initiated. We
conﬁrmed these data using Foxp3gfp knock-in mice (in which
Foxp3 and GFP are fused together), showing a perfect overlap of
Foxp3 staining and GFP expression (Supplemental Fig. 1A). By
analyzing nonconsecutive sections from the same LN, we also
established the reliability of the quantitative approach that we
used (Supplemental Fig. 1B).
To further characterize the GC Foxp3+ cells that we observed by
confocal microscopy, we analyzed follicular T cells of mesenteric
LNs by ﬂow cytometry. We conﬁrmed the existence of a Foxp3+
subpopulation within follicular T cells (Fig. 2C). We found that
follicular Foxp3+ T cells share several markers with conventional
Tregs, such as high levels of CD25, GITR, or CD103, but also
retain the expression of molecules characteristic of TFH cells, such
as CXCR5 and PD-1, and the lineage-speciﬁc transcription factor
Bcl-6 (Fig. 2C). Furthermore, we found that FACS-sorted follic-
ular Foxp3+ T cells (sorted based on CD4, PD-1, CXCR5, and
Foxp3gfp expression) had similar immune suppressive potential as
nonfollicular Foxp3+ T cells (Fig. 2D).
As a result, Foxp3+ T cells found in GCs and B cell follicles
appear to represent a subpopulation of follicular T cells, bear-
ing a distinctive phenotype from the extrafollicular conven-
tional Tregs. Importantly, Bcl-6 was recently identiﬁed as the
master transcription factor for the TFH lineage, by turning on
a widespread gene repressor program acting on key transcrip-
tional regulators of other Th cell lineages, namely Tbet (Th1)
and RORgt (Th17), as well as a large number of miRNAs (4, 5,
19). It is important to note, however, that a repressive function
toward the Treg lineage, or its key regulator Foxp3, was not
found.
Increased density of Foxp3+ GC T cells correlates with their
increased proliferation as the GCR develops
We next assessed the proliferative behavior of GC Foxp3+ T cells
by quantifying the number of cells positive for the proliferation
marker Ki67. As shown in Fig. 3, the frequency of proliferating
(Ki67+) Foxp3+ cells within the GC is greater than the frequency
of proliferating Foxp3+ cells outside the GC. In addition, there is
a signiﬁcant increase of proliferation at day 12 after immuniza-
tion—a time that, as discussed above, correlates with an increase
FIGURE 3. Kinetics of proliferation of T cells and Foxp3+ T cells during the GCR. BALB/c mice were immunized with OVA-alum as described in the
text. The frequency of proliferating T cells was quantiﬁed by confocal microscopy based on Ki67 expression. A, Proliferating GC Foxp3+ cells and GC
T cells were identiﬁed as Ki67+Foxp3+ cells and Ki67+CD3+ cells, respectively, within the PNA area and are depicted as a percentage of the total Foxp3+ or
total CD3+ cells identiﬁed in the GC. B, A similar analysis was performed for T cells outside the GC. C, Representative stainings of the proliferation of GC
T cells. Yellow arrows point to Ki67+Foxp3+ cells, white arrows to Ki67-Foxp3+ cells. Data are representative of two independent experiments. Scale bars,
20 mm (insets, 10mm). *p , 0.05, **p , 0.01 (Mann–Whitney nonparametric, two-tailed test).
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in the frequency of Foxp3+ cells within the GC. It is noteworthy
that at day 4 after immunization, the proliferation of Foxp3+ cells
increases signiﬁcantly outside the GC. On the contrary, the fre-
quency of proliferating cells within total GC T cells does not
change during the GCR.
Foxp3+ GC T cells regulate the magnitude of GCR
After observing an increased frequency of Foxp3+ GC T cells at
day 12 after immunization, we assessed the functional signiﬁcance
of such cells for the regulation of GCR. For this purpose we used
TCR-a2/2 mice, which lack a/b T cells and Tregs, and recon-
stituted those mice with OVA-speciﬁc CD4 T cells from OT2.
Rag22/2 mice (that also lack Foxp3+ T cells). The OT2 cells
were transferred alone or with sorted Tregs. We took advantage
of Foxp3gfp knock-in reporter mice to isolate a population of
Foxp3gfp+ Tregs by ﬂow cytometry. The recipient mice were im-
munized with OVA, and GCR was followed at different time
points. We studied GC resolution at day 20, instead of day 16, to
have better discrimination concerning a putative impact on the
serum titer of switched Igs.
Because TCRa2/2 mice are known to show an impaired ability
to develop GCs owing to their lack of a/b T cells (20), we ﬁrst
wanted to ensure that TCRa2/2 mice could develop GCs after
adoptive cell transfer of Ag-speciﬁc cells. Lymph node sections
from TCR-a2/2 mice transferred with OT2 cells (CD4+ T cells
from OT2.Rag22/2 mice) and immunized with OVA-alum were
analyzed for the presence of GCs by staining with PNA and anti-
IgM. This study revealed the ability of OT2 cells to mount a GCR
(Fig. 4A), with kinetics having a relatively high magnitude (Fig.
4B). However, cotransfer of Foxp3+ Tregs together with OT2 cells,
signiﬁcantly reduced the magnitude of the GCR (Fig. 4B). Con-
sistent with this ﬁnding, we also found that the adoptive transfer of
Foxp3+ Tregs had an effect on Ab production, leading to lower
serum titers of secreted OVA-speciﬁc IgG1, IgM, IgG2b, and IgA
(Fig. 4C). The Ab titres were reduced approximately 1 log by day
20, but with mice transferred with Tregs still showing lower serum
titres (Fig. 4D).
However, given the known ability of Foxp3+ Tregs to suppress
T cells responses, it was possible that the observed regulation was
acting on the generation of helper T cells during their early stage
of activation taking place in the T zone of the LN, and not within
the GC. To address this issue we took advantage of CXCR52/2
mice. These mice provided the tool to discriminate between the
in vivo physiologic effects of Tregs within and outside the fol-
licle, because Tregs from CXCR52/2 mice have a function similar
to wild type Tregs but cannot enter the follicle. Therefore, we
repeated the experiment performing an adoptive transfer of OT2
cells into TCR-a2/2 mice. Flow cytometry-sorted CD4+
CD25bright T cells (that we conﬁrmed were predominantly Foxp3+)
from Foxp3gfp or CXCR52/2 mice were transferred with the OT2
cells. As anticipated, Tregs from CXCR52/2 mice could not be
found within the GC, while the effector OT2 cells could still be
found in the GC (Fig. 4E, 4F). Moreover, the ratio of effector to
regulatory cells observed in the GC of TCR-a2/2 mice transferred
with T cells was similar to that in wild type conditions (Fig. 4E,
4F), although with a smaller number of cells. The ratio of follic-
ular Tregs to T effector cells is not too different from the ratio
observed within conventional extrafollicular populations (i.e.,
∼10%). Remarkably, we were able to show the physiologic role
of follicular Foxp3+ T cells, because we found that adoptively
transferred CXCR52/2 Tregs could not reproduce the phenotype
observed with wild type Tregs (Fig. 4G). Only mice transferred
with Tregs able to express CXCR5 had detectable Tregs within the
GC (Fig. 4H), whereas both groups of mice had transferred Tregs
in locations outside the follicle.
To address whether follicular Foxp3+ T cells derive from
nonfollicular precursors, we repeated the adoptive cell transfer
described above, but now using nonfollicular (PD-12CXCR52)
Tregs sorted from wild type or CXCR52/2 mice. We found that at
day 12 after immunization, mice transferred with Tregs from
CXCR52/2 donors had greater GCs (Fig. 4I). Furthermore, mice
transferred with Tregs deﬁcient in CXCR5 had greater titres of
serum Igs (Fig. 4J). It should be noted, however, that this defect in
regulation of isotype switch and Ab production by CXCR52/2
Tregs was not complete, probably representing a degree of
extrafollicular regulation and possibly affecting the availability of
TFH cells within the follicle.
Considering these results, it appears that CXCR5 expression by
Treg cells is essential to endow them with the ability to control the
GCR. As a result, we propose naming this Foxp3+ T cell subset
from GCs that express PD-1, CXCR5, and Bcl-6, as regulatory
follicular T cells (TFregs).
Follicular Foxp3+ T cells derive from conventional Treg cells
We then investigated whether Foxp3+ follicular T cells derive from
conventional T cells or from natural Tregs that acquire a follicular
phenotype. We conﬁrmed, as anticipated, that the thymus does not
contain a population of Foxp3+ T cells with follicular character-
istics (Fig. 5A), indicating that the follicular Foxp3+ T cells ac-
quire their phenotype in the periphery.
To establish the origin of follicular Foxp3+ cells, we adoptively
transferred sorted TFH or conventional CD25
2CD41 T cells from
wild type mice, together with PD-12CXCR52Foxp3gfp+ natural
Tregs into TCRa2/2 mice, that were subsequently immunized
with OVA-alum. Because adoptive transfer of a CD4 population
devoid of Tregs leads to inﬂammatory bowel disease (21), control
mice that did not receive Tregs were transferred with OT2 cells,
as these TCR-transgenic T cells do not lead to autoimmunity in
the absence of Tregs. We found in both cases that the majority
of follicular Foxp3+ T cells recovered from the TCR-a2/2 mice
had derived from the transferred Treg population, where GFP
was expressed together with Foxp3 (Fig. 5B–D). Intriguingly, that
fraction was larger when TFH cells were transferred together with
Foxp3gfp+ Tregs, suggesting a role for TFH cells in recruiting
Foxp3+ follicular T cells, perhaps by promoting their proliferation.
This issue remains to be further investigated.
Furthermore, we sorted TFH and conventional CD4 T cells that
were stimulated in vitro with plate-bound anti-CD3 in the pres-
ence of anti-CD28 and TGF-b—conditions that are known to
induce Foxp3 expression (22, 23). We found that TFH cells are
resistant to conversion toward a Foxp3+ phenotype (Fig. 5E).
These data suggest that TFregs derive predominantly from
natural Tregs, whereas TFH cells are not amenable to TGF-b–
dependent conversion into Foxp3+ regulatory cells.
Discussion
Owing to the absence of experimental data, there are various
mathematical models attempting to explain the regulation and
termination of the GCR. One hypothesis suggests an increasing
impairment of the engagement of B cell receptors and Ag through
either Ag consumption (24) or Ag masking (25). Both of these
concepts assume that GC termination is regulated by the amount
of Ag presented within the GC by follicular dendritic cells. An-
other hypothesis suggests GC termination is caused by increased
differentiation of GC B cells toward memory and plasma cells
because of signals from follicular dendritic cells (15). A third
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FIGURE 4. Follicular Foxp3+ T cells regulate the magnitude of GCR in vivo. A, TCRa2/2 mice were adoptively transferred with 104 OVA-speciﬁc
T cells from OT2.Rag22/2 mice. Some mice also received an equal number of Foxp3gfp+ T cells. All mice were immunized with OVA-alum. The
micrographs show GCs in mice that did not receive Foxp3+ T cells at day 12 after immunization. Scale bars, 200 mm (left), 50 mm (right). B, Quantiﬁcation
of the GC volume from LNs of mice immunized with OVA-alum in the presence or absence of adoptively transferred Foxp3+ T cells. GCs were identiﬁed as
a PNA+ region within the follicle marked by IgM. C and D, Serum titres of OVA-speciﬁc Igs of different classes were determined by ELISA at different
times after immunization. In the absence of Tregs, the mice produced signiﬁcantly higher levels of IgM, IgG1, IgG2b, and IgA. E, Quantiﬁcation of total
CD4+ T cells and (F) Foxp3+ Treg cells within GCs showing that, following adoptive cell transfers of deﬁned T cell populations into T cell-deﬁcient mice,
there was a reduced number of both T cells and Tregs compared with wild type mice, although their ratio was roughly maintained. G, TCR-a2/2 mice were
adoptively transferred with OT2 T cells and Tregs sorted from wild type or CXCR52/2 mice and immunized with OVA-alum as (Figure legend continues)
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hypothesis proposes that signaling from T cells is the responsible
for GC termination (15). After observing an increase in TFreg
numbers in the GC toward the end of the GCR, we suggest a wider
scenario whereby this cell population has a role in controlling the
magnitude and duration of the GCR.
The lack of Tregs in our transfer system profoundly modiﬁed the
outcome of the GCR, as those mice showed larger GCs at day 12,
and greater production of different classes of Ig than in the presence
of Tregs. Moreover, using Tregs isolated from CXCR52/2 mice,
we created a system with Tregs that are unable to gain access to
GC follicles. As a result, the data showed that it is speciﬁcally
the TFregs that control the GCR. Although our data do not prove
unequivocally a role for TFregs in the termination of the GCR,
they clearly show that TFregs affect the magnitude of this reaction
from midterm on. To date, it is not clear whether this regulation
operates by controlling effector TFH cells (16), and by that in-
directly affecting GC B cells, or if that regulation acts directly on
GC B cells or on both TFH and B cells (18).
A second outstanding question concerns the origin of TFregs.
We could not detect Foxp3+ cells with a TFH-like phenotype
in the thymus. Furthermore, when we transferred OT2 cells into
TCRa2/2 mice, we could not ﬁnd in vivo conversion of those
Foxp3– cells into TFregs. When we transferred natural Tregs to-
gether with CD4 T cells, some of the natural Tregs (the only ones
expressing Foxp3gfp in those mice) acquired access to the follicles
and phenotypic follicular characteristics. Therefore, we believe it
is likely that, in the same way that natural Tregs can originate TFH
cells in the PP (17), some natural Tregs can also differentiate
toward a TFreg phenotype in LNs and the spleen. This suggestion
has important implications for understanding how the dynamics
of T and B cells within GCs is controlled.
GC deregulation or malfunctions are linked to the onset of severe
diseases, as cancer and autoimmunity (26). Our data show that
follicular T cells include a new regulatory subpopulation, which
by controlling the GCR may ultimately have an effect on pre-
venting such pathologies.
FIGURE 5. Follicular Foxp3+ T cells originate from conventional Treg cells. A, Among CD4+Foxp3+ thymocytes, we could not ﬁnd cells expressing
CXCR5 and PD1. B, TCR-a2/2 mice were adoptively transferred with equal numbers of PD-12CXCR52Foxp3+ Tregs sorted from Foxp3gfp knock-in mice
and CD4+CD252 T cells (TFH: PD-1
+CXCR5+ or CD4: PD-12CXCR52) from B6 mice. Control mice were transferred with Foxp32 OT2 cells alone. All
mice were immunized with OVA-alum. The dot plots represent follicular CD4+ T cells, gated in the PD-1+CXCR5+ region, analyzed for Foxp3 and GFP
expression. Representative data are from four mice per group. C, The majority of Foxp3+ cells are also GFP+, indicating that they are derived from
adoptively transferred Tregs (from Foxp3gfp mice). n = 4; *p , 0.05, **p , 0.01, (Mann–Whitney nonparametric, two-tailed test). D, Micrograph showing
Foxp3+ T cells in the GC of adoptively transferred mice (white arrows). Scale bar, 50 mm (left), 20 mm (right). E, Foxp3gfp2 TFH (sorted as CD4
+PD-1+
CXCR5+) and non-TFH cells (sorted as CD4
+PD-12CXCR52) were cultured for 3 d with plate-bound anti-CD3 in the presence or absence of 5 ng/ml
TGF-b. The frequency of cells converted into Foxp3+ was analyzed at the end of the culture (n = 3, representative of two independent experiments).
described in A. The GC volume was quantiﬁed as detailed in the text. Data are representative of two independent experiments. H, Representative micrographs
showing that it was possible to identify Foxp3gfp+ T cells within day 12 GCs of mice adoptively transferred with Tregs, but not in mice transferred with
CXCR52/2 Tregs, where Tregs remained outside the follicle. Scale bars, 100 mm (top row), 20 mm (bottom two rows). I, TCR-a2/2 mice were adoptively
transferred with OT2 cells together with nonfollicular (CXCR52PD-12) Tregs sorted from wild type or CXCR52/2 mice and immunized with OVA-alum as
described in A. The GC volume was quantiﬁed at day 12 as detailed in the text. J, Serum titers of OVA-speciﬁc Igs of different classes were determined by
ELISA at day 12 after immunization. *p , 0.05, **p , 0.01, ***p , 0.001 (Mann–Whitney nonparametric, two-tailed test). n.d., not detected.
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Note added in proof. While our manuscript was being reviewed,
two publications have reported the identiﬁcation of follicular
Foxp3+ regulatory T cells and their functional signiﬁcance in
regulating GCR (27, 28). Those reports complement the ﬁndings
described in this study.
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Supplemental Figure 1. Validation of the quantitative studies. (A) Cryosections from 
LNs of Foxp3gfp knock-in mice, previously immunized with OVA-alum, were stained with 
anti-Foxp3 and anti-GFP antibody to confirm that both molecules allowed the 
identification of the same cells. Bar: 50 μm. (B) Balb/c mice were immunized with OVA-
alum i.p. and non-consecutive cryosections from the same LN were studied at different 
time points. The quantified cells were identified as the Foxp3+ cells within the PNA 
area.  
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Abstract
Allergic airways disease is a consequence of a Th2 response to an allergen leading to a series of manifestations such as
production of allergen-specific IgE, inflammatory infiltrates in the airways, and airway hyper-reactivity (AHR). Several
strategies have been reported for tolerance induction to allergens leading to protection from allergic airways disease. We
now show that CD4 blockade at the time of house dust mite sensitization induces antigen-specific tolerance in mice.
Tolerance induction is robust enough to be effective in pre-sensitized animals, even in those where AHR was pre-
established. Tolerant mice are protected from airways eosinophilia, Th2 lung infiltration, and AHR. Furthermore, anti-CD4
treated mice remain immune competent to mount immune responses, including Th2, to unrelated antigens. Our findings,
therefore, describe a strategy for tolerance induction potentially applicable to other immunogenic proteins besides
allergens.
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Introduction
The control of deleterious immune responses causing diseases,
such as allergy, autoimmunity and transplant rejection, has been
one of the main objectives of immunologists. Moreover, the global
prevalence of this type of diseases has been steadily increasing.
Several strategies have been recently described to induce
tolerance to allergens thus preventing allergic airways disease
[1,2,3,4]. In brief, they can rely on the induction of dendritic cell
(DC) populations or regulatory T cells (Treg) able to control
pathologic T cell clones, in a process where IL-10 and TGF-b can
participate [1,5,6,7,8,9,10]. In addition, disease prevention may be
achieved by skewing the immune response from a Th2 to a Th1
phenotype [11].
In fact, the realization of the critical importance of T cells in the
pathogenesis of allergic airways disease was well demonstrated by
studies where anti-CD4 monoclonal antibodies (MAbs) causing the
depletion of this T cell subset could prevent the disease in mice
[12]. Such pre-clinical studies with CD4 T cell depletion provided
the rationale for clinical trials with depleting anti-CD4 MAbs
where the short-term benefit observed was probably associated
with transient immune suppression [13]. As a consequence, the
interest has shifted towards MAbs capable of blocking molecular
interactions but without leading to direct cell lysis.
Some reports have shown prevention of allergic airways disease
following the blockade of T cell co-stimulatory or co-receptor
molecules with non-depleting MAbs, but it remains unclear
whether long-term antigen-specific tolerance is achieved or what
are the mechanisms involved [14,15,16,17]. We now describe
CD4 blockade at the time of exposure with a model antigen,
ovalbumin (OVA), or a clinically relevant allergen, house dust mite
(HDM), can induce antigen-specific tolerance and protection from
allergic airways disease. The mechanism leading to antigen-
specific tolerance without affecting protective immune responses
(including Th2-type responses) to additional antigens is indepen-
dent of a switch between a Th2-type and Th1-type immune
response. Since CD4 blockade is achieved with a non-depleting
MAb, T cells not activated by the antigen remain unaffected to
mount protective immune responses towards unrelated antigens at
a later time.
Tolerance induction by CD4 blockade is robust enough to be
effective in pre-sensitized animals and even in animals where AHR
was previously established. The tolerant mice show protection
from allergic manifestations elicited by intranasal exposure to the
antigen: they do not develop airways eosinophilia, goblet cell
hyperplasia, production of Th2 cytokines in the lung, production
of antigen-specific IgE or IgG1, and, importantly, do not develop
airway hyperreactivity (AHR) in response to inhaled methacholine
(MCh).
Results
Co-receptor blockade with non-depleting anti-CD4 MAb
prevents allergic sensitization in mice
Using a well established murine model of allergic airways
disease we sought to determine if non-depleting MAbs targeting
the T cell co-receptor molecule CD4 were effective in preventing
allergic sensitization with HDM or a model antigen (OVA).
BALB/c mice were sensitized with two i.p. injections of OVA-
alum or HDM-alum on days 1 and 14, and challenged with 50 mg
OVA or HDM i.n. on days 20, 21 and 22 (Figure 1A). Experimental
groups were treated with 1 mg i.p. of anti-CD4 or an isotype control
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22320
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on the days before and after each immunization, and sacrificed
24 hours following the last intranasal challenge.
Mice treated with anti-CD4 had a marked reduction in BAL
eosinophils when compared with sensitized animals, to levels
similar to naı¨ve animals or animals sensitized in the absence of the
antigen (Figure 1B, and Figure S1). The absence of goblet cell
hyperplasia and inflammatory infiltrate in the airways of anti-CD4
treated mice was confirmed by histology (Figure 1C). Further-
more, anti-CD4 treatment prevented effective generation of Th2-
driven OVA- and HDM-specific IgG1 and IgE (Figure 1D). We
could not detect Th1-driven antigen-specific IgG2a in any animal
(not shown). Animals treated with anti-CD4 showed a marked
reduction of IL-4 and IL-5 in lung homogenates to levels similar to
naive animals (Figure 1E). Importantly, we found no evidence for
Th1 or Th17 deviation (as inferred by levels of IFNc or IL-17), nor
increased levels of the immune-regulatory cytokine IL-10 (not
shown). Cytokines in BAL were similar to lung homogenates (not
shown).
Figure 1. Prevention of allergic sensitization with anti-CD4 MAb. (A) Female BALB/c mice were sensitized with 20 mg OVA-alum or 50 mg
HDM-Alum i.p. and challenged with 50 mg OVA or HDM in saline i.n. on the indicated days. Some animals were treated with 1 mg anti-CD4 or an
isotype control i.p. as shown. Naive mice, not subjected to any intervention, were also studied as a control group. (B) Cellular composition of the BAL.
Animals treated with anti-CD4 have less eosinophils in the BAL (n = 6, *** P,0.001). (C) Histological sections of lung tissue were stained with
hematoxilin/eosin and PAS (inset). Anti-CD4-treated mice have reduced inflammatory infiltrate and goblet cell hyperplasia, to levels similar to naive
controls. Bars represent 10 mm (2.5 mm in the inset). (D) Quantification of serum OVA- and HDM-specific IgG1 and IgE. Anti-CD4 MAb treated mice
show a significant reduction of the Th2-driven immunoglobulins (n = 6, *** P,0.001 and ** P,0.01 as indicated). (E) The Th2 cytokines IL-4 and IL-5
were down to basal levels in lung homogenates of anti-CD4 treated mice (n = 6, * P,0.05 and *** P,0.001). (F) Invasive measurement of respiratory
mechanics shows that animals treated with anti-CD4 MAbs had reduced airway resistance to increasing doses of inhaled MCh, when compared with
sensitized control animals (n = 8). Data (B–F) are representative of at least three independent experiments.
doi:10.1371/journal.pone.0022320.g001
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To study the functional impact of the treatment we assessed
AHR in response to increasing doses of inhaled MCh. Our data
show that anti-CD4 treatment prevented AHR (Figure 1F and
Figure S2).
The tolerance state is maintained following clearance of
the MAb
We then studied whether tolerance induction with non-
depleting anti-CD4 would protect the animals from subsequent
exposure to the same antigens, at a time the therapeutic MAb had
been cleared. For this purpose treated mice with anti-CD4 at the
time of initial sensitization with OVA or HDM, and the same mice
were again immunized with the same antigens 50 days following
the initial treatment (Figure 2A).
Sensitization with OVA-alum or HDM-alum did not lead to
airways eosinophilia in mice previously exposed to the same
antigens under the cover of non-depleting anti-CD4 (Figure 2B
and Figure S1). Furthermore, the treated mice also failed to
produce antigen-specific IgG1 and IgE to OVA-alum and HDM-
alum (Figure 2C). And importantly, AHR to increased concen-
trations of inhaled MCh was also absent in anti-CD4 treated mice
(Figure 2D and Figure S2).
We could therefore conclude that a short course of anti-CD4
was leading to long-term effects. Although the MAb we used (clone
YTS177) is known to have a non-depleting isotype [18], and we
confirmed anti-CD4 treatment was not directly leading to T cell
lysis (not shown), we had to confirm the treated mice remained
immune competent.
Tolerant mice remain immunocompetent
In order to study the antigen-specificity of tolerance induction,
we used a second unrelated antigen: b-lactoglobulin (b-LG). We
compared immune responses to OVA and b-LG, since these are
two defined antigens with similar characteristics, while HDM is a
complex protein extract containing many distinct antigens.
BALB/c mice were treated with non-depleting anti-CD4 MAb
together with OVA-alum (tOVA) or b-LG-alum (tb-LG) in order
to establish immune tolerance to those antigens (Figure 3A). At
day 50 the animals were immunized with the same antigen used at
the time of tolerization (day 0) or with the second unrelated
antigen. All mice were subsequently challenged i.n. with the same
antigen used at day 50. All animals remained protected from
mounting airways inflammation in response to the antigen used for
tolerization, but fully competent to undergo a Th2 response to the
second antigen leading to airways eosinophilia, production of IgE
and IgG1, and AHR (Figure 3B–D and Figure S2). These results
suggest that CD4-blockade affects specifically the T cells that are
being activated at the time of treatment, and sparing non-activated
cells, thus leading to antigen specific tolerance where immune
responses against different antigens are not suppressed.
Tolerance can be achieved in sensitized mice
To assess whether tolerance can be induced in pre-sensitized
mice, BALB/c mice sensitized with OVA or HDM were treated
with the same antigen under the cover of anti-CD4 50 days
following initial sensitization (Figure 4A). For consistency with
previous experiments we maintained the tolerance-inducing
regime as two administrations of antigen-alum+anti-CD4 two
weeks apart.
We found, both OVA- and HDM-sensitized mice treated with
anti-CD4 were prevented from AHR, maintaining normal airway
response to increased concentrations of inhaled MCh (Figure 4B
and Figure S2). We confirmed the efficient sensitization of all
groups of immunized animals by the presence of antigen-specific
IgG1 and IgE antibodies in sera (not shown), although the mice
had not been exposed to prior airway inflammation. As a
consequence, the protection from AHR is effective in spite of
high titres of antigen-specific immunoglobulins – possibly
representing an impact on the late-phase response, and dissoci-
ation between high IgE and AHR.
We then assessed whether tolerance induction in pre-sensitized
mice remained antigen-specific. BALB/c mice sensitized with
OVA-alum or b-LG-alum were treated with anti-CD4 MAb, 50
days following the initial intervention, in the presence of either the
initial (OVA or b-LG) or a different antigen (b-LG or OVA,
respectively; Figure 4C). Sensitized mice were protected from
airway eosinophilia when treated with anti-CD4 in the presence of
the same antigen used for sensitization (OVA .tOVA and b-LG
.tb-LG, Figure 4D). The protective effect was, therefore, not due
to the persistence of the therapeutic antibody in circulation at the
time of intranasal exposure to the antigen since mice immunized
with a different antigens not present during anti-CD4 treatment
(and therefore with equivalent doses of circulating anti-CD4 at the
time of challenge) were not protected (OVA .tb-LG and b-LG
.tOVA). The observation that animals receiving the antibody
treatment together with a different antigen than used for
immunization develop inflammatory changes similar to untreated
control animals, or animals exposed to alum in the absence of the
antigen (Figure S1), are consistent with the antigen-specificity of
the tolerance state described above.
Mice exposed to allergic airways disease can be
protected from AHR following anti-CD4 treatment
However, it is understood that the onset of inflammation in the
airways becomes a significant hurdle for immune modulation
leading to tolerance. Therefore, we investigated whether mice
sensitized to OVA or HDM and exposed to the antigen i.n. could
benefit from subsequent anti-CD4 treatment (Figure 5A). A single
i.n. challenge with antigen in sensitized mice was sufficient to
induce AHR (Figure S3).
We found that administration of HDM under the cover of non-
depleting anti-CD4 30 days following induction of allergic airways
disease was effective in preventing AHR following subsequent
challenge with the same antigen (Figure 5B). We repeated the
same studies with OVA with similar results (Figure 5B and Figure
S2).
Discussion
Our data shows that CD4 blockade is effective in inducing
antigen-specific tolerance to a clinically relevant allergen (HDM),
thus preventing the manifestations of allergic airways disease
following intranasal allergen challenge: Th2 and eosinophilic
infiltrate of the airways, goblet cell hyperplasia, and AHR. The
tolerogenic treatment is not only effective in preventing the disease
in naive animals, but also confers considerable protection to mice
previously sensitized with the allergen. Although in different
experiments we tested mice with different ages, we could not find
an age-related difference in their response to induction of allergic
airways disease (Figure S4).
It should be noted that the use of tolerogenic MAbs in
transplantation, with the same objective of preventing an
inflammatory response to non-self antigens, have resulted in a
different outcome from what we have observed. In transplanta-
tion, tolerance induction in sensitized animals has been difficult to
achieve, except when both anti-CD4 and anti-CD8 MAbs are
combined [19], with anti-CD8 MAbs probably required to control
Tolerance Induction to House Dust Mite
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pre-committed effector T cells. Co-stimulation blockade with anti-
CD40L has also been reported as less effective than anti-CD4,
requiring depletion of CD8+ T cells even in non-sensitized animals
[20,21]. The obstacle created by sensitization in relation to
tolerance induction is also evidenced by reports showing that
heterologous immunity reduces the effectiveness of tolerogenic
protocols in transplantation [22]. Our data shows that the anti-
CD4 antibody treatment can also be beneficial to already
sensitized animals. This may be due to the fact that the T effector
cell frequency is significantly lower for allergens than for
alloantigens and that the response to allergens is predominantly
restricted to the CD4+ compartment. It is likely that such different
outcome observed in transplantation versus allergy may be due to
the induction of different tolerogenic mechanisms. In fact our
preliminary data suggests that Foxp3+ Treg cells may play a more
important role in transplantation tolerance than in tolerance
induced to allergens – something that still requires further
elucidation.
Our data also suggests it is likely that in sensitized mice the
antibody treatment has an impact exclusively on the late response
(mediated by Th2 and NKT cells), without preventing the early
response mediated by mast cell degranulation in response to their
surface IgE cross-linking, as the allergen-specific IgG1 and IgE
titres remain high in treated mice. But even without targeting early
mast cell degranulation, the MAb treatment is likely to lead to a
putative long-term benefit given the importance of the Th2-
mediated response for the persistence of the inflammatory changes
associated with airways remodeling and chronic manifestations of
the disease [4]. This issue will require confirmation in chronic
models of disease.
The antigen-specificity of Treg cell-mediated tolerance has been
a controversial issue [23,24]. We show that effective tolerance
induction requires the presence of the appropriate antigen at the
time of CD4 blockade leading to antigen-specific tolerance. In
these experiments we waited 50 days following initial sensitization
to minimize the amount of antigen still present in the animal at the
time of the tolerogenic treatment. These data also established that
MAbs administered at day 50 (Figure 3) were not contributing
significantly to the prevention of the disease by being in circulation
at the time of intranasal challenge, since no beneficial effect is
observed in animals treated with the same antibody dose together
with an irrelevant antigen. Importantly, most previous studies
addressing the putative tolerance-inducing potential of monoclo-
nal antibodies, namely anti-CD4 [15], did not address the antigen-
specificity of the phenomenon or the immune competence of
treated mice.
Several MAbs have been recently used as immune modulators
in a wide range of diseases, including allergy [25]. Anti-CD4
MAbs have been evaluated both in pre-clinical non-human
primate models of transplantation and autoimmunity, as well as
in clinical studies [13,26,27]. Their therapeutic effectiveness was
modest, short-term, and likely to be a consequence of transient
immunosuppression and not tolerance. With hindsight those
unimpressive results are not surprising due to technical details
related with dosing and the MAb characteristics. The clinical trials
have used mouse or chimeric MAb that elicited immune responses
leading to their rapid clearance [28]. In addition, most of those
studies, including a clinical trial in human asthma (with the
depleting anti-CD4 MAb keliximab) [13], did not take advantage
of non-depleting anti-CD4 MAbs. Therefore, and as a conse-
quence of the adverse side effects associated with depleting
reagents, it was not possible to attain a neutralizing dose of anti-
CD4 know to be the most effective for tolerance induction. At this
time, particularly given the promising results with non-depleting
anti-CD3 in early onset diabetes patients [29], the past experience
of anti-CD4 in human patients should be reassessed in face of
Figure 3. Mice treated with anti-CD4 are competent to respond to unrelated antigens. (A) Mice initially tolerized to OVA or b-LG (as
described in previous figures) were sensitized i.p. with a different antigen at days 50 and 64, and challenged i.n. with the same antigen used at day 50.
(B) Only animals tolerized to the same antigen used for sensitization at day 50 were protected from BAL eosinophilia (n = 6, *** P,0.001).
(C) Tolerance induction to OVA did not prevent subsequent production of b-LG-driven IgE or IgG1, conversely, tolerance to b-LG did not hamper the
generation of OVA-specific IgG1 or IgE (n = 6, *** P,0.001). (D) AHR in response to MCh was observed in animals tolerized to an antigen different
from the one used for subsequent sensitization (tOVA .b-LG and tb-LG .OVA) (n = 8, * P,0.05 at 10 mg/ml MCh). Data are representative of two
independent experiments.
doi:10.1371/journal.pone.0022320.g003
Figure 2. Tolerized mice resist subsequent sensitization and challenge. (A) BALB/c mice were initially sensitized with OVA or HDM under the
cover of anti-CD4 as described in Figure 1. Those mice were sensitized with the same antigens on days 50 and 64, and subsequently challenged i.n.
(B) Animals trated with anti-CD4 were protected from BAL eosinophilia (n = 6, ** P,0.01 for OVA; * P,0.05 for HDM). (C) CD4-blockade prevented
production of IgG1 and IgE in subsequent sensitizations (n = 6, *** P,0.001 and ** P,0.01 as indicated). (D) Tolerance to OVA or HDM prevented AHR
to inhaled MCh (n = 6). Data are representative of three independent experiments.
doi:10.1371/journal.pone.0022320.g002
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current knowledge. On this note, a new non-depleting and less-
immunogenic humanized anti-CD4 MAb has been recently
engineered, and its safety evaluated in human volunteers [30].
Our results suggest the specific targeting of CD4 T cells in
allergic airways disease can have a potent effect in achieving long-
term protection from subsequent inflammatory changes induced
Figure 5. Protection from AHR in animals previously exposed to airways inflammation. (A) Balb/c mice sensitized and challenged i.n. with
HDM-alum or OVA-alum were tolerized to the same antigens on days 50 and 64, and challenged i.n. with the same antigens. (B) The animals treated
with HDM or OVA under the cover of anti-CD4 were protected from AHR in response to inhaled MCh (n = 6, ** P,0.01 or *** P,0.001 as indicated).
Data are representative of two independent experiments.
doi:10.1371/journal.pone.0022320.g005
Figure 4. Tolerogenic effect of anti-CD4 treatment is antigen-specific and effective in sensitized animals. (A) BALB/c mice sensitized
with OVA-alum or HDM-alum were tolerized to the same antigens on days 50 and 64, and challenged i.n. with the same antigens. (B) Sensitized mice
subsequently treated with OVA or HDM under the cover of anti-CD4 showed protection from AHR (n= 8 for OVA, n = 6 to HDM). Data are
representative of two independent experiments. (C) Mice were initially sensitized with OVA-alum or b-LG-alum, and tolerized to the same or a
different antigen on days 50 and 64. All mice were challenged i.n. with the same antigen used for initial sensitization. (D) Mice treated with a different
antigen together with anti-CD4 did not show reduced BAL eosinophilia (OVA .tb-LG and b-LG .tOVA) while treatment with anti-CD4 and the same
antigen used for sensitization showed a significant reduction of BAL eosinophilia (OVA.tOVA and b-LG .tb-LG; n = 6, *** P,0.001). Data are
representative of two independent experiments.
doi:10.1371/journal.pone.0022320.g004
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by the same antigens. It remains to be established whether similar
effects can be achieved in chronic allergic airways disease.
Materials and Methods
Experimental animals
BALB/c mice were bred and maintained under specific
pathogen-free facilities. Animals were sensitized, at the times
described in the text, by i.p. injection of 20 mg in 2.0 mg of
endotoxin-free aluminum hydroxide (Alu-gel-S, Serva, Heidel-
berg, Germany) of OVA or b-LG (Sigma, St Louis, USA)
previously run through a DetoxyGel column (Pierce, Rockford,
USA), or HDM extract (Greer, Lenoir, USA). In all experiments
animals were age and sex matched.
Ethics Statement
All experiments involving animals were approved by Direccao
Geral Veterinaria (approval 018831). Mice were bred and
maintained under specific pathogen free (SPF) conditions.
Antibodies and reagents
Non-depleting anti-CD4 (YTS177) [18] and the isotype control
(YKIX302) MAbs were produced in our laboratory using Integra
CL1000 flasks (IBS, Chur, Switzerland), and purified from culture
supernatants by 50% ammonium sulfate precipitation, dialyzed
against PBS, and the purity checked by native and SDS gel
electrophoresis. The hybridomas were generously provided by
Professor Herman Waldmann (Oxford, UK).
Bronchoalveolar Lavage (BAL)
Airways were washed through the trachea with 3 ml of cold
PBS 1% BSA (Sigma). The BAL was centrifuged, ressuspended in
PBS, and the cells counted with a hemocytometer. Differential cell
counts were performed on cytospin samples stained with Giemsa-
Wright (Sigma). At least 200 cells from each sample were counted,
using blinded slides, to determine the relative frequency of each
cell type. In addition, in some experiments eosinophilia was
independently confirmed by flow cytometry using GR-1 (eBios-
ciences, San Diego, CA, USA), CCR3 (BD Pharmingen, San
Diego, USA), and MHC-class II MAbs (produced in-house), with
eosinophils identified based on the SSC/FSC profile and as the
GR1intMHCclass II2CCR3+ cells [31].
Quantification of immunoglobulins and cytokines
Serum titers of OVA-specific IgG1, IgG2a, and IgE were
measured by ELISA using the following: IgG1 and IgG2a (South-
ernBiotech, Birmingham, USA) with anti-OVA IgG1 standard from
Serotec, Oxford, UK; IgE (BD-Pharmingen) with anti-OVA IgE
standard from Abcam (Cambridge, UK). Cytokine titers were
determined in fresh BAL and lung homogenates. Cytokine ELISAs
were performed using the following kits: IL-4, IL-5 (BD-Pharmingen).
Histology
Lungs were perfused with 4% formalin solution (Sigma), collected
and sectioned. Staining was performed using hematoxilin/eosin,
and periodic acid-Schiff (PAS) stain. Photographs were taken using
a Leica DM2500 microscope and a Leica DFC420 camera.
Respiratory mechanics and methacholine responsiveness
Airway responsiveness was determined 24 hours after last
intranasal OVA challenge. Changes in the respiratory input
impedance (Zrs) were measured using a modification of the low
frequency forced-oscillation technique (LFOT) in mice anesthe-
tized with 10 ml/g of xylazine (2 mg/ml, Ronpum, Bayer,
Germany) and ketamine (40 mg/ml, Merial, Lyon, France),
tracheostomized and ventilated (FlexiVent, SciReq, Montreal,
Canada). Mice were hyperventilated at 450 breaths/min and Zrs
was measured during periods of apnea using a 16 s signal
containing 19 prime sinusoidal frequencies as described else-
where [32]. Calculation of airway resistance (Raw), tissue
damping (G) and tissue elastance (H) is obtained from the Zrs
spectrum using FlexiVent software (SciReq). AHR was measured
by exposure to an aerosol containing increasing doses of MCh
(Sigma), following a baseline measurement after the delivery of a
saline aerosol.
Statistical analysis
Statistical significance was determined using the two-tailed non-
parametric Mann-Whitney test and P values ,0.05 were deemed
significant (*, P,0.05; **, P,0.01; ***, P,0.001).
Supporting Information
Figure S1 Prevention of allergic sensitization with
anti-CD4 MAbs. Female BALB/c mice were sensitized with
20 mg OVA-alum i.p. and challenged with 50 mg OVA in saline
i.n. on the indicated days. Some animals were treated with 1 mg
anti-CD4 or an isotype control i.p. as shown. Naive mice, not
subjected to any intervention, were also studied as a control group
and compared with mice injected with adjuvant in the absence of
antigen at the time of sensitization. (A) Cellular composition of the
BAL of mice treated with anti-CD4 at the time of sensitization. (B)
Cellular composition of the BAL of mice treated with anti-CD4 at
the time of initial sensitization, but subjected to additional
sensitization at a subsequent time. (C) Cellular composition of
the BAL of sensitized mice treated with anti-CD4.
(TIF)
Figure S2 Invasive measurement of respiratory
mechanics. Data showing the impact of anti-CD4 treatment in
tissue elastance and tissue damping in response to increasing doses
of inhaled MCh. These graphs complement the data on airway
resistance represented in the main figures 1 to 5.
(TIF)
Figure S3 Induction of AHR following i.n. exposure
to the antigen. Female BALB/c mice were sensitized with two
shots of 20 mg OVA-alum i.p. 14 days apart, and challenged with
50 mg OVA in saline i.n. for three consecutive days (day 20–22), or
just on day 20. Invasive measurement of respiratory mechanics
was performed on the following day in presence of increasing
doses of inhaled Mch. Both groups of mice, subjected to a single or
three challenges with i.n. antigen, displayed similar levels of AHR
(n= 6, ** P,0.01, *** P,0.001).
(TIF)
Figure S4 Allergic airways disease in mice with different
age. Female BALB/c mice were sensitized with 20 mg OVA-alum
i.p. and challenged with 50 mg OVA in saline i.n. as indicated in
Figure 1. Some animals were treated with 1 mg anti-CD4 or an
isotype control i.p. at the time of sensitization. Mice with 11 or 20
weeks of age were used. No significant differences between mice of
different ages.
(TIF)
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Monoclonal Anti-CD8 Therapy Induces
Disease Amelioration in the K/BxN Mouse Model of
Spontaneous Chronic Polyarthritis
Bruno R. Raposo,1 Paulo Rodrigues-Santos,2 Helena Carvalheiro,3 Ana M. A´gua-Doce,4
Lina Carvalho,3 Jose´ A. Pereira da Silva,5 Luis Grac¸a,4 and M. Margarida Souto-Carneiro6
Objective. CD8 T cells are part of the T cell pool
infiltrating the synovium in rheumatoid arthritis (RA).
However, their role in the pathogenesis of RA has not
been fully delineated. Using the K/BxN mouse model of
spontaneous chronic arthritis, which shares many sim-
ilarities with RA, we studied the potential of CD8 T
cell depletion with monoclonal antibodies (mAb) to stop
and reverse the progression of experimental arthritis.
Methods. CD8 T cells from the blood and
articular infiltrate of K/BxN mice were characterized for
cell surface phenotypic markers and for cytokine pro-
duction. Additionally, mice were treated with specific
anti-CD8 mAb (YTS105 and YTS169.4), with and with-
out thymectomy.
Results. CD8 T cells from the peripheral blood
and joints of K/BxN mice were mainly CD69 and
CD62LCD27 T cells expressing proinflammatory
cytokines (interferon- [IFN], tumor necrosis factor 
[TNF], interleukin-17a [IL-17A], and IL-4), and gran-
zyme B. In mice receiving anti-CD8 mAb, the arthritis
score improved 5 days after treatment. Recovery of the
CD8 T cells was associated with a new increase in the
arthritis score after 20 days. In thymectomized and
anti-CD8 mAb–treated mice, the arthritis score im-
proved permanently. Histologic analysis showed an ab-
sence of inflammatory infiltrate in the anti-CD8 mAb–
treated mice. In anti-CD8 mAb–treated mice, the
serologic levels of TNF, IFN, IL-6, and IL-5 normal-
ized. The levels of the disease-related anti–glucose-6-
phosphate isomerase antibodies did not change.
Conclusion. These results indicate that synovial
activated effector CD8 T cells locally synthesize proin-
flammatory cytokines (IFN, TNF, IL-17, IL-6) and
granzyme B in the arthritic joint, thus playing a pivotal
role in maintaining chronic synovitis in the K/BxN
mouse model of arthritis.
Approximately 40% of the T cells infiltrating the
rheumatoid synovial membrane are CD8 T cells (1).
However, their importance in the pathogenesis of rheu-
matoid arthritis (RA) remains to be fully elucidated.
The primary function of CD8 T cells is the
killing of virus- or cytosolic bacteria–infected cells.
Moreover, they seem to play several important roles in
autoimmune diseases, either protecting against or en-
hancing the disease. In experimental autoimmune en-
cephalomyelitis (EAE), an animal model of multiple
sclerosis, CD8 T cells have been shown to be crucial
for resistance to a second induction of the disease (2).
Recently, a particular subset of CD8 T cells
(CD8CD122) was shown to accelerate the recovery
of animals with EAE after CD8 T cells were trans-
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ferred (3). In contrast, insulitis failed to develop in NOD
mice treated with anti-CD8 monoclonal antibodies
(mAb) (4). This experimental treatment also inhibited
the transfer of insulin-dependent diabetes mellitus
(IDDM) and the development of spontaneous IDDM
(5).
In RA, some patients show CD8 T cell clonal
expansions with a memory phenotype that are corre-
lated with rheumatoid factor (RF) levels (6–10). This is
most likely attributable to the important role of CD8 T
cells in maintaining ectopic germinal center structures in
RA synovium (11,12).
In different animal models of collagen-induced
arthritis (CIA), the absence of CD8 T cells resulted in
a reduced incidence (13,14) and severity (15) of the
disease. However, higher susceptibility was observed
when animals were rechallenged (14,15). Additionally,
in CD8/ and CD8/ mice, a trend toward a delayed
onset of CIA was observed, without a significant impact
on disease susceptibility (16). More recently, CD8 T
cell clones generated from the arthritic joints of SKG
mice transferred to histocompatible athymic nude mice
led to joint swelling and synovitis with destruction of
cartilage and bone (17).
In order to assess the role of CD8 T cells in
experimental chronic polyarthritis, the clinical pheno-
type and cytokine production of articular and peripheral
blood CD8 T cells from K/BxN mice were studied.
Arthritis in these mice results from the simultaneous
expression of the class II major histocompatibility com-
plex Ag7 molecule and a transgenic T cell receptor
(TCR), followed by the production of autoantibodies
against glucose-6-phosphate isomerase (GPI) (18–20).
Subsequently, we assessed whether treatment with spe-
cific anti-CD8 mAb, with and without thymectomy,
improved the course of established arthritis in K/BxN
mice. Our results showed, for the first time, that K/BxN
mouse–activated and effector memory CD8 T cells are
present in the peripheral blood and joints and that they
play an important role in arthritis maintenance, because
treatment with specific anti-CD8 mAb significantly im-
proved the disease signs. These results document that
CD8 T cells should be regarded as major players in the
K/BxN mouse model of experimental arthritis, along
with CD4 T cells and B cells.
MATERIALS AND METHODS
Mice. TCR-transgenic KRN mice were a kind gift from
Dr. C. Benoist (Harvard University, Boston, MA) and were
maintained on a C57BL/6 background (K/B). Progeny bearing
the V6-transgenic TCR were identified at 3–4 weeks of age by
cytofluorometry of peripheral blood lymphocytes, using phy-
coerythrin (PE)–labeled anti-CD8 (clone YTS169.4; Instituto
Gulbenkian de Cieˆncia [IGC] Cell Imaging Unit) and fluores-
cein isothiocyanate (FITC)–labeled anti-V6 (PharMingen)
antibodies. Arthritic mice were obtained by crossing K/B mice
with NOD mice (K/BxN). C57BL/6 and NOD mice were
provided by the IGC Animal Facility. The mice were bred and
maintained under standard conditions, with food and water
available ad libitum, in a specific pathogen–free environment.
All animal studies were approved by the internal IGC Ethics
Committee.
Antibodies and immunization in mice with established
arthritis. Depleting anti-CD8 (clone YTS169.4), nondepleting
anti-CD8 (clone YTS105), and rat IgG2a isotype control
(clone YKIX302) mAb were a kind donation from Prof. H.
Waldmann (Oxford University, Oxford, UK). The aim of
combining nondepleting YTS105 mAb (21) and depleting
YTS169.4 mAb (22) was to reduce the immunogenic potential
of the antibodies (and their subsequent neutralization) that
could be created after repeated injections. Mice ages 8–10
weeks old with an arthritis score 8 were injected intraperi-
toneally with either 150 g of nondepleting anti-CD8 (n  20)
or anti-dog IgG isotype control (n  19) on day 0. A second
and third dose of 150 g of depleting anti-CD8 or anti-dog IgG
isotype control antibodies were injected intraperitoneally on
days 7 and 16 after the first injection.
Thymectomy and CD8 depletion. Five-week-old K/BxN
mice with established arthritis were subjected to total thymec-
tomy (n  5) or a sham operation (n  3). Nine days after
surgery, the mice were immunized intraperitoneally with 300
g of depleting anti-CD8 antibody.
Arthritis scoring. Each swollen fore paw or hind paw
was given a score of 1 point, each swollen wrist or ankle was
given a score of 1 point, and each swollen finger or toe was
given a score of 0.5 point, resulting in a maximum of 17 points
per mouse. Scoring was performed every second day for the
first 3 weeks and then once weekly for the remaining observa-
tion period.
Histochemical analysis. Skinless whole knee joints and
front and hind paws were fixed in 5% formalin, decalcified in
5% formic acid, and embedded in paraffin. Sections (10 m)
were prepared from the tissue blocks and stained with either
hematoxylin and eosin (H&E), MNF116 (anticytokeratin anti-
body), Herovici’s stain, or Alcian blue–periodic acidSchiff
and observed on an Olympus IMT-2 microscope. Images were
analyzed with ImageJ 1.38x software (National Institutes of
Health).
Enzyme-linked immunosorbent assay (ELISA) for
GPI. High-affinity Maxisorb 96-well ELISA plates (Nunc)
were coated with 10 nM Saccharomyces cerevisiae GPI (Sigma)
in potassium phosphate buffer. Plates were blocked with
phosphate buffered saline/Tween/1% gelatin. Anti-GPI anti-
bodies in sera were detected with horseradish peroxidase–
labeled goat anti-mouse IgG (Southern Biotechnology) fol-
lowed by incubation with tetramethylbenzidine solution
(Sigma). Absorption was measured at an optical density of
450 nm.
Flow cytometric analysis. Peripheral blood samples
were collected from the base of the tails of arthritic K/BxN
mice on days 0, 7, 14, 21, and 35 after the first treatment with
either anti-CD8 or control mAb. Mononuclear cells were
isolated through a Ficoll gradient (Amersham) and stained
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with anti-mouse mAb as follows: fluorescein isothiocyanate
(FITC)–labeled anti-CD3 (clone 145.2C11), PE-labeled anti-
CD8 (clone YTS169.4), and allophycocyanin (APC)–labeled
anti-CD4 (clone GK1.5-8) (all from the IGC Cell Imaging
Unit). To determine the differences in CXCR4 and CXCR5
expression and the frequency of CD8 T cell subsets, pe-
ripheral blood samples were collected from the tails of 8–10-
week-old untreated arthritic K/BxN mice (n  9) and their
nonarthritic littermates (n  10). Mononuclear cells were
isolated through a Ficoll gradient (Amersham) and stained
with anti-mouse mAb, as follows: FITC-labeled anti-CD19
(clone 1D3; IGC Cell Imaging Unit), PE-labeled anti-CXCR4
(eBioscience), peridinin chlorophyll A protein (PerCP)–
labeled anti-CD4 (eBioscience), APC-labeled anti-CD8 (clone
YTS169.4; IGC Cell Imaging Unit), FITC-labeled anti-CD3
(clone 145.2C11; IGC Cell Imaging Unit), PE-labeled anti-
CD8 (clone YTS169.4; IGC Cell Imaging Unit), biotinylated
anti-CD62 ligand plus streptavidin–PerCP, and APC-labeled
anti-CD27 (all from eBioscience). For determination of intra-
cellular cytokine production, saponin-permeabilized pe-
ripheral blood mononuclear cells (PBMCs) were stained with
APC-labeled anti-CD8 (clone YTS169.4; IGC Cell Imaging
Unit), PerCP-Cy5.5–labeled anti-CD3, FITC-labeled anti-
TNF, and PE-labeled anti–IL-6 (all from eBioscience). All
samples were analyzed on a 4-color FACSCalibur system
(Becton Dickinson), and data were analyzed with FlowJo 7.5.5
software (Tree Star).
Assessment of intracellular cytokine production by
reverse transcription–polymerase chain reaction (RT-PCR).
PBMCs and mononuclear cells from articular tissue were
collected from untreated arthritic mice (n  4), and PBMCs
were collected from their healthy control littermates (n  4).
CD8 T cells were isolated by magnetic cell separation using
the CD8a T Cell Isolation kit (Miltenyi Biotech).
Total RNA from sorted CD8 T cells was isolated
using an RNeasy Micro kit (Qiagen). RNA integrity and
quantification were analyzed using a 6000 Nano Chip kit in an
Agilent 2100 Bioanalyzer. RNA was reverse transcribed with
a SuperScript III First-Strand Synthesis System for RT-PCR
(Invitrogen) using oligo(dT) plus random hexamers according
to the manufacturer’s instructions.
Relative quantification of gene expression by real-time
PCR was performed using a thermocycler LightCycler 480 II
(Roche). Normalization for gene expression quantification was
performed with geNorm Housekeeping Gene Selection Mouse
kit (PrimerDesign) and geNorm software (Ghent University
Hospital, Center for Medical Genetics) to select optimal
reference genes for this study (23).
Real-time PCRs used specific Mus musculus Quanti-
Tect Primer Assays (Qiagen) with optimized primers for the
genes of interest, Gzmb (QT00114590), Ifn (QT01038821), Il10
(QT00106169), Il17a (QT00103278), Il2 (QT00112315), Il4
(QT00160678), Tnf (QT00104006), and the reference genes
Ywhaz (QT00105350) and Rn18s (QT01036875), together with
a QuantiTect SYBR Green PCR Gene Expression kit (Qia-
gen), according to the manufacturer’s instructions. Reac-
tions were performed with the following thermal profile: 10
minutes at 95°C plus 40 cycles of 15 seconds at 95°C, 30
seconds at 60°C, and 30 seconds at 72°C. Quantitative real-
time PCR results were analyzed using LightCycler 480 soft-
ware (Roche) and quantified using the qBasePlus software
package (Biogazelle).
Serum cytokine quantification. Serum samples from
arthritic K/BxN mice before (n  11) and after (n  11)
anti-CD8 treatment and from their nonarthritic control litter-
mates (n  7) were obtained from whole blood after centrif-
ugation. TNF, IFN, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70,
and monocyte chemoattractant protein 1 (MCP-1) titers in the
sera were quantified using the cytometric bead arrays, a Mouse
Th1/Th2 Cytokine kit and a Mouse Inflammation kit (Becton
Dickinson) according to the manufacturer’s instructions, and
analyzed with BD Cytometric Bead Array Software (Becton
Dickinson). IL-17a titers were determined using a Mouse
IL-17A ELISA kit (Invitrogen). Test sensitivity thresholds for
the different cytokines were as follows: for TNF, 6.3 pg/ml;
for IFN, 2.5 pg/ml; for IL-2, 5.0 pg/ml; for IL-4, 5.0 pg/ml; for
IL-5, 5.0 pg/ml; for IL-6, 5.0 pg/ml; for IL-10, 17.5 pg/ml;
for IL-12p70, 10.7 pg/ml; for IL-17a, 5.0 pg/ml; and for MCP-1,
52.7 pg/ml. Mean titers below those thresholds were consid-
ered undetectable.
Statistical analysis. Data were checked for normality,
in order to decide whether to use the parametric one-way
analysis of variance and post hoc Tukey’s test or the nonpara-
metric Kolmogorov-Smirnov test. Data were analyzed using
StatView 5.0 software (Abacus Concepts). P values less than
0.05 were considered significant.
RESULTS
Activation of K/BxN mouse CD8 T cells in the
articular infiltrate. In an effort to characterize the
CD8 T cells in K/BxN mice, mononuclear cells were
isolated from the peripheral blood and from the articu-
lar inflammatory infiltrate and analyzed for the expres-
sion of surface markers and cytokine production. In
contrast to the circulating CD4 T cell pool, a signifi-
cantly higher (P 0.05) percentage of circulating CD8
T cells from K/BxN mice expressed the V6-transgenic
TCR (mean  SD 32  10% and 84  7% for CD4 and
CD8, respectively) at 3 weeks after birth, before any
external clinical signs of arthritis could be detected.
The frequencies of CD8 T cell subsets defined
by the expression of CD27 and CD62L in the peripheral
blood and articular infiltrate from arthritic K/BxN mice
were compared with those in the peripheral blood of
healthy mice (Figure 1A). The frequency of
CD27CD62L short-lived effector CD8 T cells (Tse)
was similar in both K/BxN mouse tissue and peripheral
blood from healthy mice. However, the peripheral blood
of arthritic K/BxN mice presented a significantly (P 
0.019) higher frequency of CD27CD62L effector
memory CD8 T cells (Tem) than the peripheral blood
of healthy mice. Moreover, the frequency of this Tem
subset was higher, although not reaching statistical sig-
nificance (P  0.0791), in the articular infiltrate than in
the peripheral blood of K/BxN mice. The frequency of
CD27CD62L central memory CD8 T cells (Tcm)
was comparable in the peripheral blood of K/BxN mice
ANTI-CD8 THERAPY AMELIORATES EXPERIMENTAL ARTHRITIS 2955
and that of healthy mice. However, the frequency of Tcm
was significantly lower (P  0.008) in the articular
infiltrate of K/BxN mice than in the peripheral blood of
K/BxN mice.
In contrast to what was observed in healthy mice,
the majority of CD8 T cells circulating in K/BxN
mouse peripheral blood expressed the early activation
marker CD69 (Figure 1B), and this increased expression
of CD69 was also observed on the surface of CD8 T
cells infiltrating the joints.
To assess whether the expression of chemokine
receptors by K/BxN mouse articular CD8 T cells could
contribute to the skewed distribution of the different
CD8 T cell subsets in the articular infiltrate, the
frequencies of CD8 T cells expressing specific chemo-
kine receptors were determined (Figure 1C). Interest-
ingly, the frequency of CD8CXCR4 was significantly
increased in the articular tissue when compared with the
peripheral blood (P  0.002) of K/BxN mice. Moreover,
the peripheral blood of K/BxN mice had a significantly
(P  0.0007) decreased frequency of CD8CXCR4 T
cells when compared with that of controls. In contrast to
what has been reported in humans (24), we were not
able to clearly identify a circulating CXCR5-expressing
CD8 T cell population in either the healthy mice or the
K/BxN mice (data not shown).
To determine whether CD8 T cells infiltrating
the joints of arthritic K/BxN mice had the potential to
actively participate in the inflammatory and joint de-
struction process by producing proinflammatory cyto-
kines and cytolytic enzymes, we quantified the relative
gene expression of several cytokines and granzyme B in
unstimulated CD8 T cells. As depicted in Figure 1D,
both articular tissue and peripheral blood CD8 T cells
from arthritic K/BxN mice had similar expression of the
genes coding for granzyme B, IFN, IL-4, and TNF,
while no expression of these genes was detected in
CD8 T cells isolated from control peripheral blood.
Interestingly, more than half of the articular CD8 T
cells producing TNF also produced IL-6 (inset in
Figure 1D). However, expression of the gene coding for
IL-17a was significantly higher (P  0.01) in K/BxN
mouse peripheral blood CD8 T cells than in articular
tissue or control peripheral blood. Nevertheless, the
CD8 T cells from the articular tissue still expressed
significantly higher levels of Il17a than did the control
Figure 1. CD8 T cells of K/BxN mice present an activated effector memory phenotype, homing preferentially to the articular tissue where they
produce proinflammatory cytokines. A and C, Frequency of CD62LCD27, CD62LCD27, and CD62LCD27 CD8 T cells (A) and
frequency of CD8CXCR4 CD8 T cells in the blood of healthy control mice (open boxes; n  10), the blood of K/BxN mice (darkly shaded
boxes; n  9), and the articular tissue of arthritic K/BxN mice (lightly shaded boxes; n  9). Data are presented as box plots, where the boxes
represent the 25th to 75th percentiles, the lines within the boxes represent the median, and the lines outside the boxes represent the 10th and 90th
percentiles.  P 0.05 versus control;  P 0.05 versus K/BxN mouse blood. B, Dot plots of CD69 versus CD8 in the blood of a representative
healthy control mouse and an arthritic K/BxN mouse. D, Relative expression of several cytokine genes in unstimulated CD8 T cells isolated from
the articular tissue (lightly shaded bars; n 4) and peripheral blood (darkly shaded bars; n 4) of arthritic K/BxN mice and from control peripheral
blood (open bars; n  4). Bars show the mean and SD. Inset, Intracellular production of tumor necrosis factor  (TNF) and interleukin-6 (IL-6)
in CD8 T cells from the articular tissue of a representative K/BxN mouse.   P  0.01 versus K/BxN mouse blood and articular tissue;   P 
0.05 versus K/BxN mouse blood. IFN  interferon-; Gzmb  granzyme B.
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peripheral blood. As expected, the expression of Il10 was
increased in the CD8 T cells of all 3 tissue types, with
the control peripheral blood presenting a significantly
higher expression (P  0.05), while no Il2 gene expres-
sion was detected in any of the CD8 T cells isolated
from the different tissues.
Improvement in macroscopic and microscopic
signs of disease by depletion of CD8 T cells with mAb.
To assess the importance of CD8 T cells in the
maintenance of chronic polyarticular inflammation in
K/BxN mice, specific mAb that either blocked (YTS105)
or depleted (YTS169.4) CD8 T cells were adminis-
tered after arthritis was established (arthritis score 9).
As shown in Figure 2A, the arthritis scores for the mice
treated with anti-CD8 mAb began to improve starting
5 days after the initial treatment, as compared with the
groups receiving control mAb. Furthermore, a lower
arthritis score was maintained for more than a month
thereafter in the anti-CD8–treated group. The increase
in the arthritis score in the anti-CD8–treated mice
observed from day 21 onward corresponded to a recov-
ery of the CD8 T cell pool (Figure 2B).
Histologic analysis of the hind paw ankle joints
revealed an absence of inflammatory infiltrate accom-
panied by new bone formation and normal synovial
bursae in arthritic K/BxN mice 30 days after receiving
Figure 2. Treatment with anti-CD8 monoclonal antibodies (mAb) after polyarthritis is established ameliorates disease signs in K/BxN mice, and
disease relapse occurs with CD8 T cell recovery. A, Evolution of the disease score over 40 days in the control mAb–treated group (squares; n 
19) and the anti-CD8 mAb–treated group (diamonds; n  20). Mice received an injection of YTS105 (blocking) or mock antibody on day 0 and an
injection of YTS169.4 (depleting) or mock antibody on days 7 and 16. Values are the mean  SEM. B, Representative dot plots of CD4 versus CD8
in CD3 peripheral blood T cells on days 0, 7, 14, 21, and 35 after treatment with anti-CD8 mAb or control mAb.
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anti-CD8 mAb (Figure 3C), as opposed to mice receiv-
ing control mAb, which presented an inflamed hyper-
plastic synovium and articular erosions (Figure 3D).
To investigate whether the arthritis improvement
after anti-CD8 therapy was associated with changes in
the levels of circulating cytokines, the concentrations of
IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-17a, MCP-1,
TNF, and IFN were measured in the serum of healthy
control and K/BxN mice at baseline and 20 days after the
initial treatment (Figures 4A–D). Arthritic K/BxN mice
that were assessed before treatment had significantly
higher (P  0.02) serologic titers of IL-5, IL-6, and
TNF than healthy controls. Twenty days after anti-CD8
therapy, the serologic levels of all 3 cytokines and IFN
had significantly dropped (P  0.04) from their baseline
values and were comparable with the ones present in
healthy control mice. The serologic levels of all other
cytokines did not pass the minimum test threshold.
Prevention of arthritis relapse by complete
thymectomy followed by depletion of CD8 T cells. In
an effort to verify whether a permanent absence of
CD8 T cells could protect K/BxN mice from arthritis
relapse, 5–6-week-old K/BxN mice with established
polyarthritis (arthritis score 8) underwent total
thymectomy followed by the injection of a high dose of
depleting (YTS169.4) anti-CD8 mAb 9 days later. Con-
trol mice underwent sham operations and received an
equal dose of depleting anti-CD8 mAb 9 days later, after
which arthritis evolution was monitored for a further 90
days.
Thymectomy alone did not seem to induce a
short-term alteration of the course of the disease, since
no significant changes in the arthritis score could be
observed between day 0 and day 9. Administration of
anti-CD8 mAb led to an amelioration of the clinical
signs of arthritis in both the thymectomized and control
K/BxN mice. However, although the control mice had a
relapse of the disease 43 days after having received the
depleting anti-CD8 mAb (the longer time before relapse
observed in these mice compared with those in Figure
2A is attributable to the higher dose of anti-CD8 mAb
they received), the thymectomized mice experienced
further arthritis improvement, which lasted until the
end of the 90-day followup (Figure 5A). The absence of
complete clinical remission in the thymectomized mice
(arthritis score 0) is attributable to the effects of residual
deformities on the scoring system. In fact, the histologic
sections obtained on day 90 from the hind paws of the
thymectomized mice showed an absence of inflamma-
tory infiltrate in the synovial membrane and preserva-
tion of the articular and bone structure (Figure 5B), as
opposed to the expanded inflammatory infiltration and
extensive arthrosis observed in the sham-operated con-
trols (Figure 5C).
Effect of disease amelioration on anti-GPI anti-
body titers. The development and maintenance of
polyarthritis in K/BxN mice has been linked to the
production of anti-GPI autoantibodies, the serum con-
centration of which increases with age and disease
progression (20). Therefore, we determined the sero-
logic titers of anti-GPI IgG in K/BxN mice at baseline
(before mAb treatment or thymectomy was started) and
after 30 days of YTS105 followed by YTS169.4 anti-CD8
treatment or control anti-dog IgG treatment. Similar
assessments were performed 90 days after thymectomy
or sham operation and YTS169.4 treatment in K/BxN
mice and age-matched nonarthritic control littermates
(treated either with YTS105 followed by YTS169.4
anti-CD8 or control anti-dog IgG), but no significant
effects of treatment on the anti-GPI IgG titers were
Figure 3. Histologic assessment of articular tissue shows clearance of
the inflammatory infiltrate in anti-CD8 monoclonal antibody–treated
K/BxN mice. A, Joint section from a healthy control mouse (H&E
stained; original magnification  10). Inset, Normal synovial bursae
(Herovici stained; original magnification  200). B, Joint section from
a K/BxN mouse before treatment, showing massive inflammation and
cartilage/bone destruction (H&E stained; original magnification 
10). Upper inset, Inflamed hyperplastic synovium (Herovici stained;
original magnification  100). Lower inset, Chondral sclerosis and
fibrous ankylosis (Alcian blue–periodic acidSchiff stained; original
magnification  100). C, Joint section from an anti-CD8 monoclonal
antibody–treated K/BxN mouse 30 days after treatment, showing
complete clearance of the inflammatory infiltrate and normalization of
the articular architecture (H&E stained; original magnification  10).
Inset, Normal synovial bursae (Herovici stained; original magnifica-
tion  100). D, Joint section from a control monoclonal antibody–
treated K/BxN mouse 30 days after treatment, showing complete
destruction of the joint structure by massive infiltration of inflamma-
tory cells and fibrosis (H&E stained; original magnification  10).
Inset, Proliferative synovitis with destruction of articular cartilage
(Alcian blue–periodic acid–Schiff stained; original magnification 
100).
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observed (Figure 6). No significant effects of treatment
on anti-GPI IgG titers were observed (Figure 6). Actu-
ally, the titers of anti-GPI antibodies increased in the
thymectomized mice even though inflammation of the
joints subsided. The frequency of circulating CD138
plasma cells was also not affected by any of the treat-
ments (data not shown).
DISCUSSION
The role of CD8 T cells in the pathogenesis of
RA remains unclear. Nevertheless, several studies in
patients with RA that associated the effector functions
and the memory CD45RO and activated “false” mem-
ory CD29CD45RACD45RO phenotypes of
CD8 T cells with RF production and disease activity
point out that the contribution of CD8 T cells to RA
should be reevaluated (6,7,9,10). This is also the case in
animal models, because data from the literature on
experimental arthritis are few and contradictory. Several
studies on the CIA model of experimental polyarthritis
focusing on the involvement of CD8 T cells in initiat-
ing arthritis (13,14,25) revealed that anti-CD8 treatment
rendered experimental animals less susceptible (14) or
fully resistant (13) to the disease. Another study involv-
ing NOD/SCID mice engrafted with human rheumatoid
synovium stressed the importance of CD8 T cells for
the maintenance of synovial follicular-like structures (11).
Most studies were carried out in the CIA model
and manipulated the CD8 T cell response before
arthritis induction, thus focusing on the potential role of
CD8 cells in the initiation of the disease (13,14,16,25).
This is consistent with current paradigms regarding the
role of CD8 cells but was also favored because of the
transient nature of CIA, which would render it difficult
to distinguish between the ameliorating effect of CD8
blockade and natural disease remission. Therefore, the
contribution of CD8 T cells to the chronicity of
polyarthritis has not been addressed.
Figure 4. Treatment with anti-CD8 monoclonal antibodies normalizes the serologic levels of proinflammatory cytokines in K/BxN mice. Titers of
tumor necrosis factor  (TNF) (A), interferon- (IFN) (B), interleukin-6 (IL-6) (C), and IL-5 (D) in the blood of untreated K/BxN mice (lightly
shaded boxes; n 11), the blood of healthy control mice (open boxes; n 7), and the blood of anti-CD8–treated K/BxN mice (darkly shaded boxes;
n  11) are shown. Data are presented as box plots, where the boxes represent the 25th to 75th percentiles, the lines within the boxes represent the
median, and the lines outside the boxes represent the 10th and 90th percentiles.
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The recent development of murine models of
persistent chronic polyarthritis—the SKG (26), the
K/BxN (19), and the B10.Q/Ncf1* (27) models—provide
new tools for studying CD8 T cell involvement in
arthritis maintenance.
In the present study, we used the K/BxN mouse
model of chronic polyarthritis to show that CD8 T cells
circulating in the peripheral blood and infiltrating the
joints are responsible for maintaining chronic articular
inflammation. An evident decrease in articular swelling
and redness a few days after the initial anti-CD8 treat-
ment was confirmed by the absence of histologic signs of
inflammatory infiltrates and evidence of de novo ossifi-
cation. Moreover, normalization of the serologic levels
of proinflammatory cytokines, such as TNF, IFN,
and IL-6, in the anti-CD8 mAb–treated mice represents
evidence that the role of CD8 T cells in arthritis
maintenance is at least partially mediated through self-
production of these cytokines or by (co)stimulation of
production in other cells. Additionally, normalization of
the serologic levels of IL-5, a cytokine involved in growth
and differentiation of both B cells and eosinophils (28),
after anti-CD8 treatment accompanied a reduction in
joint inflammation. Further evidence for the involve-
ment of CD8 T cells in K/BxN mouse polyarthritis was
provided by the disease relapse observed in treated mice
as soon as the numbers of circulating CD8 T cells were
normalized.
Nevertheless, it was important to establish
whether the permanent absence of CD8 T cells pre-
vented arthritis relapse. Therefore, 5-week-old K/BxN
mice with established polyarthritis were thymectomized
and subsequently inoculated with a high dose of CD8
T cell–depleting mAb. Amelioration of the clinical signs
of arthritis was evident after 2 weeks, and no relapses
were observed in the 90-day followup period. In fact,
after those 90 days, normal levels of TCR-transgenic
CD4 T cells were still present in the circulation, and
the levels of B cells and plasma cells did not change
when compared with those in sham-operated mice. Such
observations strengthen the hypothesis that CD8 T
cells, and not only CD4 T cells and B cells (19), are
essential to the maintenance and even the initiation of
chronic polyarthritis in K/BxN mice. In contrast to
findings with therapies involving CD40 blockade (29),
no changes were observed in the serologic levels of
anti-GPI autoantibodies after any of the anti-CD8 ther-
apies, suggesting that CD8 blockade stops/reverses ar-
Figure 6. Blockade of CD8 does not reduce the serologic levels of
anti–glucose-6-phosphate isomerase (anti-GPI) autoantibodies. Bars
show the mean and SD optical density at 450 nm, measured in an
anti-GPI enzyme-linked immunosorbent assay, for untreated (n 18),
anti-CD8 monoclonal antibody–treated (n  15), or control monoclo-
nal antibody–treated (n  13) K/BxN mice and prethymectomized
(n  6) and postthymectomized (n  6) K/BxN mice as well as either
control monoclonal antibody–treated (n  9) or anti-CD8 monoclonal
antibody–treated (n  6) healthy control mice.   P  0.05 versus
controls. OD  optical density.
Figure 5. Thymectomy followed by CD8 T cell depletion stops
arthritis relapse, reduces the inflammatory infiltration of the joint, and
preserves bone and articular integrity in K/BxN mice. A, Evolution of
the arthritis score for 90 days after CD8 T cell depletion in
sham-operated control mice (squares; n 3) and thymectomized mice
(diamonds; n  5). Surgery was performed on day 9, and CD8
depletion was performed on day 0. Values are the mean  SEM. B,
Section from the hind paw of a K/BxN mouse 90 days after thymec-
tomy and CD8 T cell depletion (H&E stained; original magnification
 10). Inset, Preserved joint and synovial proliferation without inflam-
mation (MNF116 stained; original magnification  100). C, Section
from the hind paw of a K/BxN mouse 90 days after sham operation
and CD8 T cell depletion (H&E stained; original magnification
10). Inset, Arthrosis of the joint (Herovici stained; original magni-
fication  40).
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thritis progression without influencing the autoreactive
B cell and plasma cell pools.
Even though the CD8 T cells of K/BxN mice
express the transgenic V6 TCR, thus rendering them
potentially autoreactive (as extensively described for the
K/BxN mouse TCR-transgenic CD4 T cells [19]), they
have been poorly studied. A functional and phenotypic
characterization of the transgenic CD8 T cells in this
mouse model is especially important in view of its larger
and earlier expansion in comparison with CD4 T cells:
the CD8 T cell pool comprised up to 85% of TCR-
transgenic cells 21 days after birth and 2 weeks before
arthritis was established.
CD8 T cells are usually subdivided into partic-
ular phenotypes with characteristic effector functions,
homing properties, and proliferative capacity. The ex-
pansion phase after antigen presentation is dominated
by short-lived effector CD8CD27CD62L T cells
(Tse) capable of producing proinflammatory cytokines
(IFN, TNF, IL-2, IL-17) and cytotoxic molecules
(perforin, granzyme B). These cells heavily migrate into
the peripheral organs (30–32). Upon interaction with
CD154 expressed on helper CD4 T cells (33,34),
subsets of effector CD8 T cells and antigen-primed
naive CD8 T cells, respectively, develop into
CD8CD27CD62L effector memory cells (Tem) or
CD8CD27CD62L central memory cells (Tcm)
(31,35–37). While Tem accumulate in the peripheral
organs and rapidly become effector cells upon reencoun-
ter with antigen but have poor expansion and self-
renewal capacity, Tcm accumulate in the lymphoid or-
gans and are capable of large expansion upon antigen
reencounter and frequent self-renewal (31,37–39). Con-
sidering these functional and homing differences, it is
not surprising to observe that the K/BxN mouse articular
tissue showed an accumulation of the 2 effector subsets,
particularly the Tem subset, which are more likely to
participate in the local autoantigen-driven tissue
destruction.
The presence of TNF-, IL-6–, IFN-, IL-17–,
and granzyme B–producing CD8 T cells in the articu-
lar infiltrate and the elevated frequency of CD8 T cells
expressing the homing chemokine CXCR4 suggest that
the joint-infiltrating effector CD8 T cells might be
subdivided into 2 main groups. A first group might be
actively participating in joint destruction through gran-
zyme B secretion. A second group may be involved in
the recruitment and priming of other immune cells into
the joint, which are the IL-17a–producing CD8 T cells
that have been described as proinflammatory but with
reduced cytotoxic potential (40). Additionally, the ele-
vated presence of both CD69-expressing CD8 T cells,
which are markers of early activation, and Tem in the
peripheral blood of arthritic K/BxN mice suggests that
there is continuous systemic activation, and eventually
recruitment, of (pathogenic) CD8 T cells in the K/BxN
mouse model of spontaneous chronic polyarthritis.
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Identiﬁcation of Regulatory Foxp3+ Invariant NKT Cells
Induced by TGF-b
Marta Monteiro, Catarina F. Almeida, Marta Caridade, Julie C. Ribot, Joana Duarte,
Ana Agua-Doce, Ivonne Wollenberg, Bruno Silva-Santos, and Luis Graca
Invariant NKT (iNKT) cells were shown to prevent the onset of experimental autoimmune encephalomyelitis in mice following
administration of their speciﬁc TCR agonist a-galactosylceramide. We found that this protection was associated with the emer-
gence of a Foxp3+ iNKT cell population in cervical lymph nodes. We demonstrate that the differentiation of these cells is critically
dependent on TGF-b in both mice and humans. Moreover, in vivo generation of Foxp3+ iNKT cells was observed in the TGF-b–
rich environment of the murine gut. Foxp3+ iNKT cells displayed a phenotype similar to that of Foxp3+ regulatory T cells, and
they suppress through a contact-dependent, glucocorticoid-induced TNFR-mediated mechanism. Nevertheless, Foxp3+ iNKT cells
retain distinctive NKT cell characteristics, such as promyelocytic leukemia zinc ﬁnger protein expression and preferential homing
to the liver following adoptive transfer, where they stably maintained Foxp3 expression. Our data thus unveil an unexpected
capacity of iNKT cells to acquire regulatory functions that may contribute to the establishment of immunological tolerance. The
Journal of Immunology, 2010, 185: 2157–2163.
N
atural killer T cells are innate-like lymphocytes capable
of producing cytokines characteristic of Th1, Th2, or
Th17 responses (1–3). They were shown to inﬂuence
adaptive immunity by exacerbating or suppressing a diversity of
immune disorders, such as allergy, autoimmunity, or transplanta-
tion (4–7). For instance, NKT cell activation following adminis-
tration of a-galactosylceramide (a-GalCer), an NKT cell-speciﬁc
agonist, can protect mice from experimental autoimmune enceph-
alomyelitis (EAE) manifestations (5, 8).
NKT cells express a TCR and receptors typical of the NK lineage,
including NK1.1 and NKG2D (7). The best-studied NKT cell subset,
known as type I, classical, or invariant NKT (iNKT) cells, has a semi-
invariant TCR comprising an invariant a-chain and a restricted
TCR b-chain repertoire. These cells recognize glycolipids presented
by CD1d (7) and develop in the thymus, where they undergo a pos-
itive selection process mediated by double positive thymocytes act-
ing as CD1d+ APCs, instead of classical MHC-expressing thymic
epithelial cells (9). Thus, iNKT cells are generally considered a lin-
eage separate from T lymphocytes, characterized molecularly by
expression of promyelocytic leukemia zinc ﬁnger protein (PLZF)
(10). Of note, their unique TCR remains the only distinctive feature
enabling iNKTcell unambiguous detection, because they sharemany
surface molecules with T cells, namely, CD3 and CD4 in mice, as
well as CD8 in humans (7, 11).
Thus far, iNKT cell subsets identiﬁed in vivo can recapitulate in
the innate immunity context some of the functions characteristic of
conventional CD4 T lymphocytes, such as secretion of Th1, Th2, and
Th17-type cytokines (1–3, 12, 13). However, a parallel between
regulatory CD4 T cells (regulatory T [Treg] cells) and iNKT lym-
phocytes has not yet been described. Treg cells are characterized
by expression of the transcription factor Foxp3 and potent immuno-
suppressive properties. They are crucial for the maintenance of an
immunological self-tolerance state, modulating the activation, pro-
liferation, and function of effector T cells, thereby preventing path-
ological immune responses, including allergy and autoimmunity
(14). Treg cells develop in the thymus or in particular contexts at
the periphery, when activated in the presence of TGF-b (15–18).
We have now identiﬁed a population of Foxp3+ iNKT cells in
cervical lymph nodes (CLNs) of mice protected from EAE follow-
ing a-GalCer administration. We further demonstrate that murine
and human Foxp3+ iNKT cells can be induced in vitro following
activation in the presence of TGF-b. Foxp3+ iNKT cells display
Treg cell phenotypic hallmarks, including CD25, glucocorticoid-
induced TNFR (GITR), and CTLA-4, while retaining NKT cell
characteristics, namely, PLZF expression. Moreover, Foxp3+ iNKT
cells can occur in vivo, following activation in the TGF-b–rich
mucosal environment. Because of the strong suppressive properties
displayed upon Foxp3 upregulation, we termed this new NKT cell
subset “Foxp3+ NKTreg cell”.
Materials and Methods
Mice
C57BL/6J (H-2b, B6), B6.Cg-IghaThy1aGpi1a/J (H-2b, Thy1.1), BALB/
cByJ (H-2d, BALB/c), and B6.Cg-Tg(Cd4-TGFBR2)16Flv/J (H-2b, dom-
inant negative [dn] TGFbRII) obtained from The Jackson Laboratory (Bar
Harbor, ME); B6.129S6-Rag2tm1FwaN12 (H-2b, RAG22/2) obtained from
Taconic Farms (Germantown, NY); and FoxP3gfp knockin mice (H-2b)
obtained from University of Washington (Seattle, WA) were bred and
maintained in speciﬁc pathogen-free conditions at the Instituto Gulbenkian
de Cieˆncia, in Oeiras, Portugal. EAE was induced with 200 mg myelin
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oligodendrocyte glycoprotein (MOG) peptide (Biopolymers Laboratory,
Harvard Medical School, Boston, MA) in 200 mg CFA (Difco/BD Diag-
nostics, Franklin Lakes, NJ) s.c. and 200 ng pertussis toxin (List Biological
Laboratories, Campbell, CA) i.v. on days 0 and 2. Some mice received
4 mg a-GalCer (Alexis Biochemicals/Enzo Life Sciences, Plymouth Meet-
ing, PA) on days 0 and 4. Disease severity was monitored daily and graded
as follows: 1, limp tail; 2, partial hind-leg paralysis; 3, complete hind-leg
paralysis; 4, front-leg weakness; and 5, moribund. In gavage experiments,
30 mg a-GalCer was delivered three times every other day.
Human subjects
Peripheral blood samples were obtained from healthy volunteers of both
sexes after informed consent. The procedures were reviewed and approved
by the Ethical Board of the Faculty of Medicine, University of Lisbon,
Lisbon, Portugal.
Flow cytometry and cell sorting
CD1d-PBS57 tetramers were supplied by the National Institutes of Health
Tetramer Core Facility (Atlanta, GA). mAbs against mouse CD4, CD25,
CD62L, CD103, CD127, CTLA-4, Foxp3, IFN-g, IL-4, GITR, NK1.1,
NKG2D, TCR-b, Thy1.1, Thy1.2; and human CD4, CD25, CD127,
CD161, Foxp3, GITR, and TCR Vb11 were purchased from eBioscience
(San Diego, CA), BD Biosciences (San Jose, CA), Beckman Coulter
(Fullerton, CA), or BioLegend (San Diego, CA). For murine NKT cell
enrichment, cells were incubated with unconjugated anti-CD16/32 Ab
(in-house production) to block nonspeciﬁc binding to FcR and labeled
with PE-conjugated CD1d-PBS57 tetramers without washing. Anti-PE
magnetic beads were added, and the magnetically labeled fraction was
isolated in an autoMACS Cell Separator (Miltenyi Biotec, Auburn, CA).
For human NKT cell enrichment, cells were labeled with biotinylated Abs
against CD14, CD19, and CD123, bound to anti-biotin magnetic beads
and enriched on an autoMACS Cell Separator, the magnetically labeled
fraction being discarded. Intracellular ﬂow cytometry stainings were per-
formed using the Foxp3 Staining Buffer Set (eBioscience) for permeabi-
lization and ﬁxation. Samples were analyzed on a FACSCanto I (BD
Biosciences) or sorted on a FACSAria (BD Biosciences), with doublet
exclusion in all experiments. Data were analyzed by FlowJo (Tree Star,
Ashland, OR).
Cell cultures
Following magnetic enrichment, iNKT cells isolated from mouse spleens
were sorted by FACS, and 50,000 cells per well were stimulated with
3mg/ml plate-bound anti-CD3 (eBioscience). In some experiments, cultures
were supplemented with TGF-b (5 ng/ml; R&D Systems, Minneapolis,
MN), IL-2 (5 ng/ml; eBiocience), IL-15 (100 ng/ml; eBioscience), and
IL-7 (5 ng/ml; R&D Systems). Human cells were stimulated with 1 mg/ml
plate-bound anti-CD3 (BD Biosciences). In some conditions, cultures were
supplemented with TGF-b (10 ng/ml; R&D Systems), IL-2 (20 U/ml; Roche
Diagnostic Systems, Indianapolis, IN), anti–IL-12 and anti–IFN-g (5 mg/ml;
eBioscience), anti–IL-4 (5 mg/ml; R&D Systems), and anti-CD28 (2 mg/ml;
eBioscience). Culture medium was RPMI 1640 with GlutaMAX, supple-
mented with 10% FBS, 1% HEPES, 1% penicillin/streptomycin, 1% sodium
pyruvate, and 0.1% 22ME (Invitrogen, Carlsbad, CA).
In vitro proliferation and suppression assays
Regulatory cells isolated by FACS from the spleen of naive animals (natural
Treg [nTreg] cells) or from polarizing cultures (Foxp3+ and Foxp32 iNKT or
CD4 T cells) were cocultured in Terasaki plates (Greiner Bio-One, Frick-
enhausen, Germany) with mitomycin C (Sigma-Aldrich, St. Louis, MO)-
treated splenocytes and responder cells (4000 naive CD4 T cells isolated
from spleen; 1:1 ratio with splenocytes) stimulated with 2.5 mg/ml soluble
anti-CD3 for 4 d, with addition of 1 mCi [3H]thymidine (Amersham
Biosciences/GE Healthcare, Sunnyvale, CA) in the last 12 h. In some experi-
ments, 200 mg/ml anti-IL10R or 100 mg/ml anti-GITR (19) was added. In
transwell assays, 100,000 naive CD4 T responder cells labeled with 5 mM
CFSE (Invitrogen) were stimulated with mitomycin C-treated splenocytes
(250,000) and 1 mg/ml soluble anti-CD3.
Confocal microscopy
Sorted Foxp3-GFP+ cells were plated on coverslips precoated with poly-L-
lysine (Sigma-Aldrich) and incubated for 1 h at 37˚C. Slides were then
incubated with CD1d/PBS57-PE tetramer for 1 h at 4˚C, washed with ice-
cold PBS, and ﬁxed in PBS 3% paraformaldehyde (Sigma-Aldrich) for
15 min at 4˚C. Slides were mounted in DAPI Fluoromount G (Southern
Biotech, Birmingham, AL) and analyzed with a laser scanning confocal
microscope (LSM 510 META, Carl Zeiss, Oberkochen, Germany).
RNA extraction, RT, and PCR
RNA was extracted from 1,000–50,000 cells directly sorted into Buffer
RLT with RNeasy Micro Kit (Qiagen, Valencia, CA), and cDNA synthesis
was performed using random primers (Invitrogen) and Superscript III RT
(Invitrogen). Primers (Bonsai Technologies, Orissa, India) were as follows:
PLZF fwd: 59-cagtttgcgactgagaatgc-39, rev: 59-ttcccacacagcagacagaa-39;
Foxp3 fwd: 59-cccaggaaagacagcaacctt-39, rev: 59-ttctcacaaccaggccacttg-
39; EF1A fwd: 59-acacgtagattccggcaagt-39, rev: 59-aggagccctttcccatctc-
39. PCRs were performed using the Power SYBR Green PCR Master
Mix and the ABI PRISM 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA). All PCR products were run in agarose gel.
Statistical analysis
The p values were calculated by nonparametric unpaired t test with
Welch’s correction.
Results
Protection from EAE upon a-GalCer treatment leads to the
emergence of Foxp3+ iNKT cells in CLNs
Immunization with a-GalCer had been shown to prevent the onset
of EAE in wild-type mice (5, 8) (Fig. 1A). Because this protection
is known to be iNKT cell dependent (20) (Supplemental Fig. 1),
we evaluated the number and phenotype of iNKT cells at the peak
of disease. Surprisingly, we found a population of Foxp3+ iNKT
cells in CLNs (draining the CNS) of mice protected from EAE,
which was absent from other anatomical locations and in CLNs of
naive animals (Fig. 1B, 1C, Supplemental Fig. 2). In contrast to
Foxp3+ iNKT cells, the number and frequency of Foxp3+ Treg
cells remained unchanged in a-GalCer–treated mice, when com-
pared with animals with EAE or naive controls (Fig. 1D).
Foxp3 expression has thus far been noted to be conﬁned to
conventional ab T cells (21–23). Consistent with this, we found
no evidence for Foxp3 expression by iNKT cells from liver,
spleen, pooled lymph nodes, Peyer’s patches, or thymus of naive
BALB/c or C57BL/6 mice (Supplemental Fig. 3). This ﬁnding
strongly suggests that Foxp3 expression is not imprinted during
thymic iNKT cell development. Instead, our data indicate that pe-
ripheral induction of Foxp3+ iNKT cells can occur under particular
pathophysiological settings, such as EAE.
TGF-b induces de novo expression of Foxp3 in iNKT cells
We investigated the capacity of iNKT cells to express Foxp3 when
activated in the presence of TGF-b—a condition known to convert
conventional CD4 T cells into Foxp3+ “inducible” Treg cells
(14, 16). Sorted iNKT and CD4+CD25– T cells were stimulated
with plate-bound anti-CD3 in the presence of IL-2 and TGF-b.
After 3 d, Foxp3 expression was detectable in a signiﬁcant
proportion of both iNKT (29.35% 6 11.80) and CD4 (53.21% 6
12.03) T cell cultures (Fig. 2A, 2B). Similar results were obtained
with iNKT cells from mice harboring a Foxp3-GFP knockin allele
(Foxp3gfp mice) (21) and BALB/c mice (Fig. 2C, Supplemental
Fig. 4), and with iNKT cells sorted from the thymus, albeit the
latter exhibited a lower conversion efﬁciency (Fig. 2D). Foxp3gfp
iNKT cells were sorted after conversion and individual cells ana-
lyzed by confocal microscopy. As shown in Fig. 2E, staining with
CD1d tetramer loaded with the PBS57 ligand conﬁrms that these
Foxp3-expressing cells bear in their surface the invariant TCR
that recognizes glycolipid Ags, a feature exclusively attributed to
iNKT cells. Therefore, bona ﬁde iNKT cells were similar to con-
ventional CD4 T cells in their ability to upregulate the Foxp3
transcription factor when stimulated under appropriate conditions.
Of note, this property was not shared by other unconventional
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(non–MHC-restricted) T cells, such as gd T cells, which failed to
upregulate Foxp3 upon activation in the presence of TGF-b
(M. Monteiro and J. Ribot, unpublished observations).
We analyzed the kinetics of Foxp3 induction and evaluated
the stability of Foxp3 expression by iNKT cells in culture for 14 d
(Supplemental Fig. 5). We observed that, despite a lower conver-
FIGURE 1. Foxp3+ iNKT cells in a-GalCer–
treated mice. EAE was induced in C57BL/6 mice
(MOG), some of which were treated with a-GalCer
(MOG + a-GalCer). A, Mice treated with a-GalCer
were protected from EAE. n = 5; p , 0.01. B, Rep-
resentative data from CLNs of naive and a-GalCer–
treated mice (gated on iNKT cells, identiﬁed as
CD1d/PBS57+TCRb+ cells). C, Number of Foxp3+
iNKT cells in CLNs, showing increased Foxp3+
iNKT cell numbers in a-GalCer–treated mice. n =
5; pp , 0.05. D, The number of Foxp3+ Treg cells
in CLN remained constant. Data are representative of
three independent experiments.
FIGURE 2. iNKT cells upregulate Foxp3 expression
in the presence of TGF-b. A–C, Splenic iNKT cells
and CD4+CD25– T cells were sorted and stimulated
with or without added TGF-b. A, Gating strategy
used for cell sorting of iNKT cells (upper panels)
and naive CD4 T cells (lower panels). The gating
strategy used for analysis after 3 d of culture is also
depicted for iNKT cells and CD4 T cells. B, Foxp3
expression in iNKT cells (upper panels) and control
CD4 T cell cultures (lower panels) from C57BL/6
mice. C, Foxp3 expression in splenic iNKT cells
from Foxp3gfp knockin mice. D, Foxp3 expression in
iNKT cells isolated from thymi of C57BL/6 mice. E,
Foxp3 expression by iNKT cells was conﬁrmed at
single-cell level by confocal microscopy. Foxp3gfpcells
were FACS sorted after 3 d of culture, their invariant
TCR was restained with PE-labeled CD1d/PBS57 tet-
ramer (red), and the nucleus was counterstained with
DAPI (blue). Foxp3 expression ﬂuoresces in green
(original magniﬁcation 3630). F and G, Titration of
anti-CD3 or TGF-b concentration to address the
impact on Foxp3 induction in splenic iNKT cells. F,
iNKT cells cultured for 3 d in the presence of 5 ng/ml
IL-2 and TGF-b, and stimulated with the indicated
concentrations of anti-CD3. G, iNKT cells and CD4+
CD25– T cells stimulated with 3 mg/ml anti-CD3 in the
presence of 5 ng/ml of IL-2 and different concentra-
tions of TGF-b after 3 d of culture. H, Foxp3
expression in iNKT cells from MLNs of C57BL/6 or
dn TGFbRII mice following intragastric delivery of
a-GalCer over 1 wk. Results are representative of three
independent experiments with three mice per group.
The Journal of Immunology 2159
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sion efﬁciency of iNKT cells when compared with CD4 T cell
controls, iNKT cell numbers increased continuously over 14 d
in culture.
We next tested the impact of TCR signal strength, costimulation,
and cytokine addition on the conversion of iNKT cells into Foxp3
expressers. Maximal induction of Foxp3 was achieved with 3 mg/ml
plate-bound anti-CD3 and 5 ng/ml TGF-b and IL-2, whereas further
addition of IL-15 or IL-7 had little impact (Fig. 2F, Supplemental
Fig. 4). Of note, titration of TGF-b concentration clearly revealed
that this cytokine is essential for the induction of Foxp3 expression
in iNKT cells (Fig. 2G).
TGF-b is required for expression of Foxp3 in iNKT cells in vivo
Th17 cell differentiation is critical for EAE development and
requires a combination of cytokines, including TGF-b (24, 25).
Accordingly, TGF-b neutralization at the time of EAE induction
was shown to prevent the disease onset (26). Thus, to conﬁrm
TGF-b requirement for in vivo generation of Foxp3+ iNKT cells,
we adopted an alternative approach, taking advantage of the TGF-
b–rich environment of the gut mucosa. We investigated whether
intragastric delivery of a-GalCer could lead to the emergence of
Foxp3+ iNKT cells in mesenteric lymph nodes (MLNs), in the same
way oral tolerance leads to de novo induction of Foxp3+ Treg cells
(27). We observed that a-GalCer delivery led to an accumulation of
Foxp3+ iNKT cells in MLNs (Fig. 2H). Of note, most Foxp3+
iNKT cells from MLNs expressed low levels of CD25, something
observed with the in vivo peripheral conversion of Treg cells
in some conditions. To address whether in vivo generation of
Foxp3+ iNKT cells required TGF-b, we used dn TGFbRII mice
(28), whose T and NKT cells are unable to transduce TGF-b
signals, and observed no induction of Foxp3 expression in iNKT
cells (Fig. 2H). Taken together, our observations suggest Foxp3+
iNKT cells do not naturally arise during their development in the
thymus, but can be induced in the periphery in environments where
TGF-b is present.
Foxp3+ iNKT cells display phenotypic characteristics of Treg
cells and NKT cells
Once we established that iNKT lymphocytes could express Foxp3,
we examined the phenotype of the converted cells. Many of the
phenotypic characteristics of Foxp3+ iNKT cells were shared with
in vitro converted Foxp3+ CD4 Treg cells. Both populations were
predominantly CD25+, CTLA-4+, GITR+, CD103+, and IL-7Ra–
(Fig. 3A). However, we also observed some differences between the
two populations: Whereas Foxp3+ CD4 T cells were heterogeneous
for CD62L expression, Foxp3+ iNKT cells were homogeneously
CD62Llow. The absence of CD62L, in association with the high
expression of CD103, suggests that in vivo Foxp3+iNKT cells are
excluded from lymph nodes and preferentially migrate to periph-
eral tissues. Interestingly, iNKT cells that had upregulated Foxp3
expression failed to secrete IL-4 and IFN-g upon restimulation
(Supplemental Fig. 6).
We also found that the capacity to induce Foxp3 expression was
shared by CD4+ and CD4– iNKT cells, as sorted CD4– and CD4+
iNKT cells exhibited similar conversion efﬁciency (Fig. 3B) (M.
Monteiro and C.F. Almeida, unpublished data). In addition,
Foxp3+ iNKT lymphocytes were NK1.1–, and the majority
expressed NKG2D. We also could detect the expression of PLZF,
a transcription factor reported to distinguish NKT cells from
conventional ab T cells (10), in both sorted Foxp3+ and Foxp3–
iNKT cell subsets (Fig. 3C). Together, these observations indicate
that induction of Foxp3 expression in iNKT lymphocytes does not
corrupt their NKT cell nature.
Foxp3+ iNKT cells migrate to the liver and maintain Foxp3
expression in vivo
To investigate the in vivo stability of Foxp3 expression in iNKT
cells, we injected converted Foxp3-GFP+ iNKT cells or control
induced Foxp3-GFP+ CD4 T (iTreg) cells into RAG22/2 mice
(Fig. 4) or congenic Thy1.1 hosts (Supplemental Fig. 7). By con-
trast to iTreg cells, which migrated preferentially to the lymph
nodes, but could also be found in the spleen and liver, 21 d after
adoptive transfer iNKT cells could be detected only in the latter
organ, where 50–80% (in empty hosts) or up to 10% (in wild-type
congenic hosts) of iNKT cells maintained Foxp3 expression
FIGURE 3. Phenotype of Foxp3+ iNKT cells. A and
B, iNKT cells and CD4+CD25– T cells from the spleen
of BALB/c (A) or C57BL/6 (B) mice were FACS sorted
and cultured for 3 d in the presence of IL-2 and TGF-b.
Histograms represent Foxp3+ (gray) and Foxp3– (white)
cells within iNKT or CD4 T cell subpopulations after
conversion. Results are representative of two independent
experiments. C, Quantiﬁcation of Foxp3 and PLZF tran-
scripts, relative to EF1A expression, from Foxp3-GFP+
iNKT cells or CD4 T cells sorted after culture.
FIGURE 4. Foxp3+ iNKT cells migrate to the liver. A total of 5 3 104
Foxp3-GFP+ iNKT cells or CD4 T cells sorted from polarizing in vitro
cultures were injected i.v. into RAG22/2 recipients. Data show Foxp3 and
CD25 expression of iNKT cells and CD4 T cells, identiﬁed respectively as
TCRb intermediate, tetramer positive, and TCRb+CD4+ cells inside the
lymphocyte gate, in the liver, and in pLNs 21 d after adoptive transfer.
iNKT cells were detected only in the liver. Data are representative of two
independent experiments. pLNs, pooled lymph nodes.
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(Fig. 4, Supplemental Fig. 7). In fact, it is becoming apparent that
Foxp3 expression by conventional Treg cells is less stable than
initially anticipated, especially under lymphopenic conditions (29).
Our data indicate that in vivo Foxp3 stability in converted iNKT
cells is not inferior to that of iTreg cells, although both populations
have distinct homing potentials: Whereas CD4 Treg cells migrate
predominantly to secondary lymphoid organs upon adoptive trans-
fer, Foxp3+ iNKT cells preferentially home to the liver. We thus
suggest that the recruitment of regulatory iNKT cells to peripheral
tissues may be important to complement and/or reinforce the local
action of Treg cells (30).
Invariant regulatory NKT cells display contact-dependent
GITR-mediated suppressive function
To evaluate the regulatory function of Foxp3+ iNKT cells, we tested
their ability to suppress proliferation of CD4+CD25– “responder”
cells. We used iNKT cells derived from Foxp3gfp mice converted
in the presence of TGF-b and, as controls, natural (nTreg) and iTreg
cells. Titration of regulatory/responder cell ratio revealed that con-
verted Foxp3+ iNKT cells can indeed inhibit the proliferation of
responder cells with similar efﬁciency to iTreg cells, and only
slightly inferior to the efﬁciency of nTreg cells (Fig. 5A, 5B). Ad-
dition of anti-GITR (19), but not anti-IL-10R, neutralizing Abs to
the cultures reversed suppression, indicating that GITR plays a pre-
dominant role in the regulatory function of Foxp3+ iNKT lympho-
cytes (Fig. 5C). In agreement with these results, Foxp3+ iNKT cells
showed impaired suppressive effect compared with responder cell
proliferation when cultured in a separate transwell (Fig. 5D), which
excludes a major contribution for soluble factors to regulation.
These results demonstrate that, similarly to conventional Treg cells
(31, 32), induction of Foxp3 in iNKT lymphocytes endows these
cells with suppressive function exerted through a contact-dependent
FIGURE 5. Foxp3+ iNKT cells suppress T cell proliferation through a GITR-mediated contact-dependent mechanism. Foxp3+ iNKT cells and Foxp3–
iNKT cells sorted from the same cultures, iTreg cells (CD4 Foxp3+), and nTreg cells were cocultured at different ratios with responder T cells. A, Average
inhibition of proliferation from three independent experiments (each one with triplicates) normalized to proliferation of responder cells alone, assessed by
thymidine incorporation. B, Representative experiment at a 2:1 ratio. n = 3; pp , 0.05. C, Addition of anti-GITR, but not anti–IL-10R, abrogated the
suppressive effect of Foxp3+ iNKT cells. n = 4; ppp , 0.01. D, Proliferation of CFSE-labeled responder cells cultured for 72 h at 1:1 ratio with Foxp3+
iNKT cells in a transwell assay, in which the two populations were cultured in contact (black histogram) or separated by a transmembrane (gray histogram).
Dotted histogram shows proliferation in the absence of regulatory cells. Upper left numbers indicate the frequency of responder cells from the three
conditions within the indicated gate.
FIGURE 6. Foxp3 expression can be induced in
human iNKT cells. Human iNKT cells and CD4+
T cells from peripheral blood were magnetically en-
riched and cocultured for 5 d in the presence or absence
of a conversion mixture, including or not including
TGF-b. A, After culture, iNKT cells were identiﬁed by
costaining of human CD1d/PBS57 tetramer and anti–
TCR-Vb11 Ab inside the lymphocyte gate (iNKT).
Background of tetramer staining was evaluated with an
empty human CD1d tetramer (control). CD4 T cells
were gated inside the CD1d/PBS57-negative region
(CD4). B, Flow cytometry data showing the coexpres-
sion of Foxp3 along with CD25, CD127, GITR, or
CD161 in iNKT cell (upper panels) and CD4+ T cell
gates (lower panels). Results are representative of three
independent experiments from different blood donors
with at least three replicate cultures per condition.
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mechanism mediated by GITR. This parallel with Foxp3+ Treg cells
prompted us to name these Foxp3+ iNKT cells “Foxp3+ invariant reg-
ulatory NKT (iNKTreg) cells”.
TGF-b–mediated induction of Foxp3 expression in human
iNKT cells
Finally, we also evaluated whether Foxp3 expression could be in-
duced in human iNKT cells. Given the lower frequency of iNKT
lymphocytes in human peripheral blood (31), we enriched total
T cells by magnetic separation and cultured these bulk populations
in polarizing conditions that included TGF-b and a mixture of
neutralizing Abs against IL-12, IFN-g, and IL-4 (32) (Fig. 6A).
After 5 d of culture, up to 40% of human iNKT cells had up-
regulated Foxp3, an efﬁciency of conversion comparable to that
of conventional CD4+ T cells (Fig. 6B). The converted human
Foxp3+ NKT cells were CD25+, GITR+, and predominantly
CD161+, whereas CD127 was expressed by approximately half
of the Foxp3+ iNKT cells. Critically, these data establish that the
induction of Foxp3 in NKT cells is a conserved phenomenon be-
tween rodents and humans.
Discussion
Among hematopoietic cells, Foxp3 expression has been claimed to
be restricted to conventional T cells (24–27, 33). We now describe,
for the ﬁrst time, that iNKT and CD4 T lymphocyte populations
share a similar competence in responding to a tolerogenic cytokine
environment, namely, TGF-b, by expressing Foxp3 and undergoing
functional specialization toward a regulatory phenotype. It should
be noted, however, that Foxp3 induction upon activation in the
presence of TGF-b is not a common feature of all lymphocytes:
In particular, we were unable to convert sorted gd T cells by CD3
stimulation in the presence of TGF-b (M. Monteiro and J. Ribot,
unpublished observations). In addition, this potential appears to be
a conserved feature of iNKT cells, as we were able to induce Foxp3
expression in samples from different murine strains and from
human beings.
Our results clearly demonstrate that TGF-b is the critical cytokine
promoting Foxp3 upregulation in iNKT cells, as described for CD4+
T cell conversion into Foxp3+ Treg cells (15–18). As a consequence,
we took advantage of the TGF-b–rich environment of the gut to
assess in vivo conversion of Foxp3+ iNKT cells. In fact, it has
already been described that oral delivery of an Ag can lead to
a state of mucosal tolerance in which Ag-speciﬁc T cells are locally
converted into Treg cells (27). In this paper, we show that intra-
gastric delivery of a-GalCer induces the emergence of Foxp3+ iNK-
Treg cells in MLNs. However, this process was impaired in mice
with NKT cells unable to integrate the signals delivered through the
TGF-bR, thus establishing a crucial role for TGF-b in the in vivo
conversion of Foxp3+ NKT cells. Therefore, although oral tolerance
to proteic Ags, such as OVA, can be achieved in the absence of
iNKT cells, as it has been shown using TCR-transgenic RAG-
deﬁcient mice (27), our results suggest that iNKT cells in the gut,
exposed to glycolipid ligands, can convert into Foxp3+ cells and syn-
ergize with local Treg cells in the promotion of tolerance to food Ags.
Most reports have shown that Foxp3+ Treg cells suppress immune
responses through cell contact-dependent mechanisms (34, 35).
Several surface molecules preferentially expressed by Treg cells,
such as GITR, have been implicated in their suppressive function
(31, 32). We found that NKTreg cells can also suppress naive T cell
proliferation by a GITR-dependent, IL-10–independent mechanism.
Moreover, iNKTreg cells were unable to suppress responder cell
proliferation when physically separated in a transwell, which ex-
cludes the additional contribution of soluble regulatory factors.
Although iNKT cells expressing Foxp3 have never been found in
naive mice (21), the presence of this population has never been
investigated in the context of an immune response. For instance,
iNKT cells were reported to play important regulatory roles in
the development of anterior chamber-associated immune deviation,
transplantation tolerance, and prevention of autoimmunity, such as
EAE, as lack of iNKT cells or decreased iNKT cell numbers
compromise tolerance. However, in none of these studies was
Foxp3 expression assessed in iNKT cells (33). Importantly, iNKT
cell surface molecules largely overlap with those expressed by
conventional CD4 T lymphocytes, and Foxp3+ iNKT cells down-
regulate expression of NK1.1, a molecule often used in previous
studies to distinguish NKT cells from T lymphocytes. Therefore, it
is reasonable to assume that without an unambiguous identiﬁca-
tion with a speciﬁc tetramer, Foxp3+ iNKT cells could have been
erroneously detected as conventional Treg cells. Furthermore, until
the development of a conditional knockout mouse lacking Foxp3
exclusively in iNKT cells—for instance, based on a PLZF-driven
Cre expression system—it will not be possible to discriminate be-
tween the contribution of NKTreg cells and that of Treg cells in
immune pathology. Although this topic surely deserves further in-
vestigation, the results presented in this paper clearly establish
a new type of iNKT cell characterized by Foxp3 expression and
immune regulatory properties similar to those of conventional Treg
cells, one that might contribute to the maintenance of immune
tolerance in the periphery.
Finally, the strong immunosuppressive properties displayed by
NKTreg cells raise the possibility of their therapeutic application in
the control of immune-mediated diseases, in particular, liver im-
mune-mediated inﬂammation. Given their invariant speciﬁcity,
Foxp3+ NKTreg cells are assumed to have a general immunosup-
pressive action. It should be noted, however, that polyclonal Treg
cell populations are likely to have, at least in part, a similar non-
speciﬁc immunosuppressive effect, possibly due to cross-reactivity
with self-Ags (36). Indeed, these nonspeciﬁc effects can serve as the
basis of Treg cell suppression in lymphopenia-driven proliferation
and graft-versus-host disease (36–38). Notably, the invariant TCR
expressed by Foxp3+ iNKT cells might provide an advantageous,
universally applicable method for their isolation, conversion, and
expansion, regardless of genetic background or pathology.
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Supplemental Figure 1 
 
α-GalCer administration does not prevent EAE manifestations in mice lacking 
iNKT cells. EAE was induced in C57Bl/6 (B6+MOG) and in β2-microglobulin 
deficient mice (β2m+MOG) mice, some of which were treated with α-GalCer. 
Administration of ?-GalCer prevented the development of EAE in B6 but not in β2-
microglobulin deficient mice, which lack iNKT cells (n=5, P<0.01). 
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Supplemental Figure 2 
 
Foxp3+ iNKT cells generated during EAE are only detectable in cervical LNs.  EAE 
was induced in C57Bl/6 mice (MOG), some of which were treated with α-GalCer 
(MOG+α-GalCer). Panels show representative flow cytometry data of cells isolated 
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from different organs 14 days after immunization with MOG, showing iNKT 
identification with the specific tetramer and anti-CD3 or TCRβ, and Foxp3 staining 
within iNKT and CD4 T cell gates. A control dot plot obtained with an empty CD1d 
tetramer is also represented. Data are representative of three independent experiments. 
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Supplemental Figure 3 
 
iNKT cells from naïve C57Bl/6, Balb/c, and Foxp3gfp knockin mice lack Foxp3 
expression. Analysis of Foxp3 expression in lymphocytes isolated from the liver, 
pooled LNs, Peyer’s Patches (PP), spleen and thymus of C57Bl/6, Balb/c mice and 
Foxp3gfp naïve mice. iNKT cells were identified by co-staining with CD1d/PBS57 
tetramer and a pan TCR-β antibody inside the lymphocyte gate (upper row). 
Background staining of iNKT cells was assessed for every organ using an empty CD1d 
tetramer (shown for liver only). Foxp3 expression was analyzed through intracellular 
antibody staining or based on GFP fluorescence (in Foxp3gfp mice). Foxp3+ cells were 
only present among the CD1d/PBS57– cells. We confirmed these Foxp3+ cells as being 
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CD4+ T lymphocytes (right dotplot, shown only for LNs). Results are representative of 
three mice from two independent experiments. 
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Supplemental Figure 4 
 
Culture of Balb/c iNKT cells under different cytokine conditions. iNKT cells 
isolated from the spleen of Balb/c mice were FACS-sorted according to the co-
expression of a CD1d/PBS57 tetramer and a pan TCR-β antibody, and stimulated with 3 
?g/mL of plate-bound anti-CD3 for 3 days in the indicated conditions. Results are 
representative of three independent experiments. 
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Supplemental Figure 5 
 
Time-course analysis of Foxp3 induction and stability in iNKT cells. iNKT and 
naïve CD4 T cells isolated form the spleen of naïve C57BL/6 mice were sorted, 
stimulated in vitro in presence of IL-2 and TGF-β and Foxp3 expression analyzed at 
different time points. A Kinetics of Foxp3 upregulation at the indicated time-points in 
the first 72 hours of culture. The profile of NK1.1 and CD4 expression in Foxp3+ iNKT 
cells is shown in panel A, middle row. B, Graphs represent kinetics of the number of 
Foxp3+ iNKT or CD4 T cells cultured for 14 days in presence of TGF-β. Culture 
medium was replaced every 3 days and wells split when cells reached confluence. Data 
is representative of at least 2 independent experiments performed with triplicates. 
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Supplemental Figure 6 
 
 
Foxp3+ iNKT cells fail to produce IL-4 and IFN-γ. After 3 days of in vitro 
stimulation in presence of IL-2 and TGF-β, iNKT cells were stimulated with 
PMA/ionomycin and IL-4, IFN-γ and Foxp3 were detected by flow cytometry. The 
figure shows the co-staining of cytokines and Foxp3, or the respective isotype controls, 
in both iNKT (left dot plots) and CD4 T cells (right dot plots) cultured in absence (top 
row) or presence of exogenous TGF-β (second and third rows). Data are representative 
of two independent experiments performed with triplicate cultures per condition. 
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Supplemental Figure 7 
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In vivo distribution of adoptively transferred Foxp3+ iNKT cells. 1×105 Foxp3-GFP+ 
or Foxp3-GFP– iNKT cells (sorted from the same 5-day cultures) were transferred 
intravenously into congenic Thy1.1 naïve hosts. At day 7 or 21 after adoptive transfer, 
mice were sacrificed and cells recovered from different tissues were analyzed by flow 
cytometry. A, Dot plots from the cell-sorting of iNKT cultures, in which Foxp3– and 
Foxp3+ were isolated based on GFP fluorescence. Purity of sortings is also shown. B,C, 
Representative FACS data of cells isolated from the indicated organs at day 7 (B) or 21 
(C) post-transfer. To identify donor cells, we first excluded background and host cells 
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through MHC class II and Thy1.1 staining, respectively, inside the lymphocyte gate, 
gating afterwards on Thy1.2+ cells and then in tetramer and CD3 co-expressers. Foxp3 
expression was translated by GFP signal. D, Dot plots show the co-staining of Thy1.1 
and Thy1.2 of cells isolated from the indicated organs of unmanipulated Thy1.1 control 
mice gated as in B and C. 
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Abstract
Background: Rheumatoid Arthritis (RA) is a chronic immune mediated disease associated with deregulation of many cell
types. It has been reported that different T cell subsets have opposite effects in disease pathogenesis, in particular Th17 and
Treg cells.
Methodology and Findings: We investigated whether non-depleting anti-CD4 monoclonal antibodies, which have been
reported as pro-tolerogenic, can lead to protection from chronic autoimmune arthritis in SKG mice – a recently described
animal model of RA – by influencing the Th17/Treg balance. We found that non-depleting anti-CD4 prevented the onset of
chronic autoimmune arthritis in SKG mice. Moreover, treated mice were protected from the induction of arthritis up to 60
days following anti-CD4 treatment, while remaining able to mount CD4-dependent immune responses to unrelated
antigens. The antibody treatment also prevented disease progression in arthritic mice, although without leading to
remission. Protection from arthritis was associated with an increased ratio of Foxp3, and decreased IL-17 producing T cells in
the synovia. In vitro assays under Th17-polarizing conditions showed CD4-blockade prevents Th17 polarization, while
favoring Foxp3 induction.
Conclusions: Non-depleting anti-CD4 can therefore induce long-term protection from chronic autoimmune arthritis in SKG
mice through reciprocal changes in the frequency of Treg and Th17 cells in peripheral tissues, thus shifting the balance
towards immune tolerance.
Citation: Duarte J, Agua-Doce A, Oliveira VG, Fonseca JE, Graca L (2010) Modulation of IL-17 and Foxp3 Expression in the Prevention of Autoimmune Arthritis in
Mice. PLoS ONE 5(5): e10558. doi:10.1371/journal.pone.0010558
Editor: Derya Unutmaz, New York University, United States of America
Received February 26, 2010; Accepted April 16, 2010; Published May 10, 2010
Copyright:  2010 Duarte et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by SUDOE, grant number IMMUNONET-SOE1/1P1/E014, and supported by a research grant from Fundac¸a˜o para a Cieˆncia e
Tecnologia (FCT), Portugal (FCT/POCI/SAU-MMO/55974/2004). JD, AA-D, and VGO are funded with scholarships from FCT (SFRH/BD/23631/2005, SFRH/BD/49093/
2008, and SFRH/BPD/22575/2005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lgraca@fm.ul.pt
Introduction
Rheumatoid arthritis (RA) is a common chronic autoimmune
inflammatory disease characterized by destruction of the synovial
joints, leading to progressive disability, increased co-morbidity and
premature mortality [1,2]. Both genetic and environmental factors
are known to contribute to the development of the disease [3]. RA
is characterized by a complex immune mediated response with the
participation of many cell types including CD4+ T cells [4,5,6],
such as the IL-17 producing Th17 subset, which have been shown
to play an important role in the pathogenesis of the disease [7,8,9].
The participation of CD4+ T cells in the pathogenesis of RA,
namely by influencing other key cellular mediators of the disease
(such as B cells or macrophages), has prompted the development of
therapeutic strategies targeting this lymphocyte population
[10,11,12,13]. Monoclonal antibodies (MAbs) targeting key T cell
molecules (such as co-receptor and co-stimulation) have been
suggested as drugs capable of achieving long-term protection from
the disease, with the potential of leading to immune tolerance,
following a short treatment [14]. Indeed long-term transplantation
tolerance can be induced in mice following CD4 or co-stimulation
blockade [15,16,17].
The most commonly used mouse models for autoimmune
arthritis – such as collagen-induced arthritis – have been
instrumental in the development of new therapies, such as the
blockade of key cytokines, such as TNF. However, arthritis in
these mice is self-limited and, as such, pre-clinical studies of
putative tolerogenic regimens aiming for long-term effects have
been hampered by the lack of suitable animal models of chronic
autoimmune arthritis that are not TCR transgenic.
SKG mice, harboring a mutation in ZAP-70 rendering T cells
more resistant to activation and thus interfering with appropriate
negative selection in the thymus, have been recently described as
developing chronic autoimmune arthritis with several character-
istics resembling RA [18]. Arthritis in SKG mice has a centripetal
course starting with small finger joints, eventually leading to
histological changes and bone destruction similar to RA [19]. The
incidence and severity of the disease is greater in females, with
most mice developing rheumatoid factor (RF), and some animals
displaying extra-articular lesions similar to rheumatoid nodules
and pneumonitis [18]. Although CD4+ T cells, and its Th17
subset, are important in the pathogenesis of arthritis in SKG mice,
other cell populations, such as B cells, participate in the disease as
suggested by the production of RF in these animals [18].
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10558
Our data reports the long-term protection from chronic
autoimmune arthritis following a short course of non-depleting
anti-CD4 MAb in SKG mice, associated with decreased IL-17 and
increased Foxp3 expression in the synovial tissue. Furthermore,
the non-depleting nature of the therapeutic MAb preserves the
immune competence of treated mice.
Methods
Ethics Statement
All experiments involving animals were approved by the Animal
User and Ethical Committees at the Instituto Gulbenkian de
Ciencia, according with directives from Direccao Geral Veter-
inaria (PORT 1005/92). Mice were bred and maintained under
specific pathogen free (SPF) conditions.
Mice
BALB/c, DO11.10.RAG1-/-, and SKG mice (generously
provided by Professor Shimon Sakaguchi, Kyoto, Japan). Experi-
mental animals were between 8–10 weeks of age and sex matched.
Autoimmune arthritis induction and anti-CD4 treatment
BALB/c and SKG mice were injected intraperitoneally (i.p.)
with a single shot of 3mg curdlan per mouse. Treated mice were
injected with 1 mg anti-CD4 on days 0 (the day of curdlan
injection), 2 and 4. Mice treated at disease onset, were injected
with 3 shots of 1 mg anti-CD4 every other day, from the day they
have reached a clinical score of 0.5.
Clinical assessment of arthritis
Joint swelling was monitored in blinded cages by two
independent observers and scored as described elsewhere [18]:
0, no joint swelling; 0.1, swelling of one finger joint; 0.5, mild
swelling of wrist, ankle, or base of tail; and 1.0, severe swelling of
wrist, ankle or base of tail. Scores for all joints were totaled for
each mouse (with a maximum score of 5 corresponding to severe
swelling of the four paws and base of tail).
Antibodies and reagents
Curdlan (Wako, Japan) and Zymosan-A (Sigma-Aldrich, USA)
were dissolved in sterile PBS at 15 mg/ml and 20 mg/ml,
respectively. Non-depleting anti-CD4 (YTS177) and the isotype
control anti-dog CD4 (YKIX302) MAbs were produced in our
laboratory using Integra CL1000 flasks (IBS, Chur, Switzerland),
purified by 50% ammonium sulfate precipitation, dialyzed against
PBS, and purity checked by native and SDS gel electrophoresis.
The hybridomas were generously provided by Professor Herman
Waldmann (Oxford, UK).
Cytokine analysis
Evaluation of serum cytokines was performed using the mouse
inflammation cytometric bead array (BD Biosciences, San Diego,
CA), with beads specific for IL-6, TNF, IFN-c, monocyte
chemoattractant protein-1 (MCP-1), and IL-10. IL-17 was
quantified by ELISA using a kit from R&D Systems. Cytokine
concentrations were measured in duplicates, and compared with
standard curves, according to manufacturer instructions.
Quantification of rheumatoid factors
Serum levels of rheumatoid factor were measured by ELISA as
previously described [18], using 5 mg/ml mouse IgG to coat the
plates, and 1 mg/ml anti-mouse-IgM-HRP for detection (Southern
Biotech, Birmingham, USA).
Determination of ovalbumin-specific immune responses
On day 30 following anti-CD4 treatment, or treatment with an
isotype control, the mice were immunized with two injections two
weeks apart, of 20 mg ovalbumin (OVA, grade V; Sigma, St Louis,
USA), in 2.0 mg of endotoxin-free aluminum hydroxide (alum,
Alu-gel-S, Serva, Heidelberg, Germany), and sacrificed one week
after the last immunization. Non-immunized (naı¨ve) mice were
maintained as negative controls. The serum concentration of
OVA-specific immunoglobulins was determined by ELISA using
an OVA-specific IgG1 kit (SouthernBiotech, Birmingham, USA)
with anti-OVA IgG1 standard from Serotec (Oxford, UK).
Histology
Ankle and metatarso-phalangical (MTP) joints were collected
and cryopreserved in OCT (Sakura, NL). Cryosections were
stained with hematoxilin-eosin according to standard procedures.
Flow cytometry
Cells were stained for flow cytometric analysis with the following
fluorochrome-labeled monoclonal antibodies: CD3 (145-2C11),
CD4 (RM4-5), CD25 (PC61.5), and Foxp3 (FJK-16s) from
eBiosciences or BD Biosciences. Intracellular cytokines were
investigated in lymphocytes activated for three hours in PMA-
ionomycin in the presence of Brefeldin-A. Monoclonal antibodies
specific for IFN-c (XMG1.2), IL-17A (eBio17B7), and IL-10
(JES5-16E3) were used (all from eBiosciences).
Th17-polarization assays
OVA-specific CD4+ T cells from DO11.10.RAG1-/- mice were
purified by magnetic separation with CD4 (L3T4) microbeads
(Miltenyi Biotec, Germany). Cell purities were between 92–96%. The
T cells were cultured for 5 days with bone marrow derived DCs,
0.1 mM OVA peptide (New England Peptide LLC, USA), and
10 mg/ml anti-CD4 (YTS177) in IMDM 5% FBS (Invitrogen), 1%
Pen/Strep (GibCo), 0.1% b-Mercaptoethanol (GibCo), 1 ng/ml
TGF-b (R&D systems), 20 ng/ml IL-6 (R&D systems), 10 ng/ml IL-
1b (Ebiosciences), and 10 mg/ml anti-INFc (R46A2). At the end of
the culture the cells were harvested, and processed for flow cytometry.
RNA extraction and real time PCR
Total RNA was extracted from synovial tissue, dissected from
ankle joints, using lysis buffer, and following the tissue RNA kit
instructions (Omega bio-tek, USA). Foxp3 and IL-17 were
quantified by real time PCR, performed on the ABI PrismH
7000 sequence detection system (Applied Biosystems, USA). The
relative mRNA levels of the target genes were normalized against
CD3. CD3, Foxp3 and IL-17 primers are described elsewhere
[20,21,22].
Statistics
Statistical significance was determined using the two-tailed non-
parametric Student’s t test (Mann-Whitney U). P values ,0.05
were deemed significant.
Results
SKG mice develop chronic autoimmune arthritis upon
systemic curdlan immunization
Although initial reports have suggested that SKG mice develop
chronic autoimmune arthritis spontaneously [18], it was later
confirmed that disease induction requires exposure to yeast wall
extract (zymosan) or purified b-glucans, like curdlan or laminarin,
acting through the pattern recognition receptor Dectin-1 [23].
Th17/Treg Balance in Arthritis
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We confirmed that a single intraperitoneal injection of 2 mg
Zymosan (not shown) or 3 mg Curdlan is sufficient to induce
chronic disease in SKG mice, but not in wild-type controls
(Figure 1A). Both male and female mice developed arthritis,
although the disease was more severe in females (Figure 1B). Based
on these data we decided to use curdlan in female SKG mice in
subsequent experiments.
Non-depleting anti-CD4 treatment prevents the onset of
autoimmune arthritis
To assess whether non-depleting anti-CD4 MAbs, suggested in
previous studies as having tolerogenic potential, can lead to long-
term beneficial effects in chronic autoimmune arthritis, female
SKG mice were treated with non-depleting anti-CD4 together
with curdlan. Anti-CD4 treatment was effective in preventing the
development of autoimmune arthritis (n = 5, P,0.001, Figure 2A).
Since arthritic SKG mice are known to produce high titres of RF
(IgM anti-IgG), we quantified serum RF. We found that serum RF
were below the limit of detection in all mice treated with anti-CD4
(Figure 2B).
Furthermore, animals treated with anti-CD4 not only remained
without clinical manifestations of the disease, but their joints were
free from inflammatory cell infiltrates. Indeed, histological sections
of ankle and MTP joints from anti-CD4 treated mice showed
normal joint tissues, without inflammatory infiltration or bone
erosions, compared to the curdlan induced arthritic mice
(Figure 2C).
We also evaluated the presence of pro-inflammatory cytokines
in arthritic mice compared to anti-CD4 treated animals. We
observed a significant decrease in the concentration of IL-6, TNF,
MCP-1 and IFN-c in sera from anti-CD4 treated mice, suggesting
that a treatment targeting T cells can have an impact on additional
cell types producing those cytokines (Figure 2D). It should be
noted that IL-6, which has been associated with Th17 differen-
tiation, is known to be critical for the pathogenesis of chronic
autoimmune arthritis in SKG mice [24], and was not detectable in
any of the anti-CD4 treated animals. Despite the reported
association of IL-17 with arthritis in SKG mice, this cytokine
was not detected in sera from arthritic animals, remaining below
detection level in all groups (Figure 2E). This observation is in
accordance with the proposed local effect of this inflammatory
mediator.
Previous studies have suggested a protective role for IL-10 in
this murine model of autoimmune arthritis [25]. However, we did
not find any significant difference in the serum levels of IL-10,
between arthritic and anti-CD4 treated mice (n = 10, P.0.05,
Figure 2E).
Non-depleting anti-CD4 alters the balance of Treg/Th17
cells in the synovial tissue and draining LNs
It has been reported that the anti-CD4 MAb used in our study
(YTS177) has a non-depleting isotype [26]. We confirmed the
non-depleting nature of the MAb as neither the splenic frequency
(Figure 3A and B) nor the total number (not shown) of CD4+ T
cells were reduced in animals treated with anti-CD4.
Transplantation tolerance achieved with non-depleting anti-
CD4 has been associated with the induction of Treg cells, both in
the spleen and within tolerated transplants [27,28,29]. We
investigated if changes in Treg frequency could be seen in the
spleen of anti-CD4 treated mice. We found that there was no
change in T cell subpopulations of anti-CD4-treated animals,
namely Foxp3+ Treg cells, with a similar frequency of these cells in
mice exposed to curdlan in the presence or absence of anti-CD4
treatment (Figure 3A and B). In addition, the frequency of IL-17,
IFN-c or IL-10-producing T cells, identified by intracellular
cytokine staining, remained constant in all groups of animals, and
below 2% of the CD4+ T cells (not shown).
As our data show that anti-CD4 treatment can prevent joint
inflammation, even though T cell subpopulations in secondary
lymphoid organs appear to be unaffected, we investigated whether
anti-CD4 treatment was leading to alterations in the T cell
subpopulations within the synovial tissue of protected animals.
Given the technical limitations for the direct enumeration of
individual T cells from mouse synovial tissue, we used the
expression of Foxp3 and IL-17 mRNA as surrogate markers for
the relative frequency of, respectively, Tregs and Th17 cells. For
this purpose Foxp3 and IL-17 mRNA expression was measured by
quantitative real time PCR and normalized to CD3 expression
(thus controlling for different numbers of infiltrating T cells in
different samples, as the arthritic synovium contains greater
numbers of T cells). This method, of using CD3 expression for
normalization of different numbers of infiltrating T cells in tissues
with few lymphocytes has been established for other tissues with
small numbers of T cells, such as skin grafts in mice [22]. We
observed that while IL-17 expression among synovial T cells (i.e.
IL-17/CD3 mRNA ratio) was reduced in mice treated with anti-
CD4 and consequently protected from inflammatory manifesta-
tions of the disease, the expression of Foxp3 among synovial T
cells was increased in the same conditions (n = 4, P,0.05,
Figure 3C). Thus, the Foxp3/Th17 ratio in the synovial tissue is
substantially shifted following anti-CD4 treatment. In addition, the
analysis of popliteal LNs, draining affected joints, showed a
reduction in the frequency of IL-17+ T cells in anti-CD4-treated
mice (n = 8, P,0.05) while the frequency of Foxp3+ cells remained
similar in both groups of animals (Figure 3D).
CD4-blockade prevents in-vitro Th17 polarization while
favoring Foxp3 expression
Although non-depleting anti-CD4 has been widely studied for
the induction of transplantation tolerance its exact mechanism of
action has not been fully characterized. In experiments performed
with TCR-transgenic mice devoid of Foxp3+ Treg cells, it was
previously shown that CD4-blockade could directly lead to
peripheral conversion of T cells towards Foxp3+ Treg cells thus
achieving transplantation tolerance [22]. However, it was never
assessed whether CD4-blockade could directly interfere with Th17
polarization, or whether a reduction in Th17 cells (as we observed
in vivo) would be secondary to Treg-mediated suppression.
Figure 1. SKG mice develop chronic autoimmune arthritis upon
induction with curdlan. (A) Arthritis incidence in female SKG and
BALB/c mice after a single i.p. injection of 3 mg curdlan (n = 6). Curdlan
was able to induce chronic arthritis in SKG but not in BALB/c mice. Each
point represents the median per group. (B) Clinical score of 5 month-old
male (M) and female (F) SKG mice 90 days following disease induction
with curdlan. Data are from two independent experiments.
doi:10.1371/journal.pone.0010558.g001
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Figure 2. Non-depleting anti-CD4 MAb prevents the onset of autoimmune arthritis. (A) Female SKG mice were immunized with 3mg
curdlan i.p. together with 1 mg non-depleting anti-CD4 or an isotype control. The MAb was administered again on days 2 and 4. Anti-CD4 treated
mice were protected from the development of autoimmune arthritis (n = 6, P,0.001). Data, represented as mean 6 SEM, are from two independent
experiments. (B) Serum concentration of rheumatoid factor (RF) was measured by ELISA. Mice treated with anti-CD4 showed significantly lower levels
of RF (n = 6, P,0.001) (C) Histological sections stained with eosin-hematoxilin from the ankle and metatarso-phalangical joints from SKG mice in the
absence and in the presence of anti-CD4 treatment, 90 days following curdlan immunization. (D) Serum concentration of IL-6, IFN-c, TNF and MCP-1
in naive SKG mice, SKG mice exposed to curdlan, or curlan and anti-CD4. Naive SKG mice were age matched and did not develop arthritis in the
absence of curdlan immunization (no induction). The serum levels of IL-6 (P,0.05), IFN-c (P,0.01) and MCP-1 (P,0.01) were significantly lower in
anti-CD4 treated mice compared with animals injected with curldan in the absence of tolerizing MAbs. Differences in TNF concentration did not reach
statistical significance. (E) The serum concentration of IL-10 and IL-17 in SKG mice exposed to curdlan, or curlan and anti-CD4 remained similar in the
different experimental groups. Culture supernatants from Th17 cell culture were used as positive control.
doi:10.1371/journal.pone.0010558.g002
Figure 3. Anti-CD4 MAb influences the local balance of Th17/Treg cells. (A) Frequency of splenic CD4+ T cells or CD4+Foxp3+ Treg cells from
SKG mice exposed to curdlan, or curdlan + anti-CD4 treatment. No significant difference was observed between the two populations of animals. (B)
Representative dot plots showing the frequency of splenic CD4+Foxp3+ T cells from SKG mice exposed to curdlan, or curdlan + anti-CD4 treatment.
No significant difference was observed, as represented in panel A. (C) Foxp3 and IL-17 mRNA expression from the synovial membrane of SKG mice
exposed to curdlan, or curdlan + anti-CD4 (mRNA expression levels were normalized to CD3 expression). (D) Frequency of Foxp3+ and IL-17+ T cells
within draining LNs of SKG mice exposed to curdlan, or curdlan + anti-CD4.
doi:10.1371/journal.pone.0010558.g003
Th17/Treg Balance in Arthritis
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To address this issue we investigated whether CD4-blockade
could prevent in vitro Th17 polarization. We used OVA-specific
TCR-transgenic CD4+ T cells sorted from DO11.10.RAG-/- mice.
We stimulated these cells in vitro, for five days, in the presence of
DCs loaded with the appropriate peptide and under culture
conditions promoting optimal Th17 polarization (in presence of
TGF-b, IL-6, IL-1b, and anti-IFN-c)[30]. We observed that
addition of anti-CD4 led to a significant reduction of Th17 cells
(n = 6, P,0.05, Figure 4). In spite of the presence of cytokines that
promote Th17 polarization (cytokines that are known to prevent
Foxp3 induction) the addition of anti-CD4 resulted in a significant
increase in the frequency of Foxp3+ T cells (n = 6, P,0.05,
Figure 4).
Non-depleting anti-CD4 induces long- term protection
from autoimmune arthritis
To assess whether protection from arthritis induced with anti-
CD4 treatment had a long-term effect, SKG mice initially injected
with curdlan and non-depleting anti-CD4 were challenged with
curdlan 60 days following the initial treatment. Animals exposed to
curdlan in the presence of the putative tolerogenic anti-CD4 MAb
at day 0 were protected from the induction of arthritis following
curdlan administration at day 60, unlike the age-matched controls
that did not receive any treatment at day 0 (n= 6, P,0.05,
Figure 5A).
However, it should be noted, that some anti-CD4 treated mice
developed mild manifestations of arthritis following curdlan
challenge at day 60, although without progressing to the severe
manifestations of the disease observed in control groups.
Non-depleting anti-CD4 prevents progression of
established autoimmune arthritis
Given the fact that non-depleting anti-CD4 treatment prevents
the onset of autoimmune arthritis, we tested the effectiveness of a
similar course of anti-CD4 for the treatment of established arthritis
in SKG mice. Female SKG mice were immunized with curdlan
and when the clinical score reached 0.5 the arthritic mice were
randomly included in a group treated with anti-CD4 MAb or a
control group. Mice treated with non-depleting anti-CD4 showed
a long-term benefit with slower disease progression and less severe
clinical scores (n = 5, P,0.05, Figure 5B). However, remission was
only achieved in a minority of the treated animals.
Anti-CD4 treated mice remain immunocompetent
A concern of immunomodulatory or tolerogenic therapeutic
strategies is their long-term impact on the overall immune
response. We therefore assessed the immune competence of anti-
CD4-treated BALB/c mice (same genetic background as the SKG
mice, but without the ZAP70 point mutation) to mount CD4+ T
cell-dependent immune responses towards an unrelated antigen.
For this purpose, mice treated with anti-CD4 were sensitized with
20 mg OVA-alum 30 days following anti-CD4 treatment. The
quantification of OVA-specific immunoglobulins in the serum was
determined one week following sensitization. Our data show that
the concentration of OVA-specific immunoglobulins was similar in
immunized mice, regardless of previous anti-CD4 treatment, and
considerable higher than in naive controls (n = 5, P,0.05,
Figure 5C). Moreover, we confirmed the same results in SKG
mice, subjected to the same protocol (n = 2, not shown). Of note, if
OVA was administered at the time of anti-CD4 treatment in
BALB/c mice, the animals became unable to produce OVA-
specific immunoglobulins following subsequent OVA immuniza-
tion (n= 6, P,0,05, Figure 5D), thus proving that OVA-specific
IgG production is CD4-dependent, and that tolerance is only
imposed over the antigens present at the time of tolerance
induction.
Discussion
Our data show that a short course of non-depleting anti-CD4
can lead to long-term protection from the development of
autoimmune arthritis, in a murine model of chronic disease. We
have shown that our non-depleting antibody (clone YTS177) is not
affecting T cells in the spleen, but seems to be preventing
autoimmune arthritis, acting locally at the site of inflammation. It
is likely that by targeting CD4+ T cells, the pathogenic cycle of
events leading to synovial inflammation and progressive joint
destruction is abrogated, as other cellular players are not recruited
towards the articular tissue to cause inflammation. This impact of
CD4-blockade on other cell types is well illustrated by the marked
decrease of pro-inflammatory cytokines produced by dendritic
cells (DCs) and macrophages in anti-CD4 treated animals. In
addition, given Th17 cells have been described as involved in the
production of autoantibodies in experimental autoimmune
arthritis [31,32], our observation that anti-CD4-treated mice do
not produce RF is in line with the hypothesis that by maintaining
pathogenic T cell clones under control the B cells will not receive
the necessary stimuli for the production of autoantibodies. We
cannot exclude, at this time, a direct effect of non-depleting anti-
CD4 MAbs on innate cells expressing CD4, namely natural killer
T (NKT) cells that have been reported as being able to provide
‘‘help’’ to B cells, and to influence autoimmune arthritis [33].
In our experiments, we found a limited efficacy for tolerance
induction once the animals became overtly arthritic. Although we
Figure 4. CD4-blockade prevents Th17 polarization. (A) Sorted
TCR-transgenic cells were stimulated in vitro with peptide-loaded DCs
under culture conditions known to preferentially polarize Th17 cells,
with the addition of recombinant TGF-b, IL-6, IL-1b, and anti-IFN-c. After
5 days of culture we observed a significant reduction of IL-17+ cells in
the presence of anti-CD4 (n = 6, P,0.05). In contrast, anti-CD4 addition
led to an increased frequency of Foxp3+ T cells (n = 6, P,0.05). (B)
Representative dot plots from the two different culture conditions. An
independent experiment was performed with a peptide dose of 0.3 mM
with similar results.
doi:10.1371/journal.pone.0010558.g004
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do not have a complete explanation for this observation, it is
possible that such resistance to tolerance induction may be due to
the participation of other cell types, besides CD4+ T cells, at that
late time. In fact, in transplantation it is known that in pre-
sensitized animals a population of Asialo GM1+ CD8+ T cells can
create a barrier for tolerance induction with MAbs [34]. Thus, it
may be possible to enhance the efficacy of tolerance induction in
overt arthritis with reagents targeting other cell types, namely
CD8+ T cells and B cells.
It remains to be established whether the long-term protection
from arthritis afforded following anti-CD4 treatment, even after a
new curdlan challenge at a later time, can be explained by the
development of regulatory mechanisms that have been described
in other animal models of anti-CD4 induced immune tolerance
[28,35]. In fact, it is now established that CD4+ T cell activation in
the presence of TGF-b and IL-6 favors T cell conversion towards
arthritogenic Th17 cells, while activation in the same environment
devoid of IL-6 shifts the differentiation from Th17 towards Foxp3+
Treg cells [30]. SKG autoimmune arthritis development is known
to be dependent on Th17 [36].
Our data suggests that protection from arthritis induced with
anti-CD4 is associated with an overall decrease of infiltrating T
cells in synovial tissue and, within those T cells in the synovium,
with an increase in the frequency of synovial Foxp3+ Treg cells. As
a consequence, the tissue is endowed with local changes that are
likely to prevent the onset of arthritis directly within the local
environment where inflammation would occur, even following a
later exposure to curdlan at a time (day 60) where anti-CD4 MAbs
are no longer present. Moreover, the reciprocal decrease of IL-17
expression at the same time that the expression of Foxp3 increases,
in the joints of anti-CD4 treated mice, supports the hypothesis that
indeed the balance between Treg and Th17 can determine the
decision between prevention or onset of autoimmune arthritis.
The observation that IL-6 decreases in the serum of anti-CD4
treated mice is also in agreement with this hypothesis. It should be
noted, however, that the number of T cells is markedly reduced in
the synovium of treated mice, as can be seen in the histological
sections (and confirmed with greater CD3 expression in the
synovia by RT-PCR – thus the need to use CD3, rather than a
housekeeping gene, to normalize our gene expression studies). It
was recently reported that IL-17A can be produced by mast cells
in rheumatoid arthritis synovia [37]. Although we did not
investigate this possible source of IL-17, the overall quantification
of IL-17 transcripts was significantly reduced in anti-CD4 treated
animals, where T cells were also less abundant. As a consequence,
the shift in the Treg/Th17 balance in the synovial tissue is likely to
be also influenced by tissue accessibility to different types of
effector T cells.
We have also shown that CD4-blockade can directly inhibit T
cell polarization towards an IL-17-producing Th17 phenotype,
even when the most appropriate cytokine environment is
provided. In addition, our data show that even in the presence
Figure 5. Long-term protective effect of non-depleting anti-CD4 treatment does not affect immune competence. (A) Female SKG mice
were injected with 3 mg curdlan i.p. on day 0 and anti-CD4 on days 0, 2, and 4. Animals treated with anti-CD4 displayed long term protection from
arthritis (n = 5, P,0.05). On day 60, anti-CD4 treated mice and age matched SKG were challenged with 3 mg curdlan i.p. Mice previously treated with
anti-CD4 remained protected from the development of autoimmune arthritis (n = 5, P,0.05). (B) Female SKG mice were injected with 3 mg curdlan
i.p. and, when the clinical score reached 0.5, some of the animals initiated treatment with three i.p. administrations of 1 mg anti-CD4 on alternate
days. Control animals rapidly progressed to severe arthritis unlike the anti-CD4 treated mice (n = 6, P,0.05). (C) Mice were treated with non-depleting
anti-CD4 30 days before immunization with OVA-alum i.p. (aCD4…OVA). One week following sensitization the serum levels of OVA-specific IgG1 were
quantified, and compared with untreated (PBS…OVA) and non-immunized controls (PBS…PBS). Mice treated with anti-CD4 MAbs were competent to
produce OVA-specific IgG1 to titres similar to untreated controls, and considerably higher than the non-immunized mice (n = 5, P,0.05). (D) OVA-
specific IgG1 in mice where OVA was initially administered at the time of anti-CD4 treatment (tOVA…OVA), compared with animals that were not
initially treated with anti-CD4 (PBS…OVA). Mice treated with anti-CD4 at the time of sensitization with OVA, became tolerant to the subsequent OVA
immunization (n = 6, P,0.05).
doi:10.1371/journal.pone.0010558.g005
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of those cytokines known to inhibit Foxp3 induction (namely IL-6),
CD4-blockade can facilitate the peripheral conversion of Foxp3+
Treg cells. Taken together, our data complements previous studies
on the mechanism of tolerance induction in transplantation with
anti-CD4 (where peripheral induction of Foxp3+ Treg cells have
been shown critical), by demonstrating that CD4-blockade can
also lead to a direct inhibition of Th17 polarization – a critical
factor for the arthritis pathogenesis, namely in SKG mice [36].
Given the essential role of CD4+ T cells in the pathogenesis of
RA, both directly and by recruiting and activating other
participating cell types (such as B cells, DCs and macrophages),
the therapeutic targeting of CD4+ lymphocytes has been
extensively pursued [38]. Depleting and non-depleting anti-CD4
MAbs have been tested in several animal models of autoimmune
arthritis [39,40,41,42], and in clinical trials with RA patients
[43,44,45]. In spite of promising results in pre-clinical studies, the
therapeutic effectiveness of anti-CD4 in clinical trials was modest
and short-term, possibly due to transient immunosuppression and
not tolerance. In retrospect, those unimpressive results are not too
surprising due to technical details related with dosing and MAb
characteristics. In fact the immunogenicity of the mouse or
chimeric MAb used was well documented as leading to their rapid
clearance and consequent loss of efficient CD4 blockade [46]. The
reduction of the number of CD4+ T cells was also associated with a
concern of possible increased susceptibility to infection.
Our data show that non-depleting anti-CD4 can be effective in
preventing chronic autoimmune arthritis while preserving immune
competence, as treated mice remain able to mount a CD4-
dependent immune response against a different antigen (OVA).
OVA immunization is a well established protocol for the induction
of CD4-dependent production of OVA-specific immunoglobulins.
Moreover, administration of anti-CD4 together with OVA
prevents the effectiveness of subsequent immunizations with the
same antigen. Taken together, these data suggest that anti-CD4
prevents immune responses towards antigens present at the time of
treatment, without hampering immune responses to unrelated
antigens introduced in the organism at a later time, therefore
preserving immunocompetence. It should be noted that these
types of studies, on the long-term immunocompetence of treated
mice have been difficult to perform in animal models that, unlike
SKG mice, do not develop a chronic form of arthritis.
In summary, we show that therapeutic strategies leading to
synovial accumulation of Treg cells and reduction of Th17 are
capable of protecting from the onset of autoimmune arthritis, as
well as to prevent long-term disease progression, without leading
to overall immune suppression.
Acknowledgments
We thank Margarida Souto Carneiro and Marta Monteiro for helpful
suggestions. We are grateful to Professor Shimon Sakaguchi (Kyoto, Japan)
for providing the SKG mice, and to Professor Herman Waldmann
(Oxford, UK) for providing reagents used in this study.
Author Contributions
Conceived and designed the experiments: JD JEF LG. Performed the
experiments: JD AAD VO. Analyzed the data: JD AAD VO JEF LG.
Wrote the paper: JD JEF LG.
References
1. Chehata JC, Hassell AB, Clarke SA, Mattey DL, Jones MA, et al. (2001)
Mortality in rheumatoid arthritis: relationship to single and composite measures
of disease activity. Rheumatology (Oxford) 40: 447–452.
2. Gabriel SE, Crowson CS, Kremers HM, Doran MF, Turesson C, et al. (2003)
Survival in rheumatoid arthritis: a population-based analysis of trends over 40
years. Arthritis Rheum 48: 54–58.
3. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:
356–361.
4. Banerjee S, Webber C, Poole AR (1992) The induction of arthritis in mice by the
cartilage proteoglycan aggrecan: roles of CD4+ and CD8+ T cells. Cell
Immunol 144: 347–357.
5. Breedveld FC, Dynesius-Trentham R, de Sousa M, Trentham DE (1989)
Collagen arthritis in the rat is initiated by CD4+ T cells and can be amplified by
iron. Cell Immunol 121: 1–12.
6. Van Boxel JA, Paget SA (1975) Predominantly T-cell infiltrate in rheumatoid
synovial membranes. N Engl J Med 293: 517–520.
7. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, et al. (1999) Human
interleukin-17: A T cell-derived proinflammatory cytokine produced by the
rheumatoid synovium. Arthritis Rheum 42: 963–970.
8. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, et al. (1999) IL-17 in
synovial fluids from patients with rheumatoid arthritis is a potent stimulator of
osteoclastogenesis. J Clin Invest 103: 1345–1352.
9. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E,
et al. (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers
in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol
164: 2832–2838.
10. Choy EH, Connolly DJ, Rapson N, Jeal S, Brown JC, et al. (2000)
Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1
anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of
rheumatoid arthritis patients. Rheumatology (Oxford) 39: 1139–1146.
11. Graca L, Waldmann H (2006) Reprogramming the immune system using
antibodies. Methods Mol Biol 333: 247–268.
12. Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, et al. (2002) CD4
coating, but not CD4 depletion, is a predictor of efficacy with primatized
monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol 29:
220–229.
13. Schulze-Koops H, Burkhardt H, Kalden JR (1999) What we have learned from
trials of immunomodulatory agents in rheumatoid arthritis: Future directions.
Drugs Today (Barc) 35: 327–351.
14. Isaacs JD (2007) T cell immunomodulation–the Holy Grail of therapeutic
tolerance. Curr Opin Pharmacol 7: 418–425.
15. Graca L, Honey K, Adams E, Cobbold SP, Waldmann H (2000) Cutting edge:
anti-CD154 therapeutic antibodies induce infectious transplantation tolerance.
J Immunol 165: 4783–4786.
16. Graca L, Le Moine A, Cobbold SP, Waldmann H (2003) Antibody-induced
transplantation tolerance: the role of dominant regulation. Immunol Res 28:
181–191.
17. Karim M, Bushell AR, Wood KJ (2002) Regulatory T cells in transplantation.
Curr Opin Immunol 14: 584–591.
18. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, et al. (2003) Altered
thymic T-cell selection due to a mutation of the ZAP-70 gene causes
autoimmune arthritis in mice. Nature 426: 454–460.
19. Caetano-Lopes J, Henriques R, Canhao H, Duarte J, Amaral PM, et al. (2009)
Chronic arthritis directly induces quantitative and qualitative bone disturbances
leading to compromised biomechanical properties. Clin Exp Rheumatol 27:
475–482.
20. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development
by the transcription factor Foxp3. Science 299: 1057–1061.
21. Wu Q, Martin RJ, Rino JG, Breed R, Torres RM, et al. (2007) IL-23-dependent
IL-17 production is essential in neutrophil recruitment and activity in mouse
lung defense against respiratory Mycoplasma pneumoniae infection. Microbes
Infect 9: 78–86.
22. Cobbold SP, Castejon R, Adams E, Zelenika D, Graca L, et al. (2004) Induction
of foxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice
tolerized to transplants. J Immunol 172: 6003–6010.
23. Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, et al. (2005) A
role for fungal {beta}-glucans and their receptor Dectin-1 in the induction of
autoimmune arthritis in genetically susceptible mice. J Exp Med 201: 949–960.
24. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, et al. (2007)
Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via
CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204:
2803–2812.
25. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, et al. (2004)
Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated
spontaneous autoimmune arthritis in mice. J Clin Invest 114: 582–588.
26. Qin SX, Cobbold S, Benjamin R, Waldmann H (1989) Induction of classical
transplantation tolerance in the adult. J Exp Med 169: 779–794.
27. Graca L, Thompson S, Lin CY, Adams E, Cobbold SP, et al. (2002) Both
CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant
transplantation tolerance. J Immunol 168: 5558–5565.
28. Graca L, Cobbold SP, Waldmann H (2002) Identification of regulatory T cells in
tolerated allografts. J Exp Med 195: 1641–1646.
Th17/Treg Balance in Arthritis
PLoS ONE | www.plosone.org 7 May 2010 | Volume 5 | Issue 5 | e10558
29. Kingsley CI, Karim M, Bushell AR, Wood KJ (2002) CD25+CD4+ regulatory T
cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation
of alloresponses. J Immunol 168: 1080–1086.
30. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B (2006)
TGFbeta in the context of an inflammatory cytokine milieu supports de novo
differentiation of IL-17-producing T cells. Immunity 24: 179–189.
31. Hsu HC, Yang P, Wang J, Wu Q, Myers R, et al. (2008) Interleukin 17-
producing T helper cells and interleukin 17 orchestrate autoreactive germinal
center development in autoimmune BXD2 mice. Nat Immunol 9: 166–175.
32. Jacobs JP, Wu HJ, Benoist C, Mathis D (2009) IL-17-producing T cells can
augment autoantibody-induced arthritis. Proc Natl Acad Sci U S A 106:
21789–21794.
33. Coppieters K, Dewint P, Van Beneden K, Jacques P, Seeuws S, et al. (2007)
NKT cells: manipulable managers of joint inflammation. Rheumatology
(Oxford) 46: 565–571.
34. Trambley J, Bingaman AW, Lin A, Elwood ET, Waitze SY, et al. (1999) Asialo
GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant
allograft rejection. J Clin Invest 104: 1715–1722.
35. Graca L, Le Moine A, Lin CY, Fairchild PJ, Cobbold SP, et al. (2004) Donor-
specific transplantation tolerance: the paradoxical behavior of CD4+CD25+ T
cells. Proc Natl Acad Sci U S A 101: 10122–10126.
36. Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, et al. (2007) T cell
self-reactivity forms a cytokine milieu for spontaneous development of IL-17+
Th cells that cause autoimmune arthritis. J Exp Med 204: 41–47.
37. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, et al. Mast cells express IL-
17A in rheumatoid arthritis synovium J Immunol 184: 3336–3340.
38. Isaacs JD (2008) Therapeutic T-cell manipulation in rheumatoid arthritis: past,
present and future. Rheumatology (Oxford) 47: 1461–1468.
39. Chu CQ, Londei M (1996) Induction of Th2 cytokines and control of collagen-
induced arthritis by nondepleting anti-CD4 Abs. J Immunol 157: 2685–2689.
40. Mauri C, Chu CQ, Woodrow D, Mori L, Londei M (1997) Treatment of a
newly established transgenic model of chronic arthritis with nondepleting anti-
CD4 monoclonal antibody. J Immunol 159: 5032–5041.
41. Ranges GE, Fortin S, Barger MT, Sriram S, Cooper SM (1988) In vivo
modulation of murine collagen induced arthritis. Int Rev Immunol 4: 83–90.
42. Ranges GE, Sriram S, Cooper SM (1985) Prevention of type II collagen-induced
arthritis by in vivo treatment with anti-L3T4. J Exp Med 162: 1105–1110.
43. Herzog C, Walker C, Pichler W, Aeschlimann A, Wassmer P, et al. (1987)
Monoclonal anti-CD4 in arthritis. Lancet 2: 1461–1462.
44. Horneff G, Burmester GR, Emmrich F, Kalden JR (1991) Treatment of
rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum
34: 129–140.
45. Reiter C, Kakavand B, Rieber EP, Schattenkirchner M, Riethmuller G, et al.
(1991) Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-
T151. Clinical results and immunopharmacologic effects in an open study,
including repeated administration. Arthritis Rheum 34: 525–536.
46. Horneff G, Winkler T, Kalden JR, Emmrich F, Burmester GR (1991) Human
anti-mouse antibody response induced by anti-CD4 monoclonal antibody
therapy in patients with rheumatoid arthritis. Clin Immunol Immunopathol 59:
89–103.
Th17/Treg Balance in Arthritis
PLoS ONE | www.plosone.org 8 May 2010 | Volume 5 | Issue 5 | e10558
